CA2098404C - Improved humanized immunoglobulins - Google Patents
Improved humanized immunoglobulins Download PDFInfo
- Publication number
- CA2098404C CA2098404C CA002098404A CA2098404A CA2098404C CA 2098404 C CA2098404 C CA 2098404C CA 002098404 A CA002098404 A CA 002098404A CA 2098404 A CA2098404 A CA 2098404A CA 2098404 C CA2098404 C CA 2098404C
- Authority
- CA
- Canada
- Prior art keywords
- humanized
- antibody
- human
- antibodies
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 195
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 195
- 229940072221 immunoglobulins Drugs 0.000 title abstract description 91
- 239000000427 antigen Substances 0.000 claims abstract description 59
- 108091007433 antigens Proteins 0.000 claims abstract description 59
- 102000036639 antigens Human genes 0.000 claims abstract description 59
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 171
- 230000027455 binding Effects 0.000 claims description 78
- 230000001404 mediated effect Effects 0.000 claims description 19
- 229940127089 cytotoxic agent Drugs 0.000 claims description 18
- 239000002254 cytotoxic agent Substances 0.000 claims description 11
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 9
- 239000012636 effector Substances 0.000 claims description 8
- 210000000066 myeloid cell Anatomy 0.000 claims description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 102000056982 human CD33 Human genes 0.000 claims description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 156
- 230000002730 additional effect Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 169
- 241000699666 Mus <mouse, genus> Species 0.000 description 127
- 108090000623 proteins and genes Proteins 0.000 description 124
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 109
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 109
- 239000012634 fragment Substances 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 48
- 238000000034 method Methods 0.000 description 46
- 239000013612 plasmid Substances 0.000 description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 238000011282 treatment Methods 0.000 description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 29
- 241001529936 Murinae Species 0.000 description 29
- 108010076504 Protein Sorting Signals Proteins 0.000 description 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 29
- 239000000203 mixture Substances 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 238000010276 construction Methods 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 21
- 239000013598 vector Substances 0.000 description 20
- 241000700605 Viruses Species 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 101150074155 DHFR gene Proteins 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108010002350 Interleukin-2 Proteins 0.000 description 15
- 102000000588 Interleukin-2 Human genes 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 13
- 208000032839 leukemia Diseases 0.000 description 13
- 108020004635 Complementary DNA Proteins 0.000 description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 12
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 201000000050 myeloid neoplasm Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 210000003501 vero cell Anatomy 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 10
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 239000012894 fetal calf serum Substances 0.000 description 10
- 230000002637 immunotoxin Effects 0.000 description 10
- 239000002596 immunotoxin Substances 0.000 description 10
- 229940051026 immunotoxin Drugs 0.000 description 10
- 231100000608 immunotoxin Toxicity 0.000 description 10
- 239000013600 plasmid vector Substances 0.000 description 10
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 description 9
- 101900065606 Human cytomegalovirus Immediate early protein IE1 Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 101150106093 gpt gene Proteins 0.000 description 9
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
- 241000557626 Corvus corax Species 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000016784 immunoglobulin production Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000700 radioactive tracer Substances 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 229960004150 aciclovir Drugs 0.000 description 5
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 101150062015 hyg gene Proteins 0.000 description 5
- -1 i.e. Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000020023 cytomegalovirus pneumonia Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000009485 HLA-D Antigens Human genes 0.000 description 2
- 108010048896 HLA-D Antigens Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000609499 Palicourea Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- 235000016976 Quercus macrolepis Nutrition 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000004709 chorioretinitis Diseases 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- IPDRTIBDOPMMIQ-VAOFZXAKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C)O[C@H](CO)[C@@H](O)C1 IPDRTIBDOPMMIQ-VAOFZXAKSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 101000912181 Arabidopsis thaliana Cysteine synthase, mitochondrial Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 101100188739 Danio rerio opn1mw1 gene Proteins 0.000 description 1
- 101100188741 Danio rerio opn1mw2 gene Proteins 0.000 description 1
- 101100188744 Danio rerio opn1mw3 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102220468961 Ectodysplasin-A_L89Q_mutation Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102220609244 Integrin-linked protein kinase_H99D_mutation Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241001635529 Orius Species 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001474728 Satyrodes eurydice Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 102220476219 Solute carrier family 22 member 7_H34I_mutation Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102220645221 Tubulin epsilon chain_H37V_mutation Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000011572 outbred mouse model Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102220151548 rs142125596 Human genes 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940002004 the magic bullet Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008957 viral persistence Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Novel humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible addi-tional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are pro-vided for a number of antigens.
Description
WO 92/1101 PC°T/1J~91/09711 ,~ CS C~A . . ; fv .
. r 'y ~i 1 . .,' 4~ ti ii .. ii r_ IMPROVED HUMANIZED IMMUNOGLOBULINS
Field of the Invention The present invention relates generally to the combination of recombinant DNA and monoclonal antibody technologies for developing novel therapeutic agents and, more particularly, to the production of non-immunogenic antibodies having strong affinity for a predetermined antigen.
Background of the Invention The advent of monoclonal antibody technology in the mid 1970's heralded a new age of medicine. For the first time, researchers and. clinicians had access to essentially unlimited quantities of uniform antibodies capable of binding to a predetermined antigenic site and having various immunological effector functions. These proteins, known as "monoclonal antibodies" were thought to hold great promise in, era., the removal of harmful cells in vivo. Indeed, the clinical value of monoclonal antibodies seemed limitless far this use alone.
Unfortunately,. the development of appropriate therapeutic products based on these proteins has been severely hampered by a number of drawbacks inherent in monoclonal antibody production. For example, most monoclonal antibodies are mouse derived, and thus do not fix human complement well.
They also lack other important immunaglobulin functional characteristics when used in humans.
Perhaps most importantly, non-human monoclonal antibodies contain substantial stretches of amino acid a sequences that will be immunogenic when injected into a human patient. Numerous studies have shown that after injection of a foreign antibody, the immune response mounted by a patient can be quite strong, essentially eliminating the antibody's therapeutic utility after an initial treatment. Moreover, as increasing numbers of different mouse or other antigenic (to PCI°/L1S91 /09711 dV~ 92/1101$
. r 'y ~i 1 . .,' 4~ ti ii .. ii r_ IMPROVED HUMANIZED IMMUNOGLOBULINS
Field of the Invention The present invention relates generally to the combination of recombinant DNA and monoclonal antibody technologies for developing novel therapeutic agents and, more particularly, to the production of non-immunogenic antibodies having strong affinity for a predetermined antigen.
Background of the Invention The advent of monoclonal antibody technology in the mid 1970's heralded a new age of medicine. For the first time, researchers and. clinicians had access to essentially unlimited quantities of uniform antibodies capable of binding to a predetermined antigenic site and having various immunological effector functions. These proteins, known as "monoclonal antibodies" were thought to hold great promise in, era., the removal of harmful cells in vivo. Indeed, the clinical value of monoclonal antibodies seemed limitless far this use alone.
Unfortunately,. the development of appropriate therapeutic products based on these proteins has been severely hampered by a number of drawbacks inherent in monoclonal antibody production. For example, most monoclonal antibodies are mouse derived, and thus do not fix human complement well.
They also lack other important immunaglobulin functional characteristics when used in humans.
Perhaps most importantly, non-human monoclonal antibodies contain substantial stretches of amino acid a sequences that will be immunogenic when injected into a human patient. Numerous studies have shown that after injection of a foreign antibody, the immune response mounted by a patient can be quite strong, essentially eliminating the antibody's therapeutic utility after an initial treatment. Moreover, as increasing numbers of different mouse or other antigenic (to PCI°/L1S91 /09711 dV~ 92/1101$
humans) monoclonal antibodies can, be expected to be developed to treat various diseases, after one or several treatments with any non-human antibodies, subsequent treatments, even for unrelated therapies, can be ineffective or even dangerous in themselves, because of cross-reactivity.
While the production of so called "chimeric antibodies" (era., mouse variable regions joined to human constant regions) has proven somewhat successful, a significant immunogenicity problem remains. Moreover, efforts to immortalize human H-cells or generate human hybridomas capable of producing human immunoglobulins against a desired antigen have been generally unsuccessful, particularly with many important human antigens. Most recently, recombinant DNA
technology has been utilized to produce immunoglobulins which have human framework regions combined with complementarity determining regions (CDR's) from a donor mouse or rat immunoglobulin (see, .e. a., EPO Publication No. 0239400).
These new proteins are called "reshaped" or "humanized"
immunoglobulins and the process by which the donor immunoglobulin is converted into a human-like immunoglobulin by combining its CDR's with a human framework is called °'humanization". Humanized antibodies are important because they bind to the same antigen as the original antibodies, but are less immunogenic when injected into humans.
However, a major problem with humanization procedures has been a loss of affinity for the antigen (Jones e~t al., Nature, 321, 522-525 (1986)), in some instances as much as 10-fold ar more, especially when the antigen is a protein (Verhoeyen et al., Science, 239, 1534-1536 (1988)).
Loss of any affinity is, of course, highly undesirable. At the least, it means that more of the humanized antibody will have to be injected into the patient, at higher cost and greater risk of adverse effects. Even more critically, an antibody with reduced affinity may have poorer biological functions, such as complement lysis, antibody-dependent cellular cytotoxicity, or virus neutralization. For example, the loss of affinity in the partially humanized antibody WO 92/1101 . PCd'/US91/09771 ~ ~,, : , ,,., v ., .
While the production of so called "chimeric antibodies" (era., mouse variable regions joined to human constant regions) has proven somewhat successful, a significant immunogenicity problem remains. Moreover, efforts to immortalize human H-cells or generate human hybridomas capable of producing human immunoglobulins against a desired antigen have been generally unsuccessful, particularly with many important human antigens. Most recently, recombinant DNA
technology has been utilized to produce immunoglobulins which have human framework regions combined with complementarity determining regions (CDR's) from a donor mouse or rat immunoglobulin (see, .e. a., EPO Publication No. 0239400).
These new proteins are called "reshaped" or "humanized"
immunoglobulins and the process by which the donor immunoglobulin is converted into a human-like immunoglobulin by combining its CDR's with a human framework is called °'humanization". Humanized antibodies are important because they bind to the same antigen as the original antibodies, but are less immunogenic when injected into humans.
However, a major problem with humanization procedures has been a loss of affinity for the antigen (Jones e~t al., Nature, 321, 522-525 (1986)), in some instances as much as 10-fold ar more, especially when the antigen is a protein (Verhoeyen et al., Science, 239, 1534-1536 (1988)).
Loss of any affinity is, of course, highly undesirable. At the least, it means that more of the humanized antibody will have to be injected into the patient, at higher cost and greater risk of adverse effects. Even more critically, an antibody with reduced affinity may have poorer biological functions, such as complement lysis, antibody-dependent cellular cytotoxicity, or virus neutralization. For example, the loss of affinity in the partially humanized antibody WO 92/1101 . PCd'/US91/09771 ~ ~,, : , ,,., v ., .
3 ~'.~ ~.t :J =y ~a '-~:
HuVHCAMP may have caused it to lose all ability to mediate complement lysis (see, Riechmann et al., Nature, 332, 323-327 (1988); Table 1).
Thus, there is a need for humanized antibodies specifically reactive with strong affinity to predetermined antigens. These humanized immunoglobulins should remain substantially non-immunogenic in humans, yet be easily and economically produced in a manner suitable for therapeutic formulation and other uses. The present invention fulfills these and other needs.
Summary of the Invention The present invention provides novel compositions useful, for example, in the treatment of T-cell mediated human disorders, the compositions containing human-like immunoglobulins specifically capable of inhibiting the binding of human IL-2 to its receptor and/or capable of binding to the p75 protein of human TL-2 receptors. The immunoglobulins can have two pairs of light chain/heavy chain complexes, typically at least one chain comprising mouse complementarity determining regions functionally joined to human framework region segments. For example, mouse complementarity determining regions, with or without additional naturally--associated~mouse amino acid residues, can be used to produce human-like antibodies capable of binding to the p75 protein at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to p75.
The present invention also-provides novel compositions useful, for example, in the treatment of HSV
mediated human disorders, the compositions containing humanized immunoglobulins specifically capable of blocking the binding of HSV to its receptors and/or capable of binding to the HSV specific proteins. The immunoglobulins can have two pairs of light chain/heavy chain complexes, at least one chain comprising one or more mouse complementarity determining regions functionally joined to human framework region WO 92/1101 ~ P~i-/US9t /o~~~ 1 4.
segments. For example, mouse complementarity determining regions, with or without additional naturally-assbciated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to the HSV surface proteins at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR
donating mouse monoclonal antibody to HSV. These humanized immunoglobulins may be utilized alone in substantially pure form, or together with an antiviral agent, such as acyclovir or a cytotoxic agent active at viral surfaces. All of these compounds will be particularly useful in treating HsV mediated disorders.
The present invention further provides novel compositions useful, for example, in the treatment of myeloid leukemia-related human disorders, the compositions containing humanized immunoglobulins specifically capable of binding to CD33 antigen. The immunoglobulins can have two pairs of light chain/heavy chain complexes, at least one chain comprising one or more mouse complementarity determining regions functionally joined to human framework region segments. For example, mouse complementarity determining regions, with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to the CD33 antigen at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to CD33.
These humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such as cytosine arabinoside or daunorubicin active against leukemia cells, or complexed with a radionuclide such as iodine-131. All of these compounds will be particularly r useful in treating leukemia and myeloid cell-mediated disorders.
The present invention also provides novel compositions useful, for example, in the treatment of CMV-mediated human disorders, the compositions containing humanized immunoglobulins specifically capable of blocking the binding of CMV to its receptors and/or capable of binding to CMV antigens. For example, mouse complementarity determining 5 regions, with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to CMV at affinity levels stronger than about 10' M-1.
These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to CMV. These humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such a acyclovir or ganciclovir active against CMV-infected cells, or complexed with a cytotoxic agent. All of these compounds will be particularly useful in treating CMV-mediated disorders.
The present invention further provides novel compositions useful, for example, in the treatment of human autoimmune disorders, the compositions containing humanized immunoglobulins specifically capable of binding to 7-IFN. For example, mouse complementarity determining regions, with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to 7-IFN
at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to ~-IFN. The humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such as a non-steroidal anti-inflammatory drug, a corticosteroid, or an immunosuppressant. All of these compounds will be particularly useful in treating autoimmune disorders.
5a This invention provides a humanized immunoglobulin derived from the mouse M195 antibody whose light and heavy chain variable regions are shown herein, which humanized antibody has a binding affinity of at least 107 M-1 and competes with the mouse antibody for binding to human CD33 antigen.
This invention also provides the aforementioned humanized immunoglobulin comprising a humanized heavy chain variable region comprising three complementarity determining regions from the heavy chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin heavy chain, and a humanized light chain variable region comprising three complementarity determining regions from the light chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin light chain.
This invention also provides the aforementioned humanized immunoglobulins in substantially pure form and/or wherein the humanized immunoglobulin comprises a human framework substantially homologous to EU immunoglobulin framework.
The humanized immunoglobulins of this invention may be capable of mediating antibody-dependent cellular cytotoxicity in the presence of human target and effector cells.
This invention also provides the aforementioned humanized immunoglobulins conjugated to a cytotoxic agent for use as a pharmaceutical.
This invention also provides the use of the aforementioned humanized immunoglobulins for treating a myeloid cell-mediated disorder in a human patient.
This invention also provides the use of the aforementioned humanized immunoglobulins for preparation of medicaments for treating myeloid cell-mediated disorders.
This invention also provides the aforementioned uses of humanized immunoglobulins, wherein the immunoglobulin is conjugated to a cytotoxic agent.
5b BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of ____.____._.__r___.__ W~ 92/1101 PCT/LIS9i/09711 a ~'S .
the mouse Fd79 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 2. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse Fd138-80 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 3. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse M195 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences.. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 4. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse mik-(31 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences., The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
~'O 92/1101 ~ PCIf'/US9t /0971 t ~: ,,.;~ :,., a.- .:,: ;
,.: ~. .~I'~..J~::.
Figure 5. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse CMVS antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 6. Scheme for anchored polymerase chain reaction (PCR) cloning of the heavy and light chain variable domain cDNAs. RNA was prepared from about 10' hybridoma cells using the hot phenol extraction method. Briefly, cells were resuspended and vortexed in 1 ml of RNA extraction buffer (50 mM sodium acetate pH 5.2/1% SDS), extracted with 0.5 ml of phenol pH 5.2 at 65°C far 15 min, followed by another 15 min on ice. The aqueous phase was recovered and precipitated twice with ethanol. cDNA was synthesized from 10 ug of total RNA using reverse transcriptase (BRL, Betheseda, MD) and oligo-dTlz-is (Pharmacia, Piscatway, New Jersey) as primers. A
poly(dG) tail was attached to the 3' end of the cDNA using terminal deoxynucleotide transferase (BRL) (E. Y. Loh et al., Science 243, 217 (1989)), the variable domain genes (V) were amplified using AmpliTaq (Perkin Elmer-Cetus) with the primer mc045 (TAATCTAGAATTCCCCCCCCCCCCCCCCC) that hybridized to the poly(dG) tails and primers that hybridized to the constant region genes (C). For the light chain, the primer used was mc045 (TATAGAGCTCAAGCTTGGATGGTGGGAAGATGGATACAGTTGGTGC). For the heavy chain, the primer used was mc047 (TATAGAGCTCAAGCTTCCAGTGGATAGAC(CATjGATGGGG(GC)TGT(TC)GTTTTGGC) The sequence in parenthesis indicates a base degeneracy. The degeneracy was introduced so that the primer would be able to hybridize to most gamma chains. The amplified fragments were w0 92/11018 PCT/US91/U9711 s then digested with EcoRI and HindIII and cloned into pUCl8 vector for sequencing.
Figure 7. Sequences of the cDNA and translated amino acid sequences of the Light chain (A} and heavy chain (B) variable regions of the antibody mik-X31. The CDR
sequences are underlined. The mature light chain protein begins with amino acid 23 Q and the mature heavy chain protein with amino acid 20 Q, preceded by the respective signal sequences.
Figure 8. Schematic diagram of the plasmids pVgl-dhfr (A) and pVk (B). The plasmid pVgl-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell ~1, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by XbaI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant xegion gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., Mo,~ecular Cloning: A Laboratory Manual, 2nd ed,, Cold Spring Harbor Laboratory, Gold Spring Harbor, N.Y, (1989). For example, pVg1-dhfr was constructed from the plasmid pVgl (commonly assigned U.S. patent application serial No.
07/590,274 filed September 28, 1990) by replacing the Hind III-Bgl II fragment containing the hyg gene with a 660 by fragment containing the dhfr gene and extending to a Bgl II
site (Simonsen et al., Proc. Natl. Acad. Sci. USA 80, 2495 , (1983)).
Figure 9. Fluorocytometry of YTJB cells stained with ( ) Isotype matched control antibody, (---) humanized mik-~1 antibody, (...) chimeric mik-~1 antibody. Cells were suspended in FACSTM buffer (PBS + 2% BSA + 0.1% azide) at approximately 5x106/ml. 100 u1 of cell suspension was transferred to a polystyrene tube and incubated with 100 ng of purified antibody on ice for 30 min. The cells were washed with FAGS buffer and incubated with goat anti-human Ig antibody on ice for another 30 min. Then the cells were washed and incubated with FITC labeled rabbit anti-goat Ig antibody for 30 min. The cells were washed again and finally resuspended in PBS + 1% paraformaldehyde. Cells were analyzed on a FACSmate (Becton Dickinson).
Figure 10. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized mik-~1 antibody, (lower lines) and human Lay antibody (upper lines), not including signal sequences. The three CDRs in each chain are underlined. Amino acids in the framework that have been replaced with mouse amino acids or consensus human amino acids in the humanized antibody are double underlined.
Figure 11. Oligonucleotides used in the construction of the humanized mik-~1 heavy chain (B) and light chain (A). The following pairs of oligonucleotides were mixed, extended with sequenase and cut with the indicated enzymes before ligation into the pBluescriptII ks (+) vector:
wps54 and vcll with Xba I and Sal I, vcl2 and wps57 with Xba I
and Sal I, vcl6 and vcl3 with Xba I and Kpn I, vcl4 and vcl5 with Xba I and Kpn I. Then the wps54-vcll and vcl2-wps57 fragments were excised with Xba I and Sal I ligated together into the Xba I site of pVgl-dhfr: and the vcl6-vcl3 fragments and vcl4-vcl5 fragments were excised with Xba I and Kpn I and ligated together into the Xba I site of pVk.
Figure 12. Competitive binding of labeled mik-~1 tracer to YTJB cells. About 106 YTJB cells were incubated with W~ 92/11018 Pc~'/uS9a/09775 __ 3.0 ng of radio-iodinated mouse mik-,Q1 antibody (6 ~.Ci/~tg) and oaring amounts of either unlabeled mouse mik-Q1 antibody or humanized mik-Q1 antibody (o) in 200 u1 of binding buffer (PBS + 10% fetal calf serum + 0.1% NaN3 + 10 ~g/ml mouse 5 monoclonal Ig). After incubation for 2 hr at 0°C the cells.
were washed twice with binding buffer without mouse Ig and collected by centrifugation. The radioactivity bound to cells was measured and expressed as the ratio of bound/free cpm.
10 Figure 13. Inhibition of IL-2 stimulated proliferation of human PHA blasts by humanized mik-,O1 +
humanized anti-Tac antibodies. No antibody added (n), 2 ug each of humanized mik-~i1 and humanized anti-Tac added Figure 14. . Amino acid sequences of the heavy chain (A) and the light chain (B) of the murine and humanized Fd79 antibodies, and the heavy chain (C) and the light chain (D) of the murine and humanized Fd138-80 antibodies. The sequences of the murine antibody as deduced from the cDNA (upper lines) are shown aligned with the humanized antibody sequences (lower lines). The humanized Fd79' and Fd138-80 framework sequences are derived from Pom antibody and Eu antibody, respectively.
Residues are numbered according to the Kabat system~(E.A.
Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD) (1987). The three CDRs in each chain are boxed. Residues in the Pom or Eu framework that have been replaced with murine sequences or consensus human sequences are underlined.
Figure 15. Schematic diagram of the plasmids pVgl (A) and pVk (B). The plasmid pVgl was constructed from the , following fragments; an approximately 4850 base pair BamHI-EcoRT fragment from the~plasmid pSV2hph containing the amp and , hyg genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell 41, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by XbaI-BamHI
i~V~ 92/11018 PCT/US91 /097 ~
11 ~ -, w :~, .:..
t, 5u J v fragment containing the human gamma-1 constant region gene with 225 by of the preceding intron and the poly(A) signal.
The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt replacing the hyg gene.
Figure 16. Fluorocytometry of HSV-1 infected Vero cells stained with Fd79 (A) and Fd138-80 (B) antibodies.
(. .) zsotype matched control antibody, (...) humanized antibody, (~) chimeric antibody. Vero cells were infected with HSV-1 0305 mutant (F strain)) at 3 pfu/cell overnight.
Cells were trypsinized at 0.5 mg/ml for 1 minute, washed extensively with PBS and resuspended in FACS buffer (PBS + 2~
BSA + 0.1o azide) at approximately 5x106/ml. 100 al of cell suspension was transferred to a polystyrene tube and incubated with 100 ng of purified antibody on ice for 30 min. The cells were washed with FACS buffer and incubated with FITC labeled goat anti-human antibody (Cappel) on ice for another 30 min.
The cells were washed again and finally resuspended in PBS +
1~ paraformaldehyde. Cells were analyzed on a FACSmate (Becton Dickinson).
Figure 17: Neutralization of HSV-1 by Fd79 (A) and Fd138-80 (B). Serial dilutions of antibodies were mixed with 100 pfu of virus and incubated at 37°C for 1 hr. The viruses were then inoculated onto 6-well plates with confluent Vero cells and adsorbed at 37°C for 1 hr. Cells were overlayed with 1% agarose in medium and incubated for 4 days. Plaques were stained with neutral red.
Figure 18. Immunostaining of infected Vero cell monolayers to examine protection of cells from viral spread in tissue culture by (A) marine or humanized Fd79, (B) marine or humanized Fd138-80. 24-well plates of confluent Vero cells were inoculated with virus at 0.1 pfu/cell and allowed to adsorb for 2 hrs, at 37°C before adding 200 al of 10 ug/ml antibodies in medium. At the end of 4 days, culture medium VVC9 92/11018 PCT/U59~/097m s1 V ,~ n' ,9 _.
was removed and plates were dried by placing overnight in a 37°C incubator. To detect viral antigens, each well was incubated with 200 u1 of anti-gB antibody at 0.5 ug/ml for 1 hr. at 37°C, washed twice and incubated with 200 u1 of peroxidase conjugated goat anti-mouse IgG (Cappel, 1:300 dilution) for 1 hr. at 37°C. The plates were washed and then developed with the substrate 3-amino-9-ethyl-carbazole (AEC) (Sigma, St. Louis, MO) for 15 minutes at room temperature.
Reaction was stopped by rinsing with water and air dried.
Figure 19. Sequences of the cDT~IA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the antibody M195. The CDR sequences are underlined. The mature light chain protein begins with amino acid 21 D and the mature heavy chain protein with amino acid 20 E, preceded by the respective signal sequences.
Figure 20. Schematic diagram of the plasmids pVg1-dhfr (A) and pVk (B). The plasmid pVg1-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell 41, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by Xb.aI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Gold Spring Harbor, N.Y. (1989) and PCT/89/01578 filed April 13, 1989. Fox example, pVgl-dhfr was constructed from the plasmid pVg1 by replacing the Hind III-iW0 92/11018 PCT/tJS9t/097t t 13 _ . ns i.i '-_',i .:
Bgl II fragment containing the hyg gene with a 66o by fragment containing the dhfr gene and extending to a Bgl TI site (Simonsen et al., Proc. Natl. Acad. Sci. USA 80, 2495 (1983)).
Figure 21. Fluorocytometry of U937 cells stained with (. .) no antibody, (...) humanized M195 antibody, (---) chimeric M195 antibody. Cells were suspended in FRCS buffer (PBS + 2% FCS + 0.1% azide) at approximately 5x106/ml. 100 u1 of cell suspension was transferred to a polystyrene tube and incubated with 50 ng of purified antibody on ice for 30 min.
The cells were washed with FACS buffer and incubated with FITC
labeled goat anti-human Ig antibody on ice for another 3o min.
The cells were washed again and finally resuspended in PB5 +
1~ paraformaldehyde. Cells were analyzed on a FACSmate (Becton Dickinson).
Figure 22. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized M195 antibody (lower lines) and human Eu antibody (upper lines), not including signal sequences. The three CDR's in each chain are underlined. Residues in the framework that have been replaced with mouse amino acids in the humanized antibody are double underlined.
Figure 23. Oligonucleotides used in the construction of the humanized M195 heavy chain (A; mal-~) and light chain (B; may-8). The following pairs of oligonucleotides were mixed, extended with Klenow polymerase and cut with the indicated enzymes before ligation into pUClB:
mat and mat with Xba I and Kpn I, ma3 and ma4 with Xba I and Kpn I, may and ma6 with Xba I and Hind III, ma7 and maa with Xba I and Hind III. Then the mal-mat and ma3-ma4 fragments were excised from pUCl8 with Xba I and kpn I and ligated together into the Xba I site of pVgl-dhfr; and the may-ma6 and ma7-ma8 fragments were excised with Xba I and Hind III and ligated together into the Xba I site of pVk.
Figure 24. Competitive binding of labeled M195 tracer to U937 cells. About 4 x 105 0937 cells were incubated with 4.5 ng of radio-iodinated mouse M195 antibody (6 ~cci/ug) and varying amounts of either unlabeled mouse M195 antibody (~) or humanized M195 antibody (o) in 200 u1 of binding buffer (PBS + 2% fetal calf serum + 0.1% sodium azide). After incubation for 2 hr at 0°C, the cells were washed twice with binding buffer and collected by centrifugation. The radioactivity bound to cells was measured and is expressed as the ratio of bound/free cpm.
Figure 25. Sequences of the cDNA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the antibody CMV5. The CDR sequences are underlined. The start of the mature protein sequences are indicated by arrows, preceded by the respective signal sequences.
Figure 26. Schematic diagram of the plasmids pVgl-dhfr (A) and pVk (B). The plasmid pVg1-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell 41, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by XbaI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989) 14a and the commonly assigned patent application published October 19, 1989 under No. WO 89/09622. For example, pVgl-dhfr was constructed from the plasmid pVgl (see WO 89/05857 published June 29, 1989) by replacing the HindIII-BglII fragment containing the hyg gene with a 660 by fragment containing the dhfr gene and extending to a Bgl II
site (Simonsen et al., Proc. Natl. Acad. Sci. USA 80, 2495 (1983)).
Figure 27. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized CMVS antibody (lower lines) and human Wol antibody (upper lines), not including signal sequences. The three CDR's in each chain are 10 underlined. Residues in the framework replaced with mouse amino acids or typical human amino acids in the humanized antibody are double underlined.
Figure 28. Oligonucleotides used in the 15 construction of the humanized CMVS light chain (A; jbl6-jbl9) and heavy chain (B; jb20-jb22). The following pairs of oligonucleotides were mixed, extended with Klenow polymerase and cut with the indicated enzymes before ligation into pUCl8:
jbl6 and jbl7 with Xba I and EcoR I, jbl8 and jbl9 with Xba I
and EcoR I, jb20 and jb21 with Xba I and Kpn I, jb22 and jb23 with Xba I and Kpn I. Then the jbl6-jbl7 and jbl8-jbl9 fragments were excised with Xba I and Mlu I and ligated together into the Xba I site of pVk; and the jb20-jb21 and jb22-jb23 fragments were excised with Xba I and Kpn I and ligated together into the Xba I site of pVgl-dhfr.
Figure 29. Competitive binding of labeled CMV5 tracer to CMV-infected cells. Increasing amounts of mouse (~) or humanized (o) CMV5 antibody was added to CMV-infected HEL
cells with tracer radio-iodinated mouse CMVS, and the amount of tracer bound to the cells was determined.
Figure 30. Sequences of the cDNA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the antibody AF2. The CDR sequences are underlined. The mature light chain protein begins with amino acid 30 N and the mature heavy chain protein with amino acid 36 Q, preceded by the respective signal sequences.
Figure 31. Schematic diagram of the plasmids pVgl-dhfr (A) and pVk (B). The plasmid pVgl-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell ~, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively: and a 2800 by XbaI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., I~lecular Clonina~ A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989).
For example, pVgl-dhfr was constructed from the plasmid pVgl by replacing the Hind III-Bgl II fragment containing the hyg gene with a 660 by fragment containing the dhfr gene and extending to a Bgl II site (Simonsen et al., Proc. Natl Acad Sci. USA ~, 2495 (1983)).
Figure 32. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized AF2 antibody (lower lines) and human Eu antibody (upper lines), not including signal sequences. The three CDR's in each chain are underlined. Residues in the framework that have been replaced with mouse amino acids or typical human amino acids in the humanized antibody are double underlined.
w~ 92/mom PC1'/US91/09711 :-. a, ~ ~ ~~
17 ; ~ ~ ~: c~. v ei 'v Figure 33. Gligonucleotides used in the construction of the humanized AF2 light chain (A; rhlo-rhl3) and heavy chain (B~ rh20-23). The following pairs of oligonucleotides were mixed, extended with Klenow polymerase and cut with the indicated enzymes before ligation into pUCl8:
rhl0 and rhll with Xba I and Hind III, rhl2 and rhl3 with Xba I and Hind III, rh20 and rh21 with Xba I and EcoR I, rh22 and rh23 with Xba I and EcoR I. Then the rhl0-rhll and rhl2-rhl3 fragments were excised with Xba I and Hind III and ligated together into then Xba I site of pVk; and the rh20-rh21 and rh22-rh23 fragments were excised with Xba I and Xho I and ligated together into the Xba I site of pVgl-dhfr.
Figure 34. Fluorescence of HS294T cells incubated with ~-IFN plus varying concentrations of mouse AF2 antibody, and stained with an anti-HLA-D antibody.
pETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, novel humanized immunoglobulins capable of specifically binding to predetermined antigens with strong affinity are provided.
These immunoglobulins are substantially non-immunogenic in humans but have binding affinities of at least about 108 M-1, preferably 109 ~I 1 to logo M l, or stronger. The humanized immunoglobulins will have a human framework and have one or more complementary determining regions (CDR's), plus a limited number of other amino acids, from a donor immunoglobulin specifically reactive with an antigen. The immunoglobulins can be produced economically in large quantities and find use, for example, in the treatment of various human disorders by a variety of techniques.
In order that the invention may be more completely understood, several definitions are set forth. As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma (IgGl, IgG2, IgG3, VVO 92/11018 ~~r/US9a/o9~a a j~~ ~ ~' ~ al ii.
~a i~ J vi - ...
1$
IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. a?ull-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COON - terminus. Full-length immunoglobulin "heavy chains" (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.a., gamma (encoding ab~ut 330 amino acids).
One form of immunoglobulin constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain. variable regions are together responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions.
In addition to antibodies, immunoglobulins may exist in a variety of other forms including, for example, Fv, Fab, and (Fab')2, as well as bifunctional hybrid antibodies (e. a., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)) and in single chains (e~a., Huston et al., Proc. Natl. Acid. Sci.
U.S.A., 85, 5879-5883 (1988) and Bird et al., Science, 242, 423-426 (1988)). (See, generally, Hood e~ al., "Immunology°', Benjamin, N.Y., 2nd ed. (1984), and Hunkapiller and Hood, Nature, 323, 15-16 (1986)).
An immunoglobulin light ox heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also called CDR's. The extent of the framework region and CDR's have been precisely defined (see., "Sequences of Proteins of Immunological Interest," E. Kabat et , al., U.S. Department of Health and Human Sez-vices, (1983)).
The sequences of the framework regions of different light or .
heavy chains are relatively conserved within a species. As used herein, a "human framework region" is a framework region that is substantially identical (about 85% or more, usually 90-95% or more) to the framework region of a naturally s~
9~0 92/11018 rs ~, c7 ,:~ r~
~ky~tJ~.:.~ir.l_ occurring human immunoglobulin. The framework region of an antibody, that is the combined framework regians of the constituent light and heavy chains, serves to position and align the CDR's. The CDR's are primarily responsible for binding to an epitope of an antigen.
Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes belonging to different species. For example, the variable segments of the genes from a mouse monoclonal antibody may be joined to human constant segments, such as gamma 1 and gamma 3. A typical therapeutic chimeric antibody is thus a hybrid protein composed of the variable or antigen-binding domain from a mouse antibody and the constant.
or effector domain from a human antibody (ela., A.T.C.C.
Accession No. CRL 9688 secretes an anti-Tac chimeric antibody), although other mammalian species may be used.
As used herein, the term "humanized" immunoglobulin refers to an immunoglobulin comprising a human framework region and one or more CDR's from a non-human (usually a mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR's is called the "donor" and the human immunoglobulin providing the framework is called the "acceptor". Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-900, preferably about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDR's, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A "humanized antibody" is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, a humanized antibody would not encompass a typical chimeric antibody as defined above,., because the entire variable region of a chimeric antibody is non-human. One says that the donor antibody has been °'humanized", by the process of "humanization", because W~ 92/11098 PCT'/1JS91/09711 N,C)'~~~',~
~;j~..l.:.ei~:: 20 the resultant humanized antibody is expected to bind to the same antigen as the donor antibody that provides the CDR°s.
It is understood that the humanized antibodies designed by the present method may have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr.
Z0 Humanized immunoglobulins, including humanized antibodies, have been constructed by means of genetic engineering. Most humanized immunoglobulins that have been previously described (Jones et al., off. cit.; Verhoeyen et al., op. cit.: Riechmann et al., og. cit.) have comprised a framework that is identical to the framework of a particular human immunoglobulin chain, the acceptor, and three CDR's from a non-human donor immunoglobulin chain. rn one case (Riechmann et al., ~. cit.), two additional amino acids in the framework were changed to be the same as amino acids in other human framework regions. The present invention includes criteria by which a limited number of amino acids in the framework of a humanized immunoglobulin chain are chosen to be the same as the amino acids at those positions in the donor rather than in the acceptor, in order to increase the affinity of an antibody comprising the humanized immunoglobulin chain.
The present invention is based in part on the model that two contributing causes of the loss of affinity in prior means of producing humanized antibodies (using as examples mouse antibodies as the source of CDR's) are:
(1) When the mouse CDR's are combined with the human framework, the amino acids in the framework close to the , CDR's become human instead of mouse. Without intending to be bound by theory, we believe that these changed amino acids may .
slightly distort the CDR's, because they create different electrostatic or hydrophobic forces than in the donor mouse antibody, and the distorted CDR's may not make as effective W~ 92/1101 IaCT/US91/a9711 contacts with the antigen as the DR's did in the donor antibody;
(2) Also, amino acids in the oraginai mouse antibody that are close to, but not part of, the CDR's (i.e., still part of the framework), may make contacts with the antigen that contribute to affinity. These amino acids are lost when the antibody is humanized, because all framework amino acids are made human.
3) Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal antibodies (D. Shaw et al., J.
Immunol., 138, 4534-4538 (1987)). Injected humanized antibodies will presumably have a half-life more similar to naturally occurring human antibodies, allowing smaller and less frequent doses to be given.
To avoid these problems, and to produce humanized antibodies that have a very strong affinity for a desired antigen, the present invention uses one or mare of the following principles for designing humanized immunoglobulins.
Also, the criteria may be used singly, or when necessary in combination, to achieve the desired affinity or other characteristics.
A principle is that as acceptor, a framework is used from a particular human immunoglobulin that is unusually homologous to the donor immunoglobulin to be humanized, or use a consensus framework from many human antibodies. For example, comparison of the sequence of a mouse heavy (or light) chain variable region against human heavy (or light) variable regions in a data bank (for example, the National Biomedical Research Foundation Protein Identification.
Resource) shows that the extent of homology to different human regions varies greatly, typically from about 40% to about 60-70%. By choosing as the acceptor immunoglobulin one of the human heavy (respectively light) chain variable regions that is most homologous to the heavy (respectively light) chain variable region of the donor immunoglobulin, fewer amino acids will be changed in going from the donor immunoglobulin to the WO 92/11018 PC.'T/U~91109711 ~d l.' !/~ J "' ~J ~Y __ humanized immunoglobulin. Hence, and again without intending to be bound by theory, it is believed that there is a smaller chance of changing an amino acid near the CDR's that distorts their conformation. lrIoreover, the precise overall shape of a humanized antibody comprising the humanized immunoglobulin chain may more closely resemble the shape of the donor antibody, also reducing the chance of distorting the CDR's.
Typically, one of the 3-5 most homologous heavy chain variable region sequences in a representative collection of at least about 10 to 20 distinct human heavy chains will be chosen as acceptor to provide the heavy chain framework, and similarly for the light chain. Preferably, one of the 1-3 most homologous variable regions will be used. The selected acceptor immunoglobulin chain will most preferably have at least about 65% homology in the framework region to the donor immunoglobulin.
In many cases, it may be considered preferable to use light and heavy chains from the same human antibody as acceptor sequences, to be sure the humanized light and heavy chains will make favorable contacts with each other. In this case, the donor light and heavy chains will be compared only against chains from human antibodies whose complete sequence is known, ela., the Eu, Lay, Pom, Wol, Sie, Gal, Ou and WEA
antibodies (Kabat et al., op. cit.; occasionally, the last few amino acids of a human chain are not known and must be deduced by homology to other human antibodies). The human antibody will be chosen in which the light and heavy chain variable regions sequences, taken together, are overall most homologous to the donor light and heavy chain variable region sequences.
Sometimes greater weight will be given to the heavy chain sequence. The chosen human antibody will then provide both light and heavy chain acceptor sequences. In practice, it is often found that the human Eu antibody will serve this role.
Regardless of how the acceptor immunoglobulin is chosen, higher affinity may be achieved by selecting a small number of amino acids in the framework of the humanized immunoglobulin chain to be the same as the amino acids at wo 9zia aoas a',crius9aio~~a a ~> v v t~ y' 'J ':S
those positions in the donor rather than in the acceptor. A
second principle is that the following categories define what amino acids may be selected from the donor. Preferably, at many or all amino acid positions in one of these categories, the donor amino acid will in fact be selected.
Category 1: The amino acid position is in a CDR is defined by Kabat et al., ~. cit.
Category 2: If an amino acid in the framework of the human acceptor immunoglobulin is unusual (i.e., "rare", which as used herein indicates an amino acid occurring at that position in less than about 20% but usually less than about 10% of human heavy (respectively light) chain V region sequences in a representative data bank), and if the donor amino acid at that position is typical for human sequences (i.e., ''common", which as used herein indicates an amino acid occurring in more than about 25~ but usually more than about 50% of sequences in a representative data bank), then the donor amino acid rather than the acceptor may be selected. This criterion helps ensure that an atypical amino acid in the human framework does not disrupt the antibody structure. Moreover, by replacing an unusual amino acid with an amino acid from the donor antibody that happens to be typical for human antibodies, the humanized antibody may be made less immunogenic.
All human light and heavy chain variable region sequences are respectively grouped into "subgroups°' of sequences that are especially homologous to each other and have the same amino acids at certain critical positions (Kabat et al., op. cit.). When deciding whether an amino acid in a human acceptor sequence is "rare" or "common" among human sequences, it will often be preferable to consider only those human sequences in the same subgroup as the acceptor sequence.
Category 3: In the positions immediately adjacent to one or more of the 3 CDR's in the primary sequence of the humanized immunoglobulin chain, the donor amino acids) rather than WO 92/11018 f('T/~L1~91/097i 1 ~i 1)'' f-1 ~.~iC~ f:v.: 24 acceptor amino acid may be selected. These amino acids are particularly likely to interact with the amino acids in the CDR's and, if chosen from the acceptor, to distort the donor CDR's and reduce affinity. Moreover, the adjacent amino acids may interact directly with the antigen (Amit et al., Science, 233, 747°753 (1986)) and selecting these amino acids from the donor may be desirable to keep all the antigen contacts that provide affinity in the original antibody.
Category 4: A 3-dimensional model, typically of the original donor antibody, shows that certain amino acids outside of the CDR's are close to the CDR's and have a good probability of interacting with amino acids in the CDR's by hydrogen bonding, Van der Waals forces, hydrophobic interactions, ete. At those amino acid positions, the donor immunoglobulin amino acid rather than the acceptor immunoglobulin amino acid may be selected. Amino acids according to this criterion will generally have a side chain atom within about 3 angstrom units of some atom in the CDR°s and must contain an atom that could interact with the CDR
atoms according to established chemical forces, such as those listed above.
In the case of atoms that may form a hydrogen bond, the 3 angstroms is measured between their nuclei, but for atoms 'that do not form a bond, the 3 angstroms is measured between their Van der Waals surfaces. Hence, in the latter case, the nuclei must be within about 6 angstroms (3 + sum of the Van der Waals radii) for the atoms to be considered capable of interacting. In many cases the nuclei will be from 4 or 5 to 6A apart. In determining whether an amino acid can interact with the CDRs, it is preferred not to consider the last 8 amino acids of heavy chain CDR 2 as part of the CDRs, because from the viewpoint of structure, these 8 amino acids behave more as part of the framework.
Amino acids in the framework that are capable of interacting with amino acids in the CDR's, and which therefore WO 92/11018 PCflU591/09711 i1, W ~~ r~
.. . Fs '.> 2J ~ ~:: :v' belong to Category 4, may be distinguished in another way.
The solvent accessible surface area of each framework amino acid is calculated in two ways: (1) in the intact antibody, and (2) in a hypothetical molecule consisting of the antibody 5 with its CDRs removed. A significant difference between these numbers of about 10 square angstroms or more shows that access of the framework amino acid to solvent is at least partly blocked by the CDRs, and therefore that the amino acid is making contact with the CDRs. Solvent accessible surface area 10 of an amino acid may be calculated based on a 3-dimensional model of an antibody, using algorithms known in the art (e.,~, Connolly, J. Appl. Crvst. 16, 548 (1983) and Lee and Richards, J. Mol. Biol. 55, 379 (1971)). Framework amino acids may also occasionally interact with the CDR's indirectly, by affecting 15 the conformation of another framework amino acid that in turn contacts the CDR's.
The amino acids at several positions in the framework axe known to be capable of interacting with the CDRs in many antibodies (Chothia and Lesk, J. Mol. Biol. 196, 901 20 (1987), Chothia et al., Nature 342, 877 (1989), and Tramontano et al., J. Mol. Biol. 215, 175 (1990)), notably at positions 2, 48, 64 and 71 of the light chain and 26-30, 71 and 94 of the heavy chain (numbering according to Kabat, op. cit.), and therefore these amino acids will generally be in Category 4.
25 Typically, humanized immunaglobulins, of the present invention will include donor amino acids (where different) in category 4 in addition to these. The amino acids at positions 35 in the light chain and 93 and 103 in the heavy chain are also likely to interact with the CDRs. At all these numbered positions, choice of the donor amino acid rather than the acceptor amino acid (when they differ) to be in the humanized immunoglobulin is preferred. On the other hand, certain positions that may be in' Category 4 such as the first 5 amino acids of the light chain may sometimes be chosen from the acceptor immunoglobulin without loss of affinity in the humanized immunoglobulin.
Chothia and Lesk (op. cit,) define the CDRs differently from Kabat et al. (on. cit.). Notably, CDR1 is WO 92/1708 Pf_'1'/U~99109711 ~f ~ !;~ r~ ~ ~ ~t 2 6 defined as including residues 2s-32. Accordingly, Riechmann et al., (o~. cit.) chose these amino acids from the donor immunoglobulins.
Computer programs to create models of proteins such as antibodies are generally available and well known to those skilled in the art (see, Levy et al., Biochemistrv, 28, 7158-7175 (1989); Bruccoleri et al., Nature, 335, 564-56s (l9as);
Chothia e~ al., Science, 233, 755-758 (1986)). These do not form part of the invention. Indeed, because all antibodies have similar structures, the known antibody structures, which are available from the Brookhaven Protein Data Bank, can be used if necessary as rough models of other antibodies.
Commercially available computer programs can be used to display these models on a computer monitor, to calculate the distance between atoms, and to estimate the likelihood of different amino acids interacting (see, Ferrin e~ al., J. R5ol.
Graphics, 6, 13-27 (1988)).
In addition to the above categories, which describe when an amino acid in the humanized immunoglobulin may be taken from the donor, certain amino acids in the humanized immunoglobulin may be taken from neither the donor nor acceptor, if then fall in:
Category 5: If the amino acid at a given position in the donor immunoglobulin is "rare" for human sequences, and the amino acid at that position in the acceptor immunoglobuTin is also "rare" for human sequences, as defined above, then the amino acid at that position in the humanized immunoglobulin may be chosen to be some amino acid "typical" of human sequences. A preferred choice is the amino acid that occurs most often at that position in the known human sequences belonging to the same subgroup as the acceptor sequence.
Humanized antibodies generally have at least three potential advantages over mouse or in some cases chimeric antibodies for use in human therapy:
~N~O 92/11D18 PCT/ZJS91/09711 .,;:,fin a r, ~ .~ t~
1) Because the effector portion is human, it may interact better with the other parts of the human immune system (era., destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC)).
2) The human immune system should not recognize the framework or constant region of the humanized antibody as foreign, and therefore the antibody response against such an injected antibody should be less than against a totally foreign mouse antibody or a partially foreign chimeric antibody.
In one aspect, the present invention is directed to designing humanized immunoglobulins that are produced by expressing recombinant DNA segments encoding the heavy and light chain CDR's from a donor immunoglobulin capable of binding to a desired antigen, such as the human IL-2 receptor, attached to DNA segments encoding acceptor human framework regions. Exemplary DNA sequences designed in accordance with the present invention code for the polypeptide chains comprising heavy and light chain CDR's with substantially human framework regions shown in Figs. 1 through 4. Due to codon degeneracy and non-critical amino acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below. In general, the criteria of the present invention find applicability to designing substantially any humanized immunoglobulin.
The DNA segments will typically further include an expression control DNA sequence operably linked to the humanized immunoglobulin coding sequences, including naturally-associated or heterologous promoter regions.
Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection WO 92/11018 PCTltJ59i/097~1 '~.? l, ~'~ I ~ _.
n ij .._ 2 8 and purification of the humanized light chains, heavy chains, light/heavy chain dimers or intact antibodies, binding fragments or other immunoglobulin forms may follow (see, S.
Beychok, Cells of Immunocrlobulin Synthesis, Academic Press, N.Y., (1979)).
Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably immortalized B-cells (see, Kabat op. cit. and WP87/02671). ~'he CDR's for producing the immunoglobulins of the present invention will be similarly derived from monoclonal antibodies capable of binding to the predetermined antigen, such as the human IL-2 receptor, and produced by well known methods in any convenient mammalian source including, mice, rats, rabbits, or other vertebrates, capable of producing antibodies. Suitable source cells for the constant region and framework DNA sequences, and host cells for immunoglobulin expression and secretion, can be obtained from a number of sources, such as the American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas,"
sixth edition (1988) Rockville, Maryland, U.S.A.).
Tn addition to the humanized immunoglobulins specifically described herein, other "substantially homologous" modified immunoglobulins to the native sequences can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the framework regions can vary specifically from the sequences in Figs. 1 through 4 at the primary structure level by several amino acid substitutions, terminal and intermediate additions and deletions, and the like.
Moreover, a variety of different human framework regions may be used singly or in combination as a basis for the humanized immunoglobulins of the present invention. In general, modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see, Gillman and Smith, Gene, 8, 81-97 (1979) and S. Roberts et al., Nature, 328, 731-734 (1987)).
VV~ 92/1101 :, .; ~ ro :a !j ~ PC:f/1.JS91109711 N,. t; ~ ;: ~: v Substantially homologous immunoglobulin sequences are those which exhibit at least about 85% homology, usually at least about 90~, and preferably at least about 95o homology with a reference immunoglobulin protein.
Alternatively, polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (e. g., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact l0 antibodies by methods well known in the art, or by inserting stop codons at the desired locations using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab')z fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker (see, Huston et al., op. cit., and Bird et al., op.
cit.). Also because like many genes, the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities, the genes may be fused to functional regions from other genes (ea., enzymes, see, commonly assigned U.S.S.N.
132,387, filed Dec. 15, 1987) to produce fusion proteins (e. a., immunotoxins) having novel properties. The nucleic acid sequences of the present invention capable of ultimately expressing the desired humanized antibodies can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e~ct., V, J, D, and C regions), as well as by a variety of different techniques. Joining appropriate synthetic and genomic sequences is presently the most common method of production, but cDNA sequences may also be utilized (see, European Patent Publication No. 0239400 and L. Reichmann et al., Nature, 332, 323-327 (1988)).
As stated previously, the DNA sequences will be expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host organisms either as episomes W() 92/11018 PCT/US91/09711 or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.a., tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences (see, era., U.S.
5 Patent 4,704,362).
F. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention. other microbial hosts suitable for use include bacilli, such as Bacillus subtilus, and other enterobacteriaceae, such as 10 Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e~cr., an origin of replication). In addition, any number of a variety of well-15 known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences 20 and the like, for initiating and completing transcription and translation.
Other microbes, such as yeast, may also be used for expression. SaccharomYaes is a preferred host, with suitable vectors having expression control sequences, such as 25 promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.
In addition to microorganisms, mammalian tissue cell culture may also be used to express and produce the 30 polypeptides of the present invention (see, Winnacker, "From Genes to Clones," VCH Publishers, N.Y., N.Y. (1987)).
Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, preferably myeloma cell lines, etc, and transformed B-cells or hybridomas: Expression vectors for these cells can include wo 92iaa0a8 PCf/1JS91/097a3 r ~1 ':
f Fi 1:; ~:~ y ~. . . i - ~ .~ a t: .._ .. _..
expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al., Immunol.
Rev., 89, 49-68 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, Sv4o, Adenovirus, eytomegalovirus, Bovine Papilloma Virus, and the like.
the vectors containing the DNA segments of interest (e.et., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts. (See, generally, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, (1982) . ) Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the pxesent invention, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982)).
Substantially pure immunoglobulins of at least about 9o to 95%
homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired,. the polypeptides may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent stainings, and the like. (See, generally, ImmunolocLical Methods, Vols. I arid II, Lefkovits and Pernis, eds., Academic Press, New York, N.Y. (1979 and 1981)).
A preferred pharmaceutical composition of the present invention comprises the use of one or more of the subject antibodies in immunotoxins. Immunotoxins are WO 92/17~18 , f ~, ,.., ,; PCT/US91/09711 . ,_ ., a,~~::~~~,.
characterized by two components and are particularly useful for killing selected cells in vitro or in vivo. One component is a cytotoxic agent which is usually fatal to a cell when attached Or absorbed. The second component, known as the "delivery vehicle," provides a means for delivering the toxic agent to a particular cell type, such as cells comprising a carcinoma. The two components are commonly chemically bonded together by any of a variety of well-known chemical procedures. For example, when the cytotoxic agent is a to protein and the second component is an intact immunoglobulin, the linkage may be by way of heterobifunctional cross-linkers, e.cr., SPDP, carbodiimide, glutaraldehyde, or the like.
Production of various immunotoxins is well-known with the art;
and can be found, for example in '°Monoclonal Antibody-Toxin Canjugates: Aimzng the Magic Bullet," Thorpe et al., Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190 (1982). The components may also be linked genetically (see, Chaudhary et al., Nature 339, 394 (1989)).
A variety of cytotoxic agents are suitable for use in immunotoxins. Cytotoxic agents can include radionuclides, such as Iodine-131 or other isotopes of iodine, Yttrium-90, Rhenium-188, and Bismuth-212 or other alpha emittexs; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cisplatinum; and cytotoxic proteins such as 28 ribosomal inhibiting proteins like pokeweed antiviral protein, Pseudomanas exotoxin A, ricin, diphtheria toxin, ricin A
chain, etc., or an agent active at the cell surface, such as the phospholi,pase enzymes (e,~a., phospholipase C). (See, generally, W090/07861, published July 26, 1990; ''Chimeric ~30 Toxins," Olsnes and Phil, Pharmac. Ther., 25, 355-381 (1982);
and "Monoclonal Antibodies for Cancer Detection and Therapy,'°
eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press (1985).) The delivery component of the immunotoxin will 35 include the humanized immunoglobulins of the present invention. Intact immunoglobulins or their binding fragments, such as Fab, are preferably used. Typically, the antibodies W() 92/11018 y r~ ~ ~ ~ ~! ", ;l ~'CfiLJS9l~~9737 ,~ ' ~ ~ ~_= e~ ._ in the immunotoxins will be of the human IgM or IgG isotype, but other mammalian constant regions may be utilized as desired.
The humanized antibodies and pharmaceutical compositions thereof are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or in-travenously. The compositions for parenteral administration will commonly comprise a solution of the immunoglobulin or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e'a., water, buffered water, 0.4% saline, 0.3%' glycine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, human albumin, etc. The concentration of antibody in these formulations can vary widely i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1-l0 mgs of immunoglobulin. A typical composition for intravenous infusion could be made up to contain 25o ml of sterile Ringer's solution, and 150 mg of antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remincyton's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980), which is incorporated herein by reference.
w~ 92/mo~s ~ ; . ,; PC'd'/US91/09711 ~,3 ~~~ ~~ G, lay. ..
The antibodies of this invention can be frozen or lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed.
It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss {era., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be ad-justed to compensate.
The compositions containing the present humanized antibodies or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions are administered to a patient in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per dose, with dosages of from 5 to 25 mg being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life-threatening situations. In such cases, in view of the minimization of extraneous substances and the lower probability of "foreign substance" rejections which are achieved by the present humanized immunoglobulins of this in-vention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these antibodies.
In prophylactic applications, compositions containing the present immunoglobulins or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance. Such an amount is defined to be a "prophylactically effective dose." In this wo gzia~o~s ~orius~~io9~m ie C) j1 ~ ~i l? ~
3 5 C. a :.i ;~ ~-~ _ .~
use, the precise amounts again depend upon the patient°s state of health and general level of immunity, but generally range from 0.1 to 25 mg per dose.
Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat the patient.
For diagnostic purposes, the antibodies may either be labeled or unlabeled. Unlabeled antibodies can be.used in combination with other labeled antibodies (second antibodies) that are reactive with the humanized antibody, such as anti-bodies-specific for human immunoglobulin constant regions.
Alternatively, the antibodies can be directly labeled. A wide variety of labels may be employed, such as radionuclides, floors, enzymes, enzyme substrates, enzyme co- factors, enzyme inhibitors, ligands (particularly haptens), etc. Numerous types of immunoassays are available and are well known to those skilled in the art.
The following examples are offered by way of illustration, not by limitation.
The production of five specific humanized antibodies are described below. The antibodies are: Fd79 and Fd138-80 which respectively bind to the gB and gD glycoproteins of herpes simplex virus (Metcalf et al., Interviroloav 29, 39 (1988)), M195 (Tanimoto et al., Leukemia 3, 339 (1989)) which binds to the CD33 antigen, mik-,B1 (Tusdo et al., Proc. Natl.
Acad. Sci. USA 86, 1982 (1989)) which binds to the p75 chain of the TL-2 receptor, and CMVS which binds to the gH
glycoprotein of cytomegalovirus.
Basically, cDNAs for the heavy chain and light chain variable domain genes of each antibody were cloned using anchored polymerase chain reactions (Loh et al., Science 243, 219 (1989)), using 3' primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (Scheme W~0 92/11018 P~'/US91/09711 .: J-: ,a ~,~~~~~f-'~ ~ _ shown in Fig. 6). The PCR amplified fragments were digested with EcoRI and HindIII and cloned into the pUCl8 vector for sequencing. For each antibody, at least two heavy chain and two kappa clones were sequenced and found to have the same sequence. The deduced amino acid sequences of the mature light and heavy chain variable regions are shown in Figs. 1-5, upper lines.
In order to retain high binding affinity of the humanized antibodies, the principles and categories described above were utilized when designing the antibodies. Based on high sequence homology, human antibodies were selected to provide both the acceptor light and heavy chain human frameworks for the mouse antibodies, as follows: human Pom for Fd79, human Eu for Fd138-80, human Eu for M195, human Lay for mik-al, and human.Wol far CMVS.
The computer programs ABMOD and ENCAD (Levitt, J.
Mol~Biol., 168, 595 (1983) and Zilber et al., Biochemistry 29, 10032 (1990)) was used to construct a model of the variable region of each mouse antibody. The model was used to determine the amino acids in each framework that were close enough to the CDR's to potentially interact with them (category 4 above). For each antibody, the positions found to fall in the categories (1) - (5) defined above are given in Table 1, numbered as in Figs. 1-5.
W(3 92/11018 PCI'/U~91/09711 3 7 r'~ ~ .' t.:~ ~', ~~ r ~ ;~
v ~
Fd79 Antibody Category Lia ht Chain Heayy Chain 1 24-38, 54-50, 93-100 31-35, 50-66, 99-111 2 9, 45, 46, 83 82, 112 Fd138-80 Antibody Cate o~rv_ Lig ht Chain Heavy Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99-110 2 48, 63 93, 98, 111, 112, 2 0 113 , 115 3 __ 30, 67, 98, 111 4 36,.48, 27, 30, 37, 48, 67, s8, 98 M195~ Antibod y Cateaory Lic ,~ht Chain Heavy Chain 1 24-38, 54-60, 93-101 31-35, 50-66, 95-105 2 10, 52 , 67, 110 93, 95, 98, 106, 108, 110 3 ' -- 30, 67, 98, 106 4 40, 52 , 74 27, 30, 48, 68, 98 mik-Q1 Antibo dy Cateaorv Li ght Chain Heavy Chain 1 24-33, 49-55, 88-96 31-35, 50-65, 98-108 2 13 84, 89, 90 3 -- 30, 49 4 70 29, 30, 72, 73 CMV5 Antibody Cateaory Li aht Chain Heav Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99108 2 _- 69, 80 4 49 24, 27, 28, 30, 97 ~fO 92/11018 PCf/~7591/097tt 4" U ,w,, ..~ '~:
In designing each humanized antibody, at each position the amino acid was selected to be the same as in the human acceptor sequence, unless the position fell in categories (1) - (4), in which case the amino acid from the mouse donor sequence was used, or in category (5), in which , case an amino acid typical for human sequences at that position was used.
For the construction of genes for the humanized 10~ antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including signal peptides typically from the mouse antibody chains, generally utilizing colons found in the mouse sequence. Several degenerate colons were changed to create restriction sites or to remove undesirable ones. The nucleotide sequences also included splice donor signals typical for immunoglobulin genes and an XbaI site at each end.
Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides an alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal. The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was about 110-140 base long with a 15-20 base overlap. Double stranded DNA fragments were synthesized with Klenow or Taq polymerase or sequenase from each pair of oligonucleotides, digested with restriction enzymes, ligated to pUCl8 vector and sequenced. Two fragments with the respectively correct half-sequences were then ligated into the Xbal sites of pVgl (heavy chains of Fd79 and Fd138-80) or pVg1-dhfr (heavy chains of M195; mik-,01, CMVS) or pVk (all light chains) expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions were carried out under conditions well-known in the art (Maniatis et al., off. cit.).
The heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by ELISA, and antibody was purified from the best-producing clones. Antibody was purified by passing tissue culture supernatant over a column of staphylococcal protein A-SepharoseT"" CL-4B (Pharmacia). The bound antibodies were eluted with 0.2 M Glycine-HC1, pH 3.0 and neutralized with 1 M Tris pH 8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
The binding of the humanized antibodies to cell types expressing the corresponding antigens was tested:
HSV-infected cells for Fd79 and Fd138-80, U937 cells for M195, YTJB cells for mik-pl and CMV-infected cells for CMVS. By fluorocytometry, the humanized antibodies bind approximately as well as the original mouse antibodies and the corresponding chimeric antibodies. Moreover, the humanized antibodies compete approximately as well as the corresponding mouse antibodies against the radiolabeled mouse antibodies for binding to the cells, so the humanized antibodies have approximately the same binding affinity as the mouse antibodies, typically within about 2-fold or better, see, e.g., Table 2.
Binding affinities of murine and humanized antibodies.
Mouse Humanized Ka (M-1) Ka (M 1) Fd79 (anti-gB) 1.1 x 108 5.3 x 10' Fd138-80 (anti-gD) 5.2 x 10' 4.8 x 10 From the foregoing, it will be appreciated that the humanized immunoglobulins of the present invention offer numerous advantages over other antibodies. In comparison to other monoclonal antibodies, the present humanized immunoglobulin can be more economically produced and contain W~ 92/11018 PCT/US91/09771 ~~' " '' ~j 4 0 .1y,%..:
r.! L~ V .~
substantially less foreign amino acid sequences. This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.
A detailed description of each humanized immunoglobulin follows.
Example I
Humanized Immunoalobulins to n75 In mammals, the immune response is mediated by two types of cells that interact specifically with foreign material, i.e., antigens. One of these cell types, B-cells, are responsible for the production of antibodies. The second cell class, T-cells, include a wide variety of cellular subsets controlling the in vivo function of both B-cells and a wide variety of other hematopoietic cells, including T-cells.
(See, generally, Paul, W.E., ed., Fundamental Immunoloav, 2nd ed., Raven Press, New York (1989).) One way in which T-cells exert this control is through the production of a lymphokine known as interleukin-2 (IL-2), originally named T-cell growth factor. IL-2's prime function appears to be the stimulation and maintenance of T-cells. Indeed, some immunologists believe that IL-2 may be at the center of the entire immune response (see, Farrar, J., et al., Immunol. Rev. 63, 129-166 (1982)).
To exert its biological effects, IL-2 interacts with a specific high-affinity membrane receptor (Greene, W., et al., Proaress in Hematoloay XIV, E. Brown, Ed., Grune and Station, New York (1986), at pgs. 283 ff and Waldmann, Ann.
Rev. Biochem. 58, 875 (1989)). The human IL-2 receptor is a complex multichain glycoprotein, with one chain, known as the Tac peptide or alpha chain, being about 55kD in size (see, , Leonard, W., et al., J. Biol. Chem. 260, 1872 (1985)). The second chain is known as the p75 or beta chain (Tsudo et al., Proc. Nat. Acad. Sci. USA, 83, 9694 (1986) and Sharon et al., Science 234,.859 (1986)). The p55 or Tac chain and the p75 chain each independently bind IL-2 with low or intermediate affinity, while the IL-2 receptor complex of bath chains binds w~ 9zimo7~ PCT/US91/U9711 '.~,,; ~c, r_ . i 41 ~'~ v ;.~ y :~ v:
TL-2 with high affinity. The p75 chain of the human IL-2 receptor will often be called herein simply the p75 protein.
Much of the elucidation of the human IL-2 receptor°s structure and function is due to the development of specifically reactive monoclonal antibodies. In particular, one mouse monoclonal antibody, known as anti-Tac (uchiyama, et al., J. Immunol. 126, 1393 (1981)) has been used to show that IL-2 receptors can be detected on T-cells, but also on cells of the monocyte-macrophage family, Kupffer cells of the liver, Langerhans' cells of the skin and, of course, activated T-cells. Importantly, resting T-cells, B-cells or circulating macrophages typically do not display the IL-2 receptor (Herrmann, et al., J. Exo. Med. 162, 1111 (1985)). Another antibody, mik-Q1, binds to the p75 chain (Tsudo et al., Proc.
Nat. Acad. Sci. USA 86, 1982 (1989)).
The anti-Tac monoclonal antibody has also been used to define lymphocyte functions that require IL-2 interaction, and has been shown to inhibit various T-cell functions, including the generation of cytotoxic and suppressor T
lymphocytes in cell culture. Also, based on studies with anti-Tac and other antibodies, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell leukemia.
More recently, the IL-2 receptor has been shown to be an ideal target for novel therapeutic approaches to T-cell mediated diseases. It has been proposed that IL-2 receptor specific antibodies, such as the anti-Tac monoclonal antibody or mik-Q1, can be used either alone or as an immunoconjugate (e. a., with Ricin A, isotopes and the like) to effectively remove cells bearing the IL-2 receptor. These agents can, for example, theoretically eliminate IL-2 receptor-expressing leukemic cells, certain B-cells, or activated T-cells involved in a disease state, yet allow the retention of mature normal T-cells and their precursors to ensure the.capability of mounting a normal T-cell immune response as needed. In general, most other T-cell specific agents can destroy essentially all peripheral T-cells, which limits the,agents' '4v0 92/11018 PCf/US91/09711 ~ "~ (1 ~' ~ . w'. 4 2 A
~. f1 ~ ~~ .;: v aL
therapeutic efficacy. Overall, the use of appropriate monoclonal antibodies specific for the IL-2 receptor may have therapeutic utility in autoimmune diseases, organ transplantation and any unwanted response by activated T-cells. Tndeed, clinical trials have been initiated using, era., anti-Tac antibodies (Kirkman at al., Transplant. Proc. , 21, 1766 (1989) and Waldmann et al., Blood 72, 1805 (1988)).
Unfortunately, the use of anti-Tac, mik-,B1 and other non-human monoclonal antibodies have certain drawbacks, l0 particularly in repeated therapeutic regimens as explained below. Mouse monoclonal antibodies, for example, generally do not fix human complement well, and lack other important immunoglobulin functional characteristics when used in humans.
Perhaps more importantly, anti-Tac, mik-R1 and other non-human monoclonal antibodies contain substantial stretches of amino acid sequences that will be immunogenic when injected into a human patient.
In accordance with the present invention, human-like immunoglobulins specifically reactive with the p75 chain of the human IL-2 receptor are provided. These immunoglobulins, which have binding affinities of at least 10' to 108 M~1, and preferably 109 M 1 to 101° M 1 or stronger, are capable of, era. , blocking the binding of IL-2 to human IL-2 receptors. The human-like immunoglobulins will have a human-like framework and can have complementarity determining regions (CDR's) from an immunoglobulin, typically a mouse immunoglobulin, specificallx reactive with an epitope on p75 protein. The immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of T-cell mediated disorders in human patients by a variety of techniques. , In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope on the human IL-2 receptor, such as the mik-pl monoclonal antibody. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate PC3'/U~91/09711 W~ 92/11018 ~~~ ~ iW J
human-like framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the mik-al heavy and light chain CDRs, are included in Fig. 7.
Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed above.
The antibodies will typically find use individually in treating a T-cell mediated disease state. Generally, where the cell linked to a disease has been identified as IL-2 receptor bearing, then the human-like antibodies capable of blocking the binding of IL-2 to the human IL-2 receptor are suitable (see, U.S.S.N. 085,707, entitled "Treating Human Malignancies and Disorders.") For example, typical disease states suitable far treatment include graft-versus-host disease arid transplant rejection in patients undergoing an organ transplant, such as heart, lungs, kidneys, liver, etc.
Other diseases include autoimmune diseases, such as Type T
diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis.
The human-like antibodies of the present invention may also be used in combination with other antibodies, particularly human monoclonal antibodies reactive with other . markers on cells responsible for the disease. 'For example, suitable T-cell markers can include those grouped into the so-called "Clusters of Differentiation," as named by the First International Leukocyte Differentiation Workshop, Leukocyte .' T~17",plns, Bernard, et al., Eds., Springer-Verlag, N.Y. (1984).
A preferred use is the simultaneous treatment of a patient with a human-like antibody binding to p55 and a human-like antibody binding to p75 of the IL-2 receptor, i.e., humanized anti-Tac plus humanized mik-Q1. ' Human-like antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for T-cell typing, for isolating specific IL-2 receptor bearing cells or fragments.of the receptor, for vaccine preparation, or the like.
WO 92/1i0i8 P~ T/LJ59a/097aa ~~~(~~~ ~,1 _ ' J %
EXPERIMENTAL
Cloning of heavy chain and light chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain reactions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers , that hybridized to the constant regions and contained HindIII
sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoRI and HindIII and cloned into the pUCl9 vector for sequencing. For mik-/31, two gamma-2a specific and two kappa specific clones were sequenced. The two gamma-2a clones and two kappa clones are respectively identical in sequence. The cDNA variable domain sequences and the deduced amino acid sequences are shown in' Fig. 7.
Construction and expression of chimeric antibody.
Two plasmid vectors were prepared for construction and expression of the chimeric antibody genes. The plasmid pVgl-dhfr (Fig. 8A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C,~1 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen et al., Proc. Natl. Aced. Sci. USA 80, 2495 (1983)) for selection. The plasmid pVk (Fig. 8B) is similar to pVgl-dhfr but contains the human genomic Cx segment and the gpt gene. Derivatives of the mik-Q1 heavy and light, chain variable regions were prepared from the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting at the ATG codons and contained XbaI sites; the 3' primers hybridized to the last 15 nucleotides.of the 3 regions .
and contained splice donor signals and XbaI sites (see, C.
Queen et al., Proc. Natl. Aced. Sci. USA 86, 10029 (1989)).
The modified V regions were cloned into the XbaI sites of the respective plasmid vectors between the CMV promoter and the partial introns of the constant regions.
For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones secreting a maximal amount of complete 5 antibody were detected by ELISA. Purified chimeric mik-pl antibody was shown to bind to YTJB cells, which express the p75 antigen, by flow cytometry (Fig. 9).
Computer modeling of humanized antibodies.
10 In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (C. Queen et al., Proc. Natl. Acad Sci USA 86, 10029 (1989)). The more homologous a human antibody is to the original murine antibody, the less likely will combining the 15 murine CDRs with the human framework be to introduce distortions into the CDRs that could reduce affinity.
Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework seqeunces, so as to reduce the possibility of incompatibility in the assembling 20 of the two chains. Based on sequence database (performed with the MicrorGenieTM Sequence Analysis Software (Beckman)), the antibody Lay was chosen to provide the framework sequences for humanization of mik-pl.
The computer program ENCAD (M. Levitt, J. Mol. Biol.
25 168, 595 (1983)) was used to construct a model of the mik-pl variable region. The model was used to determine the amino acids in the mik-pl framework that were close enough to the CDRs to potentially interact with them (category 4 below). To design the humanized light and heavy chain mik-pl variable 30 regions, at each position the amino acid was chosen to be the same as in the Lay antibody, unless that position fell in one or more of five categories:
(1) The position fell within a CDR, (2) The Lay amino acid was unusual for human 35 antibodies at that position, whereas the mik-pl amino acid was typical for human antibodies at that position.
W~ 92/11018 PCf/US91/09791 y~ ~ ~~ J ~,~~1 ~'J, 3~ 4 6 to Zy e1 (3) The position was immediately adjacent to a CDR, (4) The model described above suggested that the amino acid may be physically close to the antigen binding region (CDRs).
For pcsitions in these categories, the amino acid from the (mouse) mik-/3l antibody was used. In addition, a position was in the fifth category if (5) The Lay amino acid was highly unusual for human antibodies at that position, and the mik-Q1 amino acid was different but also unusual.
Then an amino acid typical for human antibodies at that position may be used.
The amino acids in each category are shown in Table 3. Some amino acids may be in more than one category.
The final sequences of the humanized mik-,Q1 light and heavy chain variable domains are shown in Fig. l0, compared with the Lay sequences.
Category Light Chain Heavy Chain 1 24-33, 49-55, 88-96 31-35, 50-65, 98-108 2 13 84, 89, 90 3 30, 49 4 70 29, 30, 72, 73 For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the same signal peptides as in the mouse mik-R1 chains (Fig. 7), generally utilizing codons found in the mouse sequence. Several degenerate codons were changed to create w restriction sites or to remove undesirable ones. The nucleotide sequences also included the same splice donor signals used in the chimeric genes and an XbaI site at each end. Each gene.was constructed from four overlapping synthetic aligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides on alternating WO 92/11018 pCT/US91/0971t t~i t strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal (Fig. 11). The oligonucleotides were synthesized on an Applied Biosystems 3808 DNA synthesizer. Each oligo was about 110-140 base long with about a 20 base overlap. Double stranded DNA fragments were synthesized with sequenase from each pair of oligonucleotides, digested with restriction enzymes, ligated to pBluescriptII KS (+) (Stratagene) vector and sequenced. Two fragments.with the respectively correct half-sequences were then ligated into the Xbal sites of the pVgl-dhfr or pVk expression vectors. In vitro mutagenesis was used to change an Ala amino acid originally encoded by oligonucleotide wps54 to the Glu (E) at position 1 of the humanized heavy chain (Fig. 10B) by changing the nucleotides CT to AG. Reactions were carried out under conditions well-known in the art (Maniatis et al., op. cit.) The heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by E1TSA, and antibody was purified from the best-producing clones. Antibody was purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody was eluted with 0.2 M Glycine-HCl, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized mik-(31 antibody was characterized in comparison to the murine and chimeric antibodies. The humanized antibody bound to YTJB cells, which express p75 chain at a high level, in a fluorocytometric analysis in a manner similar to the chimeric antibody (Fig. 9), showing that it recognizes the same p75 protein.
The affinity of the humanized antibody was determined by competition with the radio-iodinated mouse w(~ 9zimoag ~crius9mo97m ,.
a. r,, t, 4 8 t~,s~i,,ty.,~x ~, ,~.
mik-;01 antibody (Fig. 12). The binding affinities were calculated according to the methods of Berzofsky (J. A.
Berzofsky and I.J. Berkower, in Fundamental Immunolocry (ed.
W.E. Paul), Raven Press (New York), 595 (1984)). The binding affinity of the humanized mik-Q1 antibody was within about 2-fold of the affinity of the mouse mik-al antibody.
The ability of humanized mik-~i1 plus humanized anti-Tac antibody (see, W090/07861 published July 26, 1990) to inhibit IL-2 stimulated proliferation of human lymphocytes was determined. Human mononuclear cells, collected from human blood by centrifugation on Ficoll-Paque (Pharmacia), were diluted to 2 x 105 cells/ml in RPMI medium + 10% fetal calf serum (FCS). A 1/200 volume of phytohemagglutinin P (Difco) was added and the cells were incubated for 4 days. The cells were incubated an additional 4 days in RPMI + 10% FCS + 10 u/ml IL-2. 10~ of these PHA activated blasts were then incubated with or without 2 ~,g.each of humanized mik-pl and humanized anti-Tac in 150 ~1 of RPMI + 10% FCS in wells of.a 96-well plate for 1 hr, to which various dilutions of IL-2 (Amgen) were then added in 50 ~cl medium. The cells were incubated 48 hr, 0.5 ~cCi methyl-3H-thymidine (Amersham, 82 Ci/
mmol) was added, and the cells were incubated 24 hr. Cells were harvested with a cell harvester and radioactivity determined. The combination of the antibodies greatly inhibited proliferation of the cells in response to IL-2 (Fig.
13), suggesting a combination of the antibodies will have strong immunosuppressive properties. Humanized mik-pl plus humanized anti-Tac inhibited proliferation much more strongly than did either antibody alone.
Example II
Humanized Immunoglobulins to HSV Antigens Herpes Simplex Virus types I and II (HSV-1 and HSV-2), are now estimated to be the second most frequent cause of a sexually transmitted diseases in the world. Although completely accurate data are not available, infection estimates range from about 20 to 40% of the U.S. population.
W(J 92/1101 PCflUS91/09711 .a. :~ di ,j i:.iJ w A large number of diseases, from asymptomatic to life-threatening, are associated with HSV infection. Of particular clinical interest, encephalitis from HSV-1 infection and transmission of HSV-2 from a pregnant mother to her fetus are often fatal. Immunosuppressed patients are also subject to severe complications when infected with the virus.
More than 50 HSV polypeptides have been identified in RSV-infected cells, including at least seven major cell surface glycoproteins (see, Whitley, R., Chapt. 66, and Roizman and Sears, Chapt. 65, Viroloay, Eds. Fields et al., 2nd ed., Raven Press, N.Y., N.Y. (1990)). The specific biologic functions of these glycoproteins are not well defined, although gB and gD have been shown to be associated with cell fusion activity (W. Car et al., J. Virol. 62, 2596 (1988) and Fuller and Spear, Proc. Natl. Acad. Sci. USA 84, 5454 (1987)). gB and gD express both type-specific and type-common antigenic determinants. Oakes and Lausch demonstrated that monoclonal antibodies against gB and gE suppress replication of HSV-1 in trigeminal ganglia (Oakes and Lausch, J. Virol. 51, 656 (1984)). Dix et al. showed that anti-gC and gD antibodies protect mice against acute virus-induced neurological disease (Dix at al., Infect. Immure. 3~, 192 (1981)). Whitley and colleagues produced a panel of marine monoclonal antibodies against HSV-1 and showed that several of the antibodies protected mice against encephalitis and death following ocular inoculation with the virus (see, Koga et al., Virology 151, 385 (1986): Metcalf et al., Cur. Eye Res. 6, 173 (1987) and Metcalf et al., Intervirology 29, 39 1988)). Clone Fd79 (anti-gB) prevented encephalitis even when immunization was delayed until 48 hours post-infection. Fd79 and Fd138-80 (anti-gD) significantly. reduced the severity of epithelial keratrtis and lowered the frequency of persistent viral infection in an outbred mouse model.
In accordance with the present invention, humanized immunoglobulins specifically reactive with HSV related epitopes either directly on the virus or on infected cells are provided. These immunoglobulins, which have binding VVO 92/ 11 d1 1 ~ P~CT/US91 /~9711 'f ~ i ~~ "j ~;'_ ~;~ '.i 5 0 t .
affinities to HSV specific antigens of at least about 10' M 1, and preferably 10a M-1 to 101° M-1 or stronger, are capable of, e.a., protecting cells from HSV transmission. The humanized immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDR'S) from an immunoglobulin, typically a mouse immunoglobulin, specifically , reactive with an HSV protein, such as gB and gD proteins. The immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of HSV mediated disorders in human patients by a variety of techniques.
The HSVs are among the most intensively investigated of all viruses, and the HSV virion structure has been shown to contain about 33 proteins. Humanized immunoglobulins utilizing CDR°s from monoclonal antibodies reactive with these proteins, particularly the eight surface glycoproteins (e. g., gB, gC, gD, gE, gG, gH and gI), represent preferred embodiments of the present invention (see, Spear, P.G., The Herpesviruses, vol. 3, pp. 315-356 (1984) (Roizman, B., ed), Plenum Press, N.Y., N.Y. and Spear, P.G., Immunochemistry of Viruses. The Basis for Serodiaqnosis and Vaccines, pp. 425-446 (1985) (Neurath, A.R., eds.), Amsterdam: Elsevier).
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope of an HSV protein, such as monoclonal antibodies reactive with HSV gB and gD glycoproteins. The DNA segments encoding these regions will typically be joined to DNA
segments encoding appropriate humanized framework regions.
, Exemplary DNA sequences code for the polypeptide chains comprising the heavy and light chain hypervariable regions (with human framework regions) from monoclonal antibodies Fd79 I
and Fd138-80, shown in Fig. 14. Due to codon degeneracy and _ non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
Any humanized immunoglobulins of the present invention may also be used in combination with other i~VO 92/11018 ' P~Cf/tJS91/09711 6~ ti c! U '.~ J ':
antibodies, particularly humanized antibodies reactive with different HSV antigens. for example, suitable HSV antigens to which a cocktail of humanized immunoglobulins may react include gC, gE, gF, gG and gH (see, Rector, J. et al., Infect.
Immun: 38, 168 (1982) and Fuller, A. et al., J. Virol. 63, 3435 (1989)), i The antibodies can also be used as separately administered compositions given in conjunction with acyclovir or other antiviral agents. Typically, the agents may include idoxuridine or trifluorothymidine, but numerous additional agents (era., vidarabine) well-known to those skilled in the art for HSV treatment may also be utilized (see, Corey, L., pp. cit.). A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins .in immunotoxins to kill cells infected by HSV.
These humanized antibodies can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for detection of HSV antigens, for isolating specific HSV infected cells or fragments of the virus, for vaccine preparation, or the like.
EXPERIMENTAL
Cloning of heavy chain and lictht chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain regions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (scheme shown in Fig. 6). This method yields clones with authentic variable domain sequences, in contrast to other methods using mixed primers designed to anneal to the variable domain sequence (J. W. Larrick et al., Bio/Technology 7, 934 (1989) and Y.L. Chiang et al., BioTech.
HuVHCAMP may have caused it to lose all ability to mediate complement lysis (see, Riechmann et al., Nature, 332, 323-327 (1988); Table 1).
Thus, there is a need for humanized antibodies specifically reactive with strong affinity to predetermined antigens. These humanized immunoglobulins should remain substantially non-immunogenic in humans, yet be easily and economically produced in a manner suitable for therapeutic formulation and other uses. The present invention fulfills these and other needs.
Summary of the Invention The present invention provides novel compositions useful, for example, in the treatment of T-cell mediated human disorders, the compositions containing human-like immunoglobulins specifically capable of inhibiting the binding of human IL-2 to its receptor and/or capable of binding to the p75 protein of human TL-2 receptors. The immunoglobulins can have two pairs of light chain/heavy chain complexes, typically at least one chain comprising mouse complementarity determining regions functionally joined to human framework region segments. For example, mouse complementarity determining regions, with or without additional naturally--associated~mouse amino acid residues, can be used to produce human-like antibodies capable of binding to the p75 protein at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to p75.
The present invention also-provides novel compositions useful, for example, in the treatment of HSV
mediated human disorders, the compositions containing humanized immunoglobulins specifically capable of blocking the binding of HSV to its receptors and/or capable of binding to the HSV specific proteins. The immunoglobulins can have two pairs of light chain/heavy chain complexes, at least one chain comprising one or more mouse complementarity determining regions functionally joined to human framework region WO 92/1101 ~ P~i-/US9t /o~~~ 1 4.
segments. For example, mouse complementarity determining regions, with or without additional naturally-assbciated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to the HSV surface proteins at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR
donating mouse monoclonal antibody to HSV. These humanized immunoglobulins may be utilized alone in substantially pure form, or together with an antiviral agent, such as acyclovir or a cytotoxic agent active at viral surfaces. All of these compounds will be particularly useful in treating HsV mediated disorders.
The present invention further provides novel compositions useful, for example, in the treatment of myeloid leukemia-related human disorders, the compositions containing humanized immunoglobulins specifically capable of binding to CD33 antigen. The immunoglobulins can have two pairs of light chain/heavy chain complexes, at least one chain comprising one or more mouse complementarity determining regions functionally joined to human framework region segments. For example, mouse complementarity determining regions, with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to the CD33 antigen at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to CD33.
These humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such as cytosine arabinoside or daunorubicin active against leukemia cells, or complexed with a radionuclide such as iodine-131. All of these compounds will be particularly r useful in treating leukemia and myeloid cell-mediated disorders.
The present invention also provides novel compositions useful, for example, in the treatment of CMV-mediated human disorders, the compositions containing humanized immunoglobulins specifically capable of blocking the binding of CMV to its receptors and/or capable of binding to CMV antigens. For example, mouse complementarity determining 5 regions, with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to CMV at affinity levels stronger than about 10' M-1.
These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to CMV. These humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such a acyclovir or ganciclovir active against CMV-infected cells, or complexed with a cytotoxic agent. All of these compounds will be particularly useful in treating CMV-mediated disorders.
The present invention further provides novel compositions useful, for example, in the treatment of human autoimmune disorders, the compositions containing humanized immunoglobulins specifically capable of binding to 7-IFN. For example, mouse complementarity determining regions, with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to 7-IFN
at affinity levels stronger than about 10' M-1. These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to ~-IFN. The humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such as a non-steroidal anti-inflammatory drug, a corticosteroid, or an immunosuppressant. All of these compounds will be particularly useful in treating autoimmune disorders.
5a This invention provides a humanized immunoglobulin derived from the mouse M195 antibody whose light and heavy chain variable regions are shown herein, which humanized antibody has a binding affinity of at least 107 M-1 and competes with the mouse antibody for binding to human CD33 antigen.
This invention also provides the aforementioned humanized immunoglobulin comprising a humanized heavy chain variable region comprising three complementarity determining regions from the heavy chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin heavy chain, and a humanized light chain variable region comprising three complementarity determining regions from the light chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin light chain.
This invention also provides the aforementioned humanized immunoglobulins in substantially pure form and/or wherein the humanized immunoglobulin comprises a human framework substantially homologous to EU immunoglobulin framework.
The humanized immunoglobulins of this invention may be capable of mediating antibody-dependent cellular cytotoxicity in the presence of human target and effector cells.
This invention also provides the aforementioned humanized immunoglobulins conjugated to a cytotoxic agent for use as a pharmaceutical.
This invention also provides the use of the aforementioned humanized immunoglobulins for treating a myeloid cell-mediated disorder in a human patient.
This invention also provides the use of the aforementioned humanized immunoglobulins for preparation of medicaments for treating myeloid cell-mediated disorders.
This invention also provides the aforementioned uses of humanized immunoglobulins, wherein the immunoglobulin is conjugated to a cytotoxic agent.
5b BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of ____.____._.__r___.__ W~ 92/1101 PCT/LIS9i/09711 a ~'S .
the mouse Fd79 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 2. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse Fd138-80 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 3. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse M195 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences.. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 4. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse mik-(31 antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences., The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
~'O 92/1101 ~ PCIf'/US9t /0971 t ~: ,,.;~ :,., a.- .:,: ;
,.: ~. .~I'~..J~::.
Figure 5. Amino acid sequences (1-letter code) of the light chain (A) and heavy chain (B) variable regions of the mouse CMVS antibody (upper lines), compared with the humanized antibody (lower lines), not including signal sequences. The three CDR's in each chain are underlined.
Residues in the humanized antibody framework replaced with mouse amino acids or typical human amino acids are double underlined. The number of the first position on each line is given on the left.
Figure 6. Scheme for anchored polymerase chain reaction (PCR) cloning of the heavy and light chain variable domain cDNAs. RNA was prepared from about 10' hybridoma cells using the hot phenol extraction method. Briefly, cells were resuspended and vortexed in 1 ml of RNA extraction buffer (50 mM sodium acetate pH 5.2/1% SDS), extracted with 0.5 ml of phenol pH 5.2 at 65°C far 15 min, followed by another 15 min on ice. The aqueous phase was recovered and precipitated twice with ethanol. cDNA was synthesized from 10 ug of total RNA using reverse transcriptase (BRL, Betheseda, MD) and oligo-dTlz-is (Pharmacia, Piscatway, New Jersey) as primers. A
poly(dG) tail was attached to the 3' end of the cDNA using terminal deoxynucleotide transferase (BRL) (E. Y. Loh et al., Science 243, 217 (1989)), the variable domain genes (V) were amplified using AmpliTaq (Perkin Elmer-Cetus) with the primer mc045 (TAATCTAGAATTCCCCCCCCCCCCCCCCC) that hybridized to the poly(dG) tails and primers that hybridized to the constant region genes (C). For the light chain, the primer used was mc045 (TATAGAGCTCAAGCTTGGATGGTGGGAAGATGGATACAGTTGGTGC). For the heavy chain, the primer used was mc047 (TATAGAGCTCAAGCTTCCAGTGGATAGAC(CATjGATGGGG(GC)TGT(TC)GTTTTGGC) The sequence in parenthesis indicates a base degeneracy. The degeneracy was introduced so that the primer would be able to hybridize to most gamma chains. The amplified fragments were w0 92/11018 PCT/US91/U9711 s then digested with EcoRI and HindIII and cloned into pUCl8 vector for sequencing.
Figure 7. Sequences of the cDNA and translated amino acid sequences of the Light chain (A} and heavy chain (B) variable regions of the antibody mik-X31. The CDR
sequences are underlined. The mature light chain protein begins with amino acid 23 Q and the mature heavy chain protein with amino acid 20 Q, preceded by the respective signal sequences.
Figure 8. Schematic diagram of the plasmids pVgl-dhfr (A) and pVk (B). The plasmid pVgl-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell ~1, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by XbaI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant xegion gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., Mo,~ecular Cloning: A Laboratory Manual, 2nd ed,, Cold Spring Harbor Laboratory, Gold Spring Harbor, N.Y, (1989). For example, pVg1-dhfr was constructed from the plasmid pVgl (commonly assigned U.S. patent application serial No.
07/590,274 filed September 28, 1990) by replacing the Hind III-Bgl II fragment containing the hyg gene with a 660 by fragment containing the dhfr gene and extending to a Bgl II
site (Simonsen et al., Proc. Natl. Acad. Sci. USA 80, 2495 , (1983)).
Figure 9. Fluorocytometry of YTJB cells stained with ( ) Isotype matched control antibody, (---) humanized mik-~1 antibody, (...) chimeric mik-~1 antibody. Cells were suspended in FACSTM buffer (PBS + 2% BSA + 0.1% azide) at approximately 5x106/ml. 100 u1 of cell suspension was transferred to a polystyrene tube and incubated with 100 ng of purified antibody on ice for 30 min. The cells were washed with FAGS buffer and incubated with goat anti-human Ig antibody on ice for another 30 min. Then the cells were washed and incubated with FITC labeled rabbit anti-goat Ig antibody for 30 min. The cells were washed again and finally resuspended in PBS + 1% paraformaldehyde. Cells were analyzed on a FACSmate (Becton Dickinson).
Figure 10. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized mik-~1 antibody, (lower lines) and human Lay antibody (upper lines), not including signal sequences. The three CDRs in each chain are underlined. Amino acids in the framework that have been replaced with mouse amino acids or consensus human amino acids in the humanized antibody are double underlined.
Figure 11. Oligonucleotides used in the construction of the humanized mik-~1 heavy chain (B) and light chain (A). The following pairs of oligonucleotides were mixed, extended with sequenase and cut with the indicated enzymes before ligation into the pBluescriptII ks (+) vector:
wps54 and vcll with Xba I and Sal I, vcl2 and wps57 with Xba I
and Sal I, vcl6 and vcl3 with Xba I and Kpn I, vcl4 and vcl5 with Xba I and Kpn I. Then the wps54-vcll and vcl2-wps57 fragments were excised with Xba I and Sal I ligated together into the Xba I site of pVgl-dhfr: and the vcl6-vcl3 fragments and vcl4-vcl5 fragments were excised with Xba I and Kpn I and ligated together into the Xba I site of pVk.
Figure 12. Competitive binding of labeled mik-~1 tracer to YTJB cells. About 106 YTJB cells were incubated with W~ 92/11018 Pc~'/uS9a/09775 __ 3.0 ng of radio-iodinated mouse mik-,Q1 antibody (6 ~.Ci/~tg) and oaring amounts of either unlabeled mouse mik-Q1 antibody or humanized mik-Q1 antibody (o) in 200 u1 of binding buffer (PBS + 10% fetal calf serum + 0.1% NaN3 + 10 ~g/ml mouse 5 monoclonal Ig). After incubation for 2 hr at 0°C the cells.
were washed twice with binding buffer without mouse Ig and collected by centrifugation. The radioactivity bound to cells was measured and expressed as the ratio of bound/free cpm.
10 Figure 13. Inhibition of IL-2 stimulated proliferation of human PHA blasts by humanized mik-,O1 +
humanized anti-Tac antibodies. No antibody added (n), 2 ug each of humanized mik-~i1 and humanized anti-Tac added Figure 14. . Amino acid sequences of the heavy chain (A) and the light chain (B) of the murine and humanized Fd79 antibodies, and the heavy chain (C) and the light chain (D) of the murine and humanized Fd138-80 antibodies. The sequences of the murine antibody as deduced from the cDNA (upper lines) are shown aligned with the humanized antibody sequences (lower lines). The humanized Fd79' and Fd138-80 framework sequences are derived from Pom antibody and Eu antibody, respectively.
Residues are numbered according to the Kabat system~(E.A.
Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD) (1987). The three CDRs in each chain are boxed. Residues in the Pom or Eu framework that have been replaced with murine sequences or consensus human sequences are underlined.
Figure 15. Schematic diagram of the plasmids pVgl (A) and pVk (B). The plasmid pVgl was constructed from the , following fragments; an approximately 4850 base pair BamHI-EcoRT fragment from the~plasmid pSV2hph containing the amp and , hyg genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell 41, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by XbaI-BamHI
i~V~ 92/11018 PCT/US91 /097 ~
11 ~ -, w :~, .:..
t, 5u J v fragment containing the human gamma-1 constant region gene with 225 by of the preceding intron and the poly(A) signal.
The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt replacing the hyg gene.
Figure 16. Fluorocytometry of HSV-1 infected Vero cells stained with Fd79 (A) and Fd138-80 (B) antibodies.
(. .) zsotype matched control antibody, (...) humanized antibody, (~) chimeric antibody. Vero cells were infected with HSV-1 0305 mutant (F strain)) at 3 pfu/cell overnight.
Cells were trypsinized at 0.5 mg/ml for 1 minute, washed extensively with PBS and resuspended in FACS buffer (PBS + 2~
BSA + 0.1o azide) at approximately 5x106/ml. 100 al of cell suspension was transferred to a polystyrene tube and incubated with 100 ng of purified antibody on ice for 30 min. The cells were washed with FACS buffer and incubated with FITC labeled goat anti-human antibody (Cappel) on ice for another 30 min.
The cells were washed again and finally resuspended in PBS +
1~ paraformaldehyde. Cells were analyzed on a FACSmate (Becton Dickinson).
Figure 17: Neutralization of HSV-1 by Fd79 (A) and Fd138-80 (B). Serial dilutions of antibodies were mixed with 100 pfu of virus and incubated at 37°C for 1 hr. The viruses were then inoculated onto 6-well plates with confluent Vero cells and adsorbed at 37°C for 1 hr. Cells were overlayed with 1% agarose in medium and incubated for 4 days. Plaques were stained with neutral red.
Figure 18. Immunostaining of infected Vero cell monolayers to examine protection of cells from viral spread in tissue culture by (A) marine or humanized Fd79, (B) marine or humanized Fd138-80. 24-well plates of confluent Vero cells were inoculated with virus at 0.1 pfu/cell and allowed to adsorb for 2 hrs, at 37°C before adding 200 al of 10 ug/ml antibodies in medium. At the end of 4 days, culture medium VVC9 92/11018 PCT/U59~/097m s1 V ,~ n' ,9 _.
was removed and plates were dried by placing overnight in a 37°C incubator. To detect viral antigens, each well was incubated with 200 u1 of anti-gB antibody at 0.5 ug/ml for 1 hr. at 37°C, washed twice and incubated with 200 u1 of peroxidase conjugated goat anti-mouse IgG (Cappel, 1:300 dilution) for 1 hr. at 37°C. The plates were washed and then developed with the substrate 3-amino-9-ethyl-carbazole (AEC) (Sigma, St. Louis, MO) for 15 minutes at room temperature.
Reaction was stopped by rinsing with water and air dried.
Figure 19. Sequences of the cDT~IA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the antibody M195. The CDR sequences are underlined. The mature light chain protein begins with amino acid 21 D and the mature heavy chain protein with amino acid 20 E, preceded by the respective signal sequences.
Figure 20. Schematic diagram of the plasmids pVg1-dhfr (A) and pVk (B). The plasmid pVg1-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell 41, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by Xb.aI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Gold Spring Harbor, N.Y. (1989) and PCT/89/01578 filed April 13, 1989. Fox example, pVgl-dhfr was constructed from the plasmid pVg1 by replacing the Hind III-iW0 92/11018 PCT/tJS9t/097t t 13 _ . ns i.i '-_',i .:
Bgl II fragment containing the hyg gene with a 66o by fragment containing the dhfr gene and extending to a Bgl TI site (Simonsen et al., Proc. Natl. Acad. Sci. USA 80, 2495 (1983)).
Figure 21. Fluorocytometry of U937 cells stained with (. .) no antibody, (...) humanized M195 antibody, (---) chimeric M195 antibody. Cells were suspended in FRCS buffer (PBS + 2% FCS + 0.1% azide) at approximately 5x106/ml. 100 u1 of cell suspension was transferred to a polystyrene tube and incubated with 50 ng of purified antibody on ice for 30 min.
The cells were washed with FACS buffer and incubated with FITC
labeled goat anti-human Ig antibody on ice for another 3o min.
The cells were washed again and finally resuspended in PB5 +
1~ paraformaldehyde. Cells were analyzed on a FACSmate (Becton Dickinson).
Figure 22. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized M195 antibody (lower lines) and human Eu antibody (upper lines), not including signal sequences. The three CDR's in each chain are underlined. Residues in the framework that have been replaced with mouse amino acids in the humanized antibody are double underlined.
Figure 23. Oligonucleotides used in the construction of the humanized M195 heavy chain (A; mal-~) and light chain (B; may-8). The following pairs of oligonucleotides were mixed, extended with Klenow polymerase and cut with the indicated enzymes before ligation into pUClB:
mat and mat with Xba I and Kpn I, ma3 and ma4 with Xba I and Kpn I, may and ma6 with Xba I and Hind III, ma7 and maa with Xba I and Hind III. Then the mal-mat and ma3-ma4 fragments were excised from pUCl8 with Xba I and kpn I and ligated together into the Xba I site of pVgl-dhfr; and the may-ma6 and ma7-ma8 fragments were excised with Xba I and Hind III and ligated together into the Xba I site of pVk.
Figure 24. Competitive binding of labeled M195 tracer to U937 cells. About 4 x 105 0937 cells were incubated with 4.5 ng of radio-iodinated mouse M195 antibody (6 ~cci/ug) and varying amounts of either unlabeled mouse M195 antibody (~) or humanized M195 antibody (o) in 200 u1 of binding buffer (PBS + 2% fetal calf serum + 0.1% sodium azide). After incubation for 2 hr at 0°C, the cells were washed twice with binding buffer and collected by centrifugation. The radioactivity bound to cells was measured and is expressed as the ratio of bound/free cpm.
Figure 25. Sequences of the cDNA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the antibody CMV5. The CDR sequences are underlined. The start of the mature protein sequences are indicated by arrows, preceded by the respective signal sequences.
Figure 26. Schematic diagram of the plasmids pVgl-dhfr (A) and pVk (B). The plasmid pVg1-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell 41, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively; and a 2800 by XbaI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989) 14a and the commonly assigned patent application published October 19, 1989 under No. WO 89/09622. For example, pVgl-dhfr was constructed from the plasmid pVgl (see WO 89/05857 published June 29, 1989) by replacing the HindIII-BglII fragment containing the hyg gene with a 660 by fragment containing the dhfr gene and extending to a Bgl II
site (Simonsen et al., Proc. Natl. Acad. Sci. USA 80, 2495 (1983)).
Figure 27. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized CMVS antibody (lower lines) and human Wol antibody (upper lines), not including signal sequences. The three CDR's in each chain are 10 underlined. Residues in the framework replaced with mouse amino acids or typical human amino acids in the humanized antibody are double underlined.
Figure 28. Oligonucleotides used in the 15 construction of the humanized CMVS light chain (A; jbl6-jbl9) and heavy chain (B; jb20-jb22). The following pairs of oligonucleotides were mixed, extended with Klenow polymerase and cut with the indicated enzymes before ligation into pUCl8:
jbl6 and jbl7 with Xba I and EcoR I, jbl8 and jbl9 with Xba I
and EcoR I, jb20 and jb21 with Xba I and Kpn I, jb22 and jb23 with Xba I and Kpn I. Then the jbl6-jbl7 and jbl8-jbl9 fragments were excised with Xba I and Mlu I and ligated together into the Xba I site of pVk; and the jb20-jb21 and jb22-jb23 fragments were excised with Xba I and Kpn I and ligated together into the Xba I site of pVgl-dhfr.
Figure 29. Competitive binding of labeled CMV5 tracer to CMV-infected cells. Increasing amounts of mouse (~) or humanized (o) CMV5 antibody was added to CMV-infected HEL
cells with tracer radio-iodinated mouse CMVS, and the amount of tracer bound to the cells was determined.
Figure 30. Sequences of the cDNA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the antibody AF2. The CDR sequences are underlined. The mature light chain protein begins with amino acid 30 N and the mature heavy chain protein with amino acid 36 Q, preceded by the respective signal sequences.
Figure 31. Schematic diagram of the plasmids pVgl-dhfr (A) and pVk (B). The plasmid pVgl-dhfr contains the following parts: an approximately 4200 base pair BamHI-EcoRI
fragment containing the amp and dhfr genes; a 630-by fragment containing the human cytomegalovirus IE1 gene promoter and enhancer (Boshart et al., Cell ~, 521 (1985)) flanked at the 5' and 3' ends by EcoRI and XbaI linkers respectively: and a 2800 by XbaI-BamHI fragment containing the human gamma-1 constant region gene with 215 by of the preceding intron and the poly(A) signal. The plasmid pVk was similarly constructed, with a 1530-by human kappa constant region gene replacing the gamma-1 gene and the gpt gene replacing the dhfr gene. The plasmids were constructed from the indicated parts using methods well-known in the art (see, Maniatis et al., I~lecular Clonina~ A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989).
For example, pVgl-dhfr was constructed from the plasmid pVgl by replacing the Hind III-Bgl II fragment containing the hyg gene with a 660 by fragment containing the dhfr gene and extending to a Bgl II site (Simonsen et al., Proc. Natl Acad Sci. USA ~, 2495 (1983)).
Figure 32. Amino acid sequences of the light chain (A) and the heavy chain (B) of the humanized AF2 antibody (lower lines) and human Eu antibody (upper lines), not including signal sequences. The three CDR's in each chain are underlined. Residues in the framework that have been replaced with mouse amino acids or typical human amino acids in the humanized antibody are double underlined.
w~ 92/mom PC1'/US91/09711 :-. a, ~ ~ ~~
17 ; ~ ~ ~: c~. v ei 'v Figure 33. Gligonucleotides used in the construction of the humanized AF2 light chain (A; rhlo-rhl3) and heavy chain (B~ rh20-23). The following pairs of oligonucleotides were mixed, extended with Klenow polymerase and cut with the indicated enzymes before ligation into pUCl8:
rhl0 and rhll with Xba I and Hind III, rhl2 and rhl3 with Xba I and Hind III, rh20 and rh21 with Xba I and EcoR I, rh22 and rh23 with Xba I and EcoR I. Then the rhl0-rhll and rhl2-rhl3 fragments were excised with Xba I and Hind III and ligated together into then Xba I site of pVk; and the rh20-rh21 and rh22-rh23 fragments were excised with Xba I and Xho I and ligated together into the Xba I site of pVgl-dhfr.
Figure 34. Fluorescence of HS294T cells incubated with ~-IFN plus varying concentrations of mouse AF2 antibody, and stained with an anti-HLA-D antibody.
pETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, novel humanized immunoglobulins capable of specifically binding to predetermined antigens with strong affinity are provided.
These immunoglobulins are substantially non-immunogenic in humans but have binding affinities of at least about 108 M-1, preferably 109 ~I 1 to logo M l, or stronger. The humanized immunoglobulins will have a human framework and have one or more complementary determining regions (CDR's), plus a limited number of other amino acids, from a donor immunoglobulin specifically reactive with an antigen. The immunoglobulins can be produced economically in large quantities and find use, for example, in the treatment of various human disorders by a variety of techniques.
In order that the invention may be more completely understood, several definitions are set forth. As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma (IgGl, IgG2, IgG3, VVO 92/11018 ~~r/US9a/o9~a a j~~ ~ ~' ~ al ii.
~a i~ J vi - ...
1$
IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. a?ull-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COON - terminus. Full-length immunoglobulin "heavy chains" (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.a., gamma (encoding ab~ut 330 amino acids).
One form of immunoglobulin constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain. variable regions are together responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions.
In addition to antibodies, immunoglobulins may exist in a variety of other forms including, for example, Fv, Fab, and (Fab')2, as well as bifunctional hybrid antibodies (e. a., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)) and in single chains (e~a., Huston et al., Proc. Natl. Acid. Sci.
U.S.A., 85, 5879-5883 (1988) and Bird et al., Science, 242, 423-426 (1988)). (See, generally, Hood e~ al., "Immunology°', Benjamin, N.Y., 2nd ed. (1984), and Hunkapiller and Hood, Nature, 323, 15-16 (1986)).
An immunoglobulin light ox heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also called CDR's. The extent of the framework region and CDR's have been precisely defined (see., "Sequences of Proteins of Immunological Interest," E. Kabat et , al., U.S. Department of Health and Human Sez-vices, (1983)).
The sequences of the framework regions of different light or .
heavy chains are relatively conserved within a species. As used herein, a "human framework region" is a framework region that is substantially identical (about 85% or more, usually 90-95% or more) to the framework region of a naturally s~
9~0 92/11018 rs ~, c7 ,:~ r~
~ky~tJ~.:.~ir.l_ occurring human immunoglobulin. The framework region of an antibody, that is the combined framework regians of the constituent light and heavy chains, serves to position and align the CDR's. The CDR's are primarily responsible for binding to an epitope of an antigen.
Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes belonging to different species. For example, the variable segments of the genes from a mouse monoclonal antibody may be joined to human constant segments, such as gamma 1 and gamma 3. A typical therapeutic chimeric antibody is thus a hybrid protein composed of the variable or antigen-binding domain from a mouse antibody and the constant.
or effector domain from a human antibody (ela., A.T.C.C.
Accession No. CRL 9688 secretes an anti-Tac chimeric antibody), although other mammalian species may be used.
As used herein, the term "humanized" immunoglobulin refers to an immunoglobulin comprising a human framework region and one or more CDR's from a non-human (usually a mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR's is called the "donor" and the human immunoglobulin providing the framework is called the "acceptor". Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-900, preferably about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDR's, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A "humanized antibody" is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, a humanized antibody would not encompass a typical chimeric antibody as defined above,., because the entire variable region of a chimeric antibody is non-human. One says that the donor antibody has been °'humanized", by the process of "humanization", because W~ 92/11098 PCT'/1JS91/09711 N,C)'~~~',~
~;j~..l.:.ei~:: 20 the resultant humanized antibody is expected to bind to the same antigen as the donor antibody that provides the CDR°s.
It is understood that the humanized antibodies designed by the present method may have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr.
Z0 Humanized immunoglobulins, including humanized antibodies, have been constructed by means of genetic engineering. Most humanized immunoglobulins that have been previously described (Jones et al., off. cit.; Verhoeyen et al., op. cit.: Riechmann et al., og. cit.) have comprised a framework that is identical to the framework of a particular human immunoglobulin chain, the acceptor, and three CDR's from a non-human donor immunoglobulin chain. rn one case (Riechmann et al., ~. cit.), two additional amino acids in the framework were changed to be the same as amino acids in other human framework regions. The present invention includes criteria by which a limited number of amino acids in the framework of a humanized immunoglobulin chain are chosen to be the same as the amino acids at those positions in the donor rather than in the acceptor, in order to increase the affinity of an antibody comprising the humanized immunoglobulin chain.
The present invention is based in part on the model that two contributing causes of the loss of affinity in prior means of producing humanized antibodies (using as examples mouse antibodies as the source of CDR's) are:
(1) When the mouse CDR's are combined with the human framework, the amino acids in the framework close to the , CDR's become human instead of mouse. Without intending to be bound by theory, we believe that these changed amino acids may .
slightly distort the CDR's, because they create different electrostatic or hydrophobic forces than in the donor mouse antibody, and the distorted CDR's may not make as effective W~ 92/1101 IaCT/US91/a9711 contacts with the antigen as the DR's did in the donor antibody;
(2) Also, amino acids in the oraginai mouse antibody that are close to, but not part of, the CDR's (i.e., still part of the framework), may make contacts with the antigen that contribute to affinity. These amino acids are lost when the antibody is humanized, because all framework amino acids are made human.
3) Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal antibodies (D. Shaw et al., J.
Immunol., 138, 4534-4538 (1987)). Injected humanized antibodies will presumably have a half-life more similar to naturally occurring human antibodies, allowing smaller and less frequent doses to be given.
To avoid these problems, and to produce humanized antibodies that have a very strong affinity for a desired antigen, the present invention uses one or mare of the following principles for designing humanized immunoglobulins.
Also, the criteria may be used singly, or when necessary in combination, to achieve the desired affinity or other characteristics.
A principle is that as acceptor, a framework is used from a particular human immunoglobulin that is unusually homologous to the donor immunoglobulin to be humanized, or use a consensus framework from many human antibodies. For example, comparison of the sequence of a mouse heavy (or light) chain variable region against human heavy (or light) variable regions in a data bank (for example, the National Biomedical Research Foundation Protein Identification.
Resource) shows that the extent of homology to different human regions varies greatly, typically from about 40% to about 60-70%. By choosing as the acceptor immunoglobulin one of the human heavy (respectively light) chain variable regions that is most homologous to the heavy (respectively light) chain variable region of the donor immunoglobulin, fewer amino acids will be changed in going from the donor immunoglobulin to the WO 92/11018 PC.'T/U~91109711 ~d l.' !/~ J "' ~J ~Y __ humanized immunoglobulin. Hence, and again without intending to be bound by theory, it is believed that there is a smaller chance of changing an amino acid near the CDR's that distorts their conformation. lrIoreover, the precise overall shape of a humanized antibody comprising the humanized immunoglobulin chain may more closely resemble the shape of the donor antibody, also reducing the chance of distorting the CDR's.
Typically, one of the 3-5 most homologous heavy chain variable region sequences in a representative collection of at least about 10 to 20 distinct human heavy chains will be chosen as acceptor to provide the heavy chain framework, and similarly for the light chain. Preferably, one of the 1-3 most homologous variable regions will be used. The selected acceptor immunoglobulin chain will most preferably have at least about 65% homology in the framework region to the donor immunoglobulin.
In many cases, it may be considered preferable to use light and heavy chains from the same human antibody as acceptor sequences, to be sure the humanized light and heavy chains will make favorable contacts with each other. In this case, the donor light and heavy chains will be compared only against chains from human antibodies whose complete sequence is known, ela., the Eu, Lay, Pom, Wol, Sie, Gal, Ou and WEA
antibodies (Kabat et al., op. cit.; occasionally, the last few amino acids of a human chain are not known and must be deduced by homology to other human antibodies). The human antibody will be chosen in which the light and heavy chain variable regions sequences, taken together, are overall most homologous to the donor light and heavy chain variable region sequences.
Sometimes greater weight will be given to the heavy chain sequence. The chosen human antibody will then provide both light and heavy chain acceptor sequences. In practice, it is often found that the human Eu antibody will serve this role.
Regardless of how the acceptor immunoglobulin is chosen, higher affinity may be achieved by selecting a small number of amino acids in the framework of the humanized immunoglobulin chain to be the same as the amino acids at wo 9zia aoas a',crius9aio~~a a ~> v v t~ y' 'J ':S
those positions in the donor rather than in the acceptor. A
second principle is that the following categories define what amino acids may be selected from the donor. Preferably, at many or all amino acid positions in one of these categories, the donor amino acid will in fact be selected.
Category 1: The amino acid position is in a CDR is defined by Kabat et al., ~. cit.
Category 2: If an amino acid in the framework of the human acceptor immunoglobulin is unusual (i.e., "rare", which as used herein indicates an amino acid occurring at that position in less than about 20% but usually less than about 10% of human heavy (respectively light) chain V region sequences in a representative data bank), and if the donor amino acid at that position is typical for human sequences (i.e., ''common", which as used herein indicates an amino acid occurring in more than about 25~ but usually more than about 50% of sequences in a representative data bank), then the donor amino acid rather than the acceptor may be selected. This criterion helps ensure that an atypical amino acid in the human framework does not disrupt the antibody structure. Moreover, by replacing an unusual amino acid with an amino acid from the donor antibody that happens to be typical for human antibodies, the humanized antibody may be made less immunogenic.
All human light and heavy chain variable region sequences are respectively grouped into "subgroups°' of sequences that are especially homologous to each other and have the same amino acids at certain critical positions (Kabat et al., op. cit.). When deciding whether an amino acid in a human acceptor sequence is "rare" or "common" among human sequences, it will often be preferable to consider only those human sequences in the same subgroup as the acceptor sequence.
Category 3: In the positions immediately adjacent to one or more of the 3 CDR's in the primary sequence of the humanized immunoglobulin chain, the donor amino acids) rather than WO 92/11018 f('T/~L1~91/097i 1 ~i 1)'' f-1 ~.~iC~ f:v.: 24 acceptor amino acid may be selected. These amino acids are particularly likely to interact with the amino acids in the CDR's and, if chosen from the acceptor, to distort the donor CDR's and reduce affinity. Moreover, the adjacent amino acids may interact directly with the antigen (Amit et al., Science, 233, 747°753 (1986)) and selecting these amino acids from the donor may be desirable to keep all the antigen contacts that provide affinity in the original antibody.
Category 4: A 3-dimensional model, typically of the original donor antibody, shows that certain amino acids outside of the CDR's are close to the CDR's and have a good probability of interacting with amino acids in the CDR's by hydrogen bonding, Van der Waals forces, hydrophobic interactions, ete. At those amino acid positions, the donor immunoglobulin amino acid rather than the acceptor immunoglobulin amino acid may be selected. Amino acids according to this criterion will generally have a side chain atom within about 3 angstrom units of some atom in the CDR°s and must contain an atom that could interact with the CDR
atoms according to established chemical forces, such as those listed above.
In the case of atoms that may form a hydrogen bond, the 3 angstroms is measured between their nuclei, but for atoms 'that do not form a bond, the 3 angstroms is measured between their Van der Waals surfaces. Hence, in the latter case, the nuclei must be within about 6 angstroms (3 + sum of the Van der Waals radii) for the atoms to be considered capable of interacting. In many cases the nuclei will be from 4 or 5 to 6A apart. In determining whether an amino acid can interact with the CDRs, it is preferred not to consider the last 8 amino acids of heavy chain CDR 2 as part of the CDRs, because from the viewpoint of structure, these 8 amino acids behave more as part of the framework.
Amino acids in the framework that are capable of interacting with amino acids in the CDR's, and which therefore WO 92/11018 PCflU591/09711 i1, W ~~ r~
.. . Fs '.> 2J ~ ~:: :v' belong to Category 4, may be distinguished in another way.
The solvent accessible surface area of each framework amino acid is calculated in two ways: (1) in the intact antibody, and (2) in a hypothetical molecule consisting of the antibody 5 with its CDRs removed. A significant difference between these numbers of about 10 square angstroms or more shows that access of the framework amino acid to solvent is at least partly blocked by the CDRs, and therefore that the amino acid is making contact with the CDRs. Solvent accessible surface area 10 of an amino acid may be calculated based on a 3-dimensional model of an antibody, using algorithms known in the art (e.,~, Connolly, J. Appl. Crvst. 16, 548 (1983) and Lee and Richards, J. Mol. Biol. 55, 379 (1971)). Framework amino acids may also occasionally interact with the CDR's indirectly, by affecting 15 the conformation of another framework amino acid that in turn contacts the CDR's.
The amino acids at several positions in the framework axe known to be capable of interacting with the CDRs in many antibodies (Chothia and Lesk, J. Mol. Biol. 196, 901 20 (1987), Chothia et al., Nature 342, 877 (1989), and Tramontano et al., J. Mol. Biol. 215, 175 (1990)), notably at positions 2, 48, 64 and 71 of the light chain and 26-30, 71 and 94 of the heavy chain (numbering according to Kabat, op. cit.), and therefore these amino acids will generally be in Category 4.
25 Typically, humanized immunaglobulins, of the present invention will include donor amino acids (where different) in category 4 in addition to these. The amino acids at positions 35 in the light chain and 93 and 103 in the heavy chain are also likely to interact with the CDRs. At all these numbered positions, choice of the donor amino acid rather than the acceptor amino acid (when they differ) to be in the humanized immunoglobulin is preferred. On the other hand, certain positions that may be in' Category 4 such as the first 5 amino acids of the light chain may sometimes be chosen from the acceptor immunoglobulin without loss of affinity in the humanized immunoglobulin.
Chothia and Lesk (op. cit,) define the CDRs differently from Kabat et al. (on. cit.). Notably, CDR1 is WO 92/1708 Pf_'1'/U~99109711 ~f ~ !;~ r~ ~ ~ ~t 2 6 defined as including residues 2s-32. Accordingly, Riechmann et al., (o~. cit.) chose these amino acids from the donor immunoglobulins.
Computer programs to create models of proteins such as antibodies are generally available and well known to those skilled in the art (see, Levy et al., Biochemistrv, 28, 7158-7175 (1989); Bruccoleri et al., Nature, 335, 564-56s (l9as);
Chothia e~ al., Science, 233, 755-758 (1986)). These do not form part of the invention. Indeed, because all antibodies have similar structures, the known antibody structures, which are available from the Brookhaven Protein Data Bank, can be used if necessary as rough models of other antibodies.
Commercially available computer programs can be used to display these models on a computer monitor, to calculate the distance between atoms, and to estimate the likelihood of different amino acids interacting (see, Ferrin e~ al., J. R5ol.
Graphics, 6, 13-27 (1988)).
In addition to the above categories, which describe when an amino acid in the humanized immunoglobulin may be taken from the donor, certain amino acids in the humanized immunoglobulin may be taken from neither the donor nor acceptor, if then fall in:
Category 5: If the amino acid at a given position in the donor immunoglobulin is "rare" for human sequences, and the amino acid at that position in the acceptor immunoglobuTin is also "rare" for human sequences, as defined above, then the amino acid at that position in the humanized immunoglobulin may be chosen to be some amino acid "typical" of human sequences. A preferred choice is the amino acid that occurs most often at that position in the known human sequences belonging to the same subgroup as the acceptor sequence.
Humanized antibodies generally have at least three potential advantages over mouse or in some cases chimeric antibodies for use in human therapy:
~N~O 92/11D18 PCT/ZJS91/09711 .,;:,fin a r, ~ .~ t~
1) Because the effector portion is human, it may interact better with the other parts of the human immune system (era., destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC)).
2) The human immune system should not recognize the framework or constant region of the humanized antibody as foreign, and therefore the antibody response against such an injected antibody should be less than against a totally foreign mouse antibody or a partially foreign chimeric antibody.
In one aspect, the present invention is directed to designing humanized immunoglobulins that are produced by expressing recombinant DNA segments encoding the heavy and light chain CDR's from a donor immunoglobulin capable of binding to a desired antigen, such as the human IL-2 receptor, attached to DNA segments encoding acceptor human framework regions. Exemplary DNA sequences designed in accordance with the present invention code for the polypeptide chains comprising heavy and light chain CDR's with substantially human framework regions shown in Figs. 1 through 4. Due to codon degeneracy and non-critical amino acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below. In general, the criteria of the present invention find applicability to designing substantially any humanized immunoglobulin.
The DNA segments will typically further include an expression control DNA sequence operably linked to the humanized immunoglobulin coding sequences, including naturally-associated or heterologous promoter regions.
Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection WO 92/11018 PCTltJ59i/097~1 '~.? l, ~'~ I ~ _.
n ij .._ 2 8 and purification of the humanized light chains, heavy chains, light/heavy chain dimers or intact antibodies, binding fragments or other immunoglobulin forms may follow (see, S.
Beychok, Cells of Immunocrlobulin Synthesis, Academic Press, N.Y., (1979)).
Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably immortalized B-cells (see, Kabat op. cit. and WP87/02671). ~'he CDR's for producing the immunoglobulins of the present invention will be similarly derived from monoclonal antibodies capable of binding to the predetermined antigen, such as the human IL-2 receptor, and produced by well known methods in any convenient mammalian source including, mice, rats, rabbits, or other vertebrates, capable of producing antibodies. Suitable source cells for the constant region and framework DNA sequences, and host cells for immunoglobulin expression and secretion, can be obtained from a number of sources, such as the American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas,"
sixth edition (1988) Rockville, Maryland, U.S.A.).
Tn addition to the humanized immunoglobulins specifically described herein, other "substantially homologous" modified immunoglobulins to the native sequences can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the framework regions can vary specifically from the sequences in Figs. 1 through 4 at the primary structure level by several amino acid substitutions, terminal and intermediate additions and deletions, and the like.
Moreover, a variety of different human framework regions may be used singly or in combination as a basis for the humanized immunoglobulins of the present invention. In general, modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see, Gillman and Smith, Gene, 8, 81-97 (1979) and S. Roberts et al., Nature, 328, 731-734 (1987)).
VV~ 92/1101 :, .; ~ ro :a !j ~ PC:f/1.JS91109711 N,. t; ~ ;: ~: v Substantially homologous immunoglobulin sequences are those which exhibit at least about 85% homology, usually at least about 90~, and preferably at least about 95o homology with a reference immunoglobulin protein.
Alternatively, polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (e. g., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact l0 antibodies by methods well known in the art, or by inserting stop codons at the desired locations using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab')z fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker (see, Huston et al., op. cit., and Bird et al., op.
cit.). Also because like many genes, the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities, the genes may be fused to functional regions from other genes (ea., enzymes, see, commonly assigned U.S.S.N.
132,387, filed Dec. 15, 1987) to produce fusion proteins (e. a., immunotoxins) having novel properties. The nucleic acid sequences of the present invention capable of ultimately expressing the desired humanized antibodies can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e~ct., V, J, D, and C regions), as well as by a variety of different techniques. Joining appropriate synthetic and genomic sequences is presently the most common method of production, but cDNA sequences may also be utilized (see, European Patent Publication No. 0239400 and L. Reichmann et al., Nature, 332, 323-327 (1988)).
As stated previously, the DNA sequences will be expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host organisms either as episomes W() 92/11018 PCT/US91/09711 or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.a., tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences (see, era., U.S.
5 Patent 4,704,362).
F. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention. other microbial hosts suitable for use include bacilli, such as Bacillus subtilus, and other enterobacteriaceae, such as 10 Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e~cr., an origin of replication). In addition, any number of a variety of well-15 known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences 20 and the like, for initiating and completing transcription and translation.
Other microbes, such as yeast, may also be used for expression. SaccharomYaes is a preferred host, with suitable vectors having expression control sequences, such as 25 promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.
In addition to microorganisms, mammalian tissue cell culture may also be used to express and produce the 30 polypeptides of the present invention (see, Winnacker, "From Genes to Clones," VCH Publishers, N.Y., N.Y. (1987)).
Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, preferably myeloma cell lines, etc, and transformed B-cells or hybridomas: Expression vectors for these cells can include wo 92iaa0a8 PCf/1JS91/097a3 r ~1 ':
f Fi 1:; ~:~ y ~. . . i - ~ .~ a t: .._ .. _..
expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al., Immunol.
Rev., 89, 49-68 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, Sv4o, Adenovirus, eytomegalovirus, Bovine Papilloma Virus, and the like.
the vectors containing the DNA segments of interest (e.et., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts. (See, generally, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, (1982) . ) Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the pxesent invention, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982)).
Substantially pure immunoglobulins of at least about 9o to 95%
homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired,. the polypeptides may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent stainings, and the like. (See, generally, ImmunolocLical Methods, Vols. I arid II, Lefkovits and Pernis, eds., Academic Press, New York, N.Y. (1979 and 1981)).
A preferred pharmaceutical composition of the present invention comprises the use of one or more of the subject antibodies in immunotoxins. Immunotoxins are WO 92/17~18 , f ~, ,.., ,; PCT/US91/09711 . ,_ ., a,~~::~~~,.
characterized by two components and are particularly useful for killing selected cells in vitro or in vivo. One component is a cytotoxic agent which is usually fatal to a cell when attached Or absorbed. The second component, known as the "delivery vehicle," provides a means for delivering the toxic agent to a particular cell type, such as cells comprising a carcinoma. The two components are commonly chemically bonded together by any of a variety of well-known chemical procedures. For example, when the cytotoxic agent is a to protein and the second component is an intact immunoglobulin, the linkage may be by way of heterobifunctional cross-linkers, e.cr., SPDP, carbodiimide, glutaraldehyde, or the like.
Production of various immunotoxins is well-known with the art;
and can be found, for example in '°Monoclonal Antibody-Toxin Canjugates: Aimzng the Magic Bullet," Thorpe et al., Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190 (1982). The components may also be linked genetically (see, Chaudhary et al., Nature 339, 394 (1989)).
A variety of cytotoxic agents are suitable for use in immunotoxins. Cytotoxic agents can include radionuclides, such as Iodine-131 or other isotopes of iodine, Yttrium-90, Rhenium-188, and Bismuth-212 or other alpha emittexs; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cisplatinum; and cytotoxic proteins such as 28 ribosomal inhibiting proteins like pokeweed antiviral protein, Pseudomanas exotoxin A, ricin, diphtheria toxin, ricin A
chain, etc., or an agent active at the cell surface, such as the phospholi,pase enzymes (e,~a., phospholipase C). (See, generally, W090/07861, published July 26, 1990; ''Chimeric ~30 Toxins," Olsnes and Phil, Pharmac. Ther., 25, 355-381 (1982);
and "Monoclonal Antibodies for Cancer Detection and Therapy,'°
eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press (1985).) The delivery component of the immunotoxin will 35 include the humanized immunoglobulins of the present invention. Intact immunoglobulins or their binding fragments, such as Fab, are preferably used. Typically, the antibodies W() 92/11018 y r~ ~ ~ ~ ~! ", ;l ~'CfiLJS9l~~9737 ,~ ' ~ ~ ~_= e~ ._ in the immunotoxins will be of the human IgM or IgG isotype, but other mammalian constant regions may be utilized as desired.
The humanized antibodies and pharmaceutical compositions thereof are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or in-travenously. The compositions for parenteral administration will commonly comprise a solution of the immunoglobulin or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e'a., water, buffered water, 0.4% saline, 0.3%' glycine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, human albumin, etc. The concentration of antibody in these formulations can vary widely i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1-l0 mgs of immunoglobulin. A typical composition for intravenous infusion could be made up to contain 25o ml of sterile Ringer's solution, and 150 mg of antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remincyton's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980), which is incorporated herein by reference.
w~ 92/mo~s ~ ; . ,; PC'd'/US91/09711 ~,3 ~~~ ~~ G, lay. ..
The antibodies of this invention can be frozen or lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed.
It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss {era., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be ad-justed to compensate.
The compositions containing the present humanized antibodies or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions are administered to a patient in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per dose, with dosages of from 5 to 25 mg being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life-threatening situations. In such cases, in view of the minimization of extraneous substances and the lower probability of "foreign substance" rejections which are achieved by the present humanized immunoglobulins of this in-vention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these antibodies.
In prophylactic applications, compositions containing the present immunoglobulins or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance. Such an amount is defined to be a "prophylactically effective dose." In this wo gzia~o~s ~orius~~io9~m ie C) j1 ~ ~i l? ~
3 5 C. a :.i ;~ ~-~ _ .~
use, the precise amounts again depend upon the patient°s state of health and general level of immunity, but generally range from 0.1 to 25 mg per dose.
Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat the patient.
For diagnostic purposes, the antibodies may either be labeled or unlabeled. Unlabeled antibodies can be.used in combination with other labeled antibodies (second antibodies) that are reactive with the humanized antibody, such as anti-bodies-specific for human immunoglobulin constant regions.
Alternatively, the antibodies can be directly labeled. A wide variety of labels may be employed, such as radionuclides, floors, enzymes, enzyme substrates, enzyme co- factors, enzyme inhibitors, ligands (particularly haptens), etc. Numerous types of immunoassays are available and are well known to those skilled in the art.
The following examples are offered by way of illustration, not by limitation.
The production of five specific humanized antibodies are described below. The antibodies are: Fd79 and Fd138-80 which respectively bind to the gB and gD glycoproteins of herpes simplex virus (Metcalf et al., Interviroloav 29, 39 (1988)), M195 (Tanimoto et al., Leukemia 3, 339 (1989)) which binds to the CD33 antigen, mik-,B1 (Tusdo et al., Proc. Natl.
Acad. Sci. USA 86, 1982 (1989)) which binds to the p75 chain of the TL-2 receptor, and CMVS which binds to the gH
glycoprotein of cytomegalovirus.
Basically, cDNAs for the heavy chain and light chain variable domain genes of each antibody were cloned using anchored polymerase chain reactions (Loh et al., Science 243, 219 (1989)), using 3' primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (Scheme W~0 92/11018 P~'/US91/09711 .: J-: ,a ~,~~~~~f-'~ ~ _ shown in Fig. 6). The PCR amplified fragments were digested with EcoRI and HindIII and cloned into the pUCl8 vector for sequencing. For each antibody, at least two heavy chain and two kappa clones were sequenced and found to have the same sequence. The deduced amino acid sequences of the mature light and heavy chain variable regions are shown in Figs. 1-5, upper lines.
In order to retain high binding affinity of the humanized antibodies, the principles and categories described above were utilized when designing the antibodies. Based on high sequence homology, human antibodies were selected to provide both the acceptor light and heavy chain human frameworks for the mouse antibodies, as follows: human Pom for Fd79, human Eu for Fd138-80, human Eu for M195, human Lay for mik-al, and human.Wol far CMVS.
The computer programs ABMOD and ENCAD (Levitt, J.
Mol~Biol., 168, 595 (1983) and Zilber et al., Biochemistry 29, 10032 (1990)) was used to construct a model of the variable region of each mouse antibody. The model was used to determine the amino acids in each framework that were close enough to the CDR's to potentially interact with them (category 4 above). For each antibody, the positions found to fall in the categories (1) - (5) defined above are given in Table 1, numbered as in Figs. 1-5.
W(3 92/11018 PCI'/U~91/09711 3 7 r'~ ~ .' t.:~ ~', ~~ r ~ ;~
v ~
Fd79 Antibody Category Lia ht Chain Heayy Chain 1 24-38, 54-50, 93-100 31-35, 50-66, 99-111 2 9, 45, 46, 83 82, 112 Fd138-80 Antibody Cate o~rv_ Lig ht Chain Heavy Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99-110 2 48, 63 93, 98, 111, 112, 2 0 113 , 115 3 __ 30, 67, 98, 111 4 36,.48, 27, 30, 37, 48, 67, s8, 98 M195~ Antibod y Cateaory Lic ,~ht Chain Heavy Chain 1 24-38, 54-60, 93-101 31-35, 50-66, 95-105 2 10, 52 , 67, 110 93, 95, 98, 106, 108, 110 3 ' -- 30, 67, 98, 106 4 40, 52 , 74 27, 30, 48, 68, 98 mik-Q1 Antibo dy Cateaorv Li ght Chain Heavy Chain 1 24-33, 49-55, 88-96 31-35, 50-65, 98-108 2 13 84, 89, 90 3 -- 30, 49 4 70 29, 30, 72, 73 CMV5 Antibody Cateaory Li aht Chain Heav Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99108 2 _- 69, 80 4 49 24, 27, 28, 30, 97 ~fO 92/11018 PCf/~7591/097tt 4" U ,w,, ..~ '~:
In designing each humanized antibody, at each position the amino acid was selected to be the same as in the human acceptor sequence, unless the position fell in categories (1) - (4), in which case the amino acid from the mouse donor sequence was used, or in category (5), in which , case an amino acid typical for human sequences at that position was used.
For the construction of genes for the humanized 10~ antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including signal peptides typically from the mouse antibody chains, generally utilizing colons found in the mouse sequence. Several degenerate colons were changed to create restriction sites or to remove undesirable ones. The nucleotide sequences also included splice donor signals typical for immunoglobulin genes and an XbaI site at each end.
Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides an alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal. The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was about 110-140 base long with a 15-20 base overlap. Double stranded DNA fragments were synthesized with Klenow or Taq polymerase or sequenase from each pair of oligonucleotides, digested with restriction enzymes, ligated to pUCl8 vector and sequenced. Two fragments with the respectively correct half-sequences were then ligated into the Xbal sites of pVgl (heavy chains of Fd79 and Fd138-80) or pVg1-dhfr (heavy chains of M195; mik-,01, CMVS) or pVk (all light chains) expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions were carried out under conditions well-known in the art (Maniatis et al., off. cit.).
The heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by ELISA, and antibody was purified from the best-producing clones. Antibody was purified by passing tissue culture supernatant over a column of staphylococcal protein A-SepharoseT"" CL-4B (Pharmacia). The bound antibodies were eluted with 0.2 M Glycine-HC1, pH 3.0 and neutralized with 1 M Tris pH 8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
The binding of the humanized antibodies to cell types expressing the corresponding antigens was tested:
HSV-infected cells for Fd79 and Fd138-80, U937 cells for M195, YTJB cells for mik-pl and CMV-infected cells for CMVS. By fluorocytometry, the humanized antibodies bind approximately as well as the original mouse antibodies and the corresponding chimeric antibodies. Moreover, the humanized antibodies compete approximately as well as the corresponding mouse antibodies against the radiolabeled mouse antibodies for binding to the cells, so the humanized antibodies have approximately the same binding affinity as the mouse antibodies, typically within about 2-fold or better, see, e.g., Table 2.
Binding affinities of murine and humanized antibodies.
Mouse Humanized Ka (M-1) Ka (M 1) Fd79 (anti-gB) 1.1 x 108 5.3 x 10' Fd138-80 (anti-gD) 5.2 x 10' 4.8 x 10 From the foregoing, it will be appreciated that the humanized immunoglobulins of the present invention offer numerous advantages over other antibodies. In comparison to other monoclonal antibodies, the present humanized immunoglobulin can be more economically produced and contain W~ 92/11018 PCT/US91/09771 ~~' " '' ~j 4 0 .1y,%..:
r.! L~ V .~
substantially less foreign amino acid sequences. This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.
A detailed description of each humanized immunoglobulin follows.
Example I
Humanized Immunoalobulins to n75 In mammals, the immune response is mediated by two types of cells that interact specifically with foreign material, i.e., antigens. One of these cell types, B-cells, are responsible for the production of antibodies. The second cell class, T-cells, include a wide variety of cellular subsets controlling the in vivo function of both B-cells and a wide variety of other hematopoietic cells, including T-cells.
(See, generally, Paul, W.E., ed., Fundamental Immunoloav, 2nd ed., Raven Press, New York (1989).) One way in which T-cells exert this control is through the production of a lymphokine known as interleukin-2 (IL-2), originally named T-cell growth factor. IL-2's prime function appears to be the stimulation and maintenance of T-cells. Indeed, some immunologists believe that IL-2 may be at the center of the entire immune response (see, Farrar, J., et al., Immunol. Rev. 63, 129-166 (1982)).
To exert its biological effects, IL-2 interacts with a specific high-affinity membrane receptor (Greene, W., et al., Proaress in Hematoloay XIV, E. Brown, Ed., Grune and Station, New York (1986), at pgs. 283 ff and Waldmann, Ann.
Rev. Biochem. 58, 875 (1989)). The human IL-2 receptor is a complex multichain glycoprotein, with one chain, known as the Tac peptide or alpha chain, being about 55kD in size (see, , Leonard, W., et al., J. Biol. Chem. 260, 1872 (1985)). The second chain is known as the p75 or beta chain (Tsudo et al., Proc. Nat. Acad. Sci. USA, 83, 9694 (1986) and Sharon et al., Science 234,.859 (1986)). The p55 or Tac chain and the p75 chain each independently bind IL-2 with low or intermediate affinity, while the IL-2 receptor complex of bath chains binds w~ 9zimo7~ PCT/US91/U9711 '.~,,; ~c, r_ . i 41 ~'~ v ;.~ y :~ v:
TL-2 with high affinity. The p75 chain of the human IL-2 receptor will often be called herein simply the p75 protein.
Much of the elucidation of the human IL-2 receptor°s structure and function is due to the development of specifically reactive monoclonal antibodies. In particular, one mouse monoclonal antibody, known as anti-Tac (uchiyama, et al., J. Immunol. 126, 1393 (1981)) has been used to show that IL-2 receptors can be detected on T-cells, but also on cells of the monocyte-macrophage family, Kupffer cells of the liver, Langerhans' cells of the skin and, of course, activated T-cells. Importantly, resting T-cells, B-cells or circulating macrophages typically do not display the IL-2 receptor (Herrmann, et al., J. Exo. Med. 162, 1111 (1985)). Another antibody, mik-Q1, binds to the p75 chain (Tsudo et al., Proc.
Nat. Acad. Sci. USA 86, 1982 (1989)).
The anti-Tac monoclonal antibody has also been used to define lymphocyte functions that require IL-2 interaction, and has been shown to inhibit various T-cell functions, including the generation of cytotoxic and suppressor T
lymphocytes in cell culture. Also, based on studies with anti-Tac and other antibodies, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell leukemia.
More recently, the IL-2 receptor has been shown to be an ideal target for novel therapeutic approaches to T-cell mediated diseases. It has been proposed that IL-2 receptor specific antibodies, such as the anti-Tac monoclonal antibody or mik-Q1, can be used either alone or as an immunoconjugate (e. a., with Ricin A, isotopes and the like) to effectively remove cells bearing the IL-2 receptor. These agents can, for example, theoretically eliminate IL-2 receptor-expressing leukemic cells, certain B-cells, or activated T-cells involved in a disease state, yet allow the retention of mature normal T-cells and their precursors to ensure the.capability of mounting a normal T-cell immune response as needed. In general, most other T-cell specific agents can destroy essentially all peripheral T-cells, which limits the,agents' '4v0 92/11018 PCf/US91/09711 ~ "~ (1 ~' ~ . w'. 4 2 A
~. f1 ~ ~~ .;: v aL
therapeutic efficacy. Overall, the use of appropriate monoclonal antibodies specific for the IL-2 receptor may have therapeutic utility in autoimmune diseases, organ transplantation and any unwanted response by activated T-cells. Tndeed, clinical trials have been initiated using, era., anti-Tac antibodies (Kirkman at al., Transplant. Proc. , 21, 1766 (1989) and Waldmann et al., Blood 72, 1805 (1988)).
Unfortunately, the use of anti-Tac, mik-,B1 and other non-human monoclonal antibodies have certain drawbacks, l0 particularly in repeated therapeutic regimens as explained below. Mouse monoclonal antibodies, for example, generally do not fix human complement well, and lack other important immunoglobulin functional characteristics when used in humans.
Perhaps more importantly, anti-Tac, mik-R1 and other non-human monoclonal antibodies contain substantial stretches of amino acid sequences that will be immunogenic when injected into a human patient.
In accordance with the present invention, human-like immunoglobulins specifically reactive with the p75 chain of the human IL-2 receptor are provided. These immunoglobulins, which have binding affinities of at least 10' to 108 M~1, and preferably 109 M 1 to 101° M 1 or stronger, are capable of, era. , blocking the binding of IL-2 to human IL-2 receptors. The human-like immunoglobulins will have a human-like framework and can have complementarity determining regions (CDR's) from an immunoglobulin, typically a mouse immunoglobulin, specificallx reactive with an epitope on p75 protein. The immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of T-cell mediated disorders in human patients by a variety of techniques. , In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope on the human IL-2 receptor, such as the mik-pl monoclonal antibody. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate PC3'/U~91/09711 W~ 92/11018 ~~~ ~ iW J
human-like framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the mik-al heavy and light chain CDRs, are included in Fig. 7.
Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed above.
The antibodies will typically find use individually in treating a T-cell mediated disease state. Generally, where the cell linked to a disease has been identified as IL-2 receptor bearing, then the human-like antibodies capable of blocking the binding of IL-2 to the human IL-2 receptor are suitable (see, U.S.S.N. 085,707, entitled "Treating Human Malignancies and Disorders.") For example, typical disease states suitable far treatment include graft-versus-host disease arid transplant rejection in patients undergoing an organ transplant, such as heart, lungs, kidneys, liver, etc.
Other diseases include autoimmune diseases, such as Type T
diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis.
The human-like antibodies of the present invention may also be used in combination with other antibodies, particularly human monoclonal antibodies reactive with other . markers on cells responsible for the disease. 'For example, suitable T-cell markers can include those grouped into the so-called "Clusters of Differentiation," as named by the First International Leukocyte Differentiation Workshop, Leukocyte .' T~17",plns, Bernard, et al., Eds., Springer-Verlag, N.Y. (1984).
A preferred use is the simultaneous treatment of a patient with a human-like antibody binding to p55 and a human-like antibody binding to p75 of the IL-2 receptor, i.e., humanized anti-Tac plus humanized mik-Q1. ' Human-like antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for T-cell typing, for isolating specific IL-2 receptor bearing cells or fragments.of the receptor, for vaccine preparation, or the like.
WO 92/1i0i8 P~ T/LJ59a/097aa ~~~(~~~ ~,1 _ ' J %
EXPERIMENTAL
Cloning of heavy chain and light chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain reactions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers , that hybridized to the constant regions and contained HindIII
sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoRI and HindIII and cloned into the pUCl9 vector for sequencing. For mik-/31, two gamma-2a specific and two kappa specific clones were sequenced. The two gamma-2a clones and two kappa clones are respectively identical in sequence. The cDNA variable domain sequences and the deduced amino acid sequences are shown in' Fig. 7.
Construction and expression of chimeric antibody.
Two plasmid vectors were prepared for construction and expression of the chimeric antibody genes. The plasmid pVgl-dhfr (Fig. 8A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C,~1 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen et al., Proc. Natl. Aced. Sci. USA 80, 2495 (1983)) for selection. The plasmid pVk (Fig. 8B) is similar to pVgl-dhfr but contains the human genomic Cx segment and the gpt gene. Derivatives of the mik-Q1 heavy and light, chain variable regions were prepared from the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting at the ATG codons and contained XbaI sites; the 3' primers hybridized to the last 15 nucleotides.of the 3 regions .
and contained splice donor signals and XbaI sites (see, C.
Queen et al., Proc. Natl. Aced. Sci. USA 86, 10029 (1989)).
The modified V regions were cloned into the XbaI sites of the respective plasmid vectors between the CMV promoter and the partial introns of the constant regions.
For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones secreting a maximal amount of complete 5 antibody were detected by ELISA. Purified chimeric mik-pl antibody was shown to bind to YTJB cells, which express the p75 antigen, by flow cytometry (Fig. 9).
Computer modeling of humanized antibodies.
10 In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (C. Queen et al., Proc. Natl. Acad Sci USA 86, 10029 (1989)). The more homologous a human antibody is to the original murine antibody, the less likely will combining the 15 murine CDRs with the human framework be to introduce distortions into the CDRs that could reduce affinity.
Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework seqeunces, so as to reduce the possibility of incompatibility in the assembling 20 of the two chains. Based on sequence database (performed with the MicrorGenieTM Sequence Analysis Software (Beckman)), the antibody Lay was chosen to provide the framework sequences for humanization of mik-pl.
The computer program ENCAD (M. Levitt, J. Mol. Biol.
25 168, 595 (1983)) was used to construct a model of the mik-pl variable region. The model was used to determine the amino acids in the mik-pl framework that were close enough to the CDRs to potentially interact with them (category 4 below). To design the humanized light and heavy chain mik-pl variable 30 regions, at each position the amino acid was chosen to be the same as in the Lay antibody, unless that position fell in one or more of five categories:
(1) The position fell within a CDR, (2) The Lay amino acid was unusual for human 35 antibodies at that position, whereas the mik-pl amino acid was typical for human antibodies at that position.
W~ 92/11018 PCf/US91/09791 y~ ~ ~~ J ~,~~1 ~'J, 3~ 4 6 to Zy e1 (3) The position was immediately adjacent to a CDR, (4) The model described above suggested that the amino acid may be physically close to the antigen binding region (CDRs).
For pcsitions in these categories, the amino acid from the (mouse) mik-/3l antibody was used. In addition, a position was in the fifth category if (5) The Lay amino acid was highly unusual for human antibodies at that position, and the mik-Q1 amino acid was different but also unusual.
Then an amino acid typical for human antibodies at that position may be used.
The amino acids in each category are shown in Table 3. Some amino acids may be in more than one category.
The final sequences of the humanized mik-,Q1 light and heavy chain variable domains are shown in Fig. l0, compared with the Lay sequences.
Category Light Chain Heavy Chain 1 24-33, 49-55, 88-96 31-35, 50-65, 98-108 2 13 84, 89, 90 3 30, 49 4 70 29, 30, 72, 73 For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the same signal peptides as in the mouse mik-R1 chains (Fig. 7), generally utilizing codons found in the mouse sequence. Several degenerate codons were changed to create w restriction sites or to remove undesirable ones. The nucleotide sequences also included the same splice donor signals used in the chimeric genes and an XbaI site at each end. Each gene.was constructed from four overlapping synthetic aligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides on alternating WO 92/11018 pCT/US91/0971t t~i t strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal (Fig. 11). The oligonucleotides were synthesized on an Applied Biosystems 3808 DNA synthesizer. Each oligo was about 110-140 base long with about a 20 base overlap. Double stranded DNA fragments were synthesized with sequenase from each pair of oligonucleotides, digested with restriction enzymes, ligated to pBluescriptII KS (+) (Stratagene) vector and sequenced. Two fragments.with the respectively correct half-sequences were then ligated into the Xbal sites of the pVgl-dhfr or pVk expression vectors. In vitro mutagenesis was used to change an Ala amino acid originally encoded by oligonucleotide wps54 to the Glu (E) at position 1 of the humanized heavy chain (Fig. 10B) by changing the nucleotides CT to AG. Reactions were carried out under conditions well-known in the art (Maniatis et al., op. cit.) The heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by E1TSA, and antibody was purified from the best-producing clones. Antibody was purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody was eluted with 0.2 M Glycine-HCl, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized mik-(31 antibody was characterized in comparison to the murine and chimeric antibodies. The humanized antibody bound to YTJB cells, which express p75 chain at a high level, in a fluorocytometric analysis in a manner similar to the chimeric antibody (Fig. 9), showing that it recognizes the same p75 protein.
The affinity of the humanized antibody was determined by competition with the radio-iodinated mouse w(~ 9zimoag ~crius9mo97m ,.
a. r,, t, 4 8 t~,s~i,,ty.,~x ~, ,~.
mik-;01 antibody (Fig. 12). The binding affinities were calculated according to the methods of Berzofsky (J. A.
Berzofsky and I.J. Berkower, in Fundamental Immunolocry (ed.
W.E. Paul), Raven Press (New York), 595 (1984)). The binding affinity of the humanized mik-Q1 antibody was within about 2-fold of the affinity of the mouse mik-al antibody.
The ability of humanized mik-~i1 plus humanized anti-Tac antibody (see, W090/07861 published July 26, 1990) to inhibit IL-2 stimulated proliferation of human lymphocytes was determined. Human mononuclear cells, collected from human blood by centrifugation on Ficoll-Paque (Pharmacia), were diluted to 2 x 105 cells/ml in RPMI medium + 10% fetal calf serum (FCS). A 1/200 volume of phytohemagglutinin P (Difco) was added and the cells were incubated for 4 days. The cells were incubated an additional 4 days in RPMI + 10% FCS + 10 u/ml IL-2. 10~ of these PHA activated blasts were then incubated with or without 2 ~,g.each of humanized mik-pl and humanized anti-Tac in 150 ~1 of RPMI + 10% FCS in wells of.a 96-well plate for 1 hr, to which various dilutions of IL-2 (Amgen) were then added in 50 ~cl medium. The cells were incubated 48 hr, 0.5 ~cCi methyl-3H-thymidine (Amersham, 82 Ci/
mmol) was added, and the cells were incubated 24 hr. Cells were harvested with a cell harvester and radioactivity determined. The combination of the antibodies greatly inhibited proliferation of the cells in response to IL-2 (Fig.
13), suggesting a combination of the antibodies will have strong immunosuppressive properties. Humanized mik-pl plus humanized anti-Tac inhibited proliferation much more strongly than did either antibody alone.
Example II
Humanized Immunoglobulins to HSV Antigens Herpes Simplex Virus types I and II (HSV-1 and HSV-2), are now estimated to be the second most frequent cause of a sexually transmitted diseases in the world. Although completely accurate data are not available, infection estimates range from about 20 to 40% of the U.S. population.
W(J 92/1101 PCflUS91/09711 .a. :~ di ,j i:.iJ w A large number of diseases, from asymptomatic to life-threatening, are associated with HSV infection. Of particular clinical interest, encephalitis from HSV-1 infection and transmission of HSV-2 from a pregnant mother to her fetus are often fatal. Immunosuppressed patients are also subject to severe complications when infected with the virus.
More than 50 HSV polypeptides have been identified in RSV-infected cells, including at least seven major cell surface glycoproteins (see, Whitley, R., Chapt. 66, and Roizman and Sears, Chapt. 65, Viroloay, Eds. Fields et al., 2nd ed., Raven Press, N.Y., N.Y. (1990)). The specific biologic functions of these glycoproteins are not well defined, although gB and gD have been shown to be associated with cell fusion activity (W. Car et al., J. Virol. 62, 2596 (1988) and Fuller and Spear, Proc. Natl. Acad. Sci. USA 84, 5454 (1987)). gB and gD express both type-specific and type-common antigenic determinants. Oakes and Lausch demonstrated that monoclonal antibodies against gB and gE suppress replication of HSV-1 in trigeminal ganglia (Oakes and Lausch, J. Virol. 51, 656 (1984)). Dix et al. showed that anti-gC and gD antibodies protect mice against acute virus-induced neurological disease (Dix at al., Infect. Immure. 3~, 192 (1981)). Whitley and colleagues produced a panel of marine monoclonal antibodies against HSV-1 and showed that several of the antibodies protected mice against encephalitis and death following ocular inoculation with the virus (see, Koga et al., Virology 151, 385 (1986): Metcalf et al., Cur. Eye Res. 6, 173 (1987) and Metcalf et al., Intervirology 29, 39 1988)). Clone Fd79 (anti-gB) prevented encephalitis even when immunization was delayed until 48 hours post-infection. Fd79 and Fd138-80 (anti-gD) significantly. reduced the severity of epithelial keratrtis and lowered the frequency of persistent viral infection in an outbred mouse model.
In accordance with the present invention, humanized immunoglobulins specifically reactive with HSV related epitopes either directly on the virus or on infected cells are provided. These immunoglobulins, which have binding VVO 92/ 11 d1 1 ~ P~CT/US91 /~9711 'f ~ i ~~ "j ~;'_ ~;~ '.i 5 0 t .
affinities to HSV specific antigens of at least about 10' M 1, and preferably 10a M-1 to 101° M-1 or stronger, are capable of, e.a., protecting cells from HSV transmission. The humanized immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDR'S) from an immunoglobulin, typically a mouse immunoglobulin, specifically , reactive with an HSV protein, such as gB and gD proteins. The immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of HSV mediated disorders in human patients by a variety of techniques.
The HSVs are among the most intensively investigated of all viruses, and the HSV virion structure has been shown to contain about 33 proteins. Humanized immunoglobulins utilizing CDR°s from monoclonal antibodies reactive with these proteins, particularly the eight surface glycoproteins (e. g., gB, gC, gD, gE, gG, gH and gI), represent preferred embodiments of the present invention (see, Spear, P.G., The Herpesviruses, vol. 3, pp. 315-356 (1984) (Roizman, B., ed), Plenum Press, N.Y., N.Y. and Spear, P.G., Immunochemistry of Viruses. The Basis for Serodiaqnosis and Vaccines, pp. 425-446 (1985) (Neurath, A.R., eds.), Amsterdam: Elsevier).
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope of an HSV protein, such as monoclonal antibodies reactive with HSV gB and gD glycoproteins. The DNA segments encoding these regions will typically be joined to DNA
segments encoding appropriate humanized framework regions.
, Exemplary DNA sequences code for the polypeptide chains comprising the heavy and light chain hypervariable regions (with human framework regions) from monoclonal antibodies Fd79 I
and Fd138-80, shown in Fig. 14. Due to codon degeneracy and _ non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
Any humanized immunoglobulins of the present invention may also be used in combination with other i~VO 92/11018 ' P~Cf/tJS91/09711 6~ ti c! U '.~ J ':
antibodies, particularly humanized antibodies reactive with different HSV antigens. for example, suitable HSV antigens to which a cocktail of humanized immunoglobulins may react include gC, gE, gF, gG and gH (see, Rector, J. et al., Infect.
Immun: 38, 168 (1982) and Fuller, A. et al., J. Virol. 63, 3435 (1989)), i The antibodies can also be used as separately administered compositions given in conjunction with acyclovir or other antiviral agents. Typically, the agents may include idoxuridine or trifluorothymidine, but numerous additional agents (era., vidarabine) well-known to those skilled in the art for HSV treatment may also be utilized (see, Corey, L., pp. cit.). A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins .in immunotoxins to kill cells infected by HSV.
These humanized antibodies can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for detection of HSV antigens, for isolating specific HSV infected cells or fragments of the virus, for vaccine preparation, or the like.
EXPERIMENTAL
Cloning of heavy chain and lictht chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain regions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (scheme shown in Fig. 6). This method yields clones with authentic variable domain sequences, in contrast to other methods using mixed primers designed to anneal to the variable domain sequence (J. W. Larrick et al., Bio/Technology 7, 934 (1989) and Y.L. Chiang et al., BioTech.
7, 360 (1989)). The PCR amplified fragments were digested' with EcoRI and HindIII and cloned into the pUCl8 vector for sequencing. For Fd79, two gamma-1 specific and 5 kappa specific clones, were sequenced. The two gamma-1 specific W~ 92/1101f3 PCf/LlS9~/09711 s ~ ~~(i ~ '~~ ~a3. ..
clones are identical in sequence. This heavy chain cDNA
fragment encodes a signal peptide of 19 amino acids, a V
region in mouse heavy chain subgroup IIIB, a D segment, and a JH1 segment with 4 alterations compared to the genomic JH1 sequence. The deduced amino acid sequence is shown in Fig.
14A.
The five kappa specific clones belong to two groups.
Two clones are identical and encode a kappa chain.in which the conserved amino acid 23 cysteine has been substituted by a tyrosine, probably representing the non-productive allele.
The other three clones have an identical sequence encoding a signal peptide sequence of 20 amino acids, a V region in mouse kappa chain subgroup III, and a Jk2 segment with a single alteration compared to the genomic Jk2 sequence (Fig. 14B).
The validity of the heavy chain and the kappa chain sequences was subsequently confirmed by the construction and expression of a chimeric antibody as discussed below.
The heavy chain and the kappa chain of Fd138-80 were cloned similarly. Three clones each of the heavy chain and the kappa chain were sequenced. All three heavy chain clones have an identical sequence encoding a signal peptide sequence of l9,amino acids, a V region in mouse heavy chain subgroup II, a D segment and the JN3 segment (Fig. 14C). The three kappa clones are also identical in sequence. This light chain fragment encodes a signal peptide sequence of 20 amino acids, a V region gene in mouse kappa chain subgroup V and the Jk5 segment (Fig. 14D). Both chains shown no irregularities in coding sequence: their validity was subsequently confirmed by construction and expression of a chimeric antibody.
Construction and expression of chimeric antibodies.
Two plasmid vectors were prepared for construction and expression of 'the chimeric antibody genes. The plasmid , pVgl (Fag. 15A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C,~1 segment including part of the preceding intron, and the hygromycin gene (Blochlinger et al., Mol.
WO 921i 1018 F'C.'T/US91/~9711 ~5 1~ ~i -' 'i ;~
~~ 4~ v ;~ :: - -= 53 Cell. Biol. 4, 2929 (1984)) for selection. The plasmid pVk (Fig. 15B) is similar to pVg1 but contains the human genomic C~
segment and the gpt gene. Derivatives of the Fd79 and Fd138°
80 heavy and light chain variable regions were prepared from 5 the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting at the ATG codons and contained XbaI sitest the 3' primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and Xbal sites (see, C. Queen et al., Froc. Natl.
Acad. Sci. USA 86, 10029 (1989)). The modified V regions ware cloned into the XbaI sites of the respective plasmid vectors between the CMV promoter and the partial introns of the constant regions.
For expression of the chimeric antibodies, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Purified chimeric Fd79 and Fd138 °80 antibodies were shown to bind to HSV-1 infected vero cells by flow cytometry. Viral neutralization assays also indicated that the chimeric antibodies retain the neutralization activities of the marine antibodies (data not shown, but see below for similar results with humanized antibodies).
Comguter modeling of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (C. -Queen et al., Proc. Natl. Aced. Sci. USA 86, 10029 (1989)). The more homologous a human antibody is to the original marine antibody, the less likely,will combining the marine CDRs with the human framework be to introduce distortions into the CDRs that could reduce affinity.
Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of. the two chains. Based on sequence homology search against 8 PCf/US91/09711 it/ ~~~~~~IJ
the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Pom was chosen to provide the framework sequences for humanization of Fd79.
The computer program ENCAD (Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the Fd79 variable region. Inspection of the refined model of murine ~'d79 revealed two amino acid residues in the framework that are close enough to have significant contacts with the CDR
residues (Table 4). Lys in light chainNBRF position 49 has contacts with 3 amino acids in CDR2 of the light chain (L50 Tyr, L53 Asn, L55 Glu) and 2 amino acids in CDR3 of the heavy chain (H99 Asp, H100 Tyr): Leu in heavy chain position 93 also shows interactions with 2 amino acids in CDR2 of the heavy chain (H35.Ser, H37 Val) and an amino acid in CDR3 of the heavy chain (H100C Phe). Hence, L49 Lys and H93 Leu were retained in the construction of humanized Fd79, as their replacement with human Pom framework residues would be likely to introduce distortions into the CDRs. Also, 7 other residues in the Pom framework (5 in the light chain and 2 in the heavy chain) were substituted with common human residues (identical to the murine Fd79 sequence in 6 of the choices) because of their rare occurrence in other human antibodies.
The elimination of unusual amino acids in the framework may further reduce immunogenicity. The murine Fd79 sequences and the corresponding humanized sequences are shown in Fig. 14A, B. Substituted residues in the Pom framework are underlined.
WO 92/1101 PC.'T/bJS91/09711 '"'~iJ~~~~':
5 :: r~
Residues in the framework sequence showing contacts with residues in the hypervariable regions.
5 Residue No.1 Amino Acid Contactinct CDR residuesz Fd79 L4g Lys L50X, L53N, L55E, H99D, HlOOX
H93 Leu H35S, H37V, H100CF
Fd138-80 L36 His L34V, L89Q
H27 Tyr H32H, H34I
H30 Tyr H32H, H53R
H48 Phe H63F
H66 Lys H63F
H67 . Ala H63F
1. The amino acid residues are numbered according to the Kabat system (E.A. Kabat et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD (1987)): the first letter (H or L) stands for the heavy chain or light chain. The following number is the residue number. The last letter is the amino acid one letter code.
2. The hypervariable regions are defined according to Kabat:
Light chain CDR1: residue 24-34t CDR2: 50-56; CDR3: 89-9,7.
Heavy chain CDRl: 31-35: CDR2: 50-65; CDR3: 95-102.
Similarly, the murine heavy chain and light chain sequences of Fd138-80 were subjected to sequence homology search against the NBRF protein sequence database. The sequences of the human antibody Eu were selected to provide the framework sequences for humanized Fd138-80. Inspection of a computer-generated model of Fd138-80 revealed 6 amino acid residues in the framework that are close enough to have < important contacts with CDR, residues. The residues and their contacting counterparts are listed in Table 4; these murine residues were retained in the construction of humanized Fd138-80. Two other residues (L87 Pile and H37 Met) show significant contacts with L98 Phe, which is immediately adjacent to CDR3, WO 92/11018 1'CT/US91/09711 ~~~~!jt~:r, .: 56 so these two mouse residues were also retained. Eight amino acids in the Eu framework (2 in the light chain and 6 in the heavy chain) were substituted with the murine residues (which are also consistent with the human consensus residues) because of their rare occurrence in other human antibodies. The murine Fd138-80 sequences and the corresponding humanized sequences are shown in Fig. 14C. Substituted residues in the Eu framework are underlined.
For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the signal peptides, generally utilizing colons found in the mouse sequence. Several degenerate colons were changed to create restriction sites or to remove undesirable ones. The nucleotide .sequences also included the same splice donor signals used in the chimeric genes and an XbaI site at each end. Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides on alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal. The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was~about 110-140 bases long with a 15 base overlap. Double stranded DNA
fragments were synthesized with Klenow polymerase, digested with restriction enzymes, ligated to pUClB vector and sequenced. The two fragments with the correct sequences were then ligated into the XbaT sites of pVgl or pVk expression vectors, The synthetic genes were then cloned into the pVgl and pVk expression vectors. For each humanized antibody constructed, the heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by ELISA, and antibody was purified from the best-producing clones. Antibodies were purified by passing tissue w0 92imo1g PCT/US91/09711 .:W-, ~ ~ ~ ,s ~ :s 5~. l..i.V: ., _ ..
culture supernatant over a column of staphylococcal protein A--Sepharose CL-4B (Pharmacia). The bound antibodies were eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized Fd79 and Fd138-80 antibodies were characterized in comparison to the marine and chimeric antibodies. Both humanized antibodies bind to Vero cells infected with HSV-1 in a fluorocytometric analysis in a manner similar to the chimeric antibodies (Fig. 16), suggesting that they recognize their respective viral antigens. To more quantitatively assess the binding activity, radioiodinated marine antibodies were bound to virally infected cells and Scatchard analysis performed.
The affinities of the humanized antibodies were determined by competition with the iodinated antibodies. Vero cells infected with HSV-1 were used as source of gB and gD
antigens. Increasing amounts of competitor antibody (mouse or humanized) were added to 1.5 ng of radioiodinated tracer mouse antibody (2uCi/ug) and incubated with 4 x 105 infected Vero cells in 0.2 ml of binding buffer (PBS + 2% FCS + 0.1% azide) for 1 hr. at 4°C. Cells were washed and pelleted, and their radioactivities were measured. The concentrations of bound and free tracer antibody were calculated. The binding affinities were calculated according to the methods of Berzofsky (J. A. Berzofsky and I.J. Berkower, in Fundamental Immunoloav (ed. W.E. Paul), Raven Press (Idew York), 595 (1984)).
The measurements indicate that there is no significant loss of binding affinities in the humanized antibodies (Table 5). Specifically, there is an approximately 2-fold decrease in affinity in humanized Fd79 compared to the marine Fd79 (Ka of 5.3 x 10' M 1 vs. 1.1 x 108 M 1) . The affinity of humanized Fd138-80 is comparable to that of the marine antibody (Ka of 4.8 x 10' M-1 vs 5.2 x 10' M 1) .
WO 92/11018 PC'1'/US91/0~?'711 Binding affinities of marine and humanized antibodies.
Mouse Humanized Ka (M 1) Ka (M 1) Fd79 (anti-gB) 1.1 x 108 5.3 x 10' 1. 0 Fd138-80 (anti-gp) 5.2 x 10~ 4.8 x 10~
Marine Fd79 and Fd138-80 have been shown to neutralize HSV-1 in vitro without complement (J. Koga et al., Virology 151, 385 (1986)), so the neutralizing activities of the humanized antibodies were compared with the mouse antibodies. Serial dilutions of equal quantities of marine and humanized antibodies were incubated with virus for 1 hr.
before inoculation onto Vero cells. After 4 days, cells were stained with neutral red to visualize plaques. Results from these plaque reduction assays indicated that both humanized Fd79 and Fd138-80 neutralize virus, as efficiently as their marine counterparts (Figs. 17A and B). Both humanized and marine Fd79 cause a 90% reduction of plaques at an antibody concentration of 10 nM (1.5 ug/ml). Similarly, humanized and marine Fd138-80 were able to cause a 90% plaque reduction at equivalent levels.
The antibodies were also investigated for their ability to protect cells from viral spread in tissue culture.
Vero cells were inoculated with virus at 0.1 pfu/cell and allowed to adsorb for 2 hrs, at 37°C before addition of to ug/ml antibody. After four days, cells were stained with an anti-gB antibody for detection of viral antigens on infected cells. Results indicated that both marine and humanized Fd79 at 10 ug/ml protected culture cells from infection (Fig. 38A):
However, neither marine nor humanized Fd138-80 were able to protect cells against viral spread (Fig. 18B), despite their ability to neutralize virus before inoculation. Both gB and gD are thought to be associated with cell fusion and virus infectivity (W. Cai et al., J. Virol. 62, 2596 (1988) and A.O.
WO 92/i i 018 PCC f/LJ531 /09711 :p f4 i C, ti ~: !!
~a"t'vt, :.:'..
Fuller and P.G. Spear, Proc. Natl. Aced. Sci. USA 84, 5454 (1987)). However, it is possible that Fd79 blocks both the infectivity and cell fusion functions of gB, while Fd138-80 blocks only the infectivity function of gD, so virus can still spread cell-to-cell.
The binding, neutralization and protection results all indicate that the humanized Fd79 and Fd138-80 antibodies have retained the binding activities and the biological properties of the marine monoclonal antibodies. The availability of humanized antibodies with specificity for HSv gB and gD, inter alia, provides an opportunity for studies of the in vivo potency and immunogenicity of humanized antibodies in treating viral diseases. The recognition by Fd79 and Fd138-80 of type-common epitopes of gB and gD (J. Koga et al., Virology 151, 385 (1986)) expands the therapeutic potential to herpes simplex virus type 2 as well as type 1.
Protection from herges simplex virus type 2 lethal infections in mouse model b~,humanized Fd79 and Fd138-80.
To determine the efficacy of humanized antibodies against herpes infections in vivo, humanized antibodies were injected into mice before and after inoculation of lethal doses of HSV-2, and the mortality rates were monitored.
Groups of animals were treated intraperitoneal with 0.9, 0.3 or 0.1 mg of each of humanized Fd79 or Fd138-80 at 24 hr before or 24 hr. after viral inoculation. Groups of 10 mice were challenged intranasally with lethal doses of Hsv-2. Mice were monitored for three weeks. The mortality rates were shown in the following tables.
The results show that significant protection against HSV-2 infection of mice was obtained with humanized Fd79 and humanized Fd138-80.
W~ 92111018 PC1'/11591 /09711 ;'.~~ 'tj ~ ~ C~ ',' A'~ . 6 0 EFFECT OF PRE-TREATMENT (-24h) WITH HSV ANTIBODY ON THE MORTALITY
Mortality Treatment Number Percent P-Value Control 13/15 87 --_ Place3~o 13/ 15 87 NS
Mu Fd 138 0.9 mg 3/10 30 <0.001 0.3 mg 5/10 50 0.01 0.1 mg 5/10 50 0.08 Hu Fd 138 0.9 mg 1/10 10 <o.ool 0.3 mg 8/10 80 NS
0.1 mg 7/10 70 NS
Mu Fd 79 0.9 mg 0/10 0 <0.001 0.3 mg 2/10 20 <0.01 O.l mg 4/10 40 <0.05 Hu Fd 79 0.9 mg 1/10 10 <0.01 0.3 mg 3/10 30 0.08 0.1 mg 5/10 50 0.08 wo 9ziaaoag p('T/lJS9a/o97a1 ;, ,.: ~a ~';
61 ~'~~
EFFECT OF POST-TREATMENT (+24h) ~IITH HSV ANTIBODY ON THE MORTALITY
OF MICE INOCULATED INTRANASALLY i9ITH HSV--2 Mortality Treatment Number Percent P-Value Control 12/15 80 ---Placebo 15/15 100 NS
Mu Fd 138 0.9 mg 2/10 20 <0.001 0.3 mg 4/10 40 0.001 0.1 mg 5/10 50 <0.01 Hu Fd 138 0.9 mg 3/10 30 <0.001 0.3 mg 3/10 30 <0.001 0.1 mg 9/10 90 NS
Mu Fd 79 0.9 mg 5/10 50 <0.01 0.3 mg 3/10 30 <0.001 0.1 mg 6/10 60 <0.05 Hu Fd 79 0.9 mg 3/10 30 <0.001 0.3 mg 3/10 30 <0.001 0.1 mg 9/10 90 NS
The use of a combination of two or more humanized antibodies in therapy is important for reducing tha development taf antibody resistant strains. Combination therapy of humanized antibodies with other antiviral agents such as acyclovir provides further opportunities to combat diseases when chemotherapeutic agents alone have not been effective. As Fd79 and Fd138-80 reduce the frequency of viral persistence in a murine ocular model (J. F. Metcalf et al., Cur. Eye Res. 6, 173 (1987)), the humanized antibodies, typically together with other antiviral agents, are capable of reducing episodes of recurrent genital infection, an area where traditional anti-viral agents have not been effective (L. Corey et al., N. Engl. J. Med. 306, 1313 (1982)).
Incorporation of the human constant domains can also enhance WO 92/11018 fC.'f/U~91/097I1 Sz ,~ , 6z ~~9~U~~.~~:1::
effector functions, such as antibody-dependent cellular cytotoxicity, leading to greater therapeutic efficiency in human patients.
Example III
Humanized Immunocrlobulins to CD33 Antigen There are about 10,000-15,000 new cases of myeloid (also called non-lymphocytic or granulocytic) leukemia in the U.S. per year (Cancer Facts & Figures, American Cancer Society, 1987). There are two major forms of myeloid , leukemia: acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). Despite treatment with chemotherapy, long-term survival in patients with AML is less than 10-20% (Clarkson et al., CRC Critical Review in Oncology/~Iematology 4, 221 (1986)), and survival with CML and related diseases such as chromic myelomonocytic leukemia (CMML), chronic monocytic .leukemia (CMMOL) and myelodysplastic syndrome (MDS) is even lower.
The p67 protein or CD33 antigen is found on the surface of progenitors of myeloid cells and of the leukemic cells of most cases of AML, but riot on lymphoid cells or non-hematopoiet~.c cells (see, Leucocyte Typing III, ed. by A.J.
McMichael, Oxford University Press, pp. 622-629 (1987).
Antibodies that are known to bind to the CD33 antigen include L4B3, L1B2 and MY9 (Andrews et al., Blood 62, 124 (1983) and Griffin et al., Leukemia Research 8, 521 (1984)).
Another antibody that binds to CD33 is M195 (Tanimoto et al., Leukemia 3, 339 (1989) and Scheinberg et al., Leukemia 3, 440 (1989)). The reactivity of M195 with a wide variety of cells and tissues was tested. Among narmal cells, M195 was reported to bind only to some monocytes and , myeloid progenitor cells. The research also reported that it does not bind to other hematopoietic cells or to non- .
hematopoietic tissues. M195 bound to cells of most cases of AML and all cases of CML in myeloblastic phase.
A phase I clinical trial of M195 in AML has been conducted (Scheinberg et al., Proc. ASCO 9, 207 (1990)). M195 ego 9aiaaoas P~-ri»s9aio9~aa .:~:si::,;,;~~t~
6 3 . ~ ~s a ~ '-:
radiolabeled with iodine-131 was found to rapidly and specifically target leukemic cells in both the blood and bone marrow.
In accordance with the present invention, humanised immunoglobulins specifically reactive with CD33 related epitopes are provided. These immunoglobulins, which have binding affinities to CD33 of at least abaut 10' M-', and preferably 108 M 1 to 101° M-1 or stronger, are capable of, era. , destroying leukemia cells. The humani2ed immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDR's) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with CD33 antigen. In a preferred embodiment, one or more of the CDR's will come from the M195 antibody.
Importantly, M195 does not bind to the ultimate hematopoietic stem cells, so M195 used in therapy will minimally interact with and destroy those cells, which are critical for generating all blood cells. Thus, the CD33 specific immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of myeloid cell-mediated disorders in human patients by a variety of techniques.
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope of CD33 antigen, such as monoclonal antibodies M195, L4B3, L1B2 ox MY9. The DNA segments encoding these regions ,will typically be joined to DNA segments encoding appropriate human framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the heavy and light chain CDR's of monoclonal antibody M195 are included in Fig. 19. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
The antibodies of the present invention will typically find use individually in treating hematologic malignancies. For example, typical disease states suitable Pt.'f/US9i /0971 i W~ 92/11018 '~ ~ u~ ~ ~y ~ ,1 __ for treatment include AML, CML, CMML, CMMOL and MDS (see, c~enerallv, Hoffbrand & Pettit, Essential Haematology, Blackwell Scientific Publications, Oxford (1980)). The antibodies may also be used for bone marrow ablation prior to bone marrow transplant.
Any humanized immunoglobulins of the present , invention may also be used in combination with other antibodies, particularly humanized antibodies reactive with different myeloid antigens. For example, suitable antigens to which a cocktail of humanized immunoglobulins may react include CD13, CD14, CD15, CD16 and CD34 (see, Leukocyte Typing III, op. cit., pp: 576-732).
The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic agents. Typically, the agents may include cytosine arabinoside and daunorubicin, but numerous additional agents (e.g., 6-thioguanine) well-known to those skilled in the art for leukemia treatment may also be utilized (see, Hoffbrund & Pettit., Op. cit.). A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill leukemia cells.
Humanized antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for detection of CD33 antigens, for isolating specific myeloid cells, or the like.
Tt will be understand that although the experiments pertain to the M195 antibody, producing humanized antibodies with high binding affinity for the CD33 antigen is also contemplated using CDR's from L4B3, L1B2, MY9 or other monoclonal antibodies that bind to an epitope of CD33.
EXPERIMENTAL
Cloning of heavy chain and light chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain reactions (E.Y. Loh et al., Science 243, 217 (1989)'), using 3' WO 92/11018 P~t.'T/US91/~9~1 t Vk '" ;?;~~~;w f-primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoRI and HindIII and 5 cloned into the pUCl8 vector for sequencing. For M195, two gamma-2a specific and two kappa specific clones were sequenced. The two gamma-2a clones and two kappa clones are respectively identical in sequence. The cDNA variable domain sequences and the deduced amino acid sequences are shown in 10 Fig. 19.
Construction and expression of chimeric antibody.
Two plasmid vectors were prepared .for construction and expression of the chimeric antibody genes. The plasmid 15 pVg1-dhfr (Fig. 20A) contains a human cytomegalovirus IEI
promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C-~1 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen -et al., Proc. Natl Acad. Sci. USA 80 , 2495 (1984)) 20 for selection. The plasmid pVk (Fig. 20B) is similar to pVgl-dhfr .but contains the human genomic Crc segment and the gpt gene. Derivatives of the M195 heavy and light chain variable regions were prepared from the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting 25 at the ATE codons and contained XbaI sites; the 3' primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and XbaI sites (see, Queen et al., Proc. Natl. Aced. Sci. USA 86, 10029 (1989)). The modified V regions were cloned into the Xbal sites of the 30 respective plasmid vectors between the CMV promoter and. the partial introns of the constant regions.
For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for 35 gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Purified chimeric M195 wU 92IttOt8 pCT/~JS91/09711 ~ll~~,°)'~'.i' antibody was shown to bind to U937 cells, which express the CD33 antigen, by flow cytometry (Fig. 21).
Computer modeling of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al. .
were followed (see, Queen et al., Proc. Natl. Acad. Sci. USA
86, 10029 (1989) and WO 90/07861). The more homologous a human antibody is to the original murine antibody, the less likely will combining the murine CDR's with the human framework be to introduce distortions into the CDR's that could reduce affinity. Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains. Based on sequence_homology search against the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Eu was chosen to provide the framework sequences for humanization of M195.
~0 The computer program ENCAD (M. Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the M195 variable region. The model was used to determine the amino acids in the M195 framework that were close enough to the CDR's to potentially interact with them (category 4 below).
To design the humanized light and heavy chain M195 variable regions, at each position the amino acid was chosen to be the same as in the Eu antibody, unless that position fell in one or more of four categorieso (1) The position fell within a CDR, 1 (2) The Eu amino acid was unusual for human antibodies at that position, whereas the M195 amino acid was typical for human antibodies at that position, (3) The position was immediately adjacent to a CDR, w0 92/1108 PC'T/L1S91/09711 ,.; ~_ ;~ ail ~Y~ ?~~ r;
i s Q~ ri a '._ ~:J a (4) The model described above suggested that the amino acid may be physically close to the antigen binding region (CDR'S).
In category (2), "unusual" is interpreted to include amino acids that occur in less than about 20% of the human sequences in the same subgroups (as defined by Kabat et al., op, cit.) as the Eu light and heavy chains, and "typical'° is interpreted to include amino acids that occur in more than about 25~ but generally more than 50% of the human sequences in those subgroups. For positions in these categories, the amino acid from the mouse M195 antibody was used: The amino acids in each category are shown in Table 8. Some amino acids may be in more than one category. The final sequences of the humanized M195 light and heavy chain variable domains are shown in Fig. 22, compared with the 1~u sequences.
Cateqorv Liaht Chain Heavy Chain 1 24-38, 54-60, 93-101 31-35, 50-66, 99-105 2 10, 52, 67, 110 93, 95, 98, 106, 107, 108, 110 ' ' 3 --. 30, 67, 98, 106 4 40, 52, 74 27, 30, 48, 68, 98 For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the same signal peptides as in the mouse M195 chains (Fig. 19), generally utilizing codons found in the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones. The nucleotide~sequences also included the same splice donor signals used in the chimeric genes and an Xbal site at each end. Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, ~VCI 92/11018 ~CClL1S91 /09711 ~i 9~ f~'~ l~ '1 -1 E,i ~ 9l (J
two pairs of overlapping oligonucleotides on alternating Strands were Syritheslzed that encompassed the entire coding sequences as well as the signal peptide and the splice donor Signal (Fl.g. 23). The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was about 110-140 bases long with about~a 15 base overlap. Double stranded DNA fragments were synthesized with Klenow polymerase from each pair of oligonucleotides, digested with restriction enzymes, ligated to the pUCl8 vector and sequenced. Two 1 to fragments with the respectively correct half-sequences were then ligated into the XbaI sites of the pVgl-dhfr or pVk expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions were carried out under conditions well°known in the art (Maniatis l~ 15 et al. , ox~. cit. ) The heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture 2~ 20 supernatant by ELISA, and antibody was purified from the best-producing clones. Antibody was purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody was eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris 2' 25 PH8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized M195 antibody was characterized in 3C 30 comparison to the murine and chimeric antibodies. The humanized antibody bound to U937 cells in a fluorocytometric analysis in a manner similar to the chimeric antibody (Fig. 21), showing that it recognizes the same CD33 antigen.
The affinity of the humanized antibody was 35 35 determined by competition with the radio-iodinated mouse M195 antibody (Fig. 24). The binding affinities were calculated according to the methods of Berzofsky (J. A. Berzofsky and I.,7.
W~ 92/11018 PCf/U~91/0971i 1% '1 Z\i .:.';J~.
Berkower, in Fundamental Immunoloav (ed. w.E. Paul), Raven Press (New York), 595 (1984)). The mouse M195 had an affinity comparable to the published value (Tanimoto et al., op. cit.) and the humanized M195 antibody had an affinity the same as the mouse M195 to within experimental error.
Humanized M195 is useful to mediate antibody-dependent cellular cytotoxicity when human effector cells and human CD33-expressing cells are used. This is analogous to other humanized antibodies, such as reported by Junghans et al., Cancer Research 50 , 1495 (1990).
Unfortunately, the use of non-human monoclonal antibodies such as M195 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens.
Example IV
Humanized Immunoqlobulins to CMV Antiaens Cytomegalovirus is a major pathogen of immunocompromised individuals, especially bone marrow transplant recipients, organ tansplant recipients, and AIDS
patients (see, aenerallv, Fields et al., Eds., Virology, 2nd ed., Raven Press, New York pp. 1981-2010 (1990)).
Approximately 15~ of bone marrow transplant patients develop CMV pneumonia, with an 85~ mortality rate (Meyers, Rev. Inf.
Dis. 11 (suppl. 7), S1691 (1989)). About 10~ of AIDS patients develop severe CMV disease; and congenitally acquired CMV, often with significant morbidity and mortality, affects 1% of newborns (Fields, o_p. cit.).
The drug ganciclovir is effective against certain forms of CMV infection, notably chorioretinitis and gastroenteritis, but is not very effective against CMV
pneumonia, and it has serious toxicity. Use of pooled human imunoglobulin preparations has shown some beneficial effect for prophylaxis of CMV in bone marrow transplant patients (Meyers, op. cit.), and a combination of high-dose immune globulin and ganciclovir has been reported effective against CMV pneumonia (Emanuel et al., Trans. Proc. XIX (suppl. 7), 132 (1987)). However, the marginal effectiveness, variable wo 9211 ~~ ~ L~ ~'. iZ ~ . PCT/US91/09711 70 .
potency and high cost of commercial human immune globulin remain serious problems. Hence, there is a great need for new drugs effective against CMV.
CMV is a member of the herpesvirus family of viruses, and as such, has a large double-stranded DNA core, a protein capsid, and an outer lipid envelope with viral glycoproteins on its surface. At least 8 proteins have been detected on the envelope of CMV (Britt et al., J. Virol. 62, 3309 (1988)) and others have been predicted to exist based on the DNA sequence of CMV (Chee et al., Nature 344, 774 (1990)).
Murine monoclonal antibodies have been produced against two especially significant CMV glycoproteins: gB, also called p130/55 or gp55-116, and gH, also called p86 (Rasmussen et al., Virology 163, 30 8 (1988) and Britt et al., op. cit.) and shown to neutralize infectivity of the virus. Three other neutralizing antibodies to gH are designated CMV5, CMV109 and CMV115. Human monoclonal antibodies to CMV have also been.
produced (Ehrlich et al., Hybridoma 6, 151 (1987)).
In animal models, murine monclonal antibodies have been shown effective in treating infections caused by various viruses, including members of the herpesvirus family (sea, e.g., Metcalf et al., Intervirol. 29, 39 (1988)). Hence, such antibodies maybe useful in treatment of CMV infections.
Unfortunately, the use of non-human monoclonal antibodies such as CMVS and CMV7,15 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens as explained below.
Thus, there is a need for improved forms of humanized immunoglobulins specific for CMV antigen that are substantially non-immunogenic in humans, yet easily and economically produced in a manner suitable for therapeutic formulation and other uses. The present invention fulfills these and other needs.
In accordance with the present invention, humanized immunoglobulins specifically reactive with CMV and CMV-infected cells are provided. These immunoglobulins, which have binding affinities to CMV specific antigens of at least .e: y) '1 ';
v .. ~. .;
~f .~ ;J
'71 about 10~ M~1, and preferably 108 M 1 to 101 M~1 or stronger, are capable of, e-ct., blocking CMV infection of cells. The humanized immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDR's) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with a CMV antigen. In a preferred embodiment, one or more of the CDR's will come from the CMV5, or CMV109 or CMV115 antibodies. The immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of cMV-mediated disorders in human patients by a variety of techniques.
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope of a CMV antigen, such as monoclonal antibodies CMV5 or CMV115. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate human framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the heavy and light chain CDR°s of monoclonal antibody CMVS are included in Fig. 25. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be' readily substituted for those sequences, as detailed below.
Polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (eTa., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in,the vectors pVk and pVg1-dhfr (Fig. 26) using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab')2 fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker (see Huston et al., op-cit., and Bird et al., op. cit.).
WO 92/11018 PCT/U~91/09711 ~J"~9toU~:::r::
The antibodies of the present invention will typically find use individually in treating CMV-related disorders. For example, typical disease states suitable for treatment include CMV pneumonia, neonatal CMV infection, CMV
mononucleosis and CMiI-related chorioretinitis and gastroenteritis: Any humanized immunoglobulins of the present invention may also be used in combination with other antibodies, particularly humanized antibodies reactive with different CMV antigens. For example, suitable antigens to which a cocktail of humanized immunoglobulins may react include the gB and gH proteins. The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic agents. Typically, the agents may include acyclovir or ganciclovir, but numerous additional agents well-known to those skilled in the art for CMV treatment may also be utilized. A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill CMV-infected cells.
CMV specific humanized antibodies of the present inven~cion can further find a wide variety of utilities zn vitro. By way of example, the antibodies can be utilized for detection of CMV antigens, for isolating specific CMV-infected cells, or the like.
In particular, the same method may be used to produce a humanized CMV109, CMV115 or other anti-CMV antibody as used to produce humanized CMVS herein.
EXPERIMENTAL
Cloning of heavy chain and light chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain reactions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers that hybridized to the constant -regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoR I sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoR I and HindIII and ll~~ 92/11018 fC.'T/11591/09711 7 3 ~ . ~ .~ :U .. .:,~ E
cloned into the pUCl8 vector for ser~uencing. For CMV5, two gamma°2a specific and two kappa specific clones were sequenced. The two gamma-2a clones and two kappa clones are respectively identical in sequence. The cDNA variable domain sequences and the deduced amino acid sequences are shown in Fig. 25A and 25B. Similarly, by using techniques, which are well-known in the art, cDNAs for the Ci~SV109 and CMV115 antibodies may be obtained and their sequence determined.
_Construction and expression of chimeric antibody.
Two plasmid vectors were prepared for construction and expression of the chimeric antibody genes. The plasmid pVgl-dhfr (Fig. 26A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C71 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen -et al., Proc. Natl. Acad. Sci. USA 80, 2495 (1983)) for selection. The plasmid pVk (Fig. 26B) is similar to pvgl-dhfr but contains the human genomic Cx segment and the gpt gene. Derivatives of the CMV5 heavy and light chain variable regions were prepared from the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting at the ATG colons and contained Xbal sites; the 3~ primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and XbaI sites (see, Queen et al., Proc. Natl. Acad. Sci. USA 86, 10029 (1989)). The modified V regions were cloned into the XbaI sites of the respective plasmid vectors between the cytomegalovirus promoter and the partial introns of the constant regions.
For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Purified chimeric CMVS
antibody was shown to bind to CMV-infected cells, which express the gH antigen, by immunostaining of CMV-infected human embryonic lung fibroblasts.
WO 92111018 F'CT/US91/09711 -d'~~'~ ~:r~
T i \.r : 1 '.v \l ~:.L
Computer modelina~ of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (see, Queen et al., Proc. Natl. Acad. Sci. USA
86, 10029 (1989) and WO 9o~o7s61). The more homologous a human antibody is to the original murine antibody, the less likely will combining the murine CDR's with the human framework be to introduce distortions into the CDR's that could reduce affinity. Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains. Based on sequence homology search against the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Wol was chosen to provide the framework sequences for humanization of CMV5.
The computer program ENCAD (M. Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the CMV5 variable region. The model was used to determine the amino acids in the CMVS framework that were close enough to the CDR's-.to potentially interact with them (category 4 below).
To design the humanized light and heavy chain CMV5 variable regions, at each position the amino acid was chosen to be the same as in the Wol antibody, unless that position fell in one or more of five categories:
(1) The position fell within a CDR, (2) The Wol amino acid was unusual for human antibodies at that position,- whereas the CMV5 amino acid was typical for human antibodies at that position, (3) The position was immediately adjacent to a CDR, (4) The model described above suggested that the amino acid may be physically close to the antigen binding region (CDR's).
In category (2), "unusual" is interpreted to include amino acids that occur in less,than about 20% of the human sequences wC~ 92/t~0~g P(.°T/US91/09711 b~cw.~~~~ a ~r. ' 7 5 ' 4>
ir. Ea' eJ t~
in the same subgroups (as defined by Kabat et al., off. cit.) as the Wol light and heavy chains, and "typical" is inter'pre'ted 'to include amino acids that occur in more than about 25% but generally more than 50% of the human sequences in those subgroups. For positions in these categories, the amino acid from the mouse CMV5 antibody was used. In addition, a position was in the fifth category if the Wol amino acid was highly unusual for human antibodies at that position, and the CMVS amino acid was different but also unusual. Then an amino acid typical for human antibodies at that position may be used.
The amino acids in each category are shown in Table 1. Some amino acids may be in more than one category.
The final sequences of the humanized CMVS light and heavy chain variable domains are shown in Fig. 27A-B, compared with the Wol sequences.
Cateqor~ Lictht Chain Heavy Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99-108 69, 80 2 69, 80 4 24, 27, 28, 30, 9?
For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the same signal peptides as in the mouse CMVS chains (Fig. 25), generally utili2ing codons found in the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones. The nucleotide sequences also included the same splice donor signals used in the chimeric genes and an XbaI site at each and. Hach gene was constructed from four overlapping W~ 92/11018 PC'~'/US91/09711 ~~ s~ ~, ...F ~.; p L! ~ C~ l~t 4. '-,, synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides on alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal (Fig. 28). The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was about 110-140 bases long with about a 15 base overlap. Double stranded DNA fragments were synthesized with Klenow polymerase from each pair of oligonucleotides, digested with restriction enzymes, ligated to the pUCl8 vector and sequenced. Two fragments with the respectively correct half-sequences were then ligated into the XbaI sites of the pVgl-dhfr or pVk .expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions were carried out under conditions well-known in the art (Maniatis et al., op. cit.) The heavy chain and light chain plasmids are transfected into Sp2/0 mouse myeloma cells by electroporation and cells are selected for gpt expression. Clones are 2o screened by assaying human antibody production in the culture supernatant by ELISA, and antibody purified from the best-producing clones. Antibody is purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody is eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer is exchanged into PBS by passing over a PD10 column (Pharmacia).
Humanized antibody was also produced by transient transfection. The heavy chain and light chain plasmids were transfected into 5194 cells (ATCC TIB 19) by the DEAE-dextran method (Queen et al., Mol. Cell. Biol. 4, 1043 (1984)), and humanized CMVS antibody was purified from the media supernatant as above. Antibody was quantitated by ELISA assay for human Ig.
WO 92/11018 PCf/U591/09711 :o ..-, r~ -~ .~ y 77 ;~,j a J ~ v~~ ;:
Properties of humanized antibodies.
The humanized CMV5 antibody was characterized in comparison to the murine and chimeric antibodies. The humanized CMV5 antibody was shown to bind about as well as the mouse and chimeric antibodies to CMV antigen, by immunostaining of CMV-infected human embryonic lung (HEL) cells (ATCC CCL 137). HEL cells monolayers in 96-well plates were infected wtih CMV at 0.01 pfu/cell, incubated for 4 days, dried at 37°C and stored wrapped at 4°C. 100 ~C1 blotto (5~
Carnation Instant Milk in PBS at pH 7.4) was added to each well and incubated at 37°C for 30 min. The blotto was poured off and 75 ~C1 of a series of 2-fold dilutions of mouse, chimeric and humanized CMVS antibody was added to the wells.
The plate was incubated 1 hr at 37°C and washed twice with blotto (each wash was .left on for 10 min). Then 75 ~1 of diluted peroxidase (HRP) conjugated goat anti-mouse or anti-human IgG (Tago) was added to each well and incubated for 1 hr at 37°C. The plate was washed 2x with PBS and 150 ~,1 of HRP
substrate solution was added to each well. Color was allowed to develop at room temperature. The plates were washed with water and air dried. The wells were examined under a microscope to determine the highest dilution of the antibodies that formed a colored precipitate on the CMV-infected cells.
For all three antibodies, 63 ng/ml was the least amount of antibody that produced a detectable precipitate, indicating that humanized CMV5 binds about as well as the mouse and chimeri.c antibodies.
To compare the affinities of mouse and humanized CMVS in another way, a competition experiment was performed.
Plates of CMV-infected HEL cells as above were incubated with blotto for 30 min at 37°C. The blotto was poured off and dilutions of mouse or humanized CMV5 were added to each well in 75 dal of PBS. Then 125 ~Cl of radio-iodinated mouse CMV5 (1 ~CCi/~g) in PBS, containing 28,000 cpm was added to each well and incubated at 37°C for 2.5 hr. The plate was washed 5 times with PBS, and the contents of each well were solubilized with 200 ~,l of 2% SDS and counted. Increasing concentrations W092/11~18 ,~ ~a :1 ,~ 9 Pf'1'/US91/~9711 " i ~ r ~ : _'., i .':
r ;,.o ~Li eJ i ~ .. _ ...
of mouse and humanized CMV5 inhibited binding of the radiolabeled CMV5 about equally well (Fig. 29), so humanized CMVS has approximatley the same binding affinity as mouse CV5.
An irrelevant antibody did not compete in this assay.
The ability of humanized CMV5 to neutralize CMV is compared to' that of mouse CMV5. Mouse and humanized CP~IVS are successively diluted by 2-fold in 100 ~1 of DME medium + 20 FCS in wells of a 96-well plate. 100 ~C1 of CMV, which has been diluted to contain 100 tissue culture infectious dose-5o%
(TCID50) units, are added to each well and incubated for 60 min at 37°C. Each well of antibody-virus mixture is added to a well of subconfluent HEL cells in a 96-well plate from which the medium has been removed. The cells are incubated for 5 days and cytopathic effect (CPE) is examined in each well under a microscope. The highest dilution of antibody that inhibits CPE by 90e is a measure of the neutralizing ability of the antibody. The humanized CMV5 antibody will neutralize CMV antibody approximately as well as the mouse CMVS antibody.
Example V
Tn mammals, the immune response is mediated by several types of cells that interact specifically with foreign material, i.e., antigens. One of these cell types, B cells, is responsible for the production of antibodies. Another cell type, T cells, include a wide variety of cellular subsets that destroy virally infected cells or control the in vivo function of both B cells and other hematopoi.etic cells, including T
cells. A third cell type, macrophages, process and present antigens in conjunction with major histocompatibility complex (MHC) proteins to T cells. Communication between these cell types is mediated in a complex manner by lymphokines, such as interleukins 1-6 and 7-IFN (see, generally, Paul, W.E., ed., Fundamental Immunology, 2nd ed., Raven Press, New York (1989)).
One important lymphokine is 7-IFN, which is secreted by some T cells. In addition to its anti-viral activity, 7-TFN stimulates natual killer (NK) cells, activates bV0 92/11~1$ PC'f/US91/~9711 7 9 , macrophages, and stimulates the expression of MHC malecules on the surface of cells (Paul, np. cit., pp. 622-624). Hence ~-IFN generally serves to enhance many aspects of immune function, and is a logical candidate for a therapeutic drug in cases where such enhancement is desired, e.g., in treating cancer. conversely, in disease states where the immune system is over-active, e.g., autoimmune diseases and organ transplant rejection, antagonists of 7--IFN may be used to treat the disease by neutralizing the stimulatory effects of 7-IFN.
One class of effective antagonists of 7-IFN are monoclonal antibodies that bind to and neutralize it (see, e.g., Van der Meide et al., J. Gen. Virol, 67, 1059 (1986)).
In in vitro and in vivo mouse models of transplants, anti-7-IFN antibodies have been shown to delay or prevent rejection (Landolfo et al., Science 229, 176 (1985) and Rosenberg et al., J. Immunol. 144, 4648 (1990)). Treatment of mice prone to develop a syndrome like systemic lupus erythematosus (SLE) with a monoclonal antibody to -~-IFN significantly delayed onset of the disease (Jacob et al., J. Exp. Med. 166, 798 (1987)). .Under some conditions, an anti-7-IFN antibody alleviated adjuvant arthritis in rats (Jacob et al., J.
Immunol. 142, 1500 (1989)), suggesting that anti-~-IFN may be effective against some cases of rheumatoid arthritis in human patients. Multiple sclerosis (MS) in patients is made worse by treatment with -~-IFN (Panitch et al., Neurology 36 (suppl.
1), 285 (1986)), so an anti-7-IFN antibody may alleviate MS.
Thus, an anti-7-IFN antibody may be effective in treating these and other autoimmune diseases.
For treatment of human patients, a murine monoclonal that binds to and neutralizes human 7-IFN (see, e.g., Yamamoto et al., Microbiol. Immunol. 32, 339 (1988)) may be used.
Another murine monoclonal antibody designated AF2 that neutralizes human 7-IFN, and inhibits binding of -~-IFN to its cellular receptor, is disclosed herein. Unfortunately, the use of non-human monoclonal antibodies such as AF2 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens.
rV~ 92/t 101 Pcavus9~ io9m 1 ..
:~. .~ ~~ .,: s I 1.. ~ i ''G 8 0 ,..
In accordance with the present invention, humanized immunoglobulins specifically reactive with 7-IFN epitopes are provided. These immunoglobulins, which have binding affinities to 7-IFN of at least about 10~ M'1, and preferably 108 M 1 to 101 M'1 or stronger, are capable of, e-ct. , neutralizing human ~-IFN. The humanized immunoglobulins will , have a human framework and will have one or more complementarity determining regions (CDR'S) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with 7-IFN. In a preferred embodiment, one or more of the CDR's will come from the AF2 antibody. Thus, the immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of autoimmune disorders in human patients by a wariety,of techniques.
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope.of 7-IFN, such as monoclonal antibody AF2. The DNA
segments encoding these regions will typically be joined to DNA segments encoding appropriate human framework regions.
Exemplary DNA sequences, which on expression code for the polypeptide.chains comprising the heavy and light chain CDR's of monoclonal antibody AF2 are included in Fig. 30. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
Alternatively, polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (e. a., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in the vectors pVk and pVgh-dhfr (Fig. 31) using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab')2 fragments. Single chain antibodies may be !3~~ 92/11018 ~(.'T/LJS91/09711 vF ~ ~l ,7 r3 ,~~ .'"
81 ~, -i~ .~' ; .~ >3 ,; '.
produced by joining VL and VH with a DNA linker (see Huston et al., op cit., and Bird et al., ob cit.).
The antibodies of the present invention will typically find use individually in treating autoimmune conditions. For example, typical disease states suitable for treatment include graft versus host disease and transplant rejection in patients undergoing an organ transplant, such as heart, lungs, kidneys, liver, etc. Other diseases include autoimmune diseases, such as Type T diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis.
F~umanized immunoglobulins of the present invention may also be used in combination with other antibodies, particularly humanized antibodies reactive with other lymphokines or lymphokine receptors. For example, suitable antigens to which a cocktail of humanized immunoglobulins may react include interleukins 1 through 10 and the p55 and p75 chains of the IL-2 receptor (see, Waldmann, Annu. Rev.
Biochem. 58, 875 (1989) and Queen et al., Proc. Natl. Acad.
Sci. USA 86, 10029 (1989)). Other antigens include those on cells responsible for the disease, e.g., the so-called "Clusters of Differentiation" (Leucocyte Typing III, ed. by A.J. McMichael, Oxford University Press (1987)). ' ' The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic agents. Typically, the agents may include non-steroidal anti-inflammatory agents (e. g., aspirin, ibuprofen), steroids (e. g., prednisone) and immunosuppressants (e. g., cyclosporin A, cytoxan), but numerous additional agents well-known to those skilled in the art may also be utilized.
A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immuriotoxins, e.g., to kill 7-IFN-secreting cells.
Humanized antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for detection of 7-IFN
antigens, or the like.
w~ 92n 1a18 F~ius9mo9~~ ~
'~ x s.,. :;
~~ j'_~.Jr1 82 EXPERIMENTAL
Cloning of heavy chain and lictht chain cDNA.
cDNAs for the heavy chain and light chain varialale .domain genes were cloned using anchored polymerise chain reactions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoR I sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoR I and HindIII and cloned into the pUCl8 vector for sequencing. For AF2, two gamma-2b specific and two kappa specific clones were sequenced. The two gamma-2b clones and two kappa clones are respectively identical in sequence. The eDNA variable domain sequences and the deduced amino acid sequences are shown in Fig. 30.
Construction and expression of chimeric antibody.
Two plasmid vectors were prepared for construction and expression of the chimeric antibody genes. The plasmid pVg1-dhfr (Fig. 31A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C71 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen et al., Proc. Natl. Acid. Sci. USA 80, 2495 (1984)) fox selection. The plasmid pVk (Fig. 31B) is similar to pVgl-dhfr but contains the human genomic Crc segment and the gpt gene. Derivatives of the AF2 heavy and light chain variable regions were prepared from the eDNAs by polymerise chain reaction. The 5' primers hybridized to the V regions starting at the ATE codons and contained XbaI sites: the 3' primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and Xbal sites (see, Queen et al., Proc. Natl. Acid. Sci. USA 86, 10029 (1989)). The modified V regions were cloned into the XbaI sites of the respective plasmid vectors between the CMV promoter and the partial introns of the constant regions.
~ ,a ,~ y'PCT/US91/09711 wo 9zono~s For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/o mouse myeloma cells by electrAporation and cells selected for gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Chimeric AF2 antibody was shown to bind to human ~y-IFN by ELISA.
Computer modeling of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (see, Queen et al., Proc. Natl. Acad. Sci. USA
86, 10029 (1989) and WO 90/07861). The more homologous a human antibody is to the original murine antibody, the less likely will combining the murine CDR's with the human framework be to introduce distortions into the CDR's that could reduce affinity. Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains. Based on sequence homology search against the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Eu was chosen to provide the framework sequences for humanization of AF2.
The computer program ENCAD (M. Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the AF2 variable region. The model was used to determine the amino acids in the AF2 framework that were close enough to the CDR's to potentially interact with them (category 4 below). To design the humanized light and heavy chain AF2 variable regions, at each position the amino acid was chosen to be the same as in the Eu antibody, unless that position fell in one or more of five categories:
(1) The position fell within a CDR, (2) The Eu amino acid was unusual for human antibodies at that position, whereas the AF2 amino acid was typical for human antibodies at that position, WO 92/11 ~18 PC.'i'/US91 /09731 ~~~~t~uf~:'.jl~y ._ (3) The position was immediately adjacent to a CDR, (4) The model described above suggested that the amino-acid may be physically close to the antigen binding region (CDR°s).
In category (2), "unusual'° is interpreted to include amino acids that occur in less than about 20% of the human sequences in the same subgroups (as defined by Kabat et al., op. cit.) as the Eu light and heavy chains, and "typical°° is interpreted to include amino acids that occur in more than about 25~ but generally more than 50% of the human sequences in those subgroups. For positions in these categories, the amino acid from the mouse AF2 antibody was used. In addition, a position was in the fifth category if the Eu amino acid was highly unusual for human antibodies at that position, and the AF2 amino acid was different but also unusual. Then an amino acid typical for human antibodies at that position may be used.
The amino acids in each category are shown in Table 10. Some amino acids may be in more than one category.
The final sequences of the humanized AF2 light and heavy chain variable domains are shown in Fig. 32, compared with the Eu sequences. _ TABLE l0 Cateaory Lictht Chain Heavy Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99-106 2 48 93, 95, 98, 107, 108, 109, 111 3 . 30, 98, 107 4 48, 70 27, 28, 30, 98, 107 For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, plus typical immunoglobulin signal sequences, generally i ~ ,~ PCT/US91/09711 i~V~ 92/1101 iatje.lJi~V v 85.
utilizing codons found in the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones. The nucleotide sequences also included the same splice donor signals used in the chimeric genes and an xbaI site at each end. Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oliganucleotides on alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal (Fig. 33) The oligonucleotides were synthesized on an Applied Biosystems 3808 DNA synthesizer. Each oligo was about 110-140 bases long with about a 15 base overlap. Double stranded DNA fragments were synthesized with Klenow polymerase from each pair of a5 oligonucleotides, digested with restriction enzymes, ligated to the pUCl8 vector and sequenced. Two fragments with the respectively correct half-sequences are then ligated into the Xbal sites of the pVgl-dhfr or pVk expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions are carried out under canditions well-known in the art (Maniatis et al., op. cit.) The heavy chain and light chain plasmids are transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones are screened by assaying human antibody production in the culture supernatant by ELISA, and antibody purified from the best-producing clones. Antibody is purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody is eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer is exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized AF2 antibody is characterized in comparison to the murine and chimeric antibodies. The humanized antibody will bind to 7-IFN in an ELISA assay in a i3'0 92/11018 PU'f/US91/09711 Lp~v~:J~w '~~ ._ $6 manner similar to the mouse and chimeric antibodies, showing that it recognizes ,7-IFN.
To compare the binding affinities of mouse AF2 antibody and humanized AF2 antibody, a competitive ELISA assay is performed. An ELISA plate is coated with human recombinant 7-IFN by adding 100 ~,1 of a 500 ng/ml solution of 7-IFN in PBS
to each well and incubating overnight at 4°C. Subsequent steps are carried out at room temperature. The -~-IFN solution is removed and 200 ~,1 of ELISA buffer (0.1o Twsen-20, 1%
Bovine serum albumin in PBS) is added to each well and incubated for 1 hr. After removing the solution, varying amounts of competitor antibody (mouse AF2 or humanized AF2) in 100 ~l PBS is added to each- well, along with an amount of biotinylated AF2 predetermined to give a good ELISA response.
The plate is incubated for 1 hr and then washed 3 times with ELISA buffer. An amount of horseradish peroxidase (HRP)-conjugated strepavidin predetermined to be in excess is added in 100 ~,1 PBS to each well and incubated for 30 min. The plate is washed 3 times in ELISA buffer, and 100 ~,1 of substrate solution for HRP is added to each well. The plate is incubated for 10-30 min, and the optical density of each well is determined with an ELISA reader (BioRad). The decrease in optical density with increasing concentrations of competitor antibodies mouse AF2 and. humanized AF2 are plotted.
Mouse AF2 and humanized AF2 will compete similarly, showing that their binding affinities for ~-IFN are approximately the same. The procedures used are well known in the art (e. g., Harlow and Lane, og. cit.).
An important biological activity of 7-IFN is the induction of expression of class II HLA antigens on cells. To determine the ability of mouse and humanized AF2 to neutralize this activity, about 5 x 104 HS294T cells (Basham et al., J.
Immunol. 130, 1492 (1983)) are plated in 1.0 ml DMEM medium + , 10% FCS in each well of a 24-well plate. After overnight incubation, 0.1 nM interferon and varying amounts of mouse or humanized AF2 are added to the cells, and the plate is incubated for 72 hr. The cells are removed from the plate with 0.05 M EDTA, stained with monoclonal antibody L243 from the American Type Culture Collection (ATCC) against HLA-D
antigen, washed, stained with FITC conjugated goat anti-mouse Ig and analyzed with a FACScan (Becton-Dickinson). Increasing concentrations of mouse AF2 reduce fluorescence of the cells (Fig. 34), indicating the antibody is preventing induction of HLA-D by 7-IFN. The humanized AF2 will act similarly to mouse AF2 in this assay, showing that it neutralizes the biological activity of 7-IFN.
From the foregoing, it will be appreciated that the humanized immunoglobulins of the present invention offer numerous advantages over other ~-IFN specific antibodies. In comparison to mouse monoclonal antibodies, the present humanized immunoglobulins can be more economically produced and contain substantially less foreign amino acid sequences.
This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.
Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
clones are identical in sequence. This heavy chain cDNA
fragment encodes a signal peptide of 19 amino acids, a V
region in mouse heavy chain subgroup IIIB, a D segment, and a JH1 segment with 4 alterations compared to the genomic JH1 sequence. The deduced amino acid sequence is shown in Fig.
14A.
The five kappa specific clones belong to two groups.
Two clones are identical and encode a kappa chain.in which the conserved amino acid 23 cysteine has been substituted by a tyrosine, probably representing the non-productive allele.
The other three clones have an identical sequence encoding a signal peptide sequence of 20 amino acids, a V region in mouse kappa chain subgroup III, and a Jk2 segment with a single alteration compared to the genomic Jk2 sequence (Fig. 14B).
The validity of the heavy chain and the kappa chain sequences was subsequently confirmed by the construction and expression of a chimeric antibody as discussed below.
The heavy chain and the kappa chain of Fd138-80 were cloned similarly. Three clones each of the heavy chain and the kappa chain were sequenced. All three heavy chain clones have an identical sequence encoding a signal peptide sequence of l9,amino acids, a V region in mouse heavy chain subgroup II, a D segment and the JN3 segment (Fig. 14C). The three kappa clones are also identical in sequence. This light chain fragment encodes a signal peptide sequence of 20 amino acids, a V region gene in mouse kappa chain subgroup V and the Jk5 segment (Fig. 14D). Both chains shown no irregularities in coding sequence: their validity was subsequently confirmed by construction and expression of a chimeric antibody.
Construction and expression of chimeric antibodies.
Two plasmid vectors were prepared for construction and expression of 'the chimeric antibody genes. The plasmid , pVgl (Fag. 15A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C,~1 segment including part of the preceding intron, and the hygromycin gene (Blochlinger et al., Mol.
WO 921i 1018 F'C.'T/US91/~9711 ~5 1~ ~i -' 'i ;~
~~ 4~ v ;~ :: - -= 53 Cell. Biol. 4, 2929 (1984)) for selection. The plasmid pVk (Fig. 15B) is similar to pVg1 but contains the human genomic C~
segment and the gpt gene. Derivatives of the Fd79 and Fd138°
80 heavy and light chain variable regions were prepared from 5 the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting at the ATG codons and contained XbaI sitest the 3' primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and Xbal sites (see, C. Queen et al., Froc. Natl.
Acad. Sci. USA 86, 10029 (1989)). The modified V regions ware cloned into the XbaI sites of the respective plasmid vectors between the CMV promoter and the partial introns of the constant regions.
For expression of the chimeric antibodies, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Purified chimeric Fd79 and Fd138 °80 antibodies were shown to bind to HSV-1 infected vero cells by flow cytometry. Viral neutralization assays also indicated that the chimeric antibodies retain the neutralization activities of the marine antibodies (data not shown, but see below for similar results with humanized antibodies).
Comguter modeling of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (C. -Queen et al., Proc. Natl. Aced. Sci. USA 86, 10029 (1989)). The more homologous a human antibody is to the original marine antibody, the less likely,will combining the marine CDRs with the human framework be to introduce distortions into the CDRs that could reduce affinity.
Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of. the two chains. Based on sequence homology search against 8 PCf/US91/09711 it/ ~~~~~~IJ
the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Pom was chosen to provide the framework sequences for humanization of Fd79.
The computer program ENCAD (Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the Fd79 variable region. Inspection of the refined model of murine ~'d79 revealed two amino acid residues in the framework that are close enough to have significant contacts with the CDR
residues (Table 4). Lys in light chainNBRF position 49 has contacts with 3 amino acids in CDR2 of the light chain (L50 Tyr, L53 Asn, L55 Glu) and 2 amino acids in CDR3 of the heavy chain (H99 Asp, H100 Tyr): Leu in heavy chain position 93 also shows interactions with 2 amino acids in CDR2 of the heavy chain (H35.Ser, H37 Val) and an amino acid in CDR3 of the heavy chain (H100C Phe). Hence, L49 Lys and H93 Leu were retained in the construction of humanized Fd79, as their replacement with human Pom framework residues would be likely to introduce distortions into the CDRs. Also, 7 other residues in the Pom framework (5 in the light chain and 2 in the heavy chain) were substituted with common human residues (identical to the murine Fd79 sequence in 6 of the choices) because of their rare occurrence in other human antibodies.
The elimination of unusual amino acids in the framework may further reduce immunogenicity. The murine Fd79 sequences and the corresponding humanized sequences are shown in Fig. 14A, B. Substituted residues in the Pom framework are underlined.
WO 92/1101 PC.'T/bJS91/09711 '"'~iJ~~~~':
5 :: r~
Residues in the framework sequence showing contacts with residues in the hypervariable regions.
5 Residue No.1 Amino Acid Contactinct CDR residuesz Fd79 L4g Lys L50X, L53N, L55E, H99D, HlOOX
H93 Leu H35S, H37V, H100CF
Fd138-80 L36 His L34V, L89Q
H27 Tyr H32H, H34I
H30 Tyr H32H, H53R
H48 Phe H63F
H66 Lys H63F
H67 . Ala H63F
1. The amino acid residues are numbered according to the Kabat system (E.A. Kabat et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD (1987)): the first letter (H or L) stands for the heavy chain or light chain. The following number is the residue number. The last letter is the amino acid one letter code.
2. The hypervariable regions are defined according to Kabat:
Light chain CDR1: residue 24-34t CDR2: 50-56; CDR3: 89-9,7.
Heavy chain CDRl: 31-35: CDR2: 50-65; CDR3: 95-102.
Similarly, the murine heavy chain and light chain sequences of Fd138-80 were subjected to sequence homology search against the NBRF protein sequence database. The sequences of the human antibody Eu were selected to provide the framework sequences for humanized Fd138-80. Inspection of a computer-generated model of Fd138-80 revealed 6 amino acid residues in the framework that are close enough to have < important contacts with CDR, residues. The residues and their contacting counterparts are listed in Table 4; these murine residues were retained in the construction of humanized Fd138-80. Two other residues (L87 Pile and H37 Met) show significant contacts with L98 Phe, which is immediately adjacent to CDR3, WO 92/11018 1'CT/US91/09711 ~~~~!jt~:r, .: 56 so these two mouse residues were also retained. Eight amino acids in the Eu framework (2 in the light chain and 6 in the heavy chain) were substituted with the murine residues (which are also consistent with the human consensus residues) because of their rare occurrence in other human antibodies. The murine Fd138-80 sequences and the corresponding humanized sequences are shown in Fig. 14C. Substituted residues in the Eu framework are underlined.
For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the signal peptides, generally utilizing colons found in the mouse sequence. Several degenerate colons were changed to create restriction sites or to remove undesirable ones. The nucleotide .sequences also included the same splice donor signals used in the chimeric genes and an XbaI site at each end. Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides on alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal. The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was~about 110-140 bases long with a 15 base overlap. Double stranded DNA
fragments were synthesized with Klenow polymerase, digested with restriction enzymes, ligated to pUClB vector and sequenced. The two fragments with the correct sequences were then ligated into the XbaT sites of pVgl or pVk expression vectors, The synthetic genes were then cloned into the pVgl and pVk expression vectors. For each humanized antibody constructed, the heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by ELISA, and antibody was purified from the best-producing clones. Antibodies were purified by passing tissue w0 92imo1g PCT/US91/09711 .:W-, ~ ~ ~ ,s ~ :s 5~. l..i.V: ., _ ..
culture supernatant over a column of staphylococcal protein A--Sepharose CL-4B (Pharmacia). The bound antibodies were eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized Fd79 and Fd138-80 antibodies were characterized in comparison to the marine and chimeric antibodies. Both humanized antibodies bind to Vero cells infected with HSV-1 in a fluorocytometric analysis in a manner similar to the chimeric antibodies (Fig. 16), suggesting that they recognize their respective viral antigens. To more quantitatively assess the binding activity, radioiodinated marine antibodies were bound to virally infected cells and Scatchard analysis performed.
The affinities of the humanized antibodies were determined by competition with the iodinated antibodies. Vero cells infected with HSV-1 were used as source of gB and gD
antigens. Increasing amounts of competitor antibody (mouse or humanized) were added to 1.5 ng of radioiodinated tracer mouse antibody (2uCi/ug) and incubated with 4 x 105 infected Vero cells in 0.2 ml of binding buffer (PBS + 2% FCS + 0.1% azide) for 1 hr. at 4°C. Cells were washed and pelleted, and their radioactivities were measured. The concentrations of bound and free tracer antibody were calculated. The binding affinities were calculated according to the methods of Berzofsky (J. A. Berzofsky and I.J. Berkower, in Fundamental Immunoloav (ed. W.E. Paul), Raven Press (Idew York), 595 (1984)).
The measurements indicate that there is no significant loss of binding affinities in the humanized antibodies (Table 5). Specifically, there is an approximately 2-fold decrease in affinity in humanized Fd79 compared to the marine Fd79 (Ka of 5.3 x 10' M 1 vs. 1.1 x 108 M 1) . The affinity of humanized Fd138-80 is comparable to that of the marine antibody (Ka of 4.8 x 10' M-1 vs 5.2 x 10' M 1) .
WO 92/11018 PC'1'/US91/0~?'711 Binding affinities of marine and humanized antibodies.
Mouse Humanized Ka (M 1) Ka (M 1) Fd79 (anti-gB) 1.1 x 108 5.3 x 10' 1. 0 Fd138-80 (anti-gp) 5.2 x 10~ 4.8 x 10~
Marine Fd79 and Fd138-80 have been shown to neutralize HSV-1 in vitro without complement (J. Koga et al., Virology 151, 385 (1986)), so the neutralizing activities of the humanized antibodies were compared with the mouse antibodies. Serial dilutions of equal quantities of marine and humanized antibodies were incubated with virus for 1 hr.
before inoculation onto Vero cells. After 4 days, cells were stained with neutral red to visualize plaques. Results from these plaque reduction assays indicated that both humanized Fd79 and Fd138-80 neutralize virus, as efficiently as their marine counterparts (Figs. 17A and B). Both humanized and marine Fd79 cause a 90% reduction of plaques at an antibody concentration of 10 nM (1.5 ug/ml). Similarly, humanized and marine Fd138-80 were able to cause a 90% plaque reduction at equivalent levels.
The antibodies were also investigated for their ability to protect cells from viral spread in tissue culture.
Vero cells were inoculated with virus at 0.1 pfu/cell and allowed to adsorb for 2 hrs, at 37°C before addition of to ug/ml antibody. After four days, cells were stained with an anti-gB antibody for detection of viral antigens on infected cells. Results indicated that both marine and humanized Fd79 at 10 ug/ml protected culture cells from infection (Fig. 38A):
However, neither marine nor humanized Fd138-80 were able to protect cells against viral spread (Fig. 18B), despite their ability to neutralize virus before inoculation. Both gB and gD are thought to be associated with cell fusion and virus infectivity (W. Cai et al., J. Virol. 62, 2596 (1988) and A.O.
WO 92/i i 018 PCC f/LJ531 /09711 :p f4 i C, ti ~: !!
~a"t'vt, :.:'..
Fuller and P.G. Spear, Proc. Natl. Aced. Sci. USA 84, 5454 (1987)). However, it is possible that Fd79 blocks both the infectivity and cell fusion functions of gB, while Fd138-80 blocks only the infectivity function of gD, so virus can still spread cell-to-cell.
The binding, neutralization and protection results all indicate that the humanized Fd79 and Fd138-80 antibodies have retained the binding activities and the biological properties of the marine monoclonal antibodies. The availability of humanized antibodies with specificity for HSv gB and gD, inter alia, provides an opportunity for studies of the in vivo potency and immunogenicity of humanized antibodies in treating viral diseases. The recognition by Fd79 and Fd138-80 of type-common epitopes of gB and gD (J. Koga et al., Virology 151, 385 (1986)) expands the therapeutic potential to herpes simplex virus type 2 as well as type 1.
Protection from herges simplex virus type 2 lethal infections in mouse model b~,humanized Fd79 and Fd138-80.
To determine the efficacy of humanized antibodies against herpes infections in vivo, humanized antibodies were injected into mice before and after inoculation of lethal doses of HSV-2, and the mortality rates were monitored.
Groups of animals were treated intraperitoneal with 0.9, 0.3 or 0.1 mg of each of humanized Fd79 or Fd138-80 at 24 hr before or 24 hr. after viral inoculation. Groups of 10 mice were challenged intranasally with lethal doses of Hsv-2. Mice were monitored for three weeks. The mortality rates were shown in the following tables.
The results show that significant protection against HSV-2 infection of mice was obtained with humanized Fd79 and humanized Fd138-80.
W~ 92111018 PC1'/11591 /09711 ;'.~~ 'tj ~ ~ C~ ',' A'~ . 6 0 EFFECT OF PRE-TREATMENT (-24h) WITH HSV ANTIBODY ON THE MORTALITY
Mortality Treatment Number Percent P-Value Control 13/15 87 --_ Place3~o 13/ 15 87 NS
Mu Fd 138 0.9 mg 3/10 30 <0.001 0.3 mg 5/10 50 0.01 0.1 mg 5/10 50 0.08 Hu Fd 138 0.9 mg 1/10 10 <o.ool 0.3 mg 8/10 80 NS
0.1 mg 7/10 70 NS
Mu Fd 79 0.9 mg 0/10 0 <0.001 0.3 mg 2/10 20 <0.01 O.l mg 4/10 40 <0.05 Hu Fd 79 0.9 mg 1/10 10 <0.01 0.3 mg 3/10 30 0.08 0.1 mg 5/10 50 0.08 wo 9ziaaoag p('T/lJS9a/o97a1 ;, ,.: ~a ~';
61 ~'~~
EFFECT OF POST-TREATMENT (+24h) ~IITH HSV ANTIBODY ON THE MORTALITY
OF MICE INOCULATED INTRANASALLY i9ITH HSV--2 Mortality Treatment Number Percent P-Value Control 12/15 80 ---Placebo 15/15 100 NS
Mu Fd 138 0.9 mg 2/10 20 <0.001 0.3 mg 4/10 40 0.001 0.1 mg 5/10 50 <0.01 Hu Fd 138 0.9 mg 3/10 30 <0.001 0.3 mg 3/10 30 <0.001 0.1 mg 9/10 90 NS
Mu Fd 79 0.9 mg 5/10 50 <0.01 0.3 mg 3/10 30 <0.001 0.1 mg 6/10 60 <0.05 Hu Fd 79 0.9 mg 3/10 30 <0.001 0.3 mg 3/10 30 <0.001 0.1 mg 9/10 90 NS
The use of a combination of two or more humanized antibodies in therapy is important for reducing tha development taf antibody resistant strains. Combination therapy of humanized antibodies with other antiviral agents such as acyclovir provides further opportunities to combat diseases when chemotherapeutic agents alone have not been effective. As Fd79 and Fd138-80 reduce the frequency of viral persistence in a murine ocular model (J. F. Metcalf et al., Cur. Eye Res. 6, 173 (1987)), the humanized antibodies, typically together with other antiviral agents, are capable of reducing episodes of recurrent genital infection, an area where traditional anti-viral agents have not been effective (L. Corey et al., N. Engl. J. Med. 306, 1313 (1982)).
Incorporation of the human constant domains can also enhance WO 92/11018 fC.'f/U~91/097I1 Sz ,~ , 6z ~~9~U~~.~~:1::
effector functions, such as antibody-dependent cellular cytotoxicity, leading to greater therapeutic efficiency in human patients.
Example III
Humanized Immunocrlobulins to CD33 Antigen There are about 10,000-15,000 new cases of myeloid (also called non-lymphocytic or granulocytic) leukemia in the U.S. per year (Cancer Facts & Figures, American Cancer Society, 1987). There are two major forms of myeloid , leukemia: acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). Despite treatment with chemotherapy, long-term survival in patients with AML is less than 10-20% (Clarkson et al., CRC Critical Review in Oncology/~Iematology 4, 221 (1986)), and survival with CML and related diseases such as chromic myelomonocytic leukemia (CMML), chronic monocytic .leukemia (CMMOL) and myelodysplastic syndrome (MDS) is even lower.
The p67 protein or CD33 antigen is found on the surface of progenitors of myeloid cells and of the leukemic cells of most cases of AML, but riot on lymphoid cells or non-hematopoiet~.c cells (see, Leucocyte Typing III, ed. by A.J.
McMichael, Oxford University Press, pp. 622-629 (1987).
Antibodies that are known to bind to the CD33 antigen include L4B3, L1B2 and MY9 (Andrews et al., Blood 62, 124 (1983) and Griffin et al., Leukemia Research 8, 521 (1984)).
Another antibody that binds to CD33 is M195 (Tanimoto et al., Leukemia 3, 339 (1989) and Scheinberg et al., Leukemia 3, 440 (1989)). The reactivity of M195 with a wide variety of cells and tissues was tested. Among narmal cells, M195 was reported to bind only to some monocytes and , myeloid progenitor cells. The research also reported that it does not bind to other hematopoietic cells or to non- .
hematopoietic tissues. M195 bound to cells of most cases of AML and all cases of CML in myeloblastic phase.
A phase I clinical trial of M195 in AML has been conducted (Scheinberg et al., Proc. ASCO 9, 207 (1990)). M195 ego 9aiaaoas P~-ri»s9aio9~aa .:~:si::,;,;~~t~
6 3 . ~ ~s a ~ '-:
radiolabeled with iodine-131 was found to rapidly and specifically target leukemic cells in both the blood and bone marrow.
In accordance with the present invention, humanised immunoglobulins specifically reactive with CD33 related epitopes are provided. These immunoglobulins, which have binding affinities to CD33 of at least abaut 10' M-', and preferably 108 M 1 to 101° M-1 or stronger, are capable of, era. , destroying leukemia cells. The humani2ed immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDR's) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with CD33 antigen. In a preferred embodiment, one or more of the CDR's will come from the M195 antibody.
Importantly, M195 does not bind to the ultimate hematopoietic stem cells, so M195 used in therapy will minimally interact with and destroy those cells, which are critical for generating all blood cells. Thus, the CD33 specific immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of myeloid cell-mediated disorders in human patients by a variety of techniques.
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope of CD33 antigen, such as monoclonal antibodies M195, L4B3, L1B2 ox MY9. The DNA segments encoding these regions ,will typically be joined to DNA segments encoding appropriate human framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the heavy and light chain CDR's of monoclonal antibody M195 are included in Fig. 19. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
The antibodies of the present invention will typically find use individually in treating hematologic malignancies. For example, typical disease states suitable Pt.'f/US9i /0971 i W~ 92/11018 '~ ~ u~ ~ ~y ~ ,1 __ for treatment include AML, CML, CMML, CMMOL and MDS (see, c~enerallv, Hoffbrand & Pettit, Essential Haematology, Blackwell Scientific Publications, Oxford (1980)). The antibodies may also be used for bone marrow ablation prior to bone marrow transplant.
Any humanized immunoglobulins of the present , invention may also be used in combination with other antibodies, particularly humanized antibodies reactive with different myeloid antigens. For example, suitable antigens to which a cocktail of humanized immunoglobulins may react include CD13, CD14, CD15, CD16 and CD34 (see, Leukocyte Typing III, op. cit., pp: 576-732).
The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic agents. Typically, the agents may include cytosine arabinoside and daunorubicin, but numerous additional agents (e.g., 6-thioguanine) well-known to those skilled in the art for leukemia treatment may also be utilized (see, Hoffbrund & Pettit., Op. cit.). A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill leukemia cells.
Humanized antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for detection of CD33 antigens, for isolating specific myeloid cells, or the like.
Tt will be understand that although the experiments pertain to the M195 antibody, producing humanized antibodies with high binding affinity for the CD33 antigen is also contemplated using CDR's from L4B3, L1B2, MY9 or other monoclonal antibodies that bind to an epitope of CD33.
EXPERIMENTAL
Cloning of heavy chain and light chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain reactions (E.Y. Loh et al., Science 243, 217 (1989)'), using 3' WO 92/11018 P~t.'T/US91/~9~1 t Vk '" ;?;~~~;w f-primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoRI and HindIII and 5 cloned into the pUCl8 vector for sequencing. For M195, two gamma-2a specific and two kappa specific clones were sequenced. The two gamma-2a clones and two kappa clones are respectively identical in sequence. The cDNA variable domain sequences and the deduced amino acid sequences are shown in 10 Fig. 19.
Construction and expression of chimeric antibody.
Two plasmid vectors were prepared .for construction and expression of the chimeric antibody genes. The plasmid 15 pVg1-dhfr (Fig. 20A) contains a human cytomegalovirus IEI
promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C-~1 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen -et al., Proc. Natl Acad. Sci. USA 80 , 2495 (1984)) 20 for selection. The plasmid pVk (Fig. 20B) is similar to pVgl-dhfr .but contains the human genomic Crc segment and the gpt gene. Derivatives of the M195 heavy and light chain variable regions were prepared from the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting 25 at the ATE codons and contained XbaI sites; the 3' primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and XbaI sites (see, Queen et al., Proc. Natl. Aced. Sci. USA 86, 10029 (1989)). The modified V regions were cloned into the Xbal sites of the 30 respective plasmid vectors between the CMV promoter and. the partial introns of the constant regions.
For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for 35 gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Purified chimeric M195 wU 92IttOt8 pCT/~JS91/09711 ~ll~~,°)'~'.i' antibody was shown to bind to U937 cells, which express the CD33 antigen, by flow cytometry (Fig. 21).
Computer modeling of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al. .
were followed (see, Queen et al., Proc. Natl. Acad. Sci. USA
86, 10029 (1989) and WO 90/07861). The more homologous a human antibody is to the original murine antibody, the less likely will combining the murine CDR's with the human framework be to introduce distortions into the CDR's that could reduce affinity. Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains. Based on sequence_homology search against the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Eu was chosen to provide the framework sequences for humanization of M195.
~0 The computer program ENCAD (M. Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the M195 variable region. The model was used to determine the amino acids in the M195 framework that were close enough to the CDR's to potentially interact with them (category 4 below).
To design the humanized light and heavy chain M195 variable regions, at each position the amino acid was chosen to be the same as in the Eu antibody, unless that position fell in one or more of four categorieso (1) The position fell within a CDR, 1 (2) The Eu amino acid was unusual for human antibodies at that position, whereas the M195 amino acid was typical for human antibodies at that position, (3) The position was immediately adjacent to a CDR, w0 92/1108 PC'T/L1S91/09711 ,.; ~_ ;~ ail ~Y~ ?~~ r;
i s Q~ ri a '._ ~:J a (4) The model described above suggested that the amino acid may be physically close to the antigen binding region (CDR'S).
In category (2), "unusual" is interpreted to include amino acids that occur in less than about 20% of the human sequences in the same subgroups (as defined by Kabat et al., op, cit.) as the Eu light and heavy chains, and "typical'° is interpreted to include amino acids that occur in more than about 25~ but generally more than 50% of the human sequences in those subgroups. For positions in these categories, the amino acid from the mouse M195 antibody was used: The amino acids in each category are shown in Table 8. Some amino acids may be in more than one category. The final sequences of the humanized M195 light and heavy chain variable domains are shown in Fig. 22, compared with the 1~u sequences.
Cateqorv Liaht Chain Heavy Chain 1 24-38, 54-60, 93-101 31-35, 50-66, 99-105 2 10, 52, 67, 110 93, 95, 98, 106, 107, 108, 110 ' ' 3 --. 30, 67, 98, 106 4 40, 52, 74 27, 30, 48, 68, 98 For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the same signal peptides as in the mouse M195 chains (Fig. 19), generally utilizing codons found in the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones. The nucleotide~sequences also included the same splice donor signals used in the chimeric genes and an Xbal site at each end. Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, ~VCI 92/11018 ~CClL1S91 /09711 ~i 9~ f~'~ l~ '1 -1 E,i ~ 9l (J
two pairs of overlapping oligonucleotides on alternating Strands were Syritheslzed that encompassed the entire coding sequences as well as the signal peptide and the splice donor Signal (Fl.g. 23). The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was about 110-140 bases long with about~a 15 base overlap. Double stranded DNA fragments were synthesized with Klenow polymerase from each pair of oligonucleotides, digested with restriction enzymes, ligated to the pUCl8 vector and sequenced. Two 1 to fragments with the respectively correct half-sequences were then ligated into the XbaI sites of the pVgl-dhfr or pVk expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions were carried out under conditions well°known in the art (Maniatis l~ 15 et al. , ox~. cit. ) The heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture 2~ 20 supernatant by ELISA, and antibody was purified from the best-producing clones. Antibody was purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody was eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris 2' 25 PH8Ø The buffer was exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized M195 antibody was characterized in 3C 30 comparison to the murine and chimeric antibodies. The humanized antibody bound to U937 cells in a fluorocytometric analysis in a manner similar to the chimeric antibody (Fig. 21), showing that it recognizes the same CD33 antigen.
The affinity of the humanized antibody was 35 35 determined by competition with the radio-iodinated mouse M195 antibody (Fig. 24). The binding affinities were calculated according to the methods of Berzofsky (J. A. Berzofsky and I.,7.
W~ 92/11018 PCf/U~91/0971i 1% '1 Z\i .:.';J~.
Berkower, in Fundamental Immunoloav (ed. w.E. Paul), Raven Press (New York), 595 (1984)). The mouse M195 had an affinity comparable to the published value (Tanimoto et al., op. cit.) and the humanized M195 antibody had an affinity the same as the mouse M195 to within experimental error.
Humanized M195 is useful to mediate antibody-dependent cellular cytotoxicity when human effector cells and human CD33-expressing cells are used. This is analogous to other humanized antibodies, such as reported by Junghans et al., Cancer Research 50 , 1495 (1990).
Unfortunately, the use of non-human monoclonal antibodies such as M195 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens.
Example IV
Humanized Immunoqlobulins to CMV Antiaens Cytomegalovirus is a major pathogen of immunocompromised individuals, especially bone marrow transplant recipients, organ tansplant recipients, and AIDS
patients (see, aenerallv, Fields et al., Eds., Virology, 2nd ed., Raven Press, New York pp. 1981-2010 (1990)).
Approximately 15~ of bone marrow transplant patients develop CMV pneumonia, with an 85~ mortality rate (Meyers, Rev. Inf.
Dis. 11 (suppl. 7), S1691 (1989)). About 10~ of AIDS patients develop severe CMV disease; and congenitally acquired CMV, often with significant morbidity and mortality, affects 1% of newborns (Fields, o_p. cit.).
The drug ganciclovir is effective against certain forms of CMV infection, notably chorioretinitis and gastroenteritis, but is not very effective against CMV
pneumonia, and it has serious toxicity. Use of pooled human imunoglobulin preparations has shown some beneficial effect for prophylaxis of CMV in bone marrow transplant patients (Meyers, op. cit.), and a combination of high-dose immune globulin and ganciclovir has been reported effective against CMV pneumonia (Emanuel et al., Trans. Proc. XIX (suppl. 7), 132 (1987)). However, the marginal effectiveness, variable wo 9211 ~~ ~ L~ ~'. iZ ~ . PCT/US91/09711 70 .
potency and high cost of commercial human immune globulin remain serious problems. Hence, there is a great need for new drugs effective against CMV.
CMV is a member of the herpesvirus family of viruses, and as such, has a large double-stranded DNA core, a protein capsid, and an outer lipid envelope with viral glycoproteins on its surface. At least 8 proteins have been detected on the envelope of CMV (Britt et al., J. Virol. 62, 3309 (1988)) and others have been predicted to exist based on the DNA sequence of CMV (Chee et al., Nature 344, 774 (1990)).
Murine monoclonal antibodies have been produced against two especially significant CMV glycoproteins: gB, also called p130/55 or gp55-116, and gH, also called p86 (Rasmussen et al., Virology 163, 30 8 (1988) and Britt et al., op. cit.) and shown to neutralize infectivity of the virus. Three other neutralizing antibodies to gH are designated CMV5, CMV109 and CMV115. Human monoclonal antibodies to CMV have also been.
produced (Ehrlich et al., Hybridoma 6, 151 (1987)).
In animal models, murine monclonal antibodies have been shown effective in treating infections caused by various viruses, including members of the herpesvirus family (sea, e.g., Metcalf et al., Intervirol. 29, 39 (1988)). Hence, such antibodies maybe useful in treatment of CMV infections.
Unfortunately, the use of non-human monoclonal antibodies such as CMVS and CMV7,15 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens as explained below.
Thus, there is a need for improved forms of humanized immunoglobulins specific for CMV antigen that are substantially non-immunogenic in humans, yet easily and economically produced in a manner suitable for therapeutic formulation and other uses. The present invention fulfills these and other needs.
In accordance with the present invention, humanized immunoglobulins specifically reactive with CMV and CMV-infected cells are provided. These immunoglobulins, which have binding affinities to CMV specific antigens of at least .e: y) '1 ';
v .. ~. .;
~f .~ ;J
'71 about 10~ M~1, and preferably 108 M 1 to 101 M~1 or stronger, are capable of, e-ct., blocking CMV infection of cells. The humanized immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDR's) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with a CMV antigen. In a preferred embodiment, one or more of the CDR's will come from the CMV5, or CMV109 or CMV115 antibodies. The immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of cMV-mediated disorders in human patients by a variety of techniques.
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope of a CMV antigen, such as monoclonal antibodies CMV5 or CMV115. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate human framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the heavy and light chain CDR°s of monoclonal antibody CMVS are included in Fig. 25. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be' readily substituted for those sequences, as detailed below.
Polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (eTa., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in,the vectors pVk and pVg1-dhfr (Fig. 26) using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab')2 fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker (see Huston et al., op-cit., and Bird et al., op. cit.).
WO 92/11018 PCT/U~91/09711 ~J"~9toU~:::r::
The antibodies of the present invention will typically find use individually in treating CMV-related disorders. For example, typical disease states suitable for treatment include CMV pneumonia, neonatal CMV infection, CMV
mononucleosis and CMiI-related chorioretinitis and gastroenteritis: Any humanized immunoglobulins of the present invention may also be used in combination with other antibodies, particularly humanized antibodies reactive with different CMV antigens. For example, suitable antigens to which a cocktail of humanized immunoglobulins may react include the gB and gH proteins. The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic agents. Typically, the agents may include acyclovir or ganciclovir, but numerous additional agents well-known to those skilled in the art for CMV treatment may also be utilized. A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill CMV-infected cells.
CMV specific humanized antibodies of the present inven~cion can further find a wide variety of utilities zn vitro. By way of example, the antibodies can be utilized for detection of CMV antigens, for isolating specific CMV-infected cells, or the like.
In particular, the same method may be used to produce a humanized CMV109, CMV115 or other anti-CMV antibody as used to produce humanized CMVS herein.
EXPERIMENTAL
Cloning of heavy chain and light chain cDNA.
cDNAs for the heavy chain and light chain variable domain genes were cloned using anchored polymerase chain reactions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers that hybridized to the constant -regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoR I sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoR I and HindIII and ll~~ 92/11018 fC.'T/11591/09711 7 3 ~ . ~ .~ :U .. .:,~ E
cloned into the pUCl8 vector for ser~uencing. For CMV5, two gamma°2a specific and two kappa specific clones were sequenced. The two gamma-2a clones and two kappa clones are respectively identical in sequence. The cDNA variable domain sequences and the deduced amino acid sequences are shown in Fig. 25A and 25B. Similarly, by using techniques, which are well-known in the art, cDNAs for the Ci~SV109 and CMV115 antibodies may be obtained and their sequence determined.
_Construction and expression of chimeric antibody.
Two plasmid vectors were prepared for construction and expression of the chimeric antibody genes. The plasmid pVgl-dhfr (Fig. 26A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C71 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen -et al., Proc. Natl. Acad. Sci. USA 80, 2495 (1983)) for selection. The plasmid pVk (Fig. 26B) is similar to pvgl-dhfr but contains the human genomic Cx segment and the gpt gene. Derivatives of the CMV5 heavy and light chain variable regions were prepared from the cDNAs by polymerase chain reaction. The 5' primers hybridized to the V regions starting at the ATG colons and contained Xbal sites; the 3~ primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and XbaI sites (see, Queen et al., Proc. Natl. Acad. Sci. USA 86, 10029 (1989)). The modified V regions were cloned into the XbaI sites of the respective plasmid vectors between the cytomegalovirus promoter and the partial introns of the constant regions.
For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Purified chimeric CMVS
antibody was shown to bind to CMV-infected cells, which express the gH antigen, by immunostaining of CMV-infected human embryonic lung fibroblasts.
WO 92111018 F'CT/US91/09711 -d'~~'~ ~:r~
T i \.r : 1 '.v \l ~:.L
Computer modelina~ of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (see, Queen et al., Proc. Natl. Acad. Sci. USA
86, 10029 (1989) and WO 9o~o7s61). The more homologous a human antibody is to the original murine antibody, the less likely will combining the murine CDR's with the human framework be to introduce distortions into the CDR's that could reduce affinity. Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains. Based on sequence homology search against the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Wol was chosen to provide the framework sequences for humanization of CMV5.
The computer program ENCAD (M. Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the CMV5 variable region. The model was used to determine the amino acids in the CMVS framework that were close enough to the CDR's-.to potentially interact with them (category 4 below).
To design the humanized light and heavy chain CMV5 variable regions, at each position the amino acid was chosen to be the same as in the Wol antibody, unless that position fell in one or more of five categories:
(1) The position fell within a CDR, (2) The Wol amino acid was unusual for human antibodies at that position,- whereas the CMV5 amino acid was typical for human antibodies at that position, (3) The position was immediately adjacent to a CDR, (4) The model described above suggested that the amino acid may be physically close to the antigen binding region (CDR's).
In category (2), "unusual" is interpreted to include amino acids that occur in less,than about 20% of the human sequences wC~ 92/t~0~g P(.°T/US91/09711 b~cw.~~~~ a ~r. ' 7 5 ' 4>
ir. Ea' eJ t~
in the same subgroups (as defined by Kabat et al., off. cit.) as the Wol light and heavy chains, and "typical" is inter'pre'ted 'to include amino acids that occur in more than about 25% but generally more than 50% of the human sequences in those subgroups. For positions in these categories, the amino acid from the mouse CMV5 antibody was used. In addition, a position was in the fifth category if the Wol amino acid was highly unusual for human antibodies at that position, and the CMVS amino acid was different but also unusual. Then an amino acid typical for human antibodies at that position may be used.
The amino acids in each category are shown in Table 1. Some amino acids may be in more than one category.
The final sequences of the humanized CMVS light and heavy chain variable domains are shown in Fig. 27A-B, compared with the Wol sequences.
Cateqor~ Lictht Chain Heavy Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99-108 69, 80 2 69, 80 4 24, 27, 28, 30, 9?
For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including the same signal peptides as in the mouse CMVS chains (Fig. 25), generally utili2ing codons found in the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones. The nucleotide sequences also included the same splice donor signals used in the chimeric genes and an XbaI site at each and. Hach gene was constructed from four overlapping W~ 92/11018 PC'~'/US91/09711 ~~ s~ ~, ...F ~.; p L! ~ C~ l~t 4. '-,, synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oligonucleotides on alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal (Fig. 28). The oligonucleotides were synthesized on an Applied Biosystems 380B DNA synthesizer. Each oligo was about 110-140 bases long with about a 15 base overlap. Double stranded DNA fragments were synthesized with Klenow polymerase from each pair of oligonucleotides, digested with restriction enzymes, ligated to the pUCl8 vector and sequenced. Two fragments with the respectively correct half-sequences were then ligated into the XbaI sites of the pVgl-dhfr or pVk .expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions were carried out under conditions well-known in the art (Maniatis et al., op. cit.) The heavy chain and light chain plasmids are transfected into Sp2/0 mouse myeloma cells by electroporation and cells are selected for gpt expression. Clones are 2o screened by assaying human antibody production in the culture supernatant by ELISA, and antibody purified from the best-producing clones. Antibody is purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody is eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer is exchanged into PBS by passing over a PD10 column (Pharmacia).
Humanized antibody was also produced by transient transfection. The heavy chain and light chain plasmids were transfected into 5194 cells (ATCC TIB 19) by the DEAE-dextran method (Queen et al., Mol. Cell. Biol. 4, 1043 (1984)), and humanized CMVS antibody was purified from the media supernatant as above. Antibody was quantitated by ELISA assay for human Ig.
WO 92/11018 PCf/U591/09711 :o ..-, r~ -~ .~ y 77 ;~,j a J ~ v~~ ;:
Properties of humanized antibodies.
The humanized CMV5 antibody was characterized in comparison to the murine and chimeric antibodies. The humanized CMV5 antibody was shown to bind about as well as the mouse and chimeric antibodies to CMV antigen, by immunostaining of CMV-infected human embryonic lung (HEL) cells (ATCC CCL 137). HEL cells monolayers in 96-well plates were infected wtih CMV at 0.01 pfu/cell, incubated for 4 days, dried at 37°C and stored wrapped at 4°C. 100 ~C1 blotto (5~
Carnation Instant Milk in PBS at pH 7.4) was added to each well and incubated at 37°C for 30 min. The blotto was poured off and 75 ~C1 of a series of 2-fold dilutions of mouse, chimeric and humanized CMVS antibody was added to the wells.
The plate was incubated 1 hr at 37°C and washed twice with blotto (each wash was .left on for 10 min). Then 75 ~1 of diluted peroxidase (HRP) conjugated goat anti-mouse or anti-human IgG (Tago) was added to each well and incubated for 1 hr at 37°C. The plate was washed 2x with PBS and 150 ~,1 of HRP
substrate solution was added to each well. Color was allowed to develop at room temperature. The plates were washed with water and air dried. The wells were examined under a microscope to determine the highest dilution of the antibodies that formed a colored precipitate on the CMV-infected cells.
For all three antibodies, 63 ng/ml was the least amount of antibody that produced a detectable precipitate, indicating that humanized CMV5 binds about as well as the mouse and chimeri.c antibodies.
To compare the affinities of mouse and humanized CMVS in another way, a competition experiment was performed.
Plates of CMV-infected HEL cells as above were incubated with blotto for 30 min at 37°C. The blotto was poured off and dilutions of mouse or humanized CMV5 were added to each well in 75 dal of PBS. Then 125 ~Cl of radio-iodinated mouse CMV5 (1 ~CCi/~g) in PBS, containing 28,000 cpm was added to each well and incubated at 37°C for 2.5 hr. The plate was washed 5 times with PBS, and the contents of each well were solubilized with 200 ~,l of 2% SDS and counted. Increasing concentrations W092/11~18 ,~ ~a :1 ,~ 9 Pf'1'/US91/~9711 " i ~ r ~ : _'., i .':
r ;,.o ~Li eJ i ~ .. _ ...
of mouse and humanized CMV5 inhibited binding of the radiolabeled CMV5 about equally well (Fig. 29), so humanized CMVS has approximatley the same binding affinity as mouse CV5.
An irrelevant antibody did not compete in this assay.
The ability of humanized CMV5 to neutralize CMV is compared to' that of mouse CMV5. Mouse and humanized CP~IVS are successively diluted by 2-fold in 100 ~1 of DME medium + 20 FCS in wells of a 96-well plate. 100 ~C1 of CMV, which has been diluted to contain 100 tissue culture infectious dose-5o%
(TCID50) units, are added to each well and incubated for 60 min at 37°C. Each well of antibody-virus mixture is added to a well of subconfluent HEL cells in a 96-well plate from which the medium has been removed. The cells are incubated for 5 days and cytopathic effect (CPE) is examined in each well under a microscope. The highest dilution of antibody that inhibits CPE by 90e is a measure of the neutralizing ability of the antibody. The humanized CMV5 antibody will neutralize CMV antibody approximately as well as the mouse CMVS antibody.
Example V
Tn mammals, the immune response is mediated by several types of cells that interact specifically with foreign material, i.e., antigens. One of these cell types, B cells, is responsible for the production of antibodies. Another cell type, T cells, include a wide variety of cellular subsets that destroy virally infected cells or control the in vivo function of both B cells and other hematopoi.etic cells, including T
cells. A third cell type, macrophages, process and present antigens in conjunction with major histocompatibility complex (MHC) proteins to T cells. Communication between these cell types is mediated in a complex manner by lymphokines, such as interleukins 1-6 and 7-IFN (see, generally, Paul, W.E., ed., Fundamental Immunology, 2nd ed., Raven Press, New York (1989)).
One important lymphokine is 7-IFN, which is secreted by some T cells. In addition to its anti-viral activity, 7-TFN stimulates natual killer (NK) cells, activates bV0 92/11~1$ PC'f/US91/~9711 7 9 , macrophages, and stimulates the expression of MHC malecules on the surface of cells (Paul, np. cit., pp. 622-624). Hence ~-IFN generally serves to enhance many aspects of immune function, and is a logical candidate for a therapeutic drug in cases where such enhancement is desired, e.g., in treating cancer. conversely, in disease states where the immune system is over-active, e.g., autoimmune diseases and organ transplant rejection, antagonists of 7--IFN may be used to treat the disease by neutralizing the stimulatory effects of 7-IFN.
One class of effective antagonists of 7-IFN are monoclonal antibodies that bind to and neutralize it (see, e.g., Van der Meide et al., J. Gen. Virol, 67, 1059 (1986)).
In in vitro and in vivo mouse models of transplants, anti-7-IFN antibodies have been shown to delay or prevent rejection (Landolfo et al., Science 229, 176 (1985) and Rosenberg et al., J. Immunol. 144, 4648 (1990)). Treatment of mice prone to develop a syndrome like systemic lupus erythematosus (SLE) with a monoclonal antibody to -~-IFN significantly delayed onset of the disease (Jacob et al., J. Exp. Med. 166, 798 (1987)). .Under some conditions, an anti-7-IFN antibody alleviated adjuvant arthritis in rats (Jacob et al., J.
Immunol. 142, 1500 (1989)), suggesting that anti-~-IFN may be effective against some cases of rheumatoid arthritis in human patients. Multiple sclerosis (MS) in patients is made worse by treatment with -~-IFN (Panitch et al., Neurology 36 (suppl.
1), 285 (1986)), so an anti-7-IFN antibody may alleviate MS.
Thus, an anti-7-IFN antibody may be effective in treating these and other autoimmune diseases.
For treatment of human patients, a murine monoclonal that binds to and neutralizes human 7-IFN (see, e.g., Yamamoto et al., Microbiol. Immunol. 32, 339 (1988)) may be used.
Another murine monoclonal antibody designated AF2 that neutralizes human 7-IFN, and inhibits binding of -~-IFN to its cellular receptor, is disclosed herein. Unfortunately, the use of non-human monoclonal antibodies such as AF2 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens.
rV~ 92/t 101 Pcavus9~ io9m 1 ..
:~. .~ ~~ .,: s I 1.. ~ i ''G 8 0 ,..
In accordance with the present invention, humanized immunoglobulins specifically reactive with 7-IFN epitopes are provided. These immunoglobulins, which have binding affinities to 7-IFN of at least about 10~ M'1, and preferably 108 M 1 to 101 M'1 or stronger, are capable of, e-ct. , neutralizing human ~-IFN. The humanized immunoglobulins will , have a human framework and will have one or more complementarity determining regions (CDR'S) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with 7-IFN. In a preferred embodiment, one or more of the CDR's will come from the AF2 antibody. Thus, the immunoglobulins of the present invention, which can be produced economically in large quantities, find use, for example, in the treatment of autoimmune disorders in human patients by a wariety,of techniques.
In one aspect, the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain CDR's from an immunoglobulin capable of binding to a desired epitope.of 7-IFN, such as monoclonal antibody AF2. The DNA
segments encoding these regions will typically be joined to DNA segments encoding appropriate human framework regions.
Exemplary DNA sequences, which on expression code for the polypeptide.chains comprising the heavy and light chain CDR's of monoclonal antibody AF2 are included in Fig. 30. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
Alternatively, polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (e. a., complement fixation activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in the vectors pVk and pVgh-dhfr (Fig. 31) using site-directed mutagenesis, such as after CH1 to produce Fab fragments or after the hinge region to produce (Fab')2 fragments. Single chain antibodies may be !3~~ 92/11018 ~(.'T/LJS91/09711 vF ~ ~l ,7 r3 ,~~ .'"
81 ~, -i~ .~' ; .~ >3 ,; '.
produced by joining VL and VH with a DNA linker (see Huston et al., op cit., and Bird et al., ob cit.).
The antibodies of the present invention will typically find use individually in treating autoimmune conditions. For example, typical disease states suitable for treatment include graft versus host disease and transplant rejection in patients undergoing an organ transplant, such as heart, lungs, kidneys, liver, etc. Other diseases include autoimmune diseases, such as Type T diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis.
F~umanized immunoglobulins of the present invention may also be used in combination with other antibodies, particularly humanized antibodies reactive with other lymphokines or lymphokine receptors. For example, suitable antigens to which a cocktail of humanized immunoglobulins may react include interleukins 1 through 10 and the p55 and p75 chains of the IL-2 receptor (see, Waldmann, Annu. Rev.
Biochem. 58, 875 (1989) and Queen et al., Proc. Natl. Acad.
Sci. USA 86, 10029 (1989)). Other antigens include those on cells responsible for the disease, e.g., the so-called "Clusters of Differentiation" (Leucocyte Typing III, ed. by A.J. McMichael, Oxford University Press (1987)). ' ' The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic agents. Typically, the agents may include non-steroidal anti-inflammatory agents (e. g., aspirin, ibuprofen), steroids (e. g., prednisone) and immunosuppressants (e. g., cyclosporin A, cytoxan), but numerous additional agents well-known to those skilled in the art may also be utilized.
A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immuriotoxins, e.g., to kill 7-IFN-secreting cells.
Humanized antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the antibodies can be utilized for detection of 7-IFN
antigens, or the like.
w~ 92n 1a18 F~ius9mo9~~ ~
'~ x s.,. :;
~~ j'_~.Jr1 82 EXPERIMENTAL
Cloning of heavy chain and lictht chain cDNA.
cDNAs for the heavy chain and light chain varialale .domain genes were cloned using anchored polymerise chain reactions (E.Y. Loh et al., Science 243, 217 (1989)), using 3' primers that hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoR I sites (scheme shown in Fig. 6). The PCR
amplified fragments were digested with EcoR I and HindIII and cloned into the pUCl8 vector for sequencing. For AF2, two gamma-2b specific and two kappa specific clones were sequenced. The two gamma-2b clones and two kappa clones are respectively identical in sequence. The eDNA variable domain sequences and the deduced amino acid sequences are shown in Fig. 30.
Construction and expression of chimeric antibody.
Two plasmid vectors were prepared for construction and expression of the chimeric antibody genes. The plasmid pVg1-dhfr (Fig. 31A) contains a human cytomegalovirus IE1 promoter and enhancer (M. Boshart et al., Cell 41, 521 (1985)), the human genomic C71 segment including part of the preceding intron, and a dihydrofolate reductase (dhfr) gene (Simonsen et al., Proc. Natl. Acid. Sci. USA 80, 2495 (1984)) fox selection. The plasmid pVk (Fig. 31B) is similar to pVgl-dhfr but contains the human genomic Crc segment and the gpt gene. Derivatives of the AF2 heavy and light chain variable regions were prepared from the eDNAs by polymerise chain reaction. The 5' primers hybridized to the V regions starting at the ATE codons and contained XbaI sites: the 3' primers hybridized to the last 15 nucleotides of the J regions and contained splice donor signals and Xbal sites (see, Queen et al., Proc. Natl. Acid. Sci. USA 86, 10029 (1989)). The modified V regions were cloned into the XbaI sites of the respective plasmid vectors between the CMV promoter and the partial introns of the constant regions.
~ ,a ,~ y'PCT/US91/09711 wo 9zono~s For expression of the chimeric antibody, the heavy chain and kappa chain plasmids were transfected into Sp2/o mouse myeloma cells by electrAporation and cells selected for gpt expression. Clones secreting a maximal amount of complete antibody were detected by ELISA. Chimeric AF2 antibody was shown to bind to human ~y-IFN by ELISA.
Computer modeling of humanized antibodies.
In order to retain high binding affinity in the humanized antibodies, the general procedures of Queen et al.
were followed (see, Queen et al., Proc. Natl. Acad. Sci. USA
86, 10029 (1989) and WO 90/07861). The more homologous a human antibody is to the original murine antibody, the less likely will combining the murine CDR's with the human framework be to introduce distortions into the CDR's that could reduce affinity. Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains. Based on sequence homology search against the NBRF protein sequence database (performed with the MicroGenie Sequence Analysis Software (Beckman)), the antibody Eu was chosen to provide the framework sequences for humanization of AF2.
The computer program ENCAD (M. Levitt, J. Mol. Biol.
168, 595 (1983)) was used to construct a model of the AF2 variable region. The model was used to determine the amino acids in the AF2 framework that were close enough to the CDR's to potentially interact with them (category 4 below). To design the humanized light and heavy chain AF2 variable regions, at each position the amino acid was chosen to be the same as in the Eu antibody, unless that position fell in one or more of five categories:
(1) The position fell within a CDR, (2) The Eu amino acid was unusual for human antibodies at that position, whereas the AF2 amino acid was typical for human antibodies at that position, WO 92/11 ~18 PC.'i'/US91 /09731 ~~~~t~uf~:'.jl~y ._ (3) The position was immediately adjacent to a CDR, (4) The model described above suggested that the amino-acid may be physically close to the antigen binding region (CDR°s).
In category (2), "unusual'° is interpreted to include amino acids that occur in less than about 20% of the human sequences in the same subgroups (as defined by Kabat et al., op. cit.) as the Eu light and heavy chains, and "typical°° is interpreted to include amino acids that occur in more than about 25~ but generally more than 50% of the human sequences in those subgroups. For positions in these categories, the amino acid from the mouse AF2 antibody was used. In addition, a position was in the fifth category if the Eu amino acid was highly unusual for human antibodies at that position, and the AF2 amino acid was different but also unusual. Then an amino acid typical for human antibodies at that position may be used.
The amino acids in each category are shown in Table 10. Some amino acids may be in more than one category.
The final sequences of the humanized AF2 light and heavy chain variable domains are shown in Fig. 32, compared with the Eu sequences. _ TABLE l0 Cateaory Lictht Chain Heavy Chain 1 24-34, 50-56, 89-97 31-35, 50-66, 99-106 2 48 93, 95, 98, 107, 108, 109, 111 3 . 30, 98, 107 4 48, 70 27, 28, 30, 98, 107 For the construction of genes for the humanized antibodies, nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, plus typical immunoglobulin signal sequences, generally i ~ ,~ PCT/US91/09711 i~V~ 92/1101 iatje.lJi~V v 85.
utilizing codons found in the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones. The nucleotide sequences also included the same splice donor signals used in the chimeric genes and an xbaI site at each end. Each gene was constructed from four overlapping synthetic oligonucleotides. For each variable domain gene, two pairs of overlapping oliganucleotides on alternating strands were synthesized that encompassed the entire coding sequences as well as the signal peptide and the splice donor signal (Fig. 33) The oligonucleotides were synthesized on an Applied Biosystems 3808 DNA synthesizer. Each oligo was about 110-140 bases long with about a 15 base overlap. Double stranded DNA fragments were synthesized with Klenow polymerase from each pair of a5 oligonucleotides, digested with restriction enzymes, ligated to the pUCl8 vector and sequenced. Two fragments with the respectively correct half-sequences are then ligated into the Xbal sites of the pVgl-dhfr or pVk expression vectors in the appropriate orientations to produce the complete heavy and light chain genes. Reactions are carried out under canditions well-known in the art (Maniatis et al., op. cit.) The heavy chain and light chain plasmids are transfected into Sp2/0 mouse myeloma cells by electroporation and cells selected for gpt expression. Clones are screened by assaying human antibody production in the culture supernatant by ELISA, and antibody purified from the best-producing clones. Antibody is purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia). The bound antibody is eluted with 0.2 M Glycine-HC1, pH3.0 and neutralized with 1 M Tris PH8Ø The buffer is exchanged into PBS by passing over a PD10 column (Pharmacia).
Properties of humanized antibodies.
The humanized AF2 antibody is characterized in comparison to the murine and chimeric antibodies. The humanized antibody will bind to 7-IFN in an ELISA assay in a i3'0 92/11018 PU'f/US91/09711 Lp~v~:J~w '~~ ._ $6 manner similar to the mouse and chimeric antibodies, showing that it recognizes ,7-IFN.
To compare the binding affinities of mouse AF2 antibody and humanized AF2 antibody, a competitive ELISA assay is performed. An ELISA plate is coated with human recombinant 7-IFN by adding 100 ~,1 of a 500 ng/ml solution of 7-IFN in PBS
to each well and incubating overnight at 4°C. Subsequent steps are carried out at room temperature. The -~-IFN solution is removed and 200 ~,1 of ELISA buffer (0.1o Twsen-20, 1%
Bovine serum albumin in PBS) is added to each well and incubated for 1 hr. After removing the solution, varying amounts of competitor antibody (mouse AF2 or humanized AF2) in 100 ~l PBS is added to each- well, along with an amount of biotinylated AF2 predetermined to give a good ELISA response.
The plate is incubated for 1 hr and then washed 3 times with ELISA buffer. An amount of horseradish peroxidase (HRP)-conjugated strepavidin predetermined to be in excess is added in 100 ~,1 PBS to each well and incubated for 30 min. The plate is washed 3 times in ELISA buffer, and 100 ~,1 of substrate solution for HRP is added to each well. The plate is incubated for 10-30 min, and the optical density of each well is determined with an ELISA reader (BioRad). The decrease in optical density with increasing concentrations of competitor antibodies mouse AF2 and. humanized AF2 are plotted.
Mouse AF2 and humanized AF2 will compete similarly, showing that their binding affinities for ~-IFN are approximately the same. The procedures used are well known in the art (e. g., Harlow and Lane, og. cit.).
An important biological activity of 7-IFN is the induction of expression of class II HLA antigens on cells. To determine the ability of mouse and humanized AF2 to neutralize this activity, about 5 x 104 HS294T cells (Basham et al., J.
Immunol. 130, 1492 (1983)) are plated in 1.0 ml DMEM medium + , 10% FCS in each well of a 24-well plate. After overnight incubation, 0.1 nM interferon and varying amounts of mouse or humanized AF2 are added to the cells, and the plate is incubated for 72 hr. The cells are removed from the plate with 0.05 M EDTA, stained with monoclonal antibody L243 from the American Type Culture Collection (ATCC) against HLA-D
antigen, washed, stained with FITC conjugated goat anti-mouse Ig and analyzed with a FACScan (Becton-Dickinson). Increasing concentrations of mouse AF2 reduce fluorescence of the cells (Fig. 34), indicating the antibody is preventing induction of HLA-D by 7-IFN. The humanized AF2 will act similarly to mouse AF2 in this assay, showing that it neutralizes the biological activity of 7-IFN.
From the foregoing, it will be appreciated that the humanized immunoglobulins of the present invention offer numerous advantages over other ~-IFN specific antibodies. In comparison to mouse monoclonal antibodies, the present humanized immunoglobulins can be more economically produced and contain substantially less foreign amino acid sequences.
This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.
Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
Claims (11)
1. A humanized immunoglobulin comprising:
a humanized heavy chain variable region comprising three complementarity determining regions specified in Figure 3B from the heavy chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin heavy chain, and a humanized light chain variable region comprising three complementarity determining regions specified in Figure 3A from the light chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin light chain;
wherein the humanized antibody has a binding affinity of at least 10 7 M-1 and competes with the mouse M195 antibody for binding to human CD33 antigen.
a humanized heavy chain variable region comprising three complementarity determining regions specified in Figure 3B from the heavy chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin heavy chain, and a humanized light chain variable region comprising three complementarity determining regions specified in Figure 3A from the light chain variable region of the mouse M195 antibody and variable region frameworks from a human immunoglobulin light chain;
wherein the humanized antibody has a binding affinity of at least 10 7 M-1 and competes with the mouse M195 antibody for binding to human CD33 antigen.
2. The humanized immunoglobulin of claim 1, wherein the humanized light chain variable region comprises a sequence shown in Fig. 3A (lower) and the humanized heavy chain variable region comprises a sequence shown in Fig. 3B
(lower) .
(lower) .
3. The humanized immunoglobulin of claim 1 or 2, in substantially pure form.
4. A humanized immunoglobulin according to any one of claims 1-3, wherein the humanized immunoglobulin comprises a human framework having at least about 85% homology to EU
immunoglobulin framework.
immunoglobulin framework.
5. A humanized immunoglobulin according to any one of claims 1-4, which is capable of mediating antibody-dependent cellular cytotoxicity in the presence of human target and effector cells.
6. The humanized immunoglobulin as defined in any one of claims 1-5, conjugated to a cytotoxic agent for use as a pharmaceutical.
7. The use of a humanized immunoglobulin as defined in any one of claims 1-5, for treating a myeloid cell-mediated disorder in a human patient.
8. The use of claim 7, wherein an effective dose of the humanized immunoglobulin is administered to the patient.
9. The use of claim 7 or 8, wherein the immunoglobulin is conjugated to a cytotoxic agent.
10. The use of a humanized immunoglobulin as defined in any one of claims 1-5, for preparation of a medicament for treating myeloid cell-mediated disorders.
11. The use of claim 10, wherein the immunoglobulin is conjugated to a cytotoxic agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US634,278 | 1990-12-19 | ||
US07/634,278 US5530101A (en) | 1988-12-28 | 1990-12-19 | Humanized immunoglobulins |
PCT/US1991/009711 WO1992011018A1 (en) | 1990-12-19 | 1991-12-19 | Improved humanized immunoglobulins |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2098404A1 CA2098404A1 (en) | 1992-06-20 |
CA2098404C true CA2098404C (en) | 2002-08-20 |
Family
ID=24543134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002098404A Expired - Lifetime CA2098404C (en) | 1990-12-19 | 1991-12-19 | Improved humanized immunoglobulins |
Country Status (9)
Country | Link |
---|---|
US (6) | US5530101A (en) |
EP (2) | EP1386932A1 (en) |
JP (1) | JP3276369B2 (en) |
KR (1) | KR100231090B1 (en) |
AT (1) | ATE251639T1 (en) |
AU (2) | AU671949B2 (en) |
CA (1) | CA2098404C (en) |
DE (1) | DE69133326T2 (en) |
WO (1) | WO1992011018A1 (en) |
Families Citing this family (5288)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
JP2581788B2 (en) * | 1987-08-17 | 1997-02-12 | アメリカ合衆国 | Methods of treating malignant and autoimmune disorders in humans |
US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US7247453B1 (en) * | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
AU640400B2 (en) * | 1989-08-07 | 1993-08-26 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US7084260B1 (en) * | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6631842B1 (en) * | 2000-06-07 | 2003-10-14 | Metrologic Instruments, Inc. | Method of and system for producing images of objects using planar laser illumination beams and image detection arrays |
GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
US20040143100A1 (en) * | 1991-03-04 | 2004-07-22 | Tan Kim Sze | High affinity humanized monoclonal antibodies |
US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
DE122004000008I1 (en) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanized heregulin antibody. |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US6685939B2 (en) | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
JP3951062B2 (en) * | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
ATE463573T1 (en) * | 1991-12-02 | 2010-04-15 | Medimmune Ltd | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
JPH05244982A (en) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
CA2103887C (en) * | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US20030229207A1 (en) * | 1991-12-13 | 2003-12-11 | Xoma Technology Ltd. | Modified antibody variable domains |
US20020102257A1 (en) * | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
NZ249633A (en) | 1992-02-06 | 1995-12-21 | Schering Corp | Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies. |
NZ249677A (en) * | 1992-02-19 | 1996-08-27 | Schering Corp | Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies |
US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US7381803B1 (en) * | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US5646253A (en) * | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
US6042828A (en) * | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
GB9221654D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
ATE367827T1 (en) * | 1992-11-16 | 2007-08-15 | Centocor Inc | METHOD FOR REDUCING THE IMMUNOGENICITY OF THE VARIABLE REGIONS OF ANTIBODIES |
US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
CZ140195A3 (en) * | 1992-12-01 | 1996-06-12 | Protein Desing Labs | Humanized antibodies reacting with l-selectin |
US6307026B1 (en) * | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
DE69322289T2 (en) | 1992-12-29 | 1999-05-20 | Genentech Inc | TREATMENT OF INFLAMMABLE INTESTINAL DISEASES WITH INTERFERON GAMMA INHIBITORS |
WO1994016094A2 (en) * | 1993-01-12 | 1994-07-21 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
US20030059428A1 (en) * | 1993-02-26 | 2003-03-27 | Boris Skurkovich | Treatment of autoimmune diseases |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US7592006B1 (en) * | 1993-03-05 | 2009-09-22 | Université Catholique de Louvain | Composition comprising the LO-CD2a antibody |
US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
JPH08500740A (en) * | 1993-06-25 | 1996-01-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Lipoprotein-related phospholipase A-2, its inhibitors and their use in diagnosis and therapy |
US6046012A (en) * | 1993-07-19 | 2000-04-04 | Hoffmann-La Roche Inc. | Antibody to IL-12 receptor |
US5847088A (en) * | 1993-10-06 | 1998-12-08 | Icos Corporation | Antibodies specific for platelet-activating factor acetylhydrolase |
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
EP0730646A1 (en) * | 1993-11-23 | 1996-09-11 | Genentech, Inc. | PROTEIN TYROSINE KINASES NAMED Rse |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5506133A (en) * | 1994-04-11 | 1996-04-09 | Human Genome Sciences, Inc. | Superoxide dismutase-4 |
US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
US5629193A (en) | 1994-07-05 | 1997-05-13 | Human Genome Sciences, Inc. | Paraoxonase |
US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
DE4425115A1 (en) * | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Method for modifying the stability of antibodies |
US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
IL114909A (en) * | 1994-08-12 | 1999-10-28 | Immunomedics Inc | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
BR9509498A (en) * | 1994-10-25 | 1997-12-23 | Glaxo Group Ltd | Binding agent use of the same pharmaceutical composition and process for treating an autoimmune inflammatory disease or an allergic disease |
US6538121B1 (en) * | 1994-11-01 | 2003-03-25 | Human Genome Sciences, Inc. | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
WO1996021000A2 (en) * | 1994-12-23 | 1996-07-11 | Smithkline Beecham Corporation | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
US7399837B2 (en) * | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
PT796280E (en) * | 1994-12-28 | 2003-08-29 | Univ Kentucky | ANTI-IDIOTIPIC MONOCLONAL 3H1 ANTIBODY OF MURINOS |
US6537764B1 (en) * | 1995-01-19 | 2003-03-25 | Children's Medical Center Corporation | Method of identifying inhibitors of C—C chemokine receptor 3 |
DK0813423T3 (en) * | 1995-01-23 | 2002-07-22 | Xenotech Inc | Preparation for the prevention of osteolysis and metastasis |
US5853721A (en) * | 1995-01-31 | 1998-12-29 | Hoffmann-La Roche Inc. | Antibody to interleukin-12 receptor |
US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US5674748A (en) * | 1995-03-14 | 1997-10-07 | Thomas Jefferson University | Human cyclin-dependent kinase-like proteins and methods of using the same |
EP0766745B1 (en) * | 1995-04-08 | 2002-10-23 | LG Chemical Limited | Monoclonal antibody specific for human 4-1bb and cell line producing same |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
IL118069A (en) | 1995-05-02 | 2000-06-01 | Japan Tobacco Inc | Monoclonal antibody reactive to human CETP and assay method for human CETP |
US20030144483A1 (en) * | 1995-05-04 | 2003-07-31 | Medarex, Inc. | Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
WO1996040921A1 (en) * | 1995-06-07 | 1996-12-19 | Ortho Farmaceutical Corporation | Cdr-grafted anti-tissue factor antibodies and methods of use thereof |
AU725609C (en) * | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
US7264963B1 (en) * | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
EP1382679A3 (en) * | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
US6048734A (en) | 1995-09-15 | 2000-04-11 | The Regents Of The University Of Michigan | Thermal microvalves in a fluid flow method |
US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
EP0881299A4 (en) * | 1996-02-15 | 2004-12-15 | Chugai Seiyakukabushiki Kaisha | Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel |
AU2232597A (en) * | 1996-03-06 | 1997-09-22 | Chugai Seiyaku Kabushiki Kaisha | Method of screening apoptosis inducing substances |
US20040048340A1 (en) * | 1996-03-14 | 2004-03-11 | Human Genome Sciences, Inc. | Apoptosis inducing molecule I |
JP2000511403A (en) * | 1996-03-20 | 2000-09-05 | イムノメディクス,インコーポレイテッド | Humanization of anti-carcinoembryonic antigen anti-idiotype antibodies and their use as tumor vaccines and for targeting applications |
US7964190B2 (en) * | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US20020165157A1 (en) * | 1996-04-01 | 2002-11-07 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
US7241568B2 (en) * | 1996-04-03 | 2007-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anti-fibroblast growth factor-8 monoclonal antibody |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
ES2193240T3 (en) * | 1996-05-15 | 2003-11-01 | Altarex Inc | METHOD AND COMPOSITION TO RECONFORM MULTI-EPITHOPIC ANTIGENS TO START AN IMMUNE RESPONSE. |
US20060159688A1 (en) * | 1996-05-15 | 2006-07-20 | Ragupathy Madiyalakan | Method for diagnosing efficacy of xenotypic antibody therapy |
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
BR9710811A (en) | 1996-05-22 | 1999-08-17 | Novopharm Biotech Inc | Antigen-binding fragments that specifically detect nucleotide cancer cells that encode the fragments and their use for the prophylaxis and detection of cancer |
CA2257357C (en) * | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
US6805869B2 (en) | 1996-06-12 | 2004-10-19 | Shanghai Cp Guojian Pharmaceutical Co., Ltd. | Cellular vaccines and immunotherapeutics and methods for their preparation |
US20050136066A1 (en) * | 1996-06-12 | 2005-06-23 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
US5908925A (en) * | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
WO1998003670A1 (en) * | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
US7147851B1 (en) † | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
EP1642908A2 (en) * | 1996-09-02 | 2006-04-05 | Okumura, Ko | Apoptosis-induced site from fas ligand |
US20030017147A1 (en) * | 1996-09-20 | 2003-01-23 | Guy L Reed | Composition and method for enhancing fibrinolysis |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
KR100847441B1 (en) * | 1996-09-26 | 2008-07-21 | 츄가이 세이야꾸 가부시키가이샤 | Antibody against Human Parathormone related Peptides |
GB2321642B8 (en) | 1996-10-01 | 2006-08-22 | Geron Corp | Human telomerase reverse transcriptase promoter |
US5908778A (en) * | 1996-10-03 | 1999-06-01 | Ludwig Institute For Cancer Research | Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof |
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
WO1998021334A2 (en) | 1996-11-13 | 1998-05-22 | Morphogenesis, Inc. | Antibody mg1 recognizing a small subset of human hematopoietic cells |
US6743604B1 (en) * | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
US20030228310A1 (en) * | 1996-12-23 | 2003-12-11 | Advanced Biotherapy, Inc. | Treatment of skin diseases |
US20030223995A1 (en) * | 1996-12-23 | 2003-12-04 | Advanced Biotherapy, Inc. | Treatment of pemphigus vulgaris |
US20030086925A1 (en) * | 1996-12-23 | 2003-05-08 | Advanced Biotherapy, Inc. | Treatment of autoimmune diseases |
US20030103967A1 (en) * | 1997-01-07 | 2003-06-05 | Habib Zaghouani | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
US6455040B1 (en) | 1997-01-14 | 2002-09-24 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
EP1862548A1 (en) * | 1997-01-28 | 2007-12-05 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L) |
US8329179B2 (en) * | 1997-01-28 | 2012-12-11 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
US7452538B2 (en) | 1997-01-28 | 2008-11-18 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
US6596850B1 (en) * | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US20010011125A1 (en) * | 1997-01-30 | 2001-08-02 | William D. Huse | Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
AU6659298A (en) | 1997-02-18 | 1998-09-08 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
US7122636B1 (en) * | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US20030109680A1 (en) * | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20040229282A1 (en) * | 1997-03-10 | 2004-11-18 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US7749498B2 (en) * | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20060235209A9 (en) * | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
CA2644454A1 (en) * | 1997-03-17 | 1998-09-24 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
US20040136951A1 (en) * | 1997-03-17 | 2004-07-15 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
US20050233958A1 (en) * | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
US20080248046A1 (en) * | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
US5935813A (en) * | 1997-03-20 | 1999-08-10 | Incyte Pharmaceuticals, Inc. | Human pancreatitis-associated protein |
US5914394A (en) * | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
US5939316A (en) * | 1997-03-27 | 1999-08-17 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5955355A (en) * | 1997-03-27 | 1999-09-21 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5866412A (en) * | 1997-03-27 | 1999-02-02 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7083786B2 (en) * | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
JP3957765B2 (en) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | Anti-VEGF antibody |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
PT994728E (en) * | 1997-04-09 | 2008-11-11 | Intellect Neurosciences Inc | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
AU6954498A (en) | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Methods for using antagonistic anti-avb3 integrin antibodies |
AU6954398A (en) | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US7115722B1 (en) | 1997-05-22 | 2006-10-03 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
US6610293B1 (en) * | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
US20020132252A1 (en) * | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
KR100220645B1 (en) * | 1997-07-04 | 1999-09-15 | 구광시 | Process for producing benzene derivatives |
US6998108B1 (en) * | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
US7087420B1 (en) | 1997-07-17 | 2006-08-08 | Cambia | Microbial β-glucuronidase genes, gene products and uses thereof |
US6391547B1 (en) * | 1997-09-09 | 2002-05-21 | Center For The Application Of Molecular Biology To International Agriculture | Microbial β-glucuronidase genes, gene products and uses thereof |
US6849258B1 (en) | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
EP1015480A2 (en) * | 1997-08-18 | 2000-07-05 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
US6737249B1 (en) * | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
US20030170794A1 (en) * | 1997-09-18 | 2003-09-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
RU2221809C2 (en) * | 1997-10-03 | 2004-01-20 | Тугаи Сейяку Кабусики Кайся | Method for preparing natural humanized antibody |
AU732306B2 (en) * | 1997-10-14 | 2001-04-12 | Chugai Seiyaku Kabushiki Kaisha | Potentiator for antibody against lymphoid tumor |
US20030207375A1 (en) * | 1997-10-24 | 2003-11-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DK1032674T3 (en) | 1997-11-21 | 2007-04-10 | Serono Genetics Inst Sa | Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
EP1032676A2 (en) | 1997-11-28 | 2000-09-06 | Genset | $i(CHLAMYDIA TRACHOMATIS) GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION |
DE69829995T2 (en) * | 1997-12-01 | 2006-02-23 | Fang, Fang, San Diego | MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HRV INFECTIONS |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
CA2312188C (en) | 1997-12-08 | 2010-06-29 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
CA2316769A1 (en) * | 1997-12-23 | 1999-07-01 | Lawrence E. Samelson | The protein tyrosine kinase substrate lat and its use in the identification of (ant)agonists of the kinase |
EP1051506B2 (en) | 1997-12-23 | 2019-08-21 | Pfizer Ireland Pharmaceuticals | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
JP2002500879A (en) * | 1998-01-23 | 2002-01-15 | イムクローン システムズ インコーポレーテッド | Population of stem cells |
US7026456B1 (en) | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
CA2321140C (en) | 1998-02-20 | 2015-04-07 | Tanox, Inc. | Inhibitors of complement activation |
AU2873999A (en) | 1998-02-24 | 1999-09-06 | Sisters Of Providence In Oregon | Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
AU2978899A (en) * | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
CA2323787A1 (en) * | 1998-03-13 | 1999-09-16 | Wayne Marasco | Humanized antibody and uses thereof |
US6342351B1 (en) | 1998-03-16 | 2002-01-29 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating chromosome-18p related disorders |
US20040176572A1 (en) * | 1998-03-16 | 2004-09-09 | Freimer Nelson B. | Methods of compositions for diagnosing and treating chromosome-18p related disorders |
HU225539B1 (en) * | 1998-03-17 | 2007-02-28 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor |
CA2323776C (en) | 1998-03-19 | 2010-04-27 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
US6077508A (en) * | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
AU752730B2 (en) | 1998-04-03 | 2002-09-26 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US20020029391A1 (en) * | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
CA2327505A1 (en) * | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
US20030186368A1 (en) * | 1998-05-13 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040022788A1 (en) * | 1998-05-19 | 2004-02-05 | Moser Tammy L. | Compositions and methods for promoting or inhibiting angiogenesis |
CA2237915A1 (en) * | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
IL139571A0 (en) * | 1998-05-20 | 2002-02-10 | Teijin Ltd | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same |
DK1082141T3 (en) | 1998-05-23 | 2005-12-05 | Univ Leiden Medical Ct | CD40-binding molecules and CTL peptides for the treatment of tumors |
US20040141975A1 (en) * | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
US5973119A (en) * | 1998-06-05 | 1999-10-26 | Amgen Inc. | Cyclin E genes and proteins |
US20030109681A1 (en) * | 1998-06-10 | 2003-06-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US7387772B1 (en) | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
US7833528B2 (en) * | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
US20030167483A1 (en) * | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
AU4834999A (en) * | 1998-06-26 | 2000-01-17 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
PT1097210E (en) * | 1998-07-10 | 2006-09-29 | Connex Gmbh | IMMUNOLOGICAL REAGENT THAT INTERACT SPECIFICALLY WITH THE EXTRACELLULAR DOMAIN OF THE HUMAN ZET CHAIN |
US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
ATE276763T1 (en) | 1998-07-13 | 2004-10-15 | Univ Texas | USE OF ANTIBODIES TO AMINOPHOSPHOLIPIDES FOR CANCER TREATMENT |
AU750414B2 (en) | 1998-07-13 | 2002-07-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
GB9815909D0 (en) * | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
BR9913645A (en) | 1998-08-11 | 2001-09-25 | Idec Pharma Corp | Combined therapies for B-cell lymphomas comprising administration of anti-cd20 antibody |
US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
US20030166132A1 (en) * | 1998-08-26 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
KR100628818B1 (en) | 1998-09-14 | 2006-09-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
ES2259478T3 (en) * | 1998-09-18 | 2006-10-01 | Dynavax Technologies Corporation | METHODS TO TREAT DISORDERS ASSOCIATED WITH IGE AND COMPOSITIONS FOR THIS USE. |
US6878528B1 (en) * | 1998-09-25 | 2005-04-12 | Schering Corporation | Polynucleotides encoding a mammalian Langerhans cell antigen |
CN100340291C (en) * | 1998-10-09 | 2007-10-03 | 路德维格癌症研究院 | F1t4(VEGFR-3) as target for tumor imaging and anti-tumor therapy |
ATE390441T1 (en) * | 1998-10-30 | 2008-04-15 | Novozymes As | LOW-ALLERGENIC PROTEIN VARIANTS |
US6406695B1 (en) | 1998-10-30 | 2002-06-18 | University Of Miami | Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
AU761844C (en) | 1998-11-09 | 2004-09-23 | F. Hoffmann-La Roche Ag | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
TWI253934B (en) * | 1998-11-09 | 2006-05-01 | Idec Pharma Corp | Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant |
US20030096976A1 (en) * | 1998-11-17 | 2003-05-22 | Hong Hyo Jeong | Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies |
US7118743B2 (en) * | 1998-11-17 | 2006-10-10 | Tanox, Inc. | Bispecific molecules cross-linking ITIM and ITAM for therapy |
AU1727500A (en) * | 1998-11-17 | 2000-06-05 | Tanox, Inc. | Bispecific molecules cross-linking itim and itam for therapy |
KR20000034847A (en) * | 1998-11-17 | 2000-06-26 | 성재갑 | Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same |
NZ552959A (en) | 1998-11-27 | 2008-06-30 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7666609B1 (en) | 1998-12-01 | 2010-02-23 | Shanghai Cp Guojian Pharmaceutical Co. Ltd. | Method and composition for diagnosis of melanocytic lesions |
WO2000032634A1 (en) * | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
WO2000034459A1 (en) | 1998-12-09 | 2000-06-15 | Protein Design Labs, Inc. | Animal model for psoriasis for the prevention and treatment of psoriasis in humans |
US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
US7507706B1 (en) | 1998-12-14 | 2009-03-24 | Genetics Institute, Llc | Cytokine receptor chain |
NZ512553A (en) | 1998-12-23 | 2004-02-27 | Pfizer | Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20050281821A1 (en) * | 1999-01-06 | 2005-12-22 | Flavia Pernasetti | Method and composition for angiogenesis inhibition |
EP1149111B1 (en) * | 1999-01-06 | 2009-08-12 | University Of Southern California | Method and composition for angiogenesis inhibition |
IL144029A0 (en) | 1999-01-07 | 2002-04-21 | Zymogenetics Inc | Soluble receptor br43x2 and methods of using |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
HUP0105044A3 (en) | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
CZ20012925A3 (en) * | 1999-02-12 | 2002-01-16 | Genetics Institute, Inc. | Humanized immunoglobulin reacting with B7 molecules and method of therapy |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US6403309B1 (en) | 1999-03-19 | 2002-06-11 | Valigen (Us), Inc. | Methods for detection of nucleic acid polymorphisms using peptide-labeled oligonucleotides and antibody arrays |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6864235B1 (en) * | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6911429B2 (en) * | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6943235B1 (en) * | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
US7244827B2 (en) * | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
CA2366514C (en) * | 1999-04-13 | 2009-09-15 | Manfred Schmitt | Diagnostic and therapeutic use of antibodies against the urokinase receptor |
AU4314900A (en) * | 1999-04-28 | 2000-11-17 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same |
US6342221B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
JP4828703B2 (en) | 1999-04-28 | 2011-11-30 | ジェネティックス インスティテュート エルエルシー | Human GIL-19 / AE289 protein and polynucleotide encoding the same |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
US8119101B2 (en) * | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
AU778787B2 (en) * | 1999-05-10 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | Method of cell cultivation |
US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US20080286821A1 (en) * | 1999-05-14 | 2008-11-20 | Eaton Dan L | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
AU5303700A (en) * | 1999-05-27 | 2000-12-18 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunoconjugates having high binding affinity |
US7166573B1 (en) * | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
DK2314315T3 (en) | 1999-06-01 | 2015-02-02 | Biogen Idec Inc | Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
US20030103948A1 (en) * | 1999-06-07 | 2003-06-05 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
FR2794865B1 (en) * | 1999-06-09 | 2003-04-18 | Pasteur Institut | METHOD OF EARLY DETECTION OF FLAVIVIRUSES AND ITS APPLICATIONS |
WO2000076538A1 (en) | 1999-06-10 | 2000-12-21 | Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
JP2003527826A (en) | 1999-06-30 | 2003-09-24 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Cancer-associated antigens and uses thereof |
US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
TWI255718B (en) * | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
CA2378519C (en) | 1999-07-07 | 2011-01-25 | Zymogenetics, Inc. | Human cytokine receptor |
WO2001004157A2 (en) * | 1999-07-13 | 2001-01-18 | University Of Southern California | NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US6693176B1 (en) * | 1999-07-23 | 2004-02-17 | University Of Massachusetts | Antitumor antibodies, proteins, and uses thereof |
US7674466B2 (en) * | 1999-08-05 | 2010-03-09 | The Trustees Of The University Of Pennsylvania | Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1 |
US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
CN1370076A (en) * | 1999-08-23 | 2002-09-18 | 中外制药株式会社 | HM 1.24 antigen expression potentiators |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (en) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | Human ctla-4 antibodies and their uses |
US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
US7419668B1 (en) | 1999-09-02 | 2008-09-02 | Board Of Trustees Of Michigan State University | Vaccine to control equine protozoal myeloencephalitis in horses |
EP1207889A4 (en) | 1999-09-02 | 2004-05-19 | Univ Michigan State | Vaccine to control equine protozoal myeloencephalitis in horses |
US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7297478B1 (en) | 2000-09-22 | 2007-11-20 | Large Scale Biology Corporation | Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules |
US7892541B1 (en) | 1999-09-30 | 2011-02-22 | Tumor Biology Investment Group, Inc. | Soluble epidermal growth factor receptor isoforms |
EP1238985B1 (en) * | 1999-09-30 | 2008-03-05 | Kyowa Hakko Kogyo Co., Ltd. | Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3 |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
AU1072701A (en) * | 1999-10-04 | 2001-05-10 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
US6790631B1 (en) * | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
US7361338B2 (en) * | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
US7947496B2 (en) * | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20080124327A1 (en) * | 1999-10-08 | 2008-05-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7252821B2 (en) | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
ES2339326T3 (en) | 1999-10-12 | 2010-05-19 | Chemocentryx, Inc. | CHEMIOQUINE RECEIVER. |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
AU1335601A (en) | 1999-10-19 | 2001-04-30 | Ludwig Institute For Cancer Research | Mage-a12 antigenic peptides and uses thereof |
IL148936A0 (en) * | 1999-10-20 | 2002-09-12 | Genentech Inc | Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
US6346249B1 (en) | 1999-10-22 | 2002-02-12 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
US6342587B1 (en) | 1999-10-22 | 2002-01-29 | Ludwig Institute For Cancer Research | A33 antigen specific immunoglobulin products and uses thereof |
SE9903895D0 (en) * | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
US20030103975A1 (en) * | 1999-11-03 | 2003-06-05 | Jones Jonathan C.R. | Modulation of angiogenesis and endothelialization |
AU2154401A (en) | 1999-11-12 | 2001-05-30 | Merck Patent Gmbh | Erythropoietin forms with improved properties |
US6979546B2 (en) * | 1999-11-15 | 2005-12-27 | Universita Di Genova | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
ES2377935T3 (en) | 1999-12-02 | 2012-04-03 | Zymogenetics, Inc. | Procedure for directing cells expressing -3 or -2 fibroblast growth factor receptor |
EP2332578A1 (en) | 1999-12-16 | 2011-06-15 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
CA2390691C (en) * | 1999-12-24 | 2016-05-10 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
IT1307309B1 (en) * | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | STABILIZING PEPTIDES, POLYPEPTIDES AND ANTIBODIES THAT INCLUDE THEM. |
KR100828058B1 (en) | 2000-01-12 | 2008-05-09 | 예일 유니버시티 | Nogo receptor-mediated blockade of axonal growth |
DE60137829D1 (en) * | 2000-01-13 | 2009-04-16 | Genentech Inc | HUMAN STRA6 POLYPEPTIDE |
WO2001055217A1 (en) | 2000-01-27 | 2001-08-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP2311951A1 (en) | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
EP1253942A4 (en) * | 2000-02-01 | 2004-06-16 | Tanox Inc | Cd40-binding apc-activating molecules |
EP2338515A3 (en) * | 2000-02-10 | 2011-11-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
CA2399388A1 (en) * | 2000-02-11 | 2001-08-16 | Michael J. Lenardo | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
DK1252192T3 (en) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Enhancement of the serum half-life of antibody-based fusion proteins |
CA2400206A1 (en) | 2000-02-17 | 2001-08-23 | Cv Therapeutics, Inc. | Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
EP1257584B2 (en) * | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
JP2003525061A (en) | 2000-03-01 | 2003-08-26 | メディミューン,インコーポレイテッド | High potency recombinant antibody and method for producing the same |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
WO2001070266A2 (en) | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
ATE435873T1 (en) | 2000-03-23 | 2009-07-15 | Genentech Inc | ANTI-C2/C2A INHIBITORS FOR COMPLEMENT ACTIVATION |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
BR0001078A (en) * | 2000-04-06 | 2003-05-13 | Maria Amalia Rotolo De Moraes | Method and apparatus for positive mental stimulation |
ES2637801T3 (en) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Multivalent antibodies and uses thereof |
CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
US7364867B2 (en) * | 2000-04-17 | 2008-04-29 | The Mount Sinai School Of Medicine | Method of identifying bitter compounds by employing TRP8, a transient receptor potential channel expressed in taste receptor cells |
US7094882B2 (en) * | 2000-04-21 | 2006-08-22 | Yeda Research And Development Co. Ltd. | Growth factor which acts through erb b-4 rtk |
US6835545B2 (en) | 2000-05-08 | 2004-12-28 | President And Fellows Of Harvard College | Methods, products and treatments for diabetes |
US7439330B2 (en) * | 2000-05-08 | 2008-10-21 | President And Fellows Of Harvard College | Anti-glycated CD59 antibodies and uses thereof |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
BR0110927A (en) * | 2000-05-19 | 2003-03-11 | Scancell Ltd | Antibody, nucleic acid, vector, cell, method of making an antibody, pharmaceutical composition, use of an antibody or nucleic acid, and method for treating or prophylaxis of cancer |
US6927320B1 (en) | 2000-05-24 | 2005-08-09 | New York University | Short-root gene, promoter, and uses thereof |
WO2001090192A2 (en) * | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
WO2001092338A1 (en) | 2000-06-01 | 2001-12-06 | The Brigham And Women's Hospital, Inc. | Diagnosis of endometrial precancers |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP2251026A1 (en) | 2000-06-08 | 2010-11-17 | Immune Disease Institute, Inc. | Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
AU7296801A (en) | 2000-06-22 | 2002-02-05 | Amgen Inc | Il-17 molecules and uses thereof |
AU2001271422B2 (en) * | 2000-06-22 | 2005-12-22 | Genentech, Inc. | Agonist anti-trk-C monoclonal antibodies |
AU7026601A (en) | 2000-06-28 | 2002-01-08 | Amgen Inc | Thymic stromal lymphopoietin receptor molecules and uses thereof |
BR0112111A (en) | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers |
JP2002017361A (en) * | 2000-07-04 | 2002-01-22 | Inst Of Physical & Chemical Res | Reelin protein cr-50 epitope region |
WO2002010217A2 (en) * | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Endothelial cell expression patterns |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
AU8009601A (en) * | 2000-08-11 | 2002-02-25 | Kirin Brewery | Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
AU2001288342A1 (en) * | 2000-08-21 | 2002-03-04 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
EP1197550A3 (en) * | 2000-08-25 | 2002-11-20 | Pfizer Products Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
US6803211B2 (en) | 2000-08-25 | 2004-10-12 | Pfizer Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
CA2420990C (en) * | 2000-08-28 | 2010-08-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
EP1320551A4 (en) * | 2000-09-01 | 2006-12-20 | Internat Bioimmune Systems Inc | The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
DE10043481A1 (en) * | 2000-09-04 | 2002-04-11 | Vectron Therapeutics Ag Imt | Human antibody against Endoglin (CD105) and its use |
CN1455680A (en) * | 2000-09-11 | 2003-11-12 | 达纳-法伯癌症协会有限公司 | MUCl extracellular domain and cancer treatment compositions and methods derived therefrom |
US20040018181A1 (en) * | 2000-09-11 | 2004-01-29 | KUFE Donald W. | MUC1 interference RNA compositions and methods derived therefrom |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
CA2421680A1 (en) * | 2000-09-29 | 2002-04-04 | Merck & Co., Inc. | Antibodies for human cytochrome p450 2d6 |
ES2357051T3 (en) * | 2000-10-02 | 2011-04-15 | Novartis Vaccines And Diagnostics, Inc. | ANTI-CD40 HUMAN ANTIBODIES. |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
US7029866B1 (en) * | 2000-10-10 | 2006-04-18 | Hanswalter Zentgraf | Cancer diagnosis by the measurement of Nup88 in body samples |
TR200602095T2 (en) * | 2000-10-13 | 2007-02-21 | Biogen Idec Ma Inc. | Humanized Anti-LT-Beta-R antibodies |
US8414892B2 (en) * | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7666424B2 (en) * | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7737258B2 (en) * | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7740845B2 (en) * | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
ES2298273T3 (en) | 2000-10-25 | 2008-05-16 | Chugai Seiyaku Kabushiki Kaisha | PREVENTIVE OR THERAPEUTIC AGENTS AGAINST PSORIASIS CONTAINING AN IL-6 ANTAGONIST AS THEIR ACTIVE INGREDIENT. |
CA2427820A1 (en) * | 2000-11-01 | 2002-06-13 | Elusys Therapeutics, Inc. | Method of producing biospecific molecules by protein trans-splicing |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
CA2428242A1 (en) | 2000-11-07 | 2002-05-16 | Zymogenetics, Inc. | Human tumor necrosis factor receptor |
US7235643B2 (en) | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
WO2002037967A1 (en) | 2000-11-07 | 2002-05-16 | Morphotek Inc. | Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics |
US6808894B1 (en) | 2000-11-07 | 2004-10-26 | Morphotek, Inc. | Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics |
US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7608704B2 (en) | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
JP4434580B2 (en) | 2000-11-28 | 2010-03-17 | メディミューン,エルエルシー | Methods for administering / prescribing anti-RSV antibodies for prevention and treatment |
US20070258987A1 (en) * | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
GB0029360D0 (en) * | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
US7700751B2 (en) * | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
WO2002046477A2 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP1341902A2 (en) * | 2000-12-08 | 2003-09-10 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP2354149B1 (en) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20030049800A1 (en) * | 2000-12-15 | 2003-03-13 | Saravis Calvin A. | Compositions and methods for producing antibodies to low molecular weight analytes |
US7981420B2 (en) | 2000-12-22 | 2011-07-19 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) |
US20020110841A1 (en) * | 2000-12-22 | 2002-08-15 | KUFE Donald W. | Regulation of cell growth by MUC1 |
EP1219637A1 (en) * | 2000-12-27 | 2002-07-03 | Innate Pharma | Polypeptides having a triggering NK activity and biological applications |
CA2433800C (en) * | 2001-01-05 | 2016-09-13 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
RU2420537C2 (en) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Fused proteins binding immunoglobulin domain |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
JP4669984B2 (en) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | F1t4 (VEGFR-3) and antitumor therapy as a target for tumor imaging |
EP1224942A1 (en) * | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
WO2002059337A1 (en) * | 2001-01-26 | 2002-08-01 | Georgetown University School Of Medicine | Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof |
EP2067486A1 (en) | 2001-01-31 | 2009-06-10 | Biogen Idec Inc. | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20020147312A1 (en) * | 2001-02-02 | 2002-10-10 | O'keefe Theresa | Hybrid antibodies and uses thereof |
WO2002064159A1 (en) * | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedies for tumor in hematopoietic organs |
US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
PT1733736E (en) * | 2001-02-07 | 2015-06-11 | Wilex Ag | Method of producing recombinant antibodies against tumours |
GB0103174D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Plc | Novel method of treatment |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
WO2002064612A2 (en) | 2001-02-09 | 2002-08-22 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
US6692700B2 (en) | 2001-02-14 | 2004-02-17 | Handylab, Inc. | Heat-reduction methods and systems related to microfluidic devices |
US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
EP1366455B1 (en) | 2001-02-19 | 2008-07-02 | MERCK PATENT GmbH | Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity |
CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
AU2002244103A1 (en) | 2001-02-22 | 2002-09-12 | University Of Florida | Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection |
US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
MXPA03008031A (en) | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety. |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
CA2441042A1 (en) | 2001-03-15 | 2002-09-26 | International Bioimmune Systems, Inc. | Monoclonal antibody therapy for pancreas cancer |
CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US20090081199A1 (en) * | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
WO2002076499A2 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
US20090123470A1 (en) * | 2001-03-26 | 2009-05-14 | The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. | Antibodies Against Cancer |
SE0101093D0 (en) | 2001-03-28 | 2001-03-28 | Pharmacia Diagnostics Ab | Novel compound for the treatment of allergy and asthma |
US8895311B1 (en) | 2001-03-28 | 2014-11-25 | Handylab, Inc. | Methods and systems for control of general purpose microfluidic devices |
US7323140B2 (en) | 2001-03-28 | 2008-01-29 | Handylab, Inc. | Moving microdroplets in a microfluidic device |
US7010391B2 (en) | 2001-03-28 | 2006-03-07 | Handylab, Inc. | Methods and systems for control of microfluidic devices |
US7829025B2 (en) | 2001-03-28 | 2010-11-09 | Venture Lending & Leasing Iv, Inc. | Systems and methods for thermal actuation of microfluidic devices |
US6852287B2 (en) | 2001-09-12 | 2005-02-08 | Handylab, Inc. | Microfluidic devices having a reduced number of input and output connections |
US6575188B2 (en) | 2001-07-26 | 2003-06-10 | Handylab, Inc. | Methods and systems for fluid control in microfluidic devices |
US7192557B2 (en) | 2001-03-28 | 2007-03-20 | Handylab, Inc. | Methods and systems for releasing intracellular material from cells within microfluidic samples of fluids |
US7270786B2 (en) | 2001-03-28 | 2007-09-18 | Handylab, Inc. | Methods and systems for processing microfluidic samples of particle containing fluids |
WO2002078598A2 (en) | 2001-03-29 | 2002-10-10 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Peptides and antibodies to muc 1 proteins |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
JP2005500018A (en) * | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | Recombinant antibody coexpressed with GnTIII |
AU2002257132A1 (en) * | 2001-04-06 | 2002-10-21 | The Trustees Of The University Of Pennsylvania | Erbb interface peptidomimetics and methods of use thereof |
AU2002303261A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
US20020146753A1 (en) * | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
WO2002081641A2 (en) * | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002303262A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene shinc-1 and diagnostic and therapeutic uses thereof |
ATE470676T1 (en) | 2001-04-13 | 2010-06-15 | Human Genome Sciences Inc | ANTI-VEGF-2 ANTIBODIES |
UA83791C2 (en) * | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Antibody to vla-1, pharmaceutical composition, containing thereof, and use of them for treatment individual having immunological disorder, mediated by vla-1 |
EP1572871A4 (en) * | 2001-04-20 | 2007-11-14 | Sinai School Medicine | T1r3 a novel taste receptor |
US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
DE60230868D1 (en) * | 2001-04-26 | 2009-03-05 | Biogen Inc | CRIPTOBLOCKING ANTIBODIES AND THEIR USE |
US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
DE60229051D1 (en) * | 2001-04-30 | 2008-11-06 | Lilly Co Eli | HUMANIZED ANTIBODIES |
EP2165714B1 (en) | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
DK1383785T3 (en) * | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Recombinant tumor-specific antibody and its use |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
US7803382B2 (en) * | 2001-05-04 | 2010-09-28 | Ludwig Institute For Cancer Research Ltd. | Method for inducing immune response to NY-CO-58 |
US6794501B2 (en) * | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
FI112501B (en) * | 2001-05-18 | 2003-12-15 | Valtion Teknillinen | Hevein-binding monoclonal antibodies |
MXPA03010523A (en) * | 2001-05-18 | 2004-07-01 | Boehringer Ingelheim Pharma | Antibodies specific for cd44v6. |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
AU2002310046A1 (en) * | 2001-05-22 | 2002-12-03 | Duke University | Compositions and methods for inhibiting metastasis |
US20020197253A1 (en) * | 2001-05-22 | 2002-12-26 | Cheek Dennis J. | Compositions and methods for promoting or inhibiting NDPK |
UY27304A1 (en) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | INHIBITORS OF THE INHIBITOR FACTOR OF MIGRATION OF MACROPHAGES AND METHODS FOR IDENTIFICATION |
US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
MXPA03010747A (en) * | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to trail receptors. |
CN101671335A (en) * | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
US7745398B2 (en) * | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
US7045605B2 (en) * | 2001-06-01 | 2006-05-16 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
US6861056B2 (en) * | 2001-06-05 | 2005-03-01 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
US20050152902A1 (en) * | 2001-06-05 | 2005-07-14 | Advanced Biotherapy, Inc. | Treatment of diabetic retinopathy |
US20040062768A1 (en) * | 2001-06-05 | 2004-04-01 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
US20040086508A1 (en) * | 2001-06-05 | 2004-05-06 | Advanced Biotherapy, Inc. | Treatment of organ transplant rejection |
US6534059B2 (en) | 2001-06-05 | 2003-03-18 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
ATE540695T1 (en) * | 2001-06-08 | 2012-01-15 | Genaera Corp | METHOD FOR MODULATING IL-13 |
ES2316574T3 (en) * | 2001-06-12 | 2009-04-16 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | HUMAN TYPE ANTIBODY AGAINST FACTOR VIII OF THE SANGUINEA COAGULATION. |
WO2002102973A2 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
AU2002316305A1 (en) * | 2001-06-20 | 2003-01-08 | Vlaams Interuniversitair Institut Voor Biotechnologie | Method of treating atherosclerosis and other inflammatory diseases |
US20040242851A1 (en) * | 2001-06-26 | 2004-12-02 | Zhenping Zhu | Bispecific antibodies that bind to vegf receptors |
US6886964B2 (en) * | 2001-06-26 | 2005-05-03 | Allan Gardiner | Illuminator with filter array and bandwidth controller |
WO2003000736A1 (en) * | 2001-06-26 | 2003-01-03 | Agen Biomedical Limited | Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
ES2674888T3 (en) | 2001-06-26 | 2018-07-04 | Amgen Inc. | OPGL antibodies |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
ATE393170T1 (en) | 2001-06-28 | 2008-05-15 | Kyowa Hakko Kogyo Kk | HUMANIZED ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR 8 AND FRAGMENT OF THE ANTIBODY |
AU2002319402B2 (en) * | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
AU2002326356A1 (en) * | 2001-07-09 | 2003-01-29 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
US7393656B2 (en) | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
CN1555488A (en) * | 2001-07-12 | 2004-12-15 | 路德维格癌症研究院 | Lymphatic endothelial cells materials and methods |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US20030113940A1 (en) * | 2001-07-16 | 2003-06-19 | Erlanger Bernard F. | Antibodies specific for nanotubes and related methods and compositions |
US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
EP1578917A4 (en) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | Multimeric proteins and methods of making and using same |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
WO2003010282A2 (en) * | 2001-07-26 | 2003-02-06 | Eli Lilly And Company | Interleukin-1 beta antibodies |
US6833441B2 (en) * | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
JP4729717B2 (en) * | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | Antibody that recognizes GM1 ganglioside-binding amyloid β protein, and DNA encoding the antibody |
WO2003014142A2 (en) * | 2001-08-03 | 2003-02-20 | University Of Virginia Patent Foundation | Phosphorylated histone h2b as an apoptosis marker |
EP1423012B1 (en) * | 2001-08-10 | 2007-11-14 | Imclone Systems, Inc. | Medical use of stem cells expressing vegfr-1 |
US20030035802A1 (en) * | 2001-08-14 | 2003-02-20 | Dewan Zeng | Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors |
US7771722B2 (en) * | 2001-08-17 | 2010-08-10 | Eli Lilly And Company | Assay method for alzheimer's disease |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
IL145279A0 (en) * | 2001-09-04 | 2002-06-30 | Yeda Res & Dev | Antibodies against caspase-8, their preparation and use |
WO2003024480A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US20070082337A1 (en) * | 2004-01-27 | 2007-04-12 | Compugen Ltd. | Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby |
AU2002326939A1 (en) | 2001-09-18 | 2003-04-01 | Fibrogen, Inc. | Methods of assaying connective tissue growth factor |
US20030219839A1 (en) * | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
CA2460587A1 (en) * | 2001-09-20 | 2003-03-27 | Alexion Pharmaceuticals, Inc. | Anti-pdgf antibodies and methods for producing engineered antibodies |
US20030124132A1 (en) * | 2001-09-27 | 2003-07-03 | Board Of Regents, The University Of Texas System | Combined compositions for tumor vasculature coaguligand treatment |
EP1432431B1 (en) | 2001-10-04 | 2017-05-10 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 activity |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2003048302A2 (en) * | 2001-10-11 | 2003-06-12 | Protein Design Labs Inc. | Identifying anti-tumor targets or agents by lipid raft immunization and proteomics |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US8165535B2 (en) * | 2006-06-04 | 2012-04-24 | Samsung Electro-Mechanics | Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators |
PL374495A1 (en) * | 2001-10-15 | 2005-10-31 | Immunomedics, Inc. | Direct targeting binding proteins |
IL161417A0 (en) * | 2001-10-15 | 2004-09-27 | Immunomedics Inc | Affinity enhancement agents |
US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
US20050238650A1 (en) * | 2002-04-17 | 2005-10-27 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
JP4750360B2 (en) | 2001-10-22 | 2011-08-17 | ザ スクリプス リサーチ インスティチュート | Antibody targeting compounds |
US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
US20040166490A1 (en) * | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
JP2005289809A (en) * | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | Mutant heavy-chain antibody |
US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
JP2005508171A (en) * | 2001-11-02 | 2005-03-31 | タノックス インコーポレーテッド | B cell lymphoma specific antigen for use in diagnosis and prevention of B cell malignancy |
WO2003039600A1 (en) * | 2001-11-09 | 2003-05-15 | Neopharm, Inc. | Selective treatment of il-13 expressing tumors |
CA2505129A1 (en) * | 2001-11-09 | 2003-05-15 | Transition Therapeutics Inc. | Pharmaceutical compositions of marine sponge microciona prolifera |
EP2308888B1 (en) * | 2001-11-14 | 2017-03-01 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
US20030157641A1 (en) * | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
JP2005535282A (en) | 2001-11-16 | 2005-11-24 | アイデック ファーマシューティカルズ コーポレイション | Polycistronic expression of antibodies |
JP2005511627A (en) * | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | Treatment of immunological diseases using anti-CD30 antibodies |
US7365167B2 (en) * | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
US7390885B2 (en) * | 2001-11-26 | 2008-06-24 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
WO2003046009A1 (en) * | 2001-11-27 | 2003-06-05 | Mochida Pharmaceutical Co., Ltd. | ANTI-IL13 RECEPTOR α1 NEUTRALIZING ANTIBODY |
AU2002357770B2 (en) | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
US20040197778A1 (en) * | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
US20040180344A1 (en) * | 2003-03-14 | 2004-09-16 | Morris David W. | Novel therapeutic targets in cancer |
US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
PT1461428E (en) * | 2001-12-03 | 2012-05-29 | Alexion Pharma Inc | Method for producing hybrid antibodies |
AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
EP1453546A2 (en) * | 2001-12-04 | 2004-09-08 | Nanospectra Biosciences, Inc. | Treatment of angiogenesis disorders using targeted nanoparticles |
CA2469306A1 (en) | 2001-12-05 | 2003-06-19 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
EP1521594B1 (en) * | 2001-12-07 | 2013-10-02 | Novartis Vaccines and Diagnostics, Inc. | Endogenous retrovirus polypeptides linked to oncogenic transformation |
WO2003049704A2 (en) * | 2001-12-11 | 2003-06-19 | University Of Massachusetts | Antibodies to treat cancer |
WO2003054216A2 (en) * | 2001-12-20 | 2003-07-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
ES2545090T3 (en) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Albumin and GCSF fusion proteins |
WO2003060080A2 (en) * | 2001-12-21 | 2003-07-24 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
PL372144A1 (en) * | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
US7923012B2 (en) * | 2001-12-28 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd. | Antibody against fibroblast growth factor-23 |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
US20050288487A1 (en) * | 2002-01-03 | 2005-12-29 | Kang Li | Human mast cell-expressed membrane proteins |
AU2003201741A1 (en) | 2002-01-09 | 2003-07-24 | Yusuke Nakamura | Cancer profiles |
US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
JP2005523688A (en) * | 2002-01-18 | 2005-08-11 | ブリストル−マイヤーズ スクイブ カンパニー | Identification of polynucleotides and polypeptides for predicting the activity of protein tyrosine kinases and / or compounds that interact with protein tyrosine kinase pathways |
US7092957B2 (en) * | 2002-01-18 | 2006-08-15 | Boundary Solutions Incorporated | Computerized national online parcel-level map data portal |
US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
BR0306979A (en) | 2002-01-18 | 2004-11-23 | Zymogenetics Inc | Isolated polypeptide, fusion protein, isolated polynucleotide molecule, expression vector, cultured cell, antibody or antibody fragment, and, methods for producing a protein, for producing an antibody, for stimulating an immune response in a mammal, for expanding cells hematopoietic and hematopoietic cell progenitors, to detect the presence of rna zcytor17lig and zcytor17lig in a biological sample, to kill cancer cells, to inhibit zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors, to reduce inflammation by zcytor17lig to suppress an inflammatory response in a mammal with inflammation, to treat a mammal affected by an inflammatory disease and to detect inflammation in a patient |
JP4460302B2 (en) | 2002-02-05 | 2010-05-12 | ジェネンテック インコーポレイテッド | Protein purification method |
ATE524739T1 (en) | 2002-02-13 | 2011-09-15 | American Diagnostica Inc | METHOD FOR SELECTING TREATMENT SCHEMES AND PREDICTING TREATMENT RESULTS IN CANCER PATIENTS |
US20050281813A1 (en) * | 2002-02-14 | 2005-12-22 | Nuvelo, Inc. | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins |
US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
JP4498746B2 (en) | 2002-02-14 | 2010-07-07 | イミューノメディクス、インコーポレイテッド | Anti-CD20 antibody and fusion protein thereof and method of use |
WO2003070889A2 (en) * | 2002-02-19 | 2003-08-28 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
JP2005526501A (en) | 2002-02-21 | 2005-09-08 | デューク・ユニヴァーシティ | Reagents and therapeutic methods for autoimmune diseases |
US20040025194A1 (en) * | 2002-02-22 | 2004-02-05 | Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US7662924B2 (en) * | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
AU2003217674C1 (en) | 2002-02-22 | 2009-03-26 | Abbvie Biotherapeutics Inc. | Anti-CCR5 antibody |
BR0307975A (en) | 2002-02-25 | 2005-01-11 | Elan Pharm Inc | Methods for chronically reducing pathological inflammation in a patient and for determining the effectiveness of a chronic administration regimen for treating pathological inflammation in an individual, composition and combined therapy for chronic treatment of pathological inflammation in a patient and use of an alpha inhibitor. 4-integrin |
US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
DE60325184D1 (en) * | 2002-03-01 | 2009-01-22 | Immunomedics Inc | RS7 ANTIBODY |
US9745380B2 (en) * | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
US7657380B2 (en) * | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US9770517B2 (en) * | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
ATE477276T1 (en) * | 2002-03-01 | 2010-08-15 | Immunomedics Inc | INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
EP1487879B1 (en) * | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US8361464B2 (en) * | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
EP1481007B1 (en) * | 2002-03-04 | 2007-01-24 | Nymox Corporation | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom |
CA2478169C (en) * | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
CN1653080A (en) * | 2002-03-07 | 2005-08-10 | 路德维格癌症研究院 | Lymphatic and blood endothelial cell genes |
AU2003220173A1 (en) * | 2002-03-08 | 2003-09-22 | Abgent, Inc. | Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
BRPI0308585B8 (en) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | isolated antibody or antigen-binding fragment thereof that binds to alfavbeta6, composition, in vitro detection method of alfavbeta6, and DNA construction |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
CN101143221A (en) * | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | Central airway administration for systemic delivery of therapeutics |
CA2479730A1 (en) * | 2002-03-21 | 2003-10-02 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
EP1497445A2 (en) * | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
GB0207533D0 (en) | 2002-04-02 | 2002-05-08 | Oxford Glycosciences Uk Ltd | Protein |
AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
CN101683520A (en) | 2002-04-09 | 2010-03-31 | 比奥根艾迪克Ma公司 | Methods for treating tweak-related conditions |
US7244565B2 (en) * | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
AU2003223600A1 (en) * | 2002-04-11 | 2003-10-27 | Altarex Medical Corporation | Binding agents and their use in targeting tumor cells |
NZ536420A (en) * | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
WO2003086458A1 (en) | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
EP1354600A1 (en) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
AU2003234194A1 (en) * | 2002-04-23 | 2003-11-10 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
WO2003102132A2 (en) | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
SI1507556T1 (en) | 2002-05-02 | 2016-10-28 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
US20070207142A1 (en) * | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
ES2685697T3 (en) | 2002-05-09 | 2018-10-10 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 as a marker of cardiovascular diseases |
GB0210783D0 (en) | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
ES2377720T3 (en) * | 2002-05-10 | 2012-03-30 | Purdue Research Foundation | AGON�? STICOS ANTIBODIES EPHA2 AND METHODS OF USE OF THE SAME. |
JP4557714B2 (en) * | 2002-05-10 | 2010-10-06 | メディミューン,エルエルシー | EphA2 monoclonal antibody and method of use thereof |
AU2003231802A1 (en) | 2002-05-17 | 2003-12-02 | Protein Design Labs | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
US20040005671A1 (en) * | 2002-05-17 | 2004-01-08 | Amrad Operations Pty Ltd. | Immunointeractive molecules |
US20030228317A1 (en) * | 2002-05-22 | 2003-12-11 | Prafulla Gokhale | Gene BRCC-1 and diagnostic and therapeutic uses thereof |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
CA2488287A1 (en) * | 2002-05-31 | 2003-12-11 | Council Of Scientific And Industrial Research | Use of a synergistic combination of chlorogenic acid and 3-o-p-coumaryl quinic acid as an anti-leukemic therapy |
DK2298278T3 (en) | 2002-06-07 | 2016-02-01 | Dyax Corp | Prevention and reduction of blood loss and inflammatory response |
US20070071744A1 (en) * | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
NZ537579A (en) * | 2002-06-10 | 2006-10-27 | Vaccinex Inc | C35 peptide epitopes and their analogs |
US6904341B2 (en) * | 2002-06-12 | 2005-06-07 | Sea-Watch Technologies, Inc. | Integrated vessel monitoring and control system |
AU2003276679A1 (en) * | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US9238081B2 (en) * | 2002-06-14 | 2016-01-19 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
EP2301968A3 (en) * | 2002-06-14 | 2011-06-29 | Immunomedics, Inc. | Humanized monoclonal antibody HPAM4 |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US9599619B2 (en) * | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US8821868B2 (en) * | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US20030232387A1 (en) * | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EP1551453A4 (en) * | 2002-06-17 | 2007-04-25 | Us Gov Health & Human Serv | Specificity grafting of a murine antibody onto a human framework |
CA2489520A1 (en) * | 2002-06-26 | 2004-01-08 | University Of Louisville Research Foundation, Inc. | A method for the detection of apoptosis |
CN1678734B (en) | 2002-06-27 | 2012-12-12 | 韦尔瓦制药有限公司 | Differentiation modulating agents and uses thereof |
WO2004003155A2 (en) | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
WO2004002500A1 (en) | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
EP1572952B1 (en) * | 2002-06-28 | 2010-09-29 | Imclone LLC | Novel polynucleotide and polypeptide sequences and uses thereof |
JP2006512895A (en) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | Ligand |
EP1524995B1 (en) * | 2002-07-01 | 2011-12-21 | Wilex AG | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
EP1539793A4 (en) * | 2002-07-01 | 2006-02-01 | Humanized anti-lymphotoyin beta receptor antibodies | |
ATE491725T1 (en) | 2002-07-15 | 2011-01-15 | Univ Texas | ANTIBODIES BOUND TO ANIONIC PHOSPHOLIPIDES AND AMINOPHOSPHOLIPIDES AND THEIR USE IN THE TREATMENT OF VIRUS INFECTIONS |
US7790162B2 (en) * | 2002-07-16 | 2010-09-07 | Woomera Therapeutics, Inc. | Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
DE60335129D1 (en) * | 2002-07-19 | 2011-01-05 | Morphotek Inc | METHOD OF GENERATING IMPROVED ANTIBODIES OF PRODUCING CELL LINES WITH IMPROVED GROWTH PROPERTIES |
AU2003260312A1 (en) * | 2002-07-19 | 2004-02-09 | Cellzome Ag | Protein complexes of the TIP60 transcriptional activator protein |
AU2003256823B9 (en) * | 2002-07-25 | 2009-01-08 | Medimmune, Llc | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
EP1539237A4 (en) * | 2002-07-30 | 2006-05-24 | Bristol Myers Squibb Co | Humanized antibodies against human 4-1bb |
ES2544527T3 (en) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
AU2003258127A1 (en) * | 2002-08-06 | 2004-02-23 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
US20040067532A1 (en) * | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US8946387B2 (en) * | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) * | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) * | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) * | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8530627B2 (en) * | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8044180B2 (en) * | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
AU2003264009A1 (en) * | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
CN101044247B (en) | 2002-08-20 | 2011-06-22 | 千年药品公司 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
CA2496789C (en) * | 2002-08-28 | 2013-12-17 | Dyax Corp. | Methods for preserving organs and tissues |
EP1542609B8 (en) | 2002-08-29 | 2013-02-20 | CytoCure LLC | Pharmaceutical compositions comprising Interferon beta for use in treating melanoma |
EP1539234A4 (en) * | 2002-09-05 | 2006-02-15 | Medimmune Inc | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
EP2213685B1 (en) | 2002-09-06 | 2013-11-27 | Amgen Inc. | Therapeutic anti-IL-1R1 monoclonal antibody |
US20060140931A1 (en) * | 2002-09-16 | 2006-06-29 | Nehal Mohamed | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
US20040052790A1 (en) * | 2002-09-18 | 2004-03-18 | Advanced Biotherapy, Inc. | Treatment of schizophrenia |
US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US20090217404A1 (en) * | 2002-09-27 | 2009-08-27 | Lowe Scott W | Cell-based RNA interference and related methods and compositions |
CA2501091A1 (en) * | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
RU2005113710A (en) * | 2002-10-04 | 2006-06-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | APPLICATION OF ANTIBODIES TO IL-2 RECEPTOR TO PREVENT THE TOXICITY ASSOCIATED WITH AMPHOTERICINE IN THE TREATMENT OF FUNGAL DISEASES |
EP1545615A4 (en) * | 2002-10-04 | 2006-03-01 | Rinat Neuroscience Corp | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
DK1556083T3 (en) * | 2002-10-08 | 2011-04-04 | Rinat Neuroscience Corp | Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same |
CA2501616C (en) | 2002-10-08 | 2015-05-12 | Immunomedics, Inc. | Antibody therapy |
US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
KR20050071564A (en) * | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
EP2298806A1 (en) * | 2002-10-16 | 2011-03-23 | Purdue Pharma L.P. | Antibodies that bind cell-associated CA 125/0722P and methods of use thereof |
JP4033390B2 (en) * | 2002-10-30 | 2008-01-16 | 独立行政法人科学技術振興機構 | Immortalized natural killer cell line |
AU2003296921A1 (en) * | 2002-10-31 | 2004-05-25 | Health Research, Inc. | Diagnostic test for west nile virus |
US20050106139A1 (en) * | 2002-10-31 | 2005-05-19 | Ivan Svendsen | Humanized tissue factor antibodies |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
AU2003287622A1 (en) * | 2002-11-06 | 2004-06-03 | Fraunhofer Usa | Expression of foreign sequences in plants using trans-activation system |
EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
US7692063B2 (en) * | 2002-11-12 | 2010-04-06 | Ibio, Inc. | Production of foreign nucleic acids and polypeptides in sprout systems |
US7683238B2 (en) * | 2002-11-12 | 2010-03-23 | iBio, Inc. and Fraunhofer USA, Inc. | Production of pharmaceutically active proteins in sprouted seedlings |
WO2004046330A2 (en) | 2002-11-15 | 2004-06-03 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
US20110091451A1 (en) * | 2002-11-15 | 2011-04-21 | Kavanaugh William M | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
AU2003291549A1 (en) * | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
US8658377B2 (en) | 2002-11-15 | 2014-02-25 | Morehouse School Of Medicine | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies |
ES2345885T3 (en) | 2002-11-15 | 2010-10-05 | Novartis Vaccines And Diagnostics, Inc. | METHODS TO PREVENT AND TREAT CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS. |
AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
GB0226731D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Method for generating immunoglobulin genes |
AU2003298783B2 (en) | 2002-11-26 | 2010-11-04 | Abbvie Biotherapeutics Inc. | Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis |
US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
JP2007531505A (en) | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | Techniques and compositions for diagnosis and treatment of cancer (MUC1) |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
CA2508519A1 (en) * | 2002-12-02 | 2004-06-17 | The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services | Recombinant immunotoxin and use in treating tumors |
MXPA05005923A (en) | 2002-12-06 | 2005-09-21 | Millennium Pharm Inc | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy. |
US20040115204A1 (en) | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
EP1944320A1 (en) * | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
JP4494977B2 (en) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its IL-2 fusion protein |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
RS20050481A (en) * | 2002-12-20 | 2007-08-03 | Biogen Idec Ma Inc., | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
US7276372B2 (en) | 2002-12-20 | 2007-10-02 | Pdl Biopharma, Inc. | Antibodies against GPR64 and uses thereof |
AU2003299818A1 (en) | 2002-12-20 | 2004-07-22 | Applera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
JP2006515750A (en) * | 2002-12-20 | 2006-06-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Multivalent lymphotoxin β receptor agonist and treatment using the same |
ES2367302T3 (en) * | 2002-12-23 | 2011-11-02 | Schering Corporation | USES OF THE MAMÍFERO CYTOCHINE IL-23; RELATED REAGENTS. |
AU2003300397A1 (en) * | 2002-12-23 | 2004-07-22 | Rinat Neuroscience Corp. | Methods for treating taxol-induced sensory neuropathy |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
CA2511598C (en) | 2002-12-24 | 2016-09-13 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
WO2004058818A2 (en) * | 2002-12-26 | 2004-07-15 | Applied Research Systems Ars Holding N.V. | Spliced variants of lgr6 |
US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
AU2004204494B2 (en) * | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP1585815A4 (en) * | 2003-01-21 | 2006-02-22 | Bristol Myers Squibb Co | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
SK50642005A3 (en) | 2003-01-24 | 2006-02-02 | Elan Pharmaceuticals, Inc. | Composition for treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
PL379264A1 (en) * | 2003-01-27 | 2006-08-07 | Biogen Idec Ma Inc. | Compositions and methods for treating cancer using igsf9 and liv-1 |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US20080014594A1 (en) * | 2003-01-31 | 2008-01-17 | Kevin Hestir | Lung-Expressed Polypeptides |
US20050169909A1 (en) * | 2004-02-02 | 2005-08-04 | Sanjaya Singh | Identification of novel IgE epitopes |
AU2004209638B2 (en) | 2003-02-01 | 2011-02-03 | Tanox, Inc. | High affinity anti-human IgE antibodies |
RU2390350C2 (en) * | 2003-02-01 | 2010-05-27 | Ньюралаб Лимитед | Active immunisation for creating soluble a-beta antibodies |
WO2004070016A2 (en) | 2003-02-03 | 2004-08-19 | Fraunhofer Usa Inc. | System for expression of genes in plants |
US8206704B2 (en) | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
NZ603330A (en) | 2003-02-11 | 2015-02-27 | Shire Human Genetic Therapies | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies |
US20040219528A1 (en) * | 2003-04-15 | 2004-11-04 | Morris David W. | Novel therapeutic targets in cancer |
AU2004212953B2 (en) | 2003-02-14 | 2010-03-11 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
US20070218071A1 (en) * | 2003-09-15 | 2007-09-20 | Morris David W | Novel therapeutic targets in cancer |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
JP2007524362A (en) | 2003-02-14 | 2007-08-30 | サイグレス ディスカバリー, インコーポレイテッド | Therapeutic GPCR targets in cancer |
US20060294604A1 (en) * | 2003-02-17 | 2006-12-28 | Fridman Jordan S | Model for studying the role of genes in tumor resistance to chemotherapy |
US20090186839A1 (en) * | 2003-02-17 | 2009-07-23 | Cold Spring Harbor Laboratory | Model for studying the role of genes in chemoresistance |
CA2516454A1 (en) | 2003-02-19 | 2004-09-02 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
ES2347959T3 (en) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | ANTI-CD70-FARMACO ANTIBODIES CONJUGATES AND THEIR USE FOR CANCER TREATMENT. |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
AU2004220525B2 (en) | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2004083387A2 (en) * | 2003-03-13 | 2004-09-30 | Corixa Corporation | Anti-ganglioside antibodies and methods of use |
US7741065B2 (en) * | 2003-03-13 | 2010-06-22 | Ramot At Tel Aviv University Ltd. | Non-invasive marker for liver function and disease |
US7785829B2 (en) * | 2003-03-19 | 2010-08-31 | Biogen Idec Ma, Inc. | Nogo receptor binding protein |
JP2007525434A (en) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof. |
WO2004084836A2 (en) * | 2003-03-20 | 2004-10-07 | Rinat Neuroscience Corp. | Methods for treating taxol-induced gut disorder |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
AU2003901325A0 (en) * | 2003-03-21 | 2003-04-03 | Stephen Locarnini | Therapeutic, prophylactic and diagnostic agents |
EA009124B1 (en) * | 2003-03-24 | 2007-10-26 | Займоджинетикс, Инк. | Anti-il-20 antibodies and binding partners and methods of using in inflammation |
WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
JP4689597B2 (en) * | 2003-03-28 | 2011-05-25 | レセプター バイオロジックス インク. | Gastrin hormone immunoassay |
US20070003992A1 (en) * | 2003-04-09 | 2007-01-04 | Pentyala Srinivas N | Methods and kits for detecting cerebrospinal fluid in a sample |
US8003765B2 (en) * | 2003-04-09 | 2011-08-23 | Stony Brook Anaesthesiology, University Faculty Practice Corporation | Methods, antibodies and kits for detecting cerebrospinal fluid in a sample |
US20040203079A1 (en) * | 2003-04-09 | 2004-10-14 | Research Foundation Of The State University Of New York | Methods and kits for detecting cerebrospinal fluid in a sample |
US20110042260A1 (en) * | 2003-04-10 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
JP4685764B2 (en) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | Modification of antibody FcRn binding affinity or serum half-life by mutagenesis |
KR20110094361A (en) | 2003-04-11 | 2011-08-23 | 메디뮨 엘엘씨 | Recombinant il-9 antibodies and uses thereof |
EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
WO2004091375A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
US20080090770A1 (en) * | 2003-04-11 | 2008-04-17 | Belmares Michael P | Modulation of Muc1 Mediated Signal Transduction |
SE0301087D0 (en) * | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
US7189694B2 (en) * | 2003-04-18 | 2007-03-13 | University Of Florida Research Foundation, Inc. | Inhibitors of autophosphorylation protein kinases |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
ES2368737T3 (en) * | 2003-04-23 | 2011-11-21 | Medarex, Inc. | HUMANIZED ANTIBODIES AGAINST THE ALFA 1 INTERFER RECEIVER (IFNAR-1). |
CN100409897C (en) * | 2003-04-23 | 2008-08-13 | 梅达雷克斯公司 | Compositions and methods for the therapy of inflammatory bowel disease |
US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
ES2639301T3 (en) * | 2003-04-30 | 2017-10-26 | Universität Zürich | Cancer treatment procedures using an immunotoxin |
ATE497783T1 (en) * | 2003-05-06 | 2011-02-15 | Syntonix Pharmaceuticals Inc | CLOTTING FACTOR VII-FC CHIMERIC PROTEINS FOR THE TREATMENT OF HEMOSTATIC DISEASES |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20050037947A1 (en) * | 2003-05-06 | 2005-02-17 | Bitonti Alan J. | Inhibition of drug binding to serum albumin |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
CA2525641A1 (en) * | 2003-05-12 | 2004-11-25 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against fiv infection |
EP2374819B1 (en) | 2003-05-12 | 2017-03-22 | Helion Biotech ApS | Antibodies to MASP-2 |
US7658927B2 (en) * | 2003-05-12 | 2010-02-09 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against FIV infection |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
WO2004110498A2 (en) * | 2003-05-14 | 2004-12-23 | Immunogen, Inc. | Drug conjugate composition |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
EP2361928B1 (en) | 2003-05-19 | 2017-04-26 | Prothena Biosciences Limited | Truncated fragments of alpha-synuclein in Lewy body disease |
WO2005026375A2 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
ATE449842T1 (en) * | 2003-05-28 | 2009-12-15 | Takeda Pharmaceutical | ANTI-BAMBI ANTIBODIES OR RNA FOR DIAGNOSIS AND THERAPY OF COLON OR LIVER CANCER |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
TWI374893B (en) * | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
WO2004108159A2 (en) * | 2003-06-05 | 2004-12-16 | The University Of Iowa Research Foundation | Gb virus c (hepatitis g virus) for the treatment of hiv |
CN1279056C (en) * | 2003-06-06 | 2006-10-11 | 马菁 | Specific antibody of tumor-associated antigen SM5-1 and use thereof |
US20050232926A1 (en) * | 2003-06-06 | 2005-10-20 | Oncomax Acquisition Corp. | Antibodies specific for cancer associated antigen SM5-1 and uses thereof |
US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20060241288A1 (en) * | 2003-06-10 | 2006-10-26 | Ace Biosciences A/S | Extracellular aspergillus polypeptides |
AU2004253868B2 (en) | 2003-06-13 | 2011-06-16 | Biogen Ma Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
ES2527102T3 (en) * | 2003-06-19 | 2015-01-20 | Genentech, Inc. | Compositions and methods for the treatment of disorders related to coagulation |
US7479546B2 (en) * | 2003-06-27 | 2009-01-20 | Diadexus, Inc. | Pro104 antibody compositions and methods of use |
CA2529945A1 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
EP2457586A1 (en) * | 2003-06-27 | 2012-05-30 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
EP1644416A4 (en) * | 2003-06-30 | 2007-08-29 | Centocor Inc | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
US20050100543A1 (en) * | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
DE602004030464D1 (en) * | 2003-07-02 | 2011-01-20 | Innate Pharma | METHOD FOR THE PRODUCTION AND EVALUATION OF THE CYTOTOXICITY OF KIR2DL NK RECEPTOR ANTIBODIES |
EP1644408A1 (en) * | 2003-07-15 | 2006-04-12 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
US20050058658A1 (en) * | 2003-07-15 | 2005-03-17 | Barros Research Institute | Compositions and methods for immunotherapy of human immunodeficiency virus (HIV) |
TW201319088A (en) | 2003-07-18 | 2013-05-16 | Amgen Inc | Specific binding agents to hepatocyte growth factor |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
EP3722309A1 (en) | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
US7727752B2 (en) * | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
CA2534077A1 (en) * | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
CA2445420A1 (en) | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
JP4996248B2 (en) | 2003-07-31 | 2012-08-08 | ハンディーラブ インコーポレイテッド | Processing of particle-containing samples |
WO2005010039A1 (en) * | 2003-07-31 | 2005-02-03 | Pfizer Products Inc. | Bsep polypeptide variants and uses thereof |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
JP2007501011A (en) * | 2003-08-01 | 2007-01-25 | ジェネンテック・インコーポレーテッド | Binding polypeptide having restriction diversity sequence |
HN2004000285A (en) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
WO2005014795A2 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
JP2007528721A (en) * | 2003-08-14 | 2007-10-18 | ダイアックス コーポレイション | Endotheliase-2 ligand |
US20050131219A1 (en) * | 2003-08-18 | 2005-06-16 | Urdea Michael S. | Methods for reducing complexity of a sample using small epitope antibodies |
AU2004286198C1 (en) | 2003-08-18 | 2011-02-24 | Medimmune, Llc | Humanization of antibodies |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
CN1839133A (en) * | 2003-08-22 | 2006-09-27 | 阿文尼尔药品公司 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
WO2005021594A2 (en) * | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
US7604994B2 (en) * | 2003-09-03 | 2009-10-20 | Morphotek, Inc. | Genetically altered antibody-producing cell lines with improved antibody characteristics |
WO2005074417A2 (en) * | 2003-09-03 | 2005-08-18 | Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
US20060216292A1 (en) * | 2003-09-05 | 2006-09-28 | Cellzome Ag | Treatment of neurodegenerative diseases |
US20070110744A1 (en) * | 2003-09-08 | 2007-05-17 | Kari Alitalo | Lymphatic and blood endothelial cell genes |
GB0321100D0 (en) | 2003-09-09 | 2003-10-08 | Celltech R&D Ltd | Biological products |
US7046714B2 (en) * | 2003-09-10 | 2006-05-16 | Intel Corporation | Method and apparatus for Raman ring resonator based laser/wavelength converter |
US7288250B2 (en) * | 2003-09-11 | 2007-10-30 | Critical Therapeutics, Inc. | Monoclonal antibodies against HMGB1 |
WO2005025509A2 (en) * | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
AU2004274487B2 (en) * | 2003-09-18 | 2011-09-01 | Macrogenics West, Inc. | KID3 and KID3 antibodies that bind thereto |
BRPI0414688A (en) * | 2003-09-23 | 2006-11-28 | Pdl Biopharma Inc | anti-il-2 receptor respiratory disease treatment |
EP1664118B1 (en) * | 2003-09-23 | 2011-05-25 | Technische Universität München | Tlr2 antagonistic antibody and use thereof |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US20050282168A1 (en) * | 2003-09-29 | 2005-12-22 | Wyeth | Cell surface molecules as markers and therapeutic agents against kidney cancers |
US20070281896A1 (en) * | 2003-09-30 | 2007-12-06 | Morris David W | Novel compositions and methods in cancer |
KR20060120652A (en) | 2003-10-07 | 2006-11-27 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
US8119340B2 (en) * | 2003-10-08 | 2012-02-21 | The Feinstein Institute For Medical Research | Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia |
US20050239700A1 (en) * | 2003-10-14 | 2005-10-27 | Biogen Idec Inc. | Treatment of cancer using antibodies to LRRC15 |
WO2005037867A1 (en) * | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
ES2346978T3 (en) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | USE OF ANTI-CD40 ANTIGONIST MONOCLONANT ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA. |
ATE516819T1 (en) | 2003-11-04 | 2011-08-15 | Novartis Vaccines & Diagnostic | METHOD FOR TREATING B-CELL-RELATED CANCER |
PT1682177E (en) | 2003-11-04 | 2010-11-29 | Xoma Technology Lt | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
CA2544852A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
PL2149585T3 (en) | 2003-11-04 | 2014-01-31 | Novartis Vaccines & Diagnostics Inc | Use of antagonistic anti-CD40 monoclonal antibodies |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
PL1692182T3 (en) | 2003-11-05 | 2010-09-30 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
US20070092515A1 (en) * | 2003-11-06 | 2007-04-26 | Icos Corporation | Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin |
AR046833A1 (en) | 2003-11-10 | 2005-12-28 | Schering Corp | ANTI-INTERLEUQUINA ANTIBODIES-10 |
CN101133083A (en) | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | Humanized anti-cd47 antibody |
JP2008504002A (en) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
AU2004290059A1 (en) * | 2003-11-12 | 2005-05-26 | Albert Einstein College Of Medicine Of Yeshiva University | Novel sequences encoding hepatitis C virus glycoproteins |
US8454963B2 (en) * | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
KR100772800B1 (en) | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | A variable region of the monoclonal antibody against a human tumor necrosis factor ? and a gene encoding the same |
SI1983000T1 (en) | 2003-11-21 | 2015-12-31 | Ucb Biopharma Sprl | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
ES2343965T3 (en) | 2003-11-25 | 2010-08-13 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | ANTI-CD22 ANTIBODIES AND MUTED IMMUNOCONGUJADOS. |
EP2405023B1 (en) | 2003-11-26 | 2014-01-08 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP1697750B1 (en) | 2003-12-01 | 2013-03-20 | Dako Denmark A/S | Methods and compositions for immuno-histochemical detection |
WO2005057223A2 (en) * | 2003-12-04 | 2005-06-23 | Applied Research Systems Ars Holding N.V. | Methods for identifying modulators of active kit tyrosine kinase receptor |
ATE526037T1 (en) * | 2003-12-04 | 2011-10-15 | Vaccinex Inc | METHOD FOR KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS |
WO2005060457A2 (en) | 2003-12-04 | 2005-07-07 | Pdl Biopharma, Inc. | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies |
US20060182742A1 (en) * | 2004-08-24 | 2006-08-17 | Ishikawa Muriel Y | System and method for magnifying a humoral immune response |
US20060047435A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to augmenting an immune system |
US20060047434A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to improving an immune system |
US20060047436A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for magnifying an immune response |
US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
US20060116824A1 (en) * | 2004-12-01 | 2006-06-01 | Ishikawa Muriel Y | System and method for modulating a humoral immune response |
US20060047437A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for heightening an immune response |
US20060095211A1 (en) * | 2003-12-05 | 2006-05-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for modulating a cell mediated immune response |
US20070249809A1 (en) * | 2003-12-08 | 2007-10-25 | Xencor, Inc. | Protein engineering with analogous contact environments |
US20060003412A1 (en) * | 2003-12-08 | 2006-01-05 | Xencor, Inc. | Protein engineering with analogous contact environments |
PL1694361T3 (en) | 2003-12-09 | 2011-08-31 | Engeneic Molecular Delivery Pty Ltd | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
CN102838675B (en) | 2003-12-10 | 2014-07-30 | 梅达雷克斯有限责任公司 | Ip-10 antibodies and their uses |
JP2007521248A (en) | 2003-12-10 | 2007-08-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Humanized anti-CCR2 antibody and methods of using the antibody |
DK1711207T3 (en) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha antibodies and their use |
WO2005058961A2 (en) * | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
EP1699487A4 (en) | 2003-12-15 | 2009-07-08 | Alexion Pharma Inc | Novel anti-dc-sign antibodies |
EP2275448A3 (en) | 2003-12-19 | 2013-02-06 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
AU2004312376A1 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
EP1704160B1 (en) | 2003-12-22 | 2010-11-10 | The Trustees of The University of Pennsylvania | Methods and compositions for identifying rna-binding proteins |
EP1700121A4 (en) | 2003-12-23 | 2008-09-03 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
PL1703893T3 (en) | 2003-12-23 | 2012-09-28 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
GB0329825D0 (en) * | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
ITRM20030601A1 (en) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED. |
KR20060124656A (en) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | Fc-erythropoietin fusion protein with improved pharmacokinetics |
EP3476861A1 (en) | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
JP4315982B2 (en) * | 2004-01-09 | 2009-08-19 | ファイザー インコーポレイティッド | Antibodies against MAdCAM |
JPWO2005068504A1 (en) * | 2004-01-19 | 2008-01-10 | 株式会社医学生物学研究所 | Inflammatory cytokine inhibitor |
CA2553692C (en) * | 2004-01-20 | 2014-10-07 | Kalobios, Inc. | Antibody specificity transfer using minimal essential binding determinants |
EP1706428B1 (en) | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Anti-cancer antibodies with reduced complement fixation |
WO2005071058A2 (en) * | 2004-01-27 | 2005-08-04 | Compugen Ltd. | Methods and systems for annotating biomolecular sequences |
AU2004315399B2 (en) * | 2004-01-29 | 2009-08-06 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of ATP7A-modulators |
ES2300852T3 (en) * | 2004-01-29 | 2008-06-16 | Cellzome Ag | TREATMENT OF NEUROGENERATIVE DISEASES THROUGH THE USE OF GPR49. |
SG135175A1 (en) | 2004-02-02 | 2007-09-28 | Engeneic Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
SG183683A1 (en) * | 2004-02-02 | 2012-09-27 | Tanox Inc | Identification of novel ige epitopes |
AU2005209909B8 (en) * | 2004-02-03 | 2009-01-15 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
EP1718967B1 (en) | 2004-02-03 | 2013-04-24 | Diadexus, Inc. | METHODS OF DETECTING Lp-PLA2 ACTIVITY |
DK1766093T3 (en) | 2004-02-06 | 2011-10-03 | Univ Massachusetts | Antibodies to clostridium difficile toxins and their use |
CA2555306A1 (en) * | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
AU2005211725B2 (en) | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
BRPI0506679A (en) * | 2004-02-11 | 2007-05-15 | Warner Lambert Co | Methods of Treating Osteoarthritis with IL-6 Antagonists |
US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US20110064754A1 (en) * | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
SI1716178T1 (en) * | 2004-02-16 | 2010-11-30 | Micromet Ag | Less immunogenic binding molecules |
EP1720908A2 (en) * | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
AU2005214382B2 (en) * | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
EP1769068B1 (en) * | 2004-02-20 | 2014-12-31 | iBio, Inc. | Systems and methods for clonal expression in plants |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
WO2005082458A1 (en) * | 2004-02-23 | 2005-09-09 | Genzyme Corporation | Muc1 antagonist enhancement of death receptor ligand-induced apoptosis |
US20040260068A1 (en) * | 2004-02-26 | 2004-12-23 | Naoya Tsurushita | Humanized chicken antibodies |
ATE498010T1 (en) | 2004-03-01 | 2011-02-15 | Immune Disease Inst Inc | NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF |
WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20060024302A1 (en) * | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
WO2005086875A2 (en) * | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
WO2005090406A2 (en) * | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
CN102718867A (en) | 2004-03-12 | 2012-10-10 | 瓦斯基因治疗公司 | Polypeptide compound for inhibiting angiogenesis and tumor growth |
EA014112B1 (en) * | 2004-03-23 | 2010-10-29 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibodies and methods of using thereof |
KR20060132006A (en) * | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | Receptor coupling agents and therapeutic uses thereof |
ATE531388T1 (en) * | 2004-03-24 | 2011-11-15 | Abbott Biotherapeutics Corp | USE OF ANTI-ALPHA5BETA1 ANTIBODIES TO INHIBIT CANCER CELL PROLIFERATION |
AR048335A1 (en) * | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
EP1786463A4 (en) * | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | Antibodies against nogo receptor |
EP1732649B1 (en) * | 2004-03-26 | 2010-01-20 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of laptm4b |
AU2005228426B2 (en) * | 2004-03-29 | 2010-07-15 | North Shore-Long Island Jewish Research Institute | Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor |
US20060099608A1 (en) * | 2004-03-29 | 2006-05-11 | Medstar Research Institute | Methods of diagnosing cardiovascular disease |
EP1730193A2 (en) * | 2004-03-29 | 2006-12-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
US7557193B2 (en) * | 2004-03-31 | 2009-07-07 | Universite De La Mediterranee | Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
JP5223072B2 (en) | 2004-04-02 | 2013-06-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Methods and compositions for treating and preventing diseases associated with avβ5 integrin |
US20070237717A1 (en) * | 2004-04-05 | 2007-10-11 | Roland Martin | Methods for Selection of Subjects for Multiple Sclerosis Therapy |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
ES2338344T3 (en) * | 2004-04-07 | 2010-05-06 | Rinat Neuroscience Corporation | PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR. |
CA2562764A1 (en) | 2004-04-23 | 2005-11-03 | Richard Kroczek | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
EP1753449A4 (en) * | 2004-04-30 | 2009-09-23 | Corthera Inc | Methods and compositions for control of fetal growth via modulation of relaxin |
US7776564B2 (en) * | 2004-04-30 | 2010-08-17 | Five Prime Therapeutics, Inc. | Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
ATE537189T1 (en) * | 2004-04-30 | 2011-12-15 | Inst Nat Sante Rech Med | ANTI-TFR ANTIBODIES |
AU2005241080B2 (en) | 2004-05-03 | 2011-08-11 | Handylab, Inc. | Processing polynucleotide-containing samples |
US8852862B2 (en) | 2004-05-03 | 2014-10-07 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
EP2423327B1 (en) | 2004-05-07 | 2014-01-08 | Celera Corporation | Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof |
US7521542B2 (en) * | 2004-05-10 | 2009-04-21 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | Modulation of immunoglobulin production and atopic disorders |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
BRPI0510909A2 (en) * | 2004-05-19 | 2008-12-16 | Medarex Inc | cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth |
WO2005116071A2 (en) * | 2004-05-28 | 2005-12-08 | University Of Massachusetts | Snares for pathogenic or infectious agents and uses related thereto |
US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
MXPA06014065A (en) | 2004-06-01 | 2007-01-31 | Genentech Inc | Antibody drug conjugates and methods. |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
AR049390A1 (en) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP3530288A3 (en) | 2004-06-10 | 2019-12-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
AU2005255019B2 (en) * | 2004-06-12 | 2011-05-19 | Oregon Health And Science University | Compositions and methods for diagnosis and treatment of orthopoxviruses |
US20050276807A1 (en) * | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
US20050276806A1 (en) * | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of autism |
ES2526194T3 (en) | 2004-06-21 | 2015-01-08 | E. R. Squibb & Sons, L.L.C. | Interferon alfa 1 receptor antibodies, and their uses |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
BRPI0512500A (en) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | treatment or conditions involving demyelination |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
EP2495252B1 (en) | 2004-07-09 | 2018-04-18 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Soluble forms of hendra and nipah virus G glycoprotein |
PL1674111T3 (en) * | 2004-07-09 | 2011-04-29 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
CA2573730A1 (en) * | 2004-07-15 | 2006-02-23 | Amgen Inc. | 1,2,3,4-tetrahydropyrazin-2-yl acetamides and their use as bradykinin antagonists for the treatment of inflammation related disorders |
US20090087376A1 (en) * | 2004-07-15 | 2009-04-02 | The General Hospital Corporation | Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease |
US6986264B1 (en) * | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
ME00226B (en) | 2004-07-15 | 2011-02-10 | Medarex Llc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
BRPI0513200A (en) * | 2004-07-16 | 2008-04-29 | Pfizer Prod Inc | use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
US20060024768A1 (en) | 2004-07-29 | 2006-02-02 | Saladax Biomedical, Inc. | Taxol immunoassay |
US7927594B2 (en) | 2004-07-30 | 2011-04-19 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide |
EP1789070B1 (en) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in neuronal function |
WO2006135382A2 (en) * | 2004-08-04 | 2006-12-21 | Chemocentryx, Inc. | Enzymatic activities in chemokine-mediated inflammation |
AU2005267722B2 (en) | 2004-08-04 | 2009-10-08 | Amgen Inc. | Antibodies to Dkk-1 |
AR051071A1 (en) * | 2004-08-05 | 2006-12-20 | Wyeth Corp | ANTAGONISM OF THE ACTIVITY OF THE INTERLEUQUINA RECEIVER-21 |
EA013752B1 (en) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
JP2008509172A (en) * | 2004-08-09 | 2008-03-27 | セルゾーム アーゲー | Treatment of neurodegenerative diseases by use of DEGS inhibitors |
US20060177445A1 (en) * | 2004-08-16 | 2006-08-10 | Boris Skurkovich | Treatment of inflammatory skin diseases |
CN101123994B (en) | 2004-08-16 | 2012-11-14 | 夸克医药公司 | Therapeutic uses of inhibitors of rtp801 |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
US20090123413A1 (en) * | 2004-08-23 | 2009-05-14 | Britta Hardy | Use of bat monoclonal antibody for immunotherapy |
US20070265818A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for heightening cell-mediated immune response |
US20060047439A1 (en) * | 2004-08-24 | 2006-03-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for improving a humoral immune response |
US20070196362A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to bolster an immune response |
US20070265788A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for augmenting cell-mediated immune response |
US20070288173A1 (en) * | 2004-08-24 | 2007-12-13 | Searete Llc, A Limited Liability Corporation Of The State Of Delware | Computational methods and systems to reinforce a humoral immune response |
US20070198196A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods relating to ameliorating an immune system |
JP4733042B2 (en) * | 2004-08-24 | 2011-07-27 | 中外製薬株式会社 | Adjuvant therapy using anti-glypican 3 antibody |
US20070265817A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods relating to fortifying an immune system |
US20070207492A1 (en) * | 2004-08-24 | 2007-09-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to adjust a humoral immune response |
US20070265819A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for improving cell-mediated immune response |
US20070265787A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc,A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for magnifying cell-mediated immune response |
MX2007002294A (en) | 2004-08-26 | 2007-10-19 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells. |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
US7655229B2 (en) * | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
CA2577405A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Anti-fc-gamma riib receptor antibody and uses therefor |
US7662926B2 (en) * | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
RU2453558C2 (en) | 2004-09-03 | 2012-06-20 | Дженентек, Инк. | Humanised anti-beta 7 antagonistic antibodies and use thereof |
US20070275874A1 (en) * | 2004-09-03 | 2007-11-29 | Yale University | Use of Leptin in Wound Healing |
EP2145954A1 (en) * | 2004-09-06 | 2010-01-20 | Kyowa Hakko Kirin Co., Ltd. | Anti-A33 antibody |
US7432359B2 (en) | 2004-09-06 | 2008-10-07 | Kirin Pharma Kabushiki Kaisha | Anti-A33 antibody |
JP2008518586A (en) * | 2004-09-09 | 2008-06-05 | ユニバーシティ オブ ワシントン | All-trans retinol, or all-trans 13,14-dihydroretinol saturase and method of use |
AR050642A1 (en) * | 2004-09-10 | 2006-11-08 | Wyeth Corp | ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5T4 ANTIBODY / CALICHEAMICINA |
GB0420466D0 (en) | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
CA2580965C (en) * | 2004-09-22 | 2014-04-08 | Receptor Biologix, Inc. | Monoclonal antibodies to progastrin |
US20060204512A1 (en) * | 2004-09-23 | 2006-09-14 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2006034456A2 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
CN101065151B (en) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | Cysteine engineered antibodies and conjugates |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
WO2006039238A2 (en) * | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
US7807804B2 (en) * | 2004-10-05 | 2010-10-05 | Wyeth Llc | Methods and compositions for improving recombinant protein production |
WO2006041641A2 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Therapeutic agents with decreased toxicity |
WO2006044263A2 (en) * | 2004-10-12 | 2006-04-27 | Advanced Biotherapy, Inc. | Treatment of herpes |
EP1814917A2 (en) * | 2004-10-13 | 2007-08-08 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
US20120294863A1 (en) * | 2004-10-15 | 2012-11-22 | Seattle Genetics, Inc. | Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders |
US8337838B2 (en) * | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP1799262A4 (en) * | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US20060121053A1 (en) * | 2004-10-18 | 2006-06-08 | Pamela Sweeney | High cell density process for growth of Listeria |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
CA2584157C (en) | 2004-10-22 | 2014-10-14 | Zymogenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
CA2584859C (en) | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
CN101068836B (en) * | 2004-10-26 | 2013-08-14 | 中外制药株式会社 | Anti-glypican 3 antibody having modified sugar chain |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
JP2008518936A (en) * | 2004-10-29 | 2008-06-05 | メディミューン,インコーポレーテッド | Methods for preventing and treating RSV infections and related conditions |
EP1814918A1 (en) * | 2004-10-29 | 2007-08-08 | Elusys Therapeutics, Inc. | Use of cr1-binding molecules in clearance and induction of immune responses |
WO2006048877A2 (en) * | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of b-cell malignancies with fgfr3 inhibitors |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
US20060135459A1 (en) | 2004-11-09 | 2006-06-22 | Epstein Alan L | Targeted innate immunity |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
WO2006132670A2 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2007001457A2 (en) * | 2004-11-12 | 2007-01-04 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
PT2343380T (en) | 2004-11-16 | 2019-09-18 | Humanigen Inc | Immunoglobulin variable region cassette exchange |
EP2377555A3 (en) * | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
WO2006055871A2 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
JP4993645B2 (en) | 2004-12-01 | 2012-08-08 | ジェネンテック, インコーポレイテッド | Antibody drug conjugates and methods |
NZ555464A (en) | 2004-12-02 | 2010-03-26 | Domantis Ltd | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
NZ556105A (en) * | 2004-12-03 | 2009-12-24 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis |
EP2283831A3 (en) | 2004-12-03 | 2013-10-23 | Merck Sharp & Dohme Corp. | Biomakers for pre-selection of patients for anti-IGF1R therapy |
WO2006061723A2 (en) | 2004-12-06 | 2006-06-15 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
US20060121574A1 (en) * | 2004-12-08 | 2006-06-08 | Icos Corporation | Recombinant method for making multimeric proteins |
EP2395109A1 (en) | 2004-12-08 | 2011-12-14 | Aventis Pharmaceuticals Inc. | Method for measuring resistance or sensitivity to docetaxel |
WO2006060871A1 (en) | 2004-12-10 | 2006-06-15 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Binding partners of antibodies specific for dendritic cell antigens |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
AR051800A1 (en) * | 2004-12-15 | 2007-02-07 | Wyeth Corp | BETA ANTIBODIES USED TO IMPROVE COGNITION |
MX2007007277A (en) * | 2004-12-16 | 2008-01-28 | Genentech Inc | Methods for treating autoimmune disorders. |
NZ555286A (en) * | 2004-12-17 | 2010-04-30 | Genentech Inc | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |
US20060134698A1 (en) * | 2004-12-20 | 2006-06-22 | Evanston Northwestern Healthcare Research Institute | Methods for treating cardiac disease by modifying an N-terminal domain of troponin I |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
US8137907B2 (en) * | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
JP2008526234A (en) | 2005-01-05 | 2008-07-24 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | CRIPTO binding molecule |
US7833725B2 (en) * | 2005-01-06 | 2010-11-16 | President And Fellows Of Harvard College | Mass spectrometric methods and products |
US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
AU2006208226A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
WO2006081553A2 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | ANTI-MUC1 α/ß ANTIBODIES |
EP1846032A4 (en) * | 2005-01-31 | 2009-01-28 | Raven Biotechnologies Inc | Luca2 and antibodies that bind thereto |
US20060174362A1 (en) | 2005-02-01 | 2006-08-03 | Origen Therapeutics, Inc. | Long-term culture of avian primordial germ cells (PGCs) |
US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
PA8660701A1 (en) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | SMALL AGONISTS AND THEIR USES |
CN101495498B (en) | 2005-02-07 | 2013-09-18 | 基因信息公司 | Mild osteoarthritis biomarkers and uses thereof |
US7722867B2 (en) * | 2005-02-07 | 2010-05-25 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
WO2006086396A2 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
US20060177883A1 (en) | 2005-02-08 | 2006-08-10 | Saladax Biomedical Inc. | 5-Fluoro-uracil immunoassay |
AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
ATE526421T1 (en) | 2005-02-14 | 2011-10-15 | Univ Iowa Res Found | METHODS AND REAGENTS FOR THE TREATMENT AND DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION |
WO2006088855A1 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
EP1848743A2 (en) | 2005-02-14 | 2007-10-31 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
CA2596986A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il-17f in diagnosis and therapy of airway inflammation |
JP5651285B2 (en) * | 2005-02-15 | 2015-01-07 | デューク ユニバーシティ | Anti-CD19 antibodies and use in oncology |
US8444973B2 (en) * | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
US20090124993A1 (en) | 2005-02-17 | 2009-05-14 | Burkly Linda C | Treating neurological disorders |
CN101124249B (en) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | Human monoclonal antibodies to prostate specific membrane antigen(PSMA) |
US20060193849A1 (en) * | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
EP1860119B1 (en) | 2005-02-28 | 2011-08-03 | Institute for Antibodies Co., Ltd. | ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME |
AU2006218489B2 (en) | 2005-03-02 | 2011-02-24 | Biogen Ma Inc. | KIM-1 antibodies for treatment of Th2-mediated conditions |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
WO2006094192A2 (en) * | 2005-03-03 | 2006-09-08 | Immunomedics, Inc. | Humanized l243 antibodies |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP1858545A2 (en) * | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
WO2006096653A2 (en) * | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
KR20060097526A (en) * | 2005-03-11 | 2006-09-14 | (주) 에이프로젠 | Monoclonal antibody specific to anthrax toxin |
EP1856296A2 (en) | 2005-03-11 | 2007-11-21 | Applera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
CA2602035C (en) | 2005-03-18 | 2015-06-16 | Medimmune, Inc. | Framework-shuffling of antibodies |
EP1863531A1 (en) | 2005-03-19 | 2007-12-12 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
US20060216767A1 (en) | 2005-03-22 | 2006-09-28 | Saladax Biomedical Inc. | Docetaxel immunoassay |
RS59399B1 (en) | 2005-03-23 | 2019-11-29 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
US8323645B2 (en) | 2005-03-24 | 2012-12-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
WO2006102191A1 (en) * | 2005-03-24 | 2006-09-28 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
PT2343320T (en) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anti-gitr antibodies and uses thereof |
EP2322622A3 (en) | 2005-03-25 | 2012-03-07 | National Research Council of Canada | Method for isolation of soluble polypeptides |
WO2006100582A1 (en) * | 2005-03-25 | 2006-09-28 | Glycart Biotechnology Ag | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
EP1875244B1 (en) | 2005-03-30 | 2019-01-23 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
CA2602849C (en) | 2005-03-30 | 2013-06-04 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
ES2720288T3 (en) | 2005-03-30 | 2019-07-19 | Minerva Biotechnologies Corp | Proliferation of cells expressing MUC1 |
ES2440953T3 (en) | 2005-03-31 | 2014-01-31 | The General Hospital Corporation | Modulation of HGF / HGFR activity to treat lymphedema |
DK2645106T3 (en) | 2005-04-04 | 2017-10-02 | Biogen Ma Inc | Methods for Evaluating an Immune Response to a Therapeutic Agent |
GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US20090214536A1 (en) | 2005-04-07 | 2009-08-27 | Guoying Yu | CACNA1E in Cancer Diagnosis, Detection and Treatment |
EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
MX2007012547A (en) | 2005-04-11 | 2008-03-11 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof. |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
GT200600148A (en) * | 2005-04-14 | 2006-11-22 | METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS | |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
ES2707152T3 (en) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Covalent diabodies and uses thereof |
CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1877087B1 (en) * | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
US20060269556A1 (en) * | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
DK1871418T3 (en) * | 2005-04-19 | 2014-06-10 | Seattle Genetics Inc | Humanized anti-CD70 binding agents and uses thereof |
US20070003557A1 (en) * | 2005-04-21 | 2007-01-04 | Andres Forero | Method for treating cancer using premedication |
US7615372B2 (en) | 2005-04-22 | 2009-11-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in endosialin-positive cells |
ITMI20050739A1 (en) * | 2005-04-22 | 2006-10-23 | Effebi Spa | VALVE-ACTUATOR CONNECTION PLATE |
AR054260A1 (en) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME |
CA2604357C (en) | 2005-04-26 | 2012-01-17 | Pfizer Inc. | P-cadherin antibodies |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
UY29504A1 (en) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
EP1885396A2 (en) * | 2005-05-04 | 2008-02-13 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
ES2561628T3 (en) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
JP5339901B2 (en) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Treatment and evaluation of inflammatory injury |
PL2559690T3 (en) | 2005-05-10 | 2016-09-30 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
WO2006124667A2 (en) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
PT1889065E (en) | 2005-05-18 | 2013-09-27 | Novartis Ag | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
LT3620171T (en) | 2005-05-18 | 2022-06-10 | Morphosys Ag | Anti-gm-csf antibodies and uses therefor |
EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
DE102005023617A1 (en) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Method for mixing colors in a display |
JP2008545712A (en) * | 2005-05-25 | 2008-12-18 | キュアーディーエム、インク. | Peptides, derivatives and analogs thereof, and methods of using them |
JP5027804B2 (en) | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス,インコーポレーテッド | Humanized anti-CD40 antibodies and methods of use thereof |
MEP35408A (en) | 2005-05-27 | 2011-02-10 | Biogen Idec Inc | Tweak binding antibodies |
US20070044164A1 (en) * | 2005-05-31 | 2007-02-22 | Cold Spring Harbor Laboratory | Methods for producing microRNAs |
US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
MX2007015454A (en) * | 2005-06-06 | 2008-02-25 | Wyeth Corp | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases. |
EP3260465A1 (en) | 2005-06-07 | 2017-12-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Stable and soluble antibodies inhibiting tnf-alpha |
ITRM20050290A1 (en) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
EP1904101A4 (en) * | 2005-06-08 | 2011-06-15 | Univ Duke | Anti-cd19 antibody therapy for the transplantation |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
JP5372500B2 (en) | 2005-06-17 | 2013-12-18 | トレラクス リクイデーティング トラスト | ILT3-binding molecules and uses thereof |
JP2008543449A (en) * | 2005-06-17 | 2008-12-04 | アボット・ラボラトリーズ | Improved treatment of degenerative spinal disease |
US8097703B2 (en) | 2005-06-20 | 2012-01-17 | Medarex, Inc. | CD19 antibodies and their uses |
WO2007094842A2 (en) * | 2005-12-02 | 2007-08-23 | Genentech, Inc. | Binding polypeptides and uses thereof |
EP1893647A2 (en) | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1893644A2 (en) * | 2005-06-24 | 2008-03-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors |
WO2007000768A2 (en) * | 2005-06-28 | 2007-01-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Gliomedin, fragments thereof and methods of using same |
HUE042561T2 (en) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23 antibodies, compositions, methods and uses |
CN101379085B (en) * | 2005-06-30 | 2013-03-27 | Abbvie公司 | IL-12/P40 binding proteins |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
CN102875681A (en) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | Anti-alpha v beta 6 antibodies and uses thereof |
WO2007008604A2 (en) * | 2005-07-08 | 2007-01-18 | Bristol-Myers Squibb Company | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof |
BRPI0613387A2 (en) | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | isolated antibody or antigen binding fragment thereof and its use, isolated polynucleotide, composition, vector, host cell, anti-sp35 antibody and method for producing the same, isolated polypeptide, in vitro method for reducing inhibition of axonal growth and in vitro method for inhibiting cone collapse growth |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
US8663634B2 (en) * | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
EP2397496A3 (en) | 2005-07-18 | 2013-05-29 | Amgen, Inc | Human anti-B7RP1 neutralizing antibodies |
PL3248613T3 (en) | 2005-07-18 | 2022-04-19 | Seagen Inc. | Beta-glucuronide drug linker conjugates |
KR20080035653A (en) * | 2005-07-22 | 2008-04-23 | 프로제닉스 파머슈티컬스, 인코포레이티드 | Methods for reducing viral load in hiv-1-infected patients |
FR2888850B1 (en) | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
SI2298815T1 (en) * | 2005-07-25 | 2015-08-31 | Emergent Product Development Seattle, Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
EP2277916A3 (en) * | 2005-07-28 | 2011-04-27 | Novartis AG | Use of antibody to M-CSF |
WO2007016285A2 (en) * | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
AU2006273753B2 (en) | 2005-07-28 | 2010-06-24 | Zoetis Services Llc | Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus |
US7858089B2 (en) * | 2005-07-29 | 2010-12-28 | Life Sciences Research Partners Vzw | Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity |
EP2216653A1 (en) * | 2005-08-02 | 2010-08-11 | XBiotech, Inc | Diagnosis, treatment and prevention of vascular disorders using il-1alpha autoantibodies |
FR2889533B1 (en) * | 2005-08-03 | 2007-10-12 | Lab Francais Du Fractionnement | ANTIBODIES AGAINST LDL RECEPTOR |
WO2007117264A2 (en) * | 2005-08-03 | 2007-10-18 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
CA2615122A1 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
FR2889534B1 (en) * | 2005-08-04 | 2012-11-02 | Lab Francais Du Fractionnement | ANTI-IDIOTYPIC ANTIBODY THAT NEUTRALIZES THE INHIBITORY ACTIVITY OF A FACTOR VIII INHIBITOR ANTIBODY |
WO2007019541A2 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc. | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
EA016083B1 (en) * | 2005-08-09 | 2012-02-28 | Займоджинетикс, Инк. | Methods for treating b-non-hodgkin's lymphoma using taci-ig fusion molecule |
AR059025A1 (en) | 2005-08-09 | 2008-03-12 | Zymogenetics Inc | METHODS FOR THE TREATMENT AND PREVENTION OF PROLIFERATION OF ABNORMAL CELLS USING TACI FUSION MOLECULES |
DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
CA2619244A1 (en) * | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
KR20080039999A (en) * | 2005-08-18 | 2008-05-07 | 젠맵 에이/에스 | Therapy with cd4 binding peptides and radiation |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
EP2500359A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
NZ609752A (en) | 2005-08-24 | 2014-08-29 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
WO2007024921A2 (en) * | 2005-08-24 | 2007-03-01 | Cell Matrix | Combination therapies for inhibiting integrin-extracellular matrix interactions |
EP2395024B1 (en) | 2005-08-26 | 2018-12-19 | Roche Glycart AG | Modified antigen binding molecules with altered cell signaling activity |
US20070071746A1 (en) * | 2005-08-31 | 2007-03-29 | Medimmune, Inc. | C/CLP antagonists and methods of use thereof |
WO2007027906A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1928807A4 (en) * | 2005-09-02 | 2011-05-04 | Picobella Llc | Oncogenic regulatory rnas for diagnostics and therapeutics |
US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
US8193328B2 (en) * | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
SG174779A1 (en) * | 2005-09-12 | 2011-10-28 | Novimmune Sa | Anti-cd3 antibody formulations |
CA2622295C (en) | 2005-09-12 | 2019-01-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
WO2007037910A2 (en) | 2005-09-14 | 2007-04-05 | Fred Hutchinson Cancer Research Center | Specific removal of activated immune cells |
ATE546160T1 (en) * | 2005-09-14 | 2012-03-15 | Ucb Pharma Sa | ANTIBODY COMB POLYMER CONJUGATE |
US7935341B2 (en) * | 2005-09-16 | 2011-05-03 | Orthologic Corp. | Antibodies to complementary peptides of thrombin or portions thereof |
CN101313216A (en) * | 2005-09-22 | 2008-11-26 | 普洛茨股份有限公司 | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
AU2006294873A1 (en) * | 2005-09-23 | 2007-04-05 | Vasgene Therapeutics, Inc. | Use of EphrinB2 directed agents for the treatment or prevention of viral infections |
AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
DK1931709T3 (en) * | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US7526409B2 (en) * | 2005-10-07 | 2009-04-28 | Oracle International Corporation | Automatic performance statistical comparison between two periods |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
WO2007043641A1 (en) * | 2005-10-14 | 2007-04-19 | Fukuoka University | Inhibitor of transplanted islet dysfunction in islet transplantation |
WO2007047907A2 (en) * | 2005-10-14 | 2007-04-26 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
AU2006305119B2 (en) * | 2005-10-21 | 2012-12-20 | Chugai Seiyaku Kabushiki Kaisha | Agents for treating cardiopathy |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
RU2421464C2 (en) | 2005-10-21 | 2011-06-20 | Новартис Аг | Human il-13 antibodies and their therapeutic application |
CA2626604A1 (en) | 2005-10-21 | 2007-04-26 | Genenews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
PE20070796A1 (en) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
ES2375843T3 (en) | 2005-10-26 | 2012-03-06 | Medarex, Inc. | PROCEDURES AND COMPOUNDS FOR THE PREPARATION OF ANC? LOGOS OF CC-1065. |
US7695911B2 (en) | 2005-10-26 | 2010-04-13 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof |
US20090155850A1 (en) * | 2005-10-28 | 2009-06-18 | The Florida International University Board Of Trustees | Horse:Human Chimeric Antibodies |
US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
US7723477B2 (en) * | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
SI2500360T1 (en) | 2005-10-31 | 2015-11-30 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
JP5129149B2 (en) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Compositions and methods for treating and diagnosing cancer |
KR20140012160A (en) | 2005-11-01 | 2014-01-29 | 애브비 바이오테크놀로지 리미티드 | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
US20090291437A1 (en) * | 2005-11-02 | 2009-11-26 | O'brien Sean | Methods for targeting quadruplex sequences |
FR2892724B1 (en) * | 2005-11-02 | 2008-01-04 | Lab Francais Du Fractionnement | CYTOTOXIC ANTIBODIES AGAINST INHIBITORY ANTIBODIES OF FACTOR VIII. |
US20070099246A1 (en) * | 2005-11-03 | 2007-05-03 | Sandy John D | Antibodies, assays and kits to quantitate cartilage destruction |
WO2007055902A1 (en) * | 2005-11-03 | 2007-05-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides and methods of use for treating and preventing cancer |
CA2628451A1 (en) | 2005-11-04 | 2007-05-18 | Biogen Idec Ma Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
UA99591C2 (en) | 2005-11-04 | 2012-09-10 | Дженентек, Инк. | Use of complement pathway inhibitors to treat ocular diseases |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
CA2628238A1 (en) | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
AU2006315580A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen |
PT2380592T (en) | 2005-11-14 | 2018-06-06 | Teva Pharmaceuticals Int Gmbh | Antagonist antibody directed against calcitonin gene-related peptide |
PE20070684A1 (en) | 2005-11-14 | 2007-08-06 | Amgen Inc | RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES |
AR057582A1 (en) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES |
EP1952147A2 (en) | 2005-11-16 | 2008-08-06 | Novartis AG | Biomarkers for anti-nogo-a antibody treatment in spinal cord injury |
CA2629147A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
CN101360826B (en) * | 2005-11-18 | 2014-04-30 | 格兰马克药品股份有限公司 | Anti-alpha2 integrin antibodies and their uses |
AU2006318580A1 (en) * | 2005-11-21 | 2007-05-31 | Merck Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
AU2006318537A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of Alzheimer's and related diseases |
WO2007061029A1 (en) * | 2005-11-25 | 2007-05-31 | Keio University | Therapeutic agent for prostate cancer |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
ES2409835T3 (en) | 2005-11-28 | 2013-06-28 | Zymogenetics, Inc. | IL-21 antagonists |
CA3046754A1 (en) | 2005-11-29 | 2007-06-07 | Cambridge Enterprise Limited | Markers for breast cancer including refsnp_id 3817198 |
KR20180058863A (en) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
WO2007062676A1 (en) | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
EP1965827B1 (en) | 2005-12-02 | 2015-02-25 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
CA2630157C (en) | 2005-12-07 | 2018-01-09 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
CA2638902C (en) | 2005-12-08 | 2014-09-23 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
UA96141C2 (en) * | 2005-12-09 | 2011-10-10 | Юсиби Фарма, С.А. | Neutralising antibody having specificity for human il-6 |
GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
KR101591223B1 (en) | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
WO2007070750A1 (en) | 2005-12-13 | 2007-06-21 | Eli Lilly And Company | Anti-il-17 antibodies |
US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
ES2535856T3 (en) | 2005-12-15 | 2015-05-18 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
DK3219328T3 (en) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | HUMANE ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND USES |
CA2635588C (en) | 2005-12-30 | 2015-11-10 | Dyax Corp. | Metalloproteinase binding proteins |
JP2009521912A (en) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-CD19 antibody with reduced immunogenicity |
EP2423321A3 (en) * | 2006-01-04 | 2012-03-14 | Fujirebio America, Inc. | Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers |
US8101365B2 (en) | 2006-01-05 | 2012-01-24 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
CA2636288C (en) | 2006-01-10 | 2015-02-24 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists |
RU2520088C2 (en) | 2006-01-12 | 2014-06-20 | Алексион Фармасьютикалз, Инк. | Antibodies to ox-2/cd200 and their application |
US20090175886A1 (en) | 2006-01-17 | 2009-07-09 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
US20070166306A1 (en) * | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
TWI428143B (en) | 2006-01-18 | 2014-03-01 | Gen Hospital Corp | Methods of increasing lymphatic function |
NL2000439C2 (en) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutic applications of inhibitors of RTP801. |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
EP1981902B1 (en) | 2006-01-27 | 2015-07-29 | Biogen MA Inc. | Nogo receptor antagonists |
CN101370521A (en) * | 2006-01-27 | 2009-02-18 | 学校法人庆应义塾 | Remedy for disease associated with choroidal angiogenesis |
US20080038761A1 (en) * | 2006-01-30 | 2008-02-14 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
US20070178103A1 (en) * | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
CA2640661A1 (en) * | 2006-02-01 | 2007-08-09 | Arana Therapeutics Limited | Domain antibody construct |
EP2441770A1 (en) | 2006-02-10 | 2012-04-18 | The University of Cincinnati | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
WO2007095320A2 (en) * | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Hpv antigens, vaccine compositions, and related methods |
US8124103B2 (en) * | 2006-02-13 | 2012-02-28 | Fraunhofer Usa, Inc | Influenza antigens, vaccine compositions, and related methods |
WO2008048344A2 (en) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
US7459280B2 (en) * | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
WO2007103290A2 (en) * | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
US7829086B2 (en) * | 2006-03-06 | 2010-11-09 | Medimmune, Llc | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CA2644903A1 (en) * | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
US8097425B2 (en) * | 2006-03-10 | 2012-01-17 | Tethys Bioscience, Inc. | Multiplex protein fractionation |
KR20080110800A (en) | 2006-03-15 | 2008-12-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
US20080208486A1 (en) * | 2006-03-23 | 2008-08-28 | Jari Natunen | Integrated System, Device and Use Thereof |
US8048421B2 (en) * | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US8883490B2 (en) | 2006-03-24 | 2014-11-11 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US8088616B2 (en) | 2006-03-24 | 2012-01-03 | Handylab, Inc. | Heater unit for microfluidic diagnostic system |
US7998708B2 (en) | 2006-03-24 | 2011-08-16 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
DK2001990T3 (en) | 2006-03-24 | 2016-10-03 | Handylab Inc | Integrated microfluidic sample processing system and method for its use |
PL1999152T3 (en) | 2006-03-27 | 2013-05-31 | Medimmune Ltd | Binding member for gm-csf receptor |
EP2003960B1 (en) * | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
US20090170773A1 (en) | 2006-03-31 | 2009-07-02 | Riken | Novel use of g-protein-conjugated receptor and ligand thereof |
CA2647671A1 (en) | 2006-03-31 | 2007-11-01 | Massachusetts Institute Of Technology | Treatment of tumors expressing mutant egf receptors |
AR059922A1 (en) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS |
DE102006015341A1 (en) * | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Use of an antibody, which specifically binds to the chemokine receptor 2, for the production of a medicament for the treatment of therapy-refractory multiple sclerosis and/or therapy-refractory rheumatoid arthritis in the subject |
KR20090005315A (en) | 2006-04-05 | 2009-01-13 | 애보트 바이오테크놀로지 리미티드 | Antibody purification |
EP2004697A2 (en) | 2006-04-07 | 2008-12-24 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
CA2648644C (en) * | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
BRPI0709481A2 (en) * | 2006-04-07 | 2011-07-19 | Government Of The Us Secretary Dept Of Health And Human Services | isolated monoclonal antibody, isolated human monoclonal antibody, pharmaceutical composition, isolated recombinant anti-igf-i and anti-igf-ii antibody or antigen-binding fragment thereof, method for detecting factor i and factor ii of human insulin growth in a sample , method for detecting human insulin growth factor i in a sample, isolated nucleic acid, recombinant cell, host cell, method for preparing an antibody, method for preparing an antibody, method for treating neoplastic disease in a mammalian individual, method for to diagnose neoplastic disease in a mammal and method to classify a drug candidate compound |
CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
EP2666479A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of juvenile rheumatoid arthritis |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
PL2013225T3 (en) * | 2006-04-12 | 2015-06-30 | Crealta Pharmaceuticals Llc | Purification of proteins with cationic surfactant |
MX2008013121A (en) | 2006-04-13 | 2009-03-25 | Novartis Vaccines & Diagnostic | Methods of treating, diagnosing or detecting cancer. |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP2019684A4 (en) | 2006-04-20 | 2009-08-26 | Jackson H M Found Military Med | Methods and compositions based on shiga toxin type 1 protein |
MEP39508A (en) | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
TWI395754B (en) | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
US20070254338A1 (en) * | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
WO2007127335A2 (en) * | 2006-04-27 | 2007-11-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways |
CA2650730A1 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
AU2007249223B2 (en) * | 2006-05-15 | 2012-08-02 | Ares Trading S.A. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
EP1918302A3 (en) * | 2006-05-18 | 2009-11-18 | AvantGen, Inc. | Methods for the identification and the isolation of epitope specific antibodies |
US20070269442A1 (en) * | 2006-05-19 | 2007-11-22 | Robert J. Webber | Chimeric monoclonal antibody recognizing iNOS |
DK2109623T3 (en) * | 2006-05-22 | 2012-01-30 | Xbiotech Inc | Cancer treatment with anti-IL-1 antibodies |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
CN105381459A (en) | 2006-05-25 | 2016-03-09 | 比奥根Ma公司 | Methods of treating stroke |
EP2021029B1 (en) * | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanized fc gamma riib-specific antibodies and methods of use thereof |
WO2007140371A2 (en) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
JP2009538924A (en) | 2006-06-01 | 2009-11-12 | エラン ファーマシューティカルズ,インコーポレイテッド | A neuroactive fragment of APP |
MX2008015138A (en) | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins. |
AR061171A1 (en) | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | PROTEINS OF UNION TO THE GROWTH FACTOR OF HEPATOCITS (FCH) |
GB0611116D0 (en) | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
TWI429658B (en) | 2006-06-07 | 2014-03-11 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
AT503690A1 (en) | 2006-06-09 | 2007-12-15 | Biomay Ag | HYPOALLERGENIC MOLECULES |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EP2037961B1 (en) * | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
US20080015465A1 (en) * | 2006-06-15 | 2008-01-17 | Scuderi Gaetano J | Methods for diagnosing and treating pain in the spinal cord |
US8101721B2 (en) * | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
AU2007345745C1 (en) * | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
CN101505793A (en) * | 2006-06-22 | 2009-08-12 | 瓦西尼斯公司 | Anti-C35 antibodies for treating cancer |
EP2040725B1 (en) | 2006-06-23 | 2014-01-15 | EnGeneIC Molecular Delivery Pty Ltd. | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
WO2007150069A2 (en) | 2006-06-23 | 2007-12-27 | Myriad Genetics, Inc. | Dpyd gene variants and use thereof |
ES2599319T3 (en) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Fc RIIB specific antibodies and their methods of use |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
FR2902799B1 (en) | 2006-06-27 | 2012-10-26 | Millipore Corp | METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) * | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
CN103316403B (en) | 2006-06-30 | 2017-05-24 | 艾伯维生物技术有限公司 | Automatic injection device |
JP5829004B2 (en) | 2006-06-30 | 2015-12-09 | ノボ・ノルデイスク・エー/エス | Anti-NKG2A antibody and use thereof |
EP2032989B2 (en) | 2006-06-30 | 2015-10-28 | Merck Sharp & Dohme Corp. | Igfbp2 biomarker |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
JP2009542810A (en) | 2006-07-10 | 2009-12-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Compositions and methods for inhibiting the growth of SMAD4-deficient cancers |
EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
NZ574046A (en) | 2006-07-13 | 2012-09-28 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
TWI608014B (en) | 2006-07-14 | 2017-12-11 | Ac免疫公司 | Anti-beta-amyloid antibodies or antigen-binding fragments thereof, the use and method of use thereof |
PL2046833T3 (en) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanized antibody against amyloid beta |
KR101528939B1 (en) | 2006-07-18 | 2015-06-15 | 사노피 | Antagonist antibody against epha2 for the treatment of cancer |
US8993295B2 (en) | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
JP5406027B2 (en) | 2006-08-04 | 2014-02-05 | ノバルティス アーゲー | EphB3-specific antibodies and uses thereof |
WO2008018472A1 (en) | 2006-08-08 | 2008-02-14 | Kyoto University | Novel monoclonal antibody and use of the same |
AR062223A1 (en) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE |
WO2008022035A2 (en) * | 2006-08-10 | 2008-02-21 | The Scripps Research Institute | Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal |
ES2506065T3 (en) * | 2006-08-11 | 2014-10-13 | Csl Limited | Treatment of pulmonary pathological conditions |
TW200817437A (en) | 2006-08-11 | 2008-04-16 | Medarex Inc | Monoclonal antibodies against stromal cell derived factor-1 (SDF-1) |
US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
JP2010502573A (en) | 2006-08-11 | 2010-01-28 | ユニヴァーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー | Luminescent compound and conjugate containing double sensitizer and use thereof |
EP2548576B1 (en) | 2006-08-14 | 2016-11-30 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis of cancer using anti-desmoglein-3 antibodies |
ME01786B (en) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimized antibodies that target cd19 |
US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
AR062435A1 (en) | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | PRLR SPECIFIC ANTIBODY (PROLACTIN RECEPTOR) AND ITS USES |
US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
EP2064243A2 (en) | 2006-08-28 | 2009-06-03 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
US8372399B2 (en) * | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
SI2594586T1 (en) | 2006-09-01 | 2014-11-28 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
PT2061810E (en) | 2006-09-05 | 2015-02-05 | Alexion Pharma Inc | Methods and compositions for the treatment of antibody mediated neuropathies |
CN101627055A (en) | 2006-09-05 | 2010-01-13 | 梅达雷克斯公司 | The antibody of bone morphogenetic protein and acceptor thereof and their using method |
CA2698583A1 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
US20080261216A1 (en) * | 2006-09-08 | 2008-10-23 | The Regents Of The University Of Michigan | HERV Group II Viruses In Lymphoma And Cancer |
MY188368A (en) | 2006-09-08 | 2021-12-06 | Abbott Lab | Interleukin-13 binding proteins |
PL2066349T3 (en) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
JPWO2008032833A1 (en) | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Antibody with enhanced ADCC activity and method for producing the same |
US8394374B2 (en) * | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
WO2008036973A2 (en) | 2006-09-22 | 2008-03-27 | St. Jude Children's Research Hospital | Modulating regulatory t cell activity via interleukin 35 |
US8088379B2 (en) * | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
US8093360B2 (en) | 2006-09-28 | 2012-01-10 | Elusys Therapeutics, Inc. | Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use |
FR2906533B1 (en) | 2006-09-28 | 2013-02-22 | Pf Medicament | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED THEREBY AND USES THEREOF |
EP2067034B1 (en) | 2006-09-29 | 2018-08-08 | Translational Therapeutics, Inc. | Eif4e regulon-based diagnostics |
PL2066694T3 (en) | 2006-09-29 | 2016-04-29 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
SI2066351T1 (en) | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Human antibodies that bind cxcr4 and uses thereof |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
WO2008042436A2 (en) | 2006-10-03 | 2008-04-10 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
US9492518B2 (en) | 2006-10-04 | 2016-11-15 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
CA3163418A1 (en) | 2006-10-06 | 2008-05-22 | Jeffrey S. Isenberg | Prevention of tissue ischemia, related methods and compositions |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
PL2698166T3 (en) | 2006-10-10 | 2016-03-31 | Regenesance B V | Complement inhibition for improved nerve regeneration |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
BRPI0719250A2 (en) * | 2006-10-12 | 2015-06-16 | Wyeth Corp | Methods and compositions with reduced opalescence. |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US8613925B2 (en) | 2006-10-19 | 2013-12-24 | Csl Limited | Anti-IL-13Rα1 antibodies and their uses thereof |
WO2008051511A2 (en) | 2006-10-20 | 2008-05-02 | Applera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
WO2008066626A2 (en) * | 2006-10-25 | 2008-06-05 | The Rockefeller University | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR |
FI20060946A0 (en) * | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenza virus nucleic acids and peptides |
JP5399710B2 (en) * | 2006-10-26 | 2014-01-29 | 株式会社ジーンテクノサイエンス | Antibody against amino acid sequence RGD of extracellular matrix protein and its production and use |
EP1916259A1 (en) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
CN101687031B (en) | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | Compositions and methods for treating ocular diseases and conditions |
PT2845866T (en) | 2006-10-27 | 2017-08-09 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
JP5795833B2 (en) * | 2006-10-27 | 2015-10-14 | エルパス・インコーポレイテッドLpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
CA2667502A1 (en) * | 2006-10-31 | 2008-06-19 | Immunogen, Inc. | Methods for improving antibody production |
EP2442107B1 (en) | 2006-11-01 | 2014-03-12 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
US20110038856A1 (en) * | 2006-11-02 | 2011-02-17 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
ES2541546T3 (en) * | 2006-11-03 | 2015-07-21 | Wyeth Llc | Substances that inhibit glycolysis in cell culture |
US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
WO2008061013A2 (en) * | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US8709787B2 (en) | 2006-11-14 | 2014-04-29 | Handylab, Inc. | Microfluidic cartridge and method of using same |
JP2010510235A (en) | 2006-11-15 | 2010-04-02 | ファンクショナル・ジェネティクス・インコーポレーテッド | Anti-TSG101 antibody and its use for the treatment of viral infections |
EA200970477A1 (en) | 2006-11-15 | 2009-12-30 | Медарекс, Инк. | HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION |
EP2700410A1 (en) * | 2006-11-21 | 2014-02-26 | Abbott Laboratories | Neutralizing monoclonal antibodies against the Nogo-66 receptor (NGR) and uses thereof |
WO2008064306A2 (en) * | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
US8142791B2 (en) * | 2006-11-27 | 2012-03-27 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Multi-modal cancer therapy using viral hitch-hiking |
US20080199475A1 (en) | 2006-11-27 | 2008-08-21 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
LT2662091T (en) * | 2006-12-01 | 2018-12-10 | Novartis Ag | Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases |
US20110212096A1 (en) | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
KR20150067395A (en) | 2006-12-01 | 2015-06-17 | 메다렉스, 엘.엘.시. | Human antibodies that bind cd22 and uses thereof |
US8945565B2 (en) | 2006-12-01 | 2015-02-03 | Selexys Pharmaceuticals Corporation | Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies |
PT2099823E (en) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Variant target binding agents and uses thereof |
US20090010929A1 (en) * | 2006-12-04 | 2009-01-08 | Good Michael F | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates |
US8288110B2 (en) * | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
MX2009006034A (en) | 2006-12-07 | 2009-10-12 | Novartis Ag | Antagonist antibodies against ephb3. |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
US20080139790A1 (en) * | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
DK2121751T3 (en) | 2006-12-08 | 2017-04-24 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies to ANGPTL3 |
GB0624687D0 (en) * | 2006-12-11 | 2007-01-17 | Univ Aston | Treatment of cachexia |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
NZ578354A (en) | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
WO2008076321A1 (en) | 2006-12-14 | 2008-06-26 | Schering Corporation | Engineered anti-tslp antibody |
EP2099827B1 (en) | 2006-12-18 | 2018-11-21 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
US8362217B2 (en) * | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
US8163886B2 (en) * | 2006-12-21 | 2012-04-24 | Emd Millipore Corporation | Purification of proteins |
EP2094302A4 (en) * | 2006-12-21 | 2010-12-08 | Macrogenics Inc | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
US8569464B2 (en) * | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
WO2008083169A2 (en) * | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
EP2119453B1 (en) * | 2006-12-26 | 2015-05-20 | Centro de Inmunolgía Molecular | Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
JP5481199B2 (en) * | 2006-12-27 | 2014-04-23 | ザ ジョンズ ホプキンス ユニバーシティー | Compositions and methods for treating inflammation and autoimmune diseases |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
NZ704295A (en) | 2006-12-27 | 2016-06-24 | Harvard College | Compositions and methods for the treatment of infections and tumors |
TWI412367B (en) | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
EP2144613B1 (en) | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
SI2436696T1 (en) | 2007-01-05 | 2017-10-30 | University Of Zurich | Anti-Beta-Amyloid-Antikorper und Verwendung davon |
IL199534A (en) * | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
DK2068887T3 (en) | 2007-01-09 | 2014-05-19 | Biogen Idec Inc | SP35 antibodies and their applications |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
EP2102236B1 (en) | 2007-01-12 | 2014-08-06 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | GP100-specific T cell receptors and related materials and methods of use |
WO2008088823A2 (en) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
WO2008087260A1 (en) | 2007-01-18 | 2008-07-24 | Suomen Punainen Risti, Veripalvelu | Novel specific cell binders |
WO2008087258A1 (en) | 2007-01-18 | 2008-07-24 | Suomen Punainen Risti, Veripalvelu | Novel carbohydrate from human cells and methods for analysis and modification thereof |
UA95996C2 (en) | 2007-01-18 | 2011-09-26 | Эли Лилли Энд Компани | Pegylated fab antibody fragment that specifically binds human a-beta peptide |
US8435752B2 (en) * | 2007-01-18 | 2013-05-07 | University Of Southern California | Gene polymorphisms predictive for dual TKI therapy |
WO2008091740A2 (en) | 2007-01-22 | 2008-07-31 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
CN101646459B (en) * | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | Chronic rejection inhibitor |
JP5618544B2 (en) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | Compositions and methods for diagnosis and treatment of cancer |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
CA2676613A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
MX2009008104A (en) * | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use. |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
US7871784B2 (en) * | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
US7834154B2 (en) | 2007-02-09 | 2010-11-16 | Genentech, Inc. | Anti-ROBO4 antibodies and uses therefor |
EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
US20090208491A1 (en) * | 2007-02-14 | 2009-08-20 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
AR065368A1 (en) * | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | ANTIBODIES FOR IGE MOLECULES |
AU2008215926B2 (en) * | 2007-02-15 | 2012-07-19 | Astrazeneca Ab | Binding members for IgE molecules |
US8685666B2 (en) * | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
WO2008101184A2 (en) * | 2007-02-16 | 2008-08-21 | The Board Of Trustees Of Southern Illinois University | Arl-1 specific antibodies |
AR065404A1 (en) * | 2007-02-21 | 2009-06-03 | Medarex Inc | PHARMACO-BINDING CONJUGATES, THOSE WHO JOIN POWERFUL CYTOTOXINS, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM AND THEIR USE TO DELAY OR STOP THE GROWTH OF A TUMOR IN A MAMMER |
CN104189885A (en) | 2007-02-23 | 2014-12-10 | 纽约哥伦比亚大学理事会 | METHODS TO ACTIVATE OR BLOCK THE HLA-E/Qa-1 RESTRICTED CD8+T CELL REGULATORY PATHWAY TO TREAT IMMUNOLOGICAL DISEASE |
HUE043966T2 (en) | 2007-02-23 | 2019-09-30 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic disease |
JP5558834B2 (en) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | Prevention and treatment of synucleinopathies and amyloidogenic diseases |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2008112988A2 (en) | 2007-03-14 | 2008-09-18 | Novartis Ag | Apcdd1 inhibitors for treating, diagnosing or detecting cancer |
WO2008112311A1 (en) | 2007-03-14 | 2008-09-18 | Washington University | Methods for identifying diabetes and obesity therapeutics |
DK2125894T3 (en) | 2007-03-22 | 2019-03-18 | Biogen Ma Inc | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF |
CN101687021B (en) * | 2007-03-22 | 2013-04-17 | 斯隆-凯特琳癌症研究院 | Uses of monoclonal antibody 8H9 |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
EP2308514B1 (en) | 2007-03-23 | 2013-06-05 | to-BBB Holding B.V. | Conjugates for targeted drug delivery across the blood-brain barrier |
EP1975184A3 (en) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Serine or threonine phosphorylation sites |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
RU2476442C2 (en) * | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Crystalline human il-12 antibodies |
WO2008121391A2 (en) * | 2007-03-29 | 2008-10-09 | Fujirebio Diagnostics, Inc. | Use of he4 for assessment of breast cancers |
JP5167338B2 (en) | 2007-03-30 | 2013-03-21 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | Intact bacterially derived minicells containing plasmid-free functional nucleic acids for in vivo delivery to mammalian cells |
US20100209434A1 (en) | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
CN101680014B (en) | 2007-04-03 | 2018-09-28 | 奥克西雷恩英国有限公司 | The glycosylation of molecule |
US7807168B2 (en) * | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
US20100261640A1 (en) | 2007-04-10 | 2010-10-14 | Branco Luis M | Soluble and membrane anchored forms of lassa virus subunit proteins |
EP2139921A2 (en) * | 2007-04-17 | 2010-01-06 | Imclone LLC | PDGFRbeta-SPECIFIC INHIBITORS |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
CN101970000A (en) * | 2007-04-18 | 2011-02-09 | 杨森阿尔茨海默氏症免疫治疗公司 | Prevention and treatment of cerebral amyloid angiopathy |
EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP1983002A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US20100077496A1 (en) * | 2007-04-20 | 2010-03-25 | Mt. Sinai School Of Medicine | MO-1, A Gene Associated With Morbid Obesity |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
WO2008131376A2 (en) * | 2007-04-23 | 2008-10-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
US20080267977A1 (en) * | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
EP2377952A1 (en) | 2007-04-26 | 2011-10-19 | Ludwig Institute For Cancer Research | Methods for diagnosing and treating astrocytomas |
EP2139916A1 (en) | 2007-04-26 | 2010-01-06 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
WO2008134643A2 (en) * | 2007-04-28 | 2008-11-06 | Fraunhofer Usa, Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
CA2685875C (en) * | 2007-05-01 | 2015-10-06 | Hill's Pet Nutrition, Inc. | Methods and compositions for diagnosing osteoarthritis in a feline |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
ES2540807T3 (en) | 2007-05-04 | 2015-07-13 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Variable domains of rabbit antibodies modified by genetic engineering and uses thereof |
WO2008141275A1 (en) | 2007-05-11 | 2008-11-20 | The Johns Hopkins University | Biomarkers for melanoma |
EP2155250B1 (en) * | 2007-05-14 | 2015-04-15 | Vancouver Biotech Ltd. | Carbohydrate-containing pan cancer marker |
NZ599278A (en) | 2007-05-14 | 2013-12-20 | Medimmune Llc | Methods of reducing eosinophil levels |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
PT3187506T (en) | 2007-05-21 | 2019-04-24 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US20100150924A1 (en) * | 2007-05-22 | 2010-06-17 | Elior Peles | Regulation of myelination by nectin-like (necl) molecules |
WO2008147526A1 (en) | 2007-05-23 | 2008-12-04 | The Trustees Of The University Of Pennsylvania | Targeted carriers for intracellular drug delivery |
AU2008262489B2 (en) * | 2007-05-23 | 2013-11-28 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
WO2008150841A1 (en) | 2007-05-30 | 2008-12-11 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US20090175847A1 (en) * | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
US7709215B2 (en) | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
PE20090321A1 (en) | 2007-06-04 | 2009-04-20 | Genentech Inc | ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION |
WO2008149147A2 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US20110008343A1 (en) * | 2007-06-08 | 2011-01-13 | Lambris John D | Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CA2690434C (en) * | 2007-06-12 | 2018-05-22 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
AU2008267038B2 (en) * | 2007-06-12 | 2014-08-07 | Ac Immune S.A. | Humanized antibodies to amyloid beta |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
DK2170390T3 (en) | 2007-06-14 | 2019-01-21 | Biogen Ma Inc | NATALIZUMABANTISTIC FORMULATIONS |
TWI478939B (en) * | 2007-06-15 | 2015-04-01 | Deutsches Krebsforsch | Treatment of tumors using specific anti-l1 antibody |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
US20080317768A1 (en) | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
EP3424951A1 (en) | 2007-06-21 | 2019-01-09 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
EP2171450B1 (en) | 2007-06-22 | 2012-03-21 | GENERA ISTRAZIVANJA d.o.o. | Adamts4 as a blood biomarker and therapeutic target for chronic renal failure |
US20090324596A1 (en) * | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US8563259B2 (en) * | 2007-06-29 | 2013-10-22 | The Trustees Of The University Of Pennsylvania | Complement-mediated thrombophilic assay |
EP2173379B2 (en) | 2007-07-02 | 2023-07-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
JP5529732B2 (en) | 2007-07-06 | 2014-06-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Recurrent gene fusion in prostate cancer |
DK3597659T3 (en) | 2007-07-09 | 2023-04-03 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
CA2692933C (en) | 2007-07-11 | 2016-10-18 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
EP3124046B1 (en) * | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
USD621060S1 (en) | 2008-07-14 | 2010-08-03 | Handylab, Inc. | Microfluidic cartridge |
US8182763B2 (en) | 2007-07-13 | 2012-05-22 | Handylab, Inc. | Rack for sample tubes and reagent holders |
US8287820B2 (en) | 2007-07-13 | 2012-10-16 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
US9618139B2 (en) | 2007-07-13 | 2017-04-11 | Handylab, Inc. | Integrated heater and magnetic separator |
US20090136385A1 (en) | 2007-07-13 | 2009-05-28 | Handylab, Inc. | Reagent Tube |
US9186677B2 (en) | 2007-07-13 | 2015-11-17 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US8324372B2 (en) | 2007-07-13 | 2012-12-04 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
US8133671B2 (en) | 2007-07-13 | 2012-03-13 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
US8105783B2 (en) | 2007-07-13 | 2012-01-31 | Handylab, Inc. | Microfluidic cartridge |
EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
SG183023A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
US8524241B2 (en) | 2007-07-20 | 2013-09-03 | The General Hospital Corporation | Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A |
WO2009014633A1 (en) * | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
EP2185593B1 (en) * | 2007-07-25 | 2017-12-13 | Alexion Pharmaceuticals, Inc. | Compositions for treating autoimmune disease |
JP2010534685A (en) * | 2007-07-27 | 2010-11-11 | ファセット バイオテック コーポレイション | Pharmaceutical combination comprising a tyrosine kinase inhibitor and an antibody against integrin α5β1 (CD49E) |
CA2694034A1 (en) * | 2007-07-27 | 2009-02-05 | Pfizer Limited | Antibody purification process by precipitation |
US8974791B2 (en) | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
CN101848724A (en) | 2007-08-03 | 2010-09-29 | 奥普索纳医疗有限公司 | The purposes of TRL-2 antagonist in treatment reperfusion injury and tissue injury |
EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
JP5749009B2 (en) * | 2007-08-13 | 2015-07-15 | バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. | Cancer therapeutic agent using humanized antibody binding to EphB4 |
JP5406187B2 (en) | 2007-08-16 | 2014-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Metabolic profiling of prostate cancer |
CN101820903A (en) * | 2007-08-20 | 2010-09-01 | 美国弗劳恩霍夫股份有限公司 | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
CA2696402A1 (en) | 2007-08-21 | 2009-02-26 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
SG10201500328QA (en) | 2007-08-21 | 2015-03-30 | Amgen Inc | Human c-fms antigen binding proteins |
JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
EP2615114B1 (en) | 2007-08-23 | 2022-04-06 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
CN111909273B (en) | 2007-08-29 | 2024-03-26 | 塞诺菲-安万特股份有限公司 | humanized anti-CXCR 5 antibodies, derivatives thereof and uses thereof |
MY165889A (en) * | 2007-08-30 | 2018-05-18 | Curedm Group Holdings Llc | Compositions and methods of using proislet peptides and analogs thereof |
PT2769729T (en) | 2007-09-04 | 2019-05-08 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
EP2033971A1 (en) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application |
US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
BRPI0817099A2 (en) | 2007-09-13 | 2015-03-24 | Delenex Therapeutics Ag | An isolated antibody that selectively binds to beta-amyloid peptide, a pharmaceutical composition comprising said antibody, nucleic acid sequence, vector and host cell |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
BRPI0816785A2 (en) | 2007-09-14 | 2017-05-02 | Adimab Inc | rationally designed synthetic antibody libraries, and uses thereof |
CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
CN101836117B (en) | 2007-09-18 | 2014-07-23 | 丹麦达科有限公司 | A rapid and sensitive method for detection of biological targets |
WO2009039310A2 (en) | 2007-09-18 | 2009-03-26 | La Jolla Institute For Allergy And Immunology | Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
US8728477B2 (en) * | 2007-09-19 | 2014-05-20 | Immune Pharmaceuticals Ltd. | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof |
AU2008304615A1 (en) | 2007-09-24 | 2009-04-02 | Cornell University | Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon |
CA2700536A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
ES2667729T3 (en) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusions of antibodies with double specificity |
WO2009040426A1 (en) | 2007-09-28 | 2009-04-02 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
BRPI0817233A2 (en) | 2007-09-28 | 2012-11-06 | Intrexon Corp | therapeutic constructs of trca gene and bireactors for the expression of biotherapeutic molecules, and uses thereof |
CN103446579B (en) | 2007-09-28 | 2015-04-22 | 普托拉制药有限公司 | Antidotes for factor xa inhibitors and methods of using the same |
SG188082A1 (en) | 2007-10-02 | 2013-03-28 | Theranos Inc | Modular point-of-care devices and uses thereof |
EP3714906A1 (en) | 2007-10-03 | 2020-09-30 | Cornell University | Treatment of proliferative disorders using radiolabelled antibodies to psma |
EP3241846B1 (en) | 2007-10-04 | 2022-02-23 | ZymoGenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
SG178809A1 (en) | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
SI2238166T1 (en) | 2007-10-05 | 2014-03-31 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
US8114681B2 (en) | 2007-10-05 | 2012-02-14 | Affymetrix, Inc. | Highly multiplexed particle-based assays |
AU2008311251B9 (en) * | 2007-10-11 | 2014-04-17 | Biogen Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
ATE545033T1 (en) * | 2007-10-15 | 2012-02-15 | King S College London | DIAGNOSTIC METHODS FOR HIV INFECTION |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
EP3072963B1 (en) | 2007-10-18 | 2020-04-01 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
CA2702555A1 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
CN101909647A (en) | 2007-10-23 | 2010-12-08 | 诺瓦提斯公司 | Use of TrkB antibodies for the treatment of respiratory disorders |
AU2008316811B2 (en) | 2007-10-23 | 2015-01-22 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein A-1 and mimetic peptides |
WO2009053987A1 (en) * | 2007-10-25 | 2009-04-30 | University Of Bristol | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
WO2009052628A1 (en) | 2007-10-25 | 2009-04-30 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
EP2214708A4 (en) | 2007-10-26 | 2011-01-12 | Centocor Ortho Biotech Inc | Vectors, host cells, and methods of production and uses |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
PL2565206T3 (en) | 2007-10-30 | 2017-08-31 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
WO2009059319A1 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Assessing susceptibility to vascular disorders |
PL2567709T3 (en) | 2007-11-02 | 2018-06-29 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
ES2557352T3 (en) | 2007-11-05 | 2016-01-25 | Medimmune, Llc | Methods of treatment of scleroderma |
US8039212B2 (en) | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
BRPI0819262A2 (en) | 2007-11-08 | 2017-05-02 | Neogenix Oncology Inc | recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
CA2702630C (en) * | 2007-11-08 | 2017-11-21 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
US8637435B2 (en) * | 2007-11-16 | 2014-01-28 | Merck Sharp & Dohme Corp. | Eukaryotic cell display systems |
CA2705923A1 (en) | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
JP5580205B2 (en) | 2007-11-19 | 2014-08-27 | セレラ コーポレーション | Lung cancer markers and their use |
SI3002298T1 (en) | 2007-11-21 | 2019-12-31 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
DK2602263T3 (en) | 2007-11-21 | 2019-10-21 | Roskilde Univ | Polypeptides comprising an ice-binding activity |
US20090203043A1 (en) | 2007-11-21 | 2009-08-13 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways |
EP3192807A1 (en) | 2007-11-27 | 2017-07-19 | The University Of British Columbia | 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis |
JP5490714B2 (en) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | Protein preparation |
TWI468417B (en) | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
KR101603109B1 (en) | 2007-12-07 | 2016-03-25 | 지모제넥틱스, 인코포레이티드 | Humanized antibody molecules specific for il-31 |
EP2233501B1 (en) * | 2007-12-13 | 2012-07-11 | Shanghai Guojian Bio-Tech Institute | Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof |
CA3102704A1 (en) | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
CA2707400A1 (en) * | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
CN101918448A (en) | 2007-12-18 | 2010-12-15 | 生物联合公司 | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
US20090169549A1 (en) * | 2007-12-19 | 2009-07-02 | The Board Of Regents Of The University Of Texas System | Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
US8795667B2 (en) * | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
WO2009080054A1 (en) * | 2007-12-21 | 2009-07-02 | Ifxa A/S | Protease inhibitor |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
CA2710680C (en) | 2007-12-26 | 2018-10-16 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
RU2537265C2 (en) * | 2007-12-26 | 2014-12-27 | Биотест Аг | Cd138-targeted cell agents and using them |
HUE024291T2 (en) * | 2007-12-26 | 2016-01-28 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | Fc variants with altered binding to fcrn |
US9011864B2 (en) * | 2007-12-26 | 2015-04-21 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
ES2543201T3 (en) * | 2007-12-26 | 2015-08-17 | Biotest Ag | Methods and agents that improve the direction to tumor cells expressing CD138 |
WO2009086398A2 (en) * | 2007-12-27 | 2009-07-09 | Abbott Laboratories | Anti-t. cruzi antibodies and methods of use |
CA2710984C (en) | 2007-12-28 | 2018-05-29 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
GB0800277D0 (en) | 2008-01-08 | 2008-02-13 | Imagination Tech Ltd | Video motion compensation |
CA2711771C (en) | 2008-01-11 | 2017-01-24 | Gene Techno Science Co., Ltd. | Humanized anti-.alpha.9 integrin antibodies and the uses thereof |
WO2009092011A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
AR070141A1 (en) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR |
US9567390B2 (en) * | 2008-01-23 | 2017-02-14 | Department Of Biotechnology | Humanized high affinity recombinant antibody against Hepatitis B surface antigen |
EP2247619A1 (en) | 2008-01-24 | 2010-11-10 | Novo Nordisk A/S | Humanized anti-human nkg2a monoclonal antibody |
JP5701064B2 (en) | 2008-01-25 | 2015-04-15 | アムジエン・インコーポレーテツド | Ferroportin antibody and method of use thereof |
IL295449A (en) | 2008-01-31 | 2022-10-01 | Genentech Inc | Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
AU2009208607B2 (en) * | 2008-01-31 | 2013-08-01 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
ES2848323T3 (en) | 2008-01-31 | 2021-08-06 | Inst Nat Sante Rech Med | Antibodies against human CD39 and their use to inhibit the activity of regulatory T cells |
PL2252633T3 (en) * | 2008-02-04 | 2014-02-28 | Lay Line Genomics Spa | Anti-trka antibodies and derivatives thereof |
EP2650017A3 (en) | 2008-02-05 | 2014-01-22 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
ES2617604T3 (en) | 2008-02-08 | 2017-06-19 | Immunas Pharma, Inc. | Antibodies capable of specifically binding to beta amyloid oligomers, and their use |
KR101666229B1 (en) | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Anti-ifnar1 antibodies with reduced fc ligand affinity |
EP2254411A4 (en) * | 2008-02-19 | 2012-06-13 | Univ Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
US20090221620A1 (en) | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
CA2715212A1 (en) | 2008-03-03 | 2009-09-11 | Glycofi, Inc. | Surface display of recombinant proteins in lower eukaryotes |
US8293239B2 (en) | 2008-03-04 | 2012-10-23 | Pfizer Limited | Methods of treating chronic pain |
WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
MX2010010028A (en) * | 2008-03-13 | 2011-08-17 | Biotest Ag | Agent for treating disease. |
KR20100135808A (en) * | 2008-03-13 | 2010-12-27 | 바이오테스트 아게 | Agent for treating disease |
ES2569217T3 (en) * | 2008-03-13 | 2016-05-09 | Biotest Ag | Agent to treat diseases |
TW201513883A (en) | 2008-03-18 | 2015-04-16 | Abbvie Inc | Methods for treating psoriasis |
NO2842575T3 (en) | 2008-03-18 | 2018-02-24 | ||
EP2260102A1 (en) | 2008-03-25 | 2010-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
EP2271672B1 (en) | 2008-03-26 | 2015-11-11 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
PT2274008E (en) | 2008-03-27 | 2014-05-12 | Zymogenetics Inc | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
EA201071137A1 (en) | 2008-03-28 | 2011-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | METHODS OF TREATMENT |
US8802093B2 (en) | 2008-04-02 | 2014-08-12 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
EP3045475B1 (en) | 2008-04-02 | 2017-10-04 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
CA2720013C (en) | 2008-04-03 | 2016-02-16 | Bart De Strooper | Single domain antibodies capable of modulating bace activity |
US9908943B2 (en) | 2008-04-03 | 2018-03-06 | Vib Vzw | Single domain antibodies capable of modulating BACE activity |
EP2274417B1 (en) | 2008-04-04 | 2013-07-24 | Massachusetts Institute of Technology | Cellular production of glucaric acid |
HUE036780T2 (en) | 2008-04-09 | 2018-07-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
CN102144163A (en) | 2008-04-10 | 2011-08-03 | 麻省理工学院 | Methods for identification and use of agents targeting cancer stem cells |
AU2009234389B2 (en) | 2008-04-10 | 2014-08-21 | Cell Signaling Technology, Inc. | Compositions and methods for detecting EGFR mutations in cancer |
WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
KR102269708B1 (en) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2009126920A2 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
EP2300041B1 (en) | 2008-04-16 | 2016-01-27 | The Johns Hopkins University | Method for determining risk of recurrence of prostate cancer |
AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
US8398973B2 (en) * | 2008-04-18 | 2013-03-19 | Trustees Of Boston University | Methods and compositions for preventing adhesion |
WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
WO2009131256A1 (en) | 2008-04-24 | 2009-10-29 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
US20090269786A1 (en) * | 2008-04-25 | 2009-10-29 | The Board Of Trustees Of The University Of Illinois | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies |
KR101837329B1 (en) | 2008-04-25 | 2018-03-09 | 다이액스 코포레이션 | Antibodies against fcrn and use thereof |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
ES2487846T3 (en) | 2008-05-01 | 2014-08-25 | Amgen, Inc. | Anti-hepcindin antibodies and methods of use |
ES2620285T3 (en) | 2008-05-02 | 2017-06-28 | Novartis Ag | Binding molecules based on improved fibronectin and their uses |
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
WO2009136382A2 (en) * | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
US8673644B2 (en) | 2008-05-13 | 2014-03-18 | Battelle Memorial Institute | Serum markers for type II diabetes mellitus |
EP2279004B1 (en) * | 2008-05-16 | 2015-01-14 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
KR101537460B1 (en) | 2008-05-23 | 2015-07-16 | 시와 코퍼레이션 | Methods, compositions and apparatus for facilitating regeneration |
CA2726131C (en) | 2008-05-29 | 2018-03-13 | Baoming Jiang | Expression and assembly of human group c rotavirus-like particles and uses thereof |
WO2009148896A2 (en) | 2008-05-29 | 2009-12-10 | Nuclea Biotechnologies, LLC | Anti-phospho-akt antibodies |
AU2009255305B2 (en) | 2008-05-29 | 2014-10-30 | Galaxy Biotech, Llc | Monoclonal antibodies to basic fibroblast growth factor |
KR20150127300A (en) | 2008-05-30 | 2015-11-16 | 엑스바이오테크, 인크. | Interleukin-1 alpha antibodies and methods of use |
CA3138282A1 (en) | 2008-06-02 | 2009-12-10 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
US20090297439A1 (en) * | 2008-06-02 | 2009-12-03 | Metheresis Translational Research Sa, | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |
JP2011523853A (en) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | Dual variable domain immunoglobulins and uses thereof |
KR20110016959A (en) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
CA2726845C (en) * | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
TWI528973B (en) * | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
US8999702B2 (en) * | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
ES2595362T3 (en) | 2008-06-16 | 2016-12-29 | Patrys Limited | LM antibodies, functional fragments, LM-1 target antigen and methods to prepare and use them |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
US8410251B2 (en) * | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
WO2009154025A1 (en) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME |
US20110123542A1 (en) * | 2008-06-24 | 2011-05-26 | Hadasit Medical Research Services And Development Ltd. | Ccl20-specific antibodies for cancer therapy |
HUE032894T2 (en) | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | Stable and soluble antibodies inhibiting vegf |
RU2567100C2 (en) * | 2008-06-25 | 2015-10-27 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
PL3628686T3 (en) | 2008-06-25 | 2022-02-28 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
PL2307458T3 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
CA2729012A1 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
DK2824100T3 (en) | 2008-07-08 | 2018-04-16 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase |
FR2933702A1 (en) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR |
WO2010005567A2 (en) | 2008-07-08 | 2010-01-14 | Oncomed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
RU2559525C2 (en) | 2008-07-08 | 2015-08-10 | Эббви Инк | Proteins binding prostaglandin e2 and using them |
SG192489A1 (en) * | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
US8216786B2 (en) | 2008-07-09 | 2012-07-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
NZ590605A (en) * | 2008-07-09 | 2012-11-30 | Biogen Idec Inc | Compositions comprising antibodies to lingo or fragments thereof |
US8067339B2 (en) | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
USD618820S1 (en) | 2008-07-11 | 2010-06-29 | Handylab, Inc. | Reagent holder |
USD787087S1 (en) | 2008-07-14 | 2017-05-16 | Handylab, Inc. | Housing |
WO2010009271A2 (en) | 2008-07-15 | 2010-01-21 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
WO2010008051A1 (en) | 2008-07-16 | 2010-01-21 | 株式会社医学生物学研究所 | Anti-human clcp1 antibody and use thereof |
US8148088B2 (en) * | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
JP6049163B2 (en) * | 2008-07-21 | 2016-12-21 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | Antibody structural variants for improved therapeutic characteristics |
US20100021472A1 (en) * | 2008-07-25 | 2010-01-28 | Geetha Srikrishna | Methods for diagnosing and treating cancer |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
SG10201405377XA (en) | 2008-08-05 | 2014-12-30 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
CN102137681B (en) * | 2008-08-08 | 2014-12-03 | 埃姆诺医药有限公司 | Anti-pancreatic cancer antibodies |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
US20100041133A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20120034156A1 (en) * | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
KR20160116056A (en) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-il-12/il-23 antibodies |
ES2527943T5 (en) | 2008-08-14 | 2019-03-07 | Genentech Inc | Methods to remove a contaminant using protein displacement ion exchange membrane chromatography |
WO2010022225A1 (en) * | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
US9180160B2 (en) | 2008-08-20 | 2015-11-10 | The Trustees Of The University Of Pennsylvania | Complement inhibitors for treatment of injury from intracerebral hemorrhage |
CA2736799A1 (en) | 2008-08-25 | 2010-03-11 | Burnham Institute For Medical Research | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
EP2318437A2 (en) * | 2008-08-28 | 2011-05-11 | Abbott Biotherapeutics Corp. | Method for treating multiple sclerosis patients with anti-il2r antibodies |
BRPI0823049A2 (en) | 2008-09-07 | 2015-06-16 | Glyconex Inc | Anti-extended type 1 glycosphingolipid antibodies, derivatives thereof and use. |
ES2727627T3 (en) * | 2008-09-10 | 2019-10-17 | Univ Bradford | Compositions and methods to modulate skin pigmentation |
WO2010030992A2 (en) * | 2008-09-12 | 2010-03-18 | The Board Of Trustees Of The University Of Illinois | Novel plasmodium falciparum gene encoding signal peptide peptidase and methods of using inhibitors thereof for inhibiting malarial infection |
TWI445716B (en) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9 antagonists |
US8242074B2 (en) * | 2008-09-12 | 2012-08-14 | Xbiotech, Inc. | Modulation of the amount or function of pathogenic CD14+CD16+ monocytes |
WO2010029534A1 (en) * | 2008-09-15 | 2010-03-18 | Yeda Research And Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
CN102292353B (en) | 2008-09-17 | 2015-04-29 | Xencor公司 | Novel compositions and methods for treating ige-mediated disorders |
CA2737758C (en) * | 2008-09-19 | 2017-10-31 | Soldano Ferrone | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
RU2518278C2 (en) | 2008-09-19 | 2014-06-10 | Пфайзер Инк. | Stable liquid preparation of antibody |
US20100075329A1 (en) | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
CA2738605A1 (en) * | 2008-09-24 | 2010-04-01 | Luke Anthony O'neill | Composition and method for treatment of preterm labor |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
CN103002911B (en) | 2008-09-26 | 2015-08-26 | 昂考梅德药品有限公司 | FZ is in conjunction with medicament and application thereof |
US8734803B2 (en) | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
BRPI0919489A2 (en) * | 2008-09-29 | 2015-12-01 | Biotest Ag | composition, kit, methods of treating a rheumatic disease, and rheumatoid arthritis in a patient, agent capable of activating cd4 + cd25 + regulatory t cells and methotrexate, and use of an agent capable of activating cd4 + cd25 + regulatory t cells and methotrexate |
WO2010039690A1 (en) | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
EP2355847A1 (en) | 2008-10-07 | 2011-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
KR20170110740A (en) | 2008-10-09 | 2017-10-11 | 미네르바 바이오테크놀로지 코포레이션 | Method for inducing pluripotency in cells |
MX341149B (en) | 2008-10-10 | 2016-08-09 | Amgen Inc | Fgf21 mutants and uses thereof. |
EP2349329A4 (en) | 2008-10-14 | 2012-10-31 | Dyax Corp | Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
JP5836125B2 (en) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof |
CN105111309A (en) | 2008-10-20 | 2015-12-02 | Abbvie公司 | Isolation and purification of antibodies using protein an appinity chromatography |
AU2009308422B2 (en) | 2008-10-24 | 2017-01-05 | The Government of the United States of America as represented by The Secretary, Department of Health and Human Services, Center for Disease Control and Prevention | Human Ebola virus species and compositions and methods thereof |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
MX2011004558A (en) | 2008-10-29 | 2011-06-01 | Wyeth Llc | Methods for purification of single domain antigen binding molecules. |
MX345226B (en) | 2008-10-29 | 2017-01-20 | Ablynx Nv | Formulations of single domain antigen binding molecules. |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
PT2365828E (en) | 2008-11-07 | 2014-12-12 | Galaxy Biotech Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
WO2010052288A1 (en) | 2008-11-07 | 2010-05-14 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
EP2352847B1 (en) | 2008-11-10 | 2014-01-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Gene signature for predicting prognosis of patients with solid tumors |
LT2356462T (en) | 2008-11-11 | 2017-03-10 | The Regents Of The University Of Michigan | Anti-cxcr1 compositions and methods |
US8309306B2 (en) * | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
JP5789192B2 (en) | 2008-11-13 | 2015-10-07 | フェムタ ファーマシューティカルズ インコーポレイテッドFemta Pharmaceuticals,Inc. | Humanized anti-IL-6 antibody |
DK2186829T3 (en) * | 2008-11-14 | 2015-04-07 | Canadian Blood Services | Antibodies to GPIbalfa |
KR20110112301A (en) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | Human serum albumin linkers and conjugates thereof |
PA8849001A1 (en) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | C-MET ANTIBODIES |
NZ602166A (en) | 2008-11-25 | 2014-02-28 | Alder Biopharmaceuticals Inc | Antibodies to il-6 and use thereof |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
CN102301235B (en) * | 2008-11-28 | 2014-11-19 | Abbvie公司 | Stable Antibody Compositions And Methods For Stabilizing Same |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
AU2009319701B2 (en) | 2008-11-28 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods for the treatment of infections and tumors |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
AR074439A1 (en) | 2008-12-02 | 2011-01-19 | Pf Medicament | ANTI-CMET ANTIBODY (C-MET RECEIVER) |
RU2011127198A (en) * | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION |
EP2193790A1 (en) * | 2008-12-04 | 2010-06-09 | Klinikum der Universität Regensburg | IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage |
CA2745436A1 (en) * | 2008-12-05 | 2010-06-10 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
US8401799B2 (en) * | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
US8183346B2 (en) * | 2008-12-05 | 2012-05-22 | Eli Lilly And Company | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
CA2745492A1 (en) | 2008-12-08 | 2010-06-17 | Compugen Ltd. | A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide |
US8962341B2 (en) | 2008-12-12 | 2015-02-24 | The Commonwealth Medical College | Cell-based detection of APF through its interaction with CKAP4 for diagnosis of interstitial cystitis |
SG171446A1 (en) | 2008-12-16 | 2011-07-28 | Millipore Corp | Stirred tank reactor and method |
SG171764A1 (en) * | 2008-12-16 | 2011-07-28 | Millipore Corp | Purification of proteins |
EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
WO2010071208A1 (en) | 2008-12-19 | 2010-06-24 | 武田薬品工業株式会社 | Antibody purification method |
JP5734201B2 (en) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and use thereof |
US20100159485A1 (en) * | 2008-12-19 | 2010-06-24 | Centre For Dna Fingerprinting And Diagnostics | Detection of mycobacterium tuberculosis |
JO3382B1 (en) | 2008-12-23 | 2019-03-13 | Amgen Inc | Human cgrp receptor binding antibodies |
WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
WO2010075417A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
WO2010081001A2 (en) | 2009-01-09 | 2010-07-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
JP2012515158A (en) | 2009-01-12 | 2012-07-05 | 武田薬品工業株式会社 | Cancer preventive / therapeutic agent |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
GB0900425D0 (en) | 2009-01-12 | 2009-02-11 | Ucb Pharma Sa | Biological products |
WO2010082134A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
EP2387627B1 (en) | 2009-01-15 | 2016-03-30 | Adaptive Biotechnologies Corporation | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
JP2012515202A (en) | 2009-01-16 | 2012-07-05 | マサチューセッツ インスティテュート オブ テクノロジー | Diagnosis and treatment of autism zone disorders |
US9181341B2 (en) | 2009-01-19 | 2015-11-10 | Innate Pharma | Anti-KIR3D antibodies |
US20130122052A1 (en) * | 2009-01-20 | 2013-05-16 | Homayoun H. Zadeh | Antibody mediated osseous regeneration |
EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
CA2750581A1 (en) | 2009-01-21 | 2010-07-29 | Oxford Biotherapeutics Ltd. | Pta089 protein |
US8679765B2 (en) | 2009-01-22 | 2014-03-25 | Ludwig Institute For Cancer Research Ltd. | Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies |
US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
RU2011135768A (en) * | 2009-01-29 | 2013-03-10 | Эбботт Лэборетриз | PROTEINS BINDING IL-1 |
US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
WO2010091182A2 (en) | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
WO2010091328A1 (en) | 2009-02-09 | 2010-08-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnostic and therapeutic uses of gnptab, gnptg, and nagpa in stuttering |
US9079942B2 (en) * | 2009-02-09 | 2015-07-14 | Epitomics, Inc. | CDR-anchored amplification method |
US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
DK2396652T3 (en) | 2009-02-11 | 2018-01-29 | Cedars Sinai Medical Center | DIAGNOSIS OF INFLAMMATORY GAS SYNDROME BASED ON CYTOLETALLY EFFECTIVE TOXIN |
CA2744236C (en) | 2009-02-12 | 2021-03-16 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
US20110014190A1 (en) | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
US8715928B2 (en) | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
PL2939683T3 (en) | 2009-02-16 | 2017-07-31 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I Mimics |
CA2752510C (en) | 2009-02-17 | 2024-01-23 | Neil Bander | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
LT2398498T (en) | 2009-02-17 | 2019-01-10 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
US9671400B2 (en) * | 2009-02-19 | 2017-06-06 | Dako Denmark A/S | Conjugate molecules |
GB0902916D0 (en) | 2009-02-20 | 2009-04-08 | Fusion Antibodies Ltd | Antibody therapy |
US8030026B2 (en) * | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
CN102333543B (en) | 2009-02-24 | 2014-05-14 | 国立大学法人宫崎大学 | Cell adhesion inhibitor and use thereof |
EP2400981A4 (en) * | 2009-02-26 | 2013-02-27 | Lpath Inc | Humanized platelet activating factor antibody design using anti-lipid antibody templates |
US8435488B2 (en) | 2009-02-27 | 2013-05-07 | Genentech, Inc. | Methods and compositions for protein labelling |
US20100248265A1 (en) * | 2009-02-27 | 2010-09-30 | The Salk Institute For Biological Studies | Compositions and methods for diagnosis and treatment of cancer |
PT2403878T (en) | 2009-03-05 | 2017-09-01 | Squibb & Sons Llc | Fully human antibodies specific to cadm1 |
PE20121094A1 (en) | 2009-03-05 | 2012-09-13 | Abbvie Inc | IL-17 BINDING PROTEINS |
US20110311521A1 (en) | 2009-03-06 | 2011-12-22 | Pico Caroni | Novel therapy for anxiety |
JP2012519711A (en) | 2009-03-06 | 2012-08-30 | アジェンシス,インコーポレイテッド | Antibody drug conjugate (ADC) that binds to 24P4C12 protein |
EP2406285B1 (en) | 2009-03-10 | 2016-03-09 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
EP2228059A1 (en) | 2009-03-12 | 2010-09-15 | Universitätsspital Basel | Chemotherapeutic composition for the treatment of cancer |
UA108349C2 (en) | 2009-03-16 | 2015-04-27 | Сефалон Острейліа Пті Лтд | Humanized antibody with antitumor activity |
EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
EP2408474B1 (en) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
EP2408468B1 (en) | 2009-03-19 | 2014-04-30 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | USE OF NKp46 FOR PREVENTING TYPE 1 DIABETES |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
TWI461211B (en) | 2009-03-20 | 2014-11-21 | Genentech Inc | Anti-her antibodies |
US8242248B2 (en) * | 2009-03-23 | 2012-08-14 | Nodality, Inc. | Kits for multiparametric phospho analysis |
CA2753388C (en) | 2009-03-23 | 2016-11-29 | Quark Pharmaceuticals, Inc. | Endo180 antibody to treat cancer and fibrotic disease |
RU2542394C2 (en) | 2009-03-24 | 2015-02-20 | ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. | Humanised anti-light antibodies and using them |
HUE025726T2 (en) | 2009-03-25 | 2016-04-28 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
EP2414517B1 (en) | 2009-03-30 | 2016-09-21 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
US8496937B2 (en) | 2009-03-30 | 2013-07-30 | Edimer Pharmaceuticals, Inc. | Preparation of isolated agonist anti-EDAR monoclonal antibodies |
KR20120057563A (en) | 2009-03-31 | 2012-06-05 | 노파르티스 아게 | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit |
WO2010112033A2 (en) | 2009-03-31 | 2010-10-07 | Østjysk Innovation A/S | Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x |
WO2010120566A2 (en) * | 2009-04-01 | 2010-10-21 | Cornell University | METHODS FOR TREATING IgE-MEDIATED DISORDER |
HU0900195D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis and treatment of gluten-induced autoimmune diseases |
WO2010117057A1 (en) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | Method for treatment of blood tumor using anti-tim-3 antibody |
AR075989A1 (en) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | ANTIBODY DKK -1 (DICKKOPF-1) HUMAN DESIGNED BY ENGINEERING |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
US8722860B2 (en) | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
AU2010236257A1 (en) * | 2009-04-17 | 2011-11-03 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
EP2419446A4 (en) * | 2009-04-17 | 2013-01-23 | Lpath Inc | Humanized antibody compositions and methods for binding lysophosphatidic acid |
WO2010119704A1 (en) * | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
NZ595792A (en) | 2009-04-20 | 2014-01-31 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17 |
WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
US9074002B2 (en) | 2009-04-27 | 2015-07-07 | Cold Spring Harbor Laboratory | PTP1B inhibitors |
KR101732201B1 (en) | 2009-04-27 | 2017-05-02 | 교와 핫꼬 기린 가부시키가이샤 | Anti-il-3r antibody for use in treatment of blood tumor |
CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
HUE035240T2 (en) | 2009-04-27 | 2018-05-02 | Novartis Ag | Compositions and methods for increasing muscle growth |
TW201043961A (en) * | 2009-04-27 | 2010-12-16 | Facet Biotech Corp | Methods for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients |
US8741581B2 (en) | 2009-04-27 | 2014-06-03 | Technion Research And Development Foundation Ltd. | Markers for cancer detection |
KR101721906B1 (en) | 2009-04-29 | 2017-03-31 | 애브비 바이오테크놀로지 리미티드 | Automatic injection device |
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
ES2725356T3 (en) | 2009-04-29 | 2019-09-23 | Henry M Jackson Found Advancement Military Medicine Inc | ERG2 monoclonal antibodies and their therapeutic use |
EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
SI3248610T1 (en) | 2009-05-05 | 2024-03-29 | Amgen Inc., | Fgf21 mutants and uses thereof |
AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
WO2010128265A2 (en) | 2009-05-07 | 2010-11-11 | Stallergenes S.A. | Use of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa |
KR101754433B1 (en) | 2009-05-08 | 2017-07-05 | 백시넥스 인코포레이티드 | Anti-cd100 antibodies and methods for using the same |
FR2945538B1 (en) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE. |
TWI614267B (en) | 2009-05-13 | 2018-02-11 | 建新公司 | Anti-human cd52 immunoglobulins |
US9989533B2 (en) | 2009-05-28 | 2018-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anti-TNF induced apoptosis (ATIA) diagnostic markers and therapies |
LT2437790T (en) | 2009-06-03 | 2019-06-10 | Immunogen, Inc. | Conjugation methods |
WO2010142603A1 (en) | 2009-06-08 | 2010-12-16 | Vib Vzw | Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation |
US20100317539A1 (en) * | 2009-06-12 | 2010-12-16 | Guo-Liang Yu | Library of Engineered-Antibody Producing Cells |
DK2443149T3 (en) | 2009-06-15 | 2016-12-12 | Vib Vzw | BACE1 inhibitory ANTIBODIES |
WO2010145846A1 (en) | 2009-06-15 | 2010-12-23 | Bayer Bioscience N.V. | Nicotiana benthamiana plants deficient in xylosyltransferase activity |
EP2443150B1 (en) | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
WO2010148142A1 (en) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
CA2765989C (en) | 2009-06-18 | 2016-11-29 | Pfizer Inc. | Anti notch-1 antibodies |
US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
WO2010151823A1 (en) | 2009-06-25 | 2010-12-29 | Savient Pharmaceuticals Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
EP2445925A1 (en) | 2009-06-25 | 2012-05-02 | Bristol-Myers Squibb Company | Protein purification by caprylic acid (octanoic acid) precipitation |
TWI513465B (en) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
WO2011000054A1 (en) | 2009-07-03 | 2011-01-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
JP5946766B2 (en) | 2009-07-03 | 2016-07-06 | ビオノール イミュノ エーエスBionor Immuno As | Combinations or fusions of HIV-related peptides for use in HIV vaccine compositions or as diagnostic tools |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
DK2451279T3 (en) | 2009-07-06 | 2019-05-20 | Aerpio Therapeutics Inc | Benzosulfonamide derivatives compounds thereof and their use to prevent metastases of cancer cells |
CN102481380A (en) | 2009-07-09 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | In vivo tumor vasculature imaging |
SI2454373T1 (en) * | 2009-07-15 | 2015-03-31 | Abb Vie Inc. | Enhancement of cellular production through mechanotransduction |
US9056106B2 (en) | 2009-07-15 | 2015-06-16 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same |
WO2011011797A2 (en) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine compositions and methods of use thereof |
US10087252B2 (en) | 2009-07-24 | 2018-10-02 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with αvβ5 integrin |
UY32808A (en) * | 2009-07-29 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME |
ES2793348T3 (en) | 2009-08-11 | 2020-11-13 | Hoffmann La Roche | Protein production in glutamine-free cell culture media |
JP5883384B2 (en) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | How to regulate immune function |
JP5762408B2 (en) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
US20180057602A1 (en) * | 2009-08-17 | 2018-03-01 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
CN102711809B (en) * | 2009-08-17 | 2015-09-30 | 特雷康制药公司 | Use anti-endoglin antibody and anti-VEGF agent therapeutic alliance cancer |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
WO2011021146A1 (en) | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
CA2772298A1 (en) * | 2009-08-26 | 2011-03-03 | Research Development Foundation | Methods for creating antibody libraries |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
US9125846B2 (en) * | 2010-10-15 | 2015-09-08 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
TWI412375B (en) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | Humanized anti-cdcp1 antibodies |
KR101778813B1 (en) | 2009-08-28 | 2017-09-14 | 리제너론 파마슈티칼스 인코포레이티드 | Antikine antibodies that bind to multiple cc chemokines |
KR101519192B1 (en) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
CN102002104A (en) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | Anti-VEGF monoclonal antibody and medicinal composition containing same |
EP2470568A2 (en) | 2009-08-29 | 2012-07-04 | Abbott Laboratories | Therapeutic dll4 binding proteins |
CA2771335A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Biotherapeutics Corp. | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
CN102741293B (en) * | 2009-08-31 | 2015-04-01 | 罗切格利卡特公司 | Affinity-matured humanized anti CEA monoclonal antibodies |
US8454956B2 (en) * | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
US20120283115A1 (en) | 2009-08-31 | 2012-11-08 | Ludwig Institute For Cancer Research Ltd. | Seromic analysis of ovarian cancer |
IN2012DN02753A (en) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
SG178602A1 (en) * | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
BR112012004697B8 (en) | 2009-09-01 | 2021-05-25 | Genentech Inc | method for purifying a polypeptide comprising a ch2/ch3 region |
US20110059111A1 (en) | 2009-09-01 | 2011-03-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
JP5887270B2 (en) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | Mutant SMOOTHENED AND METHOD OF USING THE SAME |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
IN2012DN03025A (en) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
EP2475398B1 (en) | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Improved pseudomonas exotoxin a with reduced immunogenicity |
US8293483B2 (en) | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
AU2010291927A1 (en) * | 2009-09-14 | 2012-04-12 | AbbVie Deutschland GmbH & Co. KG | Methods for treating psoriasis |
EP2305717A1 (en) | 2009-09-21 | 2011-04-06 | Koninklijke Nederlandse Akademie van Wetenschappen | Inhibiting TNIK for treating colon cancer |
US9547007B2 (en) | 2009-09-22 | 2017-01-17 | The Trustees Of The University Of Pennslyvania | Methods and compositions for in-vivo enzyme capture |
EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
US20120178910A1 (en) | 2009-09-23 | 2012-07-12 | Medarex, Inc. | Cation exchange chromatography (methods) |
US20120183546A1 (en) | 2009-09-23 | 2012-07-19 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
WO2011037271A1 (en) | 2009-09-24 | 2011-03-31 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
US9175070B2 (en) | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
WO2011039634A2 (en) | 2009-09-29 | 2011-04-07 | Universiteit Gent | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
JP6077745B2 (en) * | 2009-09-30 | 2017-02-08 | 富士フイルムRiファーマ株式会社 | Anti-podoplanin antibody and pharmaceutical composition comprising anti-podoplanin antibody |
EP2308895A1 (en) | 2009-10-01 | 2011-04-13 | Universität Duisburg-Essen | Anti-HSV antibody |
WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
DK2483289T3 (en) | 2009-10-02 | 2019-06-11 | Biogen Ma Inc | PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULATION CONNECTIONS |
UY32914A (en) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
JP5898082B2 (en) | 2009-10-07 | 2016-04-06 | マクロジェニクス,インコーポレーテッド | Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof |
ES2725200T3 (en) * | 2009-10-09 | 2019-09-20 | Armagen Inc | Methods and compositions to increase the activity of iduronate 2-sulfatase in the CNS |
EP2308897A1 (en) | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
EP2485763A4 (en) | 2009-10-10 | 2013-10-30 | Univ Leland Stanford Junior | Il-17 family cytokine compositions and uses |
CA2776756A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
EP2488548A1 (en) | 2009-10-14 | 2012-08-22 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung | A low density lipoprotein-related protein 1 splice variant as cancer marker |
BR112012008833A2 (en) | 2009-10-15 | 2015-09-08 | Abbott Lab | double variable domain immunoglobulins and uses thereof |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
PT2488203T (en) | 2009-10-16 | 2017-03-10 | Univ Leicester | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
EA201791876A1 (en) | 2009-10-16 | 2018-01-31 | Ле Лаборатуар Сервье | MONOCLONAL PROTECTIVE ANTIBODIES AND THEIR APPLICATION |
ES2895226T3 (en) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
JP5889794B2 (en) | 2009-10-19 | 2016-03-22 | ジェネンテック, インコーポレイテッド | Regulation of hepatocyte growth factor activator |
US9091691B2 (en) | 2009-10-20 | 2015-07-28 | Dako Denmark A/S | Immunochemical detection of single target entities |
RS60577B1 (en) | 2009-10-20 | 2020-08-31 | Abbvie Inc | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
JP5814925B2 (en) | 2009-10-22 | 2015-11-17 | ジェネンテック, インコーポレイテッド | Anti-hepsin antibody and method of use thereof |
RU2539772C2 (en) | 2009-10-22 | 2015-01-27 | Дженентек, Инк. | Methods and compositions for hepsin modulation of macrophage-stimulating protein |
CN110054692A (en) | 2009-10-23 | 2019-07-26 | 米伦纽姆医药公司 | Anti- GCC antibody molecule and its compositions related and method |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
JO3244B1 (en) | 2009-10-26 | 2018-03-08 | Amgen Inc | Human il-23 antigen binding proteins |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
US20110098862A1 (en) | 2009-10-27 | 2011-04-28 | ExxonMobil Research Engineering Company Law Department | Multi-stage processes and control thereof |
WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
EP2493926B1 (en) | 2009-10-27 | 2020-03-11 | UCB Biopharma SRL | Function modifying nav 1.7 antibodies |
CA2777825A1 (en) | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
UY32979A (en) * | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011053777A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Biotherapeutics Corp. | Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
WO2011054007A1 (en) | 2009-11-02 | 2011-05-05 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
CA2779384C (en) | 2009-11-04 | 2018-02-27 | Schering Corporation | Engineered anti-tslp antibody |
JP5888728B2 (en) | 2009-11-05 | 2016-03-22 | 国立大学法人大阪大学 | Autoimmune disease or allergy therapeutic agent and screening method thereof |
RU2585488C2 (en) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Methods and composition for secretion of heterologous polypeptides |
JP5822841B2 (en) | 2009-11-05 | 2015-11-24 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Treatment of cancer containing mutant KRAS or BRAF gene |
EP2496604B1 (en) | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
WO2011062997A2 (en) | 2009-11-17 | 2011-05-26 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
EP3431608A3 (en) | 2009-11-17 | 2019-02-20 | E. R. Squibb & Sons, L.L.C. | Method for enhanced protein production |
SG177025A1 (en) | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
CN102834509A (en) | 2009-11-19 | 2012-12-19 | 奥克西雷恩英国有限公司 | Yeast strains producing mammalian-like complex N-glycans |
WO2011063198A2 (en) | 2009-11-20 | 2011-05-26 | St. Jude Children's Research Hospital | Methods and compositions for modulating the activity of the interleukin-35 receptor complex |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
NZ600899A (en) | 2009-11-30 | 2014-09-26 | Biotest Ag | Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) |
US9428586B2 (en) | 2009-12-01 | 2016-08-30 | Compugen Ltd | Heparanase splice variant |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
AU2010326024A1 (en) | 2009-12-02 | 2012-07-05 | Amgen Inc. | Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CA2782459A1 (en) | 2009-12-04 | 2011-06-09 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Arf6 as a new target for treating alzheimer's disease |
UA109888C2 (en) | 2009-12-07 | 2015-10-26 | ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES | |
CA2783563A1 (en) | 2009-12-07 | 2011-06-16 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
CA2780069C (en) | 2009-12-08 | 2018-07-17 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
EA024629B1 (en) | 2009-12-09 | 2016-10-31 | Институт Насьональ Де Ла Сант Де Ла Решерше Медикаль | Monoclonal antibodies that bind b7h6 and uses thereof |
EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
WO2011072266A2 (en) | 2009-12-11 | 2011-06-16 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
TWI619521B (en) | 2009-12-15 | 2018-04-01 | 艾伯維生物技術有限責任公司 | Automatic injection device, automatic injection method and method for preventing misfiring |
US8937159B2 (en) | 2009-12-16 | 2015-01-20 | Abbvie Biotherapeutics Inc. | Anti-HER2 antibodies and their uses |
AU2010330907A1 (en) | 2009-12-16 | 2012-06-14 | Bosch, Phillip | Methods of treating interstitial cystitis |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
HUE028629T2 (en) | 2009-12-23 | 2016-12-28 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
WO2011079283A1 (en) * | 2009-12-23 | 2011-06-30 | Bioalliance C.V. | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
ES2585350T3 (en) | 2009-12-23 | 2016-10-05 | F. Hoffmann-La Roche Ag | Anti Bv8 antibodies and uses thereof |
WO2011075786A1 (en) | 2009-12-23 | 2011-06-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
WO2011080322A1 (en) | 2009-12-30 | 2011-07-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia |
ES2688093T3 (en) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Plasma kallikrein binding proteins |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
US8900588B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
EP2523680A4 (en) * | 2010-01-11 | 2013-06-19 | Ct Molecular Med & Immunology | Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011088215A2 (en) | 2010-01-13 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
WO2011088193A2 (en) | 2010-01-13 | 2011-07-21 | University Of Medicine And Dentistry Of New Jersey | Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency |
LT2523688T (en) | 2010-01-15 | 2018-03-12 | Kirin-Amgen, Inc. | Antibody formulation and therapeutic regimens |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
AR079944A1 (en) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT |
AU2011207253B2 (en) | 2010-01-20 | 2015-02-12 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
CA2787755A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
SG182647A1 (en) | 2010-01-21 | 2012-08-30 | Oxyrane Uk Ltd | Methods and compositions for displaying a poypeptide on a yeast cell surface |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
EP2529033B1 (en) | 2010-01-26 | 2017-05-24 | National Jewish Health | Methods for risk prediction, diagnosis, prognosis of pulmonary disorders |
JP2013518590A (en) | 2010-02-02 | 2013-05-23 | アボツト・バイオテクノロジー・リミテツド | Methods and compositions for predicting responsiveness to treatment with a TNF-α inhibitor |
GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
US9056068B2 (en) | 2010-02-04 | 2015-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccine and methods of use against Strongyloide stercoralis infection |
WO2011097527A2 (en) | 2010-02-04 | 2011-08-11 | Xencor, Inc. | Immunoprotection of therapeutic moieties using enhanced fc regions |
WO2011095596A1 (en) | 2010-02-04 | 2011-08-11 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
JP6046494B2 (en) | 2010-02-08 | 2016-12-14 | アジェンシス,インコーポレイテッド | Antibody drug conjugate (ADC) that binds to 161P2F10B protein |
JP5841072B2 (en) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | CD20 antibody and use thereof |
CN102770767A (en) | 2010-02-10 | 2012-11-07 | 诺瓦提斯公司 | Methods and compounds for muscle growth |
AU2011215685B2 (en) | 2010-02-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
SG183356A1 (en) * | 2010-02-18 | 2012-09-27 | Univ California | INTEGRIN aVß8 NEUTRALIZING ANTIBODY |
WO2011103426A2 (en) | 2010-02-19 | 2011-08-25 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
AR080291A1 (en) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES |
KR20230044026A (en) | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
WO2011106635A1 (en) | 2010-02-25 | 2011-09-01 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
EP2538965B1 (en) * | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
US20110212088A1 (en) * | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
PE20130479A1 (en) | 2010-03-04 | 2013-05-12 | Macrogenics Inc | ANTIBODIES REACTIVE WITH B7-H3, IMMULOGICALLY ACTIVE FRAGMENTS OF THE SAME AND USES OF THE SAME |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
KR20120138241A (en) | 2010-03-11 | 2012-12-24 | 화이자 인코포레이티드 | Antibodies with ph dependent antigen binding |
WO2011110604A1 (en) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
BR112012023010A8 (en) | 2010-03-12 | 2017-12-26 | Immunogen Inc | ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO CD37, IMMUNOCONJUGATE COMPRISING THE SAME, USE OF THE SAID ANTIBODY, FRAGMENT AND IMMUNOCONJUGATE, COMPOSITION COMPRISING THE SAME, KIT, ISOLATED CELL, AS WELL AS IN VITRO METHOD TO INHIBIT GROWTH MENT OF A CELL THAT EXPRESSES CD37 |
DK2547359T3 (en) | 2010-03-15 | 2016-06-06 | The Board Of Trustees Of The Univ Of Illionis | Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS |
MX354867B (en) | 2010-03-22 | 2018-03-23 | Genentech Inc Star | Compositions and methods useful for stabilizing protein-containing formulations. |
NZ602992A (en) | 2010-03-24 | 2014-11-28 | Servier Lab | Prophylaxis of colorectal and gastrointestinal cancer |
EP2550297B1 (en) | 2010-03-25 | 2019-01-23 | UCB Biopharma SPRL | Disulfide stabilized dvd-lg molecules |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
WO2011119906A1 (en) | 2010-03-26 | 2011-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7) |
CA3079122A1 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
LT2552961T (en) | 2010-03-30 | 2018-02-12 | Janssen Biotech, Inc. | Humanized il-25 antibodies |
EP2371863A1 (en) | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
WO2011123518A1 (en) | 2010-03-31 | 2011-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
CN102971337B (en) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | FZ combines medicament and application thereof |
SG184473A1 (en) * | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
ES2566602T3 (en) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
MX2012011667A (en) | 2010-04-09 | 2013-03-05 | Critical Care Diagnostics Inc | Soluble human st-2 antibodies and assays. |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US20110280881A1 (en) | 2010-04-13 | 2011-11-17 | Riken | Novel anti-hsp90 monoclonal antibody |
WO2011127580A1 (en) | 2010-04-14 | 2011-10-20 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
JP5965389B2 (en) | 2010-04-15 | 2016-08-03 | プロゲニクス ファーマシューティカルズ インコーポレーテッドProgenics Pharmaceuticals, Inc. | Antibodies for the treatment of Clostridium difficile-related infections and diseases |
US9127066B2 (en) | 2010-04-16 | 2015-09-08 | National Cheng Kung University | Methods for treating osteoporosis with anti-IL-20 receptor antibodies |
US8435525B1 (en) | 2010-04-16 | 2013-05-07 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
CN103038257A (en) | 2010-04-16 | 2013-04-10 | 比奥根艾迪克Ma公司 | Anti-VLA-4 antibodies |
US9226960B2 (en) | 2010-04-16 | 2016-01-05 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
US20110269735A1 (en) | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
EP2561076A1 (en) | 2010-04-19 | 2013-02-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
EP2561355B1 (en) | 2010-04-20 | 2014-06-18 | Cornell University | Method for diagnosing melanocytic proliferations |
BR112012026886B1 (en) | 2010-04-21 | 2020-11-24 | Abbvie Biotechnology Ltd. | wearable automatic injection device for controlled delivery of therapeutic agents |
EP2563380B1 (en) | 2010-04-26 | 2018-05-30 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
EP2380909A1 (en) | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
AU2011248614B2 (en) | 2010-04-27 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
US8993723B2 (en) | 2010-04-28 | 2015-03-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases |
CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
EP2563383B1 (en) | 2010-04-29 | 2017-03-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
ES2623805T3 (en) | 2010-05-03 | 2017-07-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic and antibody compositions related to phenylalanyl-alpha-tRNA synthetase protein fragments |
WO2011139986A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
CN103140233B (en) | 2010-05-03 | 2017-04-05 | Atyr 医药公司 | Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase |
WO2011140182A2 (en) | 2010-05-04 | 2011-11-10 | Medimmune, Llc | Optimized degenerative muscle disease diagnostics and treatments |
NZ603193A (en) | 2010-05-04 | 2014-07-25 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
JP6008844B2 (en) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of the p38 MULTI-tRNA synthetase complex |
AU2011249782B2 (en) | 2010-05-06 | 2014-10-02 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies |
ES2659406T3 (en) | 2010-05-06 | 2018-03-15 | Novartis Ag | Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6) |
DK3195880T3 (en) | 2010-05-14 | 2020-03-02 | Amgen Inc | Highly Concentrated Anti-Sclerostin Antibody Formulations |
JP6166177B2 (en) * | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Humanized and chimeric monoclonal antibodies against CD47 |
US8623376B2 (en) | 2010-05-14 | 2014-01-07 | Baxter International Inc. | Chimeric OspA genes, proteins, and methods of use thereof |
UY33386A (en) | 2010-05-14 | 2011-12-30 | Abbott Laboratoires | IL-1 UNION PROTEINS |
AU2011252990B2 (en) | 2010-05-14 | 2017-04-20 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
CN107312062B (en) | 2010-05-17 | 2021-03-16 | Emd密理博公司 | Stimulus responsive polymers for purification of biomolecules |
US20110287018A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of Treating Interstitial Cystitis |
WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
EP2575856B1 (en) | 2010-05-27 | 2017-08-16 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
DK2576580T3 (en) | 2010-05-28 | 2016-10-17 | Hoffmann La Roche | LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE |
RS63800B1 (en) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Antitumor t cell response enhancer |
KR20130098165A (en) | 2010-06-03 | 2013-09-04 | 제넨테크, 인크. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
WO2011161545A2 (en) | 2010-06-04 | 2011-12-29 | The Netherlands Cancer Institute | Non-hydrolyzable protein conjugates, methods and compositions related thereto |
WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
EP2580239A1 (en) | 2010-06-10 | 2013-04-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
JO3330B1 (en) | 2010-06-10 | 2019-03-13 | Lilly Co Eli | Cgrp antibodies |
AU2011262758B8 (en) * | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
US9405884B2 (en) | 2010-06-16 | 2016-08-02 | Abbvie Inc. | Methods and systems for the analysis of protein samples |
ES2611479T3 (en) | 2010-06-16 | 2017-05-09 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Endoplasmin antibodies and their use |
TW201207383A (en) | 2010-06-16 | 2012-02-16 | Abbott Lab | Comparison of protein samples |
WO2011159976A2 (en) | 2010-06-18 | 2011-12-22 | Xbiotech, Inc. | Arthritis treatment |
EP2582722A4 (en) * | 2010-06-19 | 2013-12-18 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
WO2011163401A2 (en) | 2010-06-22 | 2011-12-29 | Neogenix Oncology, Inc. | Colon and pancreas cancer specific antigens and antibodies |
US9168297B2 (en) | 2010-06-23 | 2015-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (NRG-1) |
AU2011270828B2 (en) | 2010-06-24 | 2015-09-24 | Genentech, Inc. | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
AU2011268780A1 (en) | 2010-06-25 | 2013-02-07 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
CN102985564A (en) * | 2010-06-30 | 2013-03-20 | 奥林巴斯株式会社 | ACF detection method |
JP2013532627A (en) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | Combination of cMET inhibitor with antibody against HGF and / or cMET |
WO2012003472A1 (en) | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
US8603478B2 (en) | 2010-07-06 | 2013-12-10 | Aveo Pharmaceuticals, Inc. | Anti-RON antibodies |
US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN103097412B (en) | 2010-07-09 | 2016-08-10 | 克鲁塞尔荷兰公司 | Anti-human respiratory syncytial virus (RSV) antibody and using method |
WO2013009475A1 (en) | 2011-07-11 | 2013-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Photosensitizing antibody-phuorophore conjugates |
AU2011274510A1 (en) | 2010-07-09 | 2013-01-24 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
WO2012021247A2 (en) | 2010-07-12 | 2012-02-16 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
WO2012007880A2 (en) | 2010-07-16 | 2012-01-19 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
EP3741883B1 (en) | 2010-07-16 | 2022-12-14 | Adimab, LLC | Antibody libraries |
CN103108886B (en) | 2010-07-20 | 2016-08-24 | 赛法隆澳大利亚控股有限公司 | Anti-il-23 heterodimer specific antibody |
WO2012010696A1 (en) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
ES2871092T3 (en) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Methods and compositions for the therapy of liver cancer |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
DK3029066T3 (en) | 2010-07-29 | 2019-05-20 | Xencor Inc | ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS |
HUE041590T2 (en) | 2010-07-29 | 2019-05-28 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
EP2412724A1 (en) | 2010-07-29 | 2012-02-01 | Centre National de la Recherche Scientifique (C.N.R.S) | Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof |
MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
US8747844B2 (en) | 2010-07-30 | 2014-06-10 | Saint Louis University | Methods of treating pain |
EP2598529A2 (en) | 2010-07-30 | 2013-06-05 | Novartis AG | Fibronectin cradle molecules and libraries thereof |
CN103154025B (en) | 2010-08-02 | 2015-07-01 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
MX341579B (en) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Dual variable domain immunoglobulins and uses thereof. |
US20120034225A1 (en) * | 2010-08-03 | 2012-02-09 | National Cheng Kung University | Suppressing Bone Loss with Anti-IL-19 Antibody |
US8377441B2 (en) | 2010-08-03 | 2013-02-19 | National Cheng Kung University | Treating breast cancer with anti-IL-19 antibody |
US20120034224A1 (en) * | 2010-08-03 | 2012-02-09 | National Cheng Kung University | Treating Rheumatoid Arthritis with Anti-IL-19 Antibody |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
CA2807440A1 (en) | 2010-08-04 | 2012-02-09 | Cizzle Biotechnology Limited | Methods and compounds for the diagnosis and treatment of cancer |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
JP5980207B2 (en) | 2010-08-12 | 2016-08-31 | イーライ リリー アンド カンパニー | Anti-N3pGlu amyloid β peptide antibody and use thereof |
CA2808185A1 (en) | 2010-08-13 | 2012-02-16 | Genentech, Inc. | Antibodies to il-1.beta. and il-18, for treatment of disease |
CN103298833B (en) | 2010-08-14 | 2015-12-16 | Abbvie公司 | Amyloid beta associated proteins |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
PL3333188T3 (en) | 2010-08-19 | 2022-05-09 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
CN103080134B (en) | 2010-08-20 | 2015-11-25 | 诺华股份有限公司 | The antibody of EGF-R ELISA 3 (HER3) |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
NZ607472A (en) | 2010-08-23 | 2014-09-26 | Xbiotech Inc | Treatment for neoplastic diseases |
WO2012027493A1 (en) | 2010-08-24 | 2012-03-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Molecular imaging of cancer cells in vivo |
WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
WO2012027555A2 (en) | 2010-08-25 | 2012-03-01 | President And Fellows Of Harvard College | Glycated cd59 peptides, their preparation, and uses thereof |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
EP2614080A1 (en) | 2010-09-10 | 2013-07-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
US8945860B2 (en) | 2010-09-13 | 2015-02-03 | Abbvie Inc. | Highly sensitive monoclonal antibody residual detection assay |
EP2616100B1 (en) | 2010-09-17 | 2016-08-31 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
SG188616A1 (en) | 2010-09-20 | 2013-04-30 | Abbvie Inc | Purification of antibodies using simulated moving bed chromatography |
CN103124740B (en) | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | Anti-SSX-2T cell receptor and associated materials and using method |
US9362094B2 (en) | 2010-09-22 | 2016-06-07 | The Board Of Trustees Of The University Of Arkansas | Biomarkers for determining breast cancer bone metastasis |
EP2622091B1 (en) | 2010-09-23 | 2019-03-13 | Precision Biologics, Inc. | Colon and pancreas cancer peptidomimetics |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
JP5946459B2 (en) | 2010-09-27 | 2016-07-06 | ゼスタジェン, エス.アー.Zestagen, S.A. | Compositions and methods for treating neoplasia |
SG189108A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
SG189110A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | De-mannosylation of phosphorylated n-glycans |
KR102504750B1 (en) | 2010-09-29 | 2023-03-02 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
EP2621954A1 (en) | 2010-10-01 | 2013-08-07 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
ES2664989T3 (en) | 2010-10-01 | 2018-04-24 | National Research Council Of Canada | ANTI-CEACAM6 antibodies and their uses |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
UA112062C2 (en) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | CD33-Binding Agent |
EP2625203A1 (en) | 2010-10-05 | 2013-08-14 | Novartis AG | Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders |
EP2625197B1 (en) | 2010-10-05 | 2016-06-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CN106563128B (en) | 2010-10-22 | 2020-05-22 | 西雅图遗传学公司 | Use of auristatin-based antibody drug conjugates and mTOR-binding inhibitors in the manufacture of a medicament for the treatment of cancer |
WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
AR083495A1 (en) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | STABLE AND SOLUBLE ANTIBODIES |
CA2815888C (en) | 2010-10-25 | 2020-06-30 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
EP2632492B1 (en) | 2010-10-25 | 2017-10-04 | Biogen MA Inc. | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS |
EP2632951B1 (en) | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
EP2632953A1 (en) | 2010-10-27 | 2013-09-04 | Pierre Fabre Medicament | Antibodies for the treatment of hiv |
DK2634194T3 (en) | 2010-10-29 | 2018-10-01 | Perseus Proteomics Inc | ANTI-CDH3 ANTIBODY WITH HIGH INTERNALIZATION CAPACITY |
US20120108651A1 (en) | 2010-11-02 | 2012-05-03 | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
WO2012061281A1 (en) | 2010-11-04 | 2012-05-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnostic assays and methods of use for detection of filarial infection |
US20130224116A1 (en) | 2010-11-05 | 2013-08-29 | TransBio Ltd. | Markers of Endothelial Progenitor Cells and Uses Thereof |
CN103201627B (en) | 2010-11-08 | 2016-10-12 | 丹麦达科有限公司 | In histological sample, single target molecules is quantitative |
US9309322B2 (en) * | 2010-11-12 | 2016-04-12 | Scott & White Healthcare (Swh) | Antibodies to tumor endothelial marker 8 |
US20140093506A1 (en) | 2010-11-15 | 2014-04-03 | Marc Buehler | Anti-fungal-agents |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
PE20140633A1 (en) | 2010-11-19 | 2014-05-30 | Eisai Randd Man Co Ltd | NEUTRALIZING ANTIBODIES ANTI-CCL20 |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US8992908B2 (en) | 2010-11-23 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
CA2821515A1 (en) | 2010-12-01 | 2012-06-07 | Alder Biopharmaceuticals, Inc. | Anti-ngf compositions and use thereof |
CN103534392A (en) | 2010-12-01 | 2014-01-22 | 默沙东公司 | Surface, anchored FC-bait antibody display system |
WO2012074097A1 (en) * | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | Anti-cd33 antibody |
US10718777B2 (en) | 2010-12-06 | 2020-07-21 | Agilent Technologies, Inc. | Combined histological stain |
CA2819038C (en) | 2010-12-06 | 2023-10-17 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
JP6076913B2 (en) | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | Methods for inhibiting metastasis from cancer |
UA112170C2 (en) | 2010-12-10 | 2016-08-10 | Санофі | ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB |
KR101781546B1 (en) | 2010-12-14 | 2017-09-26 | 내셔널 유니버시티 오브 싱가포르 | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
JP6016800B2 (en) | 2010-12-15 | 2016-10-26 | ワイス・エルエルシー | Anti-notch1 antibody |
EP2465928A1 (en) | 2010-12-16 | 2012-06-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Treatment of Th17-mediated diseases |
JP2014508511A (en) | 2010-12-20 | 2014-04-10 | メドイミューン・リミテッド | Anti-IL-18 antibodies and their use |
EP2655401B1 (en) | 2010-12-20 | 2016-03-09 | The Regents of the University of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
WO2012121775A2 (en) | 2010-12-21 | 2012-09-13 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
PL2654781T3 (en) | 2010-12-21 | 2018-09-28 | Novartis Ag | Anti-p-selectin antibodies and methods of their use and identification |
TW201307388A (en) | 2010-12-21 | 2013-02-16 | Abbott Lab | IL-1 binding proteins |
KR101941514B1 (en) | 2010-12-22 | 2019-01-23 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Modified antibody with improved half-life |
EP2654789B1 (en) | 2010-12-22 | 2018-05-30 | Orega Biotech | Antibodies against human cd39 and use thereof |
JP6106837B2 (en) | 2010-12-27 | 2017-04-05 | 公益財団法人ヒューマンサイエンス振興財団 | Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV neutralizing antibody titer using the same |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
CA2823044C (en) | 2010-12-31 | 2022-08-16 | Jay M. Short | Express humanization of antibodies |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
EP2661450A4 (en) | 2011-01-06 | 2014-04-23 | Dyax Corp | Plasma kallikrein binding proteins |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
EP2663578A2 (en) | 2011-01-14 | 2013-11-20 | Five Prime Therapeutics, Inc. | Il-27 antagonists for treating inflammatory diseases |
CN103384682B (en) | 2011-01-14 | 2017-04-12 | Ucb医药有限公司 | Antibody molecules which bind IL-17A and IL-17F |
WO2012099871A1 (en) | 2011-01-17 | 2012-07-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulation of lrch4 activity and therapeutic application thereof |
DK3020730T3 (en) * | 2011-01-19 | 2019-04-15 | Cantargia Ab | ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATMENT OF SOLID TUMORS |
CA2824885A1 (en) | 2011-01-19 | 2012-07-26 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
TWI690594B (en) | 2011-01-21 | 2020-04-11 | 美商賽瑞諾斯Ip有限責任公司 | Systems and methods for sample use maximization |
EP2667918B1 (en) | 2011-01-24 | 2017-03-01 | AbbVie Biotechnology Ltd | Automatic injection devices having overmolded gripping surfaces |
WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
AU2012209059B2 (en) | 2011-01-25 | 2016-10-20 | Elixirgen, Llc | ZSCAN4 as a marker for pancreatic stem cells and progenitor cells and use thereof |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
CA3042620A1 (en) | 2011-02-02 | 2012-11-29 | Emory University | Antagonism of the vip signaling pathway |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
CA3146962A1 (en) | 2011-02-11 | 2012-08-16 | The Rockefeller University | Treatment of angiogenesis disorders |
EP2675485A4 (en) | 2011-02-15 | 2014-10-15 | Immunomedics Inc | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
WO2012110500A1 (en) | 2011-02-15 | 2012-08-23 | Vib Vzw | Means and methods for improvement of synaptic dysfunction disorders |
WO2012112842A2 (en) | 2011-02-17 | 2012-08-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating poliovirus |
WO2012110824A1 (en) | 2011-02-18 | 2012-08-23 | Astrazeneca Ab | Binding agents with specificity for a nucleic acid modification |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
WO2012110843A1 (en) | 2011-02-18 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis |
AR085302A1 (en) | 2011-02-24 | 2013-09-18 | Sanofi Sa | METHOD OF PRODUCTION OF STIRATED ANTIBODIES |
KR102147548B1 (en) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc antibody |
CA2828405A1 (en) | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
JP2014509588A (en) | 2011-03-01 | 2014-04-21 | アムジエン・インコーポレーテツド | Bispecific binding agent |
EA029300B1 (en) | 2011-03-02 | 2018-03-30 | Роше Гликарт Аг | Antibody which binds membrane-bound human carcinoembryonic antigen, production and use thereof |
PE20180776A1 (en) | 2011-03-02 | 2018-05-07 | Berg Llc | CELL-BASED INTERROGATORY TESTS AND THE USE OF THEM |
WO2012120130A1 (en) | 2011-03-09 | 2012-09-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods to characterize patients suffering from hemolysis |
KR101938343B1 (en) | 2011-03-09 | 2019-01-14 | 셀 시그널링 테크놀러지, 인크. | Methods and reagents for creating monoclonal antibodies |
JP2014515598A (en) | 2011-03-10 | 2014-07-03 | エイチシーオー アンティボディ, インク. | Bispecific three-chain antibody-like molecule |
ES2733646T3 (en) | 2011-03-11 | 2019-12-02 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antibodies and uses thereof |
EP2686016B1 (en) | 2011-03-14 | 2019-05-01 | Cellmid Limited | Antibody recognizing n-domain of midkine |
WO2012125735A1 (en) | 2011-03-15 | 2012-09-20 | Abott Laboratories | An integrated approach to the isolation and purification of antibodies |
US20130344074A1 (en) | 2011-03-16 | 2013-12-26 | Sanofi | Uses of a dual v region antibody-like protein |
EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
US9555108B2 (en) | 2011-03-24 | 2017-01-31 | Texas Tech University System | TCR mimic antibodies as vascular targeting tools |
SG10201701634PA (en) | 2011-03-25 | 2017-04-27 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
KR20220009505A (en) | 2011-03-29 | 2022-01-24 | 이뮤노젠 아이엔씨 | Preparation of maytansinoid antibody conjugates by a one-step process |
WO2012135522A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
AP2013007046A0 (en) | 2011-03-30 | 2013-08-31 | Boehringer Ingelheim Int | Anticoagulant antidotes |
JP6130350B2 (en) | 2011-03-30 | 2017-05-17 | アブリンクス エン.ヴェー. | Methods of treating immune disorders with single domain antibodies against TNFα |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
ES2612914T3 (en) | 2011-03-31 | 2017-05-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Antibodies directed against Icos and their uses |
US20140219999A1 (en) | 2011-04-01 | 2014-08-07 | The Trustees Of The University Of Pennsylvania | Treatment of colon cancer using complement inhibitors |
CN110201157A (en) | 2011-04-01 | 2019-09-06 | 埃克斯生物科技公司 | The treatment of dermatology symptom |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
CN103619881B (en) | 2011-04-07 | 2017-07-28 | 安姆根有限公司 | New EGFR associated proteins |
EP2696898A4 (en) | 2011-04-07 | 2014-10-01 | Univ Emory | Compositions comprising saccharide binding moieties and methods for targeted therapy |
CN103596981B (en) | 2011-04-08 | 2017-06-16 | 美国卫生和人力服务部 | Anti-epidermal growth factor receptor variant III Chimeric antigen receptors and its purposes for treating cancer |
EP2508176A1 (en) | 2011-04-08 | 2012-10-10 | Lipotarg Gmbh | Novel combination treatment of cancer |
PL3287142T3 (en) | 2011-04-08 | 2021-12-27 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2012142174A1 (en) | 2011-04-12 | 2012-10-18 | Electronic Biosciences Inc. | Site specific chemically modified nanopore devices |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
US20140157443A1 (en) | 2011-04-14 | 2014-06-05 | St. Jude Children's Research Hospital | Methods and compositions for detecting and modulating a novel mtor complex |
GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
EP2697256A1 (en) | 2011-04-15 | 2014-02-19 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
BR112013026451B1 (en) | 2011-04-15 | 2021-02-09 | Becton, Dickinson And Company | system and method to perform molecular diagnostic tests on several samples in parallel and simultaneously amplification in real time in plurality of amplification reaction chambers |
EP2998320B1 (en) | 2011-04-19 | 2018-07-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
CA2832907C (en) | 2011-04-19 | 2020-07-14 | Dako Denmark A/S | New method for enzyme-mediated signal amplification |
RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
EP2699597B1 (en) | 2011-04-21 | 2016-06-01 | Garvan Institute of Medical Research | Modified variable domain molecules and methods for producing and using them b |
MX345747B (en) | 2011-04-21 | 2017-02-14 | Abbvie Inc | Wearable automatic injection device. |
RU2754446C2 (en) | 2011-04-22 | 2021-09-02 | ВАЙЕТ ЭлЭлСи | Compositions related to mutant toxin clostridium difficile and their application methods |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9700579B2 (en) | 2011-04-27 | 2017-07-11 | Yale University | Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits |
JP2014515759A (en) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | Applications related to methods of treating squamous cell carcinoma |
UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
CN108969469A (en) | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | The preparation of 4 β of anti alpha, 7 antibody |
WO2012151465A1 (en) | 2011-05-04 | 2012-11-08 | Pop Test, Llc | Diagnostic device |
RU2600067C2 (en) | 2011-05-06 | 2016-10-20 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез | Recombinant immunotoxin aimed at mesothelin |
CA2835094C (en) * | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
JP5980202B2 (en) | 2011-05-09 | 2016-08-31 | 株式会社ペルセウスプロテオミクス | Antibodies that can specifically recognize transferrin receptor |
JOP20200043A1 (en) | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
JP6236383B2 (en) | 2011-05-13 | 2017-11-22 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Methods for preventing and removing trisulfide bonds |
CN103842383B (en) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | Polyspecific FAB fusion proteins and its application method |
US9040047B2 (en) | 2011-05-16 | 2015-05-26 | Yeda Research And Development Co. Ltd. | Combinations of anti ErbB antibodies for the treatment of cancer |
WO2012158989A2 (en) | 2011-05-19 | 2012-11-22 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
WO2012156532A1 (en) | 2011-05-19 | 2012-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human-her3 antibodies and uses thereof |
SG194974A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
EP2710039B1 (en) | 2011-05-20 | 2019-01-09 | AlderBio Holdings LLC | Anti-cgrp compositions and use thereof |
KR101965461B1 (en) | 2011-05-20 | 2019-04-04 | 앨더바이오 홀딩스 엘엘씨 | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
MX347818B (en) | 2011-05-21 | 2017-05-15 | Macrogenics Inc | Deimmunized serum-binding domains and their use for extending serum half-life. |
ES2704038T3 (en) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Multivalent and monovalent multispecific complexes and their uses |
US8426143B2 (en) | 2011-05-24 | 2013-04-23 | Saladax Biomedical Inc. | Gemcitabine immunoassay |
AR086543A1 (en) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION |
MX347514B (en) | 2011-05-25 | 2017-04-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders. |
WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
EP2714094B1 (en) | 2011-06-02 | 2016-02-24 | The University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
CA2837527C (en) | 2011-06-02 | 2019-05-28 | Dyax Corp. | Fc receptor binding proteins |
EP2717911A1 (en) | 2011-06-06 | 2014-04-16 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
WO2012170071A1 (en) | 2011-06-06 | 2012-12-13 | Elan Pharmaceuticas, Inc | Mcam antagonists and methods of treatment |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US20140221607A1 (en) * | 2011-06-08 | 2014-08-07 | Indiana University Research And Technology Corp. | Monoclonal antibody and antigens for diagnosing and treating lung disease and injury |
BR112013031262A2 (en) | 2011-06-09 | 2016-11-22 | Us Health | "exotoxins a from pseudomonas with less immunogenic bet cell epitopes, and their use in cancer treatment and prevention, as well as chimeric molecule, nucleic acid, expression vector, cells, pharmaceutical composition and methods to inhibit target cell growth and endotoxin production and pseudomonas and chimeric molecule ". |
CA2837357C (en) | 2011-06-10 | 2020-07-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Anti-ricin antibodies and uses thereof |
US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
MX349886B (en) | 2011-06-10 | 2017-08-17 | Medimmune Llc | Anti-pseudomonas psl binding molecules and uses thereof. |
CA2835231A1 (en) | 2011-06-10 | 2012-12-13 | Corimmun Gmbh | Binding compounds to human .beta.1-adrenoreceptor (.beta.1-ar) and their use in the measurement of auto-anti-.beta.1-ar antibodies |
CA2838246C (en) | 2011-06-13 | 2018-07-10 | Csl Limited | Antibodies against g-csfr and uses thereof |
WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
US20140227265A1 (en) | 2011-06-17 | 2014-08-14 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using clec-2 |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
BR112013032899A2 (en) | 2011-06-22 | 2017-01-24 | Inserm Inst Nat De La Santé Et De La Rech Médicale | anti-axl antibodies and uses thereof |
EP2723376B1 (en) | 2011-06-22 | 2018-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2012175735A1 (en) | 2011-06-23 | 2012-12-27 | Vib Vzw | A20 inhibitors for the treatment of respiratory viral infections |
US9345763B2 (en) | 2011-06-23 | 2016-05-24 | Children's Hospital Medical Center | Methods of treating allergic inflammatory conditions by administering an anti-cadherin-like 26-based therapeutic |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
CA2840537C (en) | 2011-06-28 | 2021-12-14 | Oxford Biotherapeutics Ltd. | Antibodies to adp-ribosyl cyclase 2 |
SI2726094T1 (en) | 2011-06-28 | 2017-04-26 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
CN103764665A (en) | 2011-06-28 | 2014-04-30 | 怀特黑德生物医学研究所 | Using sortases to install click chemistry handles for protein ligation |
WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
AU2012277376B2 (en) | 2011-06-30 | 2016-11-24 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
SI2726099T1 (en) | 2011-07-01 | 2018-11-30 | Novartis Ag | Method for treating metabolic disorders |
CN103813805B (en) | 2011-07-06 | 2017-02-22 | 索兰徳特医院 | EGFR targeted therapy |
EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
US9475858B2 (en) | 2011-07-08 | 2016-10-25 | Momenta Pharmaceuticals, Inc. | Cell culture process |
EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
CA3158257A1 (en) | 2011-07-11 | 2013-01-17 | Ichnos Sciences SA | Antibodies that bind to ox40 and their uses |
KR20140061403A (en) | 2011-07-13 | 2014-05-21 | 애브비 인코포레이티드 | Methods and compositions for treating asthma using anti-il-13 antibodies |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
AU2012284254B2 (en) | 2011-07-15 | 2015-07-09 | Oncomed Pharmaceuticals, Inc. | RSPO binding agents and uses thereof |
JP2014526886A (en) | 2011-07-15 | 2014-10-09 | モルフォシス・アー・ゲー | Antibodies cross-reactive with macrophage migration inhibitory factor (MIF) and D-dopachrome tomerase (D-DT) |
EP2734546A1 (en) | 2011-07-18 | 2014-05-28 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
CA2842195A1 (en) | 2011-07-18 | 2013-01-24 | Immunomedics, Inc. | Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
KR102042982B1 (en) * | 2011-07-22 | 2019-11-11 | 체에스엘 베링 게엠베하 | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses |
WO2013014538A2 (en) | 2011-07-25 | 2013-01-31 | American University In Cairo | Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
US9181532B2 (en) | 2011-07-29 | 2015-11-10 | Icon Genetics Gmbh | Production of galactosylated N-glycans in plants |
WO2013019817A1 (en) | 2011-08-03 | 2013-02-07 | Quidel Corporation | N-acetyl-d-glucosamine for enhanced specificity of strep a immunoassay |
ES2667554T3 (en) | 2011-08-04 | 2018-05-11 | Amgen Inc. | Method for the treatment of bone space defects |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
EP2741773A1 (en) | 2011-08-08 | 2014-06-18 | AbbVie Biotherapeutics Inc. | Methods of treating progressive forms of multiple sclerosis |
EP3939613A1 (en) | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
US9694049B2 (en) | 2011-08-11 | 2017-07-04 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Unitversity Of Nevada, Reno | Methods for treating muscular dystrophy |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
EP3348575A1 (en) | 2011-08-16 | 2018-07-18 | Emory University | Jaml specific binding agents, antibodies, and uses related thereto |
JP6093360B2 (en) | 2011-08-17 | 2017-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibody binding to integrin α-vβ-8 |
ES2682254T3 (en) | 2011-08-18 | 2018-09-19 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
BR112014004162A2 (en) | 2011-08-22 | 2018-04-24 | Cangene Corp | antibodies to clostridium difficile |
WO2013033073A1 (en) | 2011-08-31 | 2013-03-07 | Ventana Medical Systems, Inc. | Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US20140234903A1 (en) | 2011-09-05 | 2014-08-21 | Eth Zurich | Biosynthetic gene cluster for the production of peptide/protein analogues |
CA2846667A1 (en) | 2011-09-06 | 2013-03-14 | Guy L. Reed | Serpinf2-binding molecules and methods of use |
AU2012306341B2 (en) | 2011-09-09 | 2017-08-31 | Cambridge Enterprise Limited | Anti-Siglec-15 antibodies and uses thereof |
CA2847245A1 (en) | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
US8435738B2 (en) | 2011-09-25 | 2013-05-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
EP3392270B1 (en) | 2011-09-15 | 2020-08-26 | The United States of America, as Represented by the Secretary Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
JP2014528715A (en) | 2011-09-15 | 2014-10-30 | ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター | Immunotherapy and diagnosis of mucormycosis using CotH |
ES2656505T3 (en) | 2011-09-16 | 2018-02-27 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin A with less immunogenic B lymphocyte epitopes |
PE20141547A1 (en) | 2011-09-16 | 2014-10-25 | Ucb Pharma Sa | NEUTRALIZING ANTIBODIES AGAINST THE MAIN EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE |
CN103827145A (en) | 2011-09-21 | 2014-05-28 | 富士瑞必欧株式会社 | Antibody against affinity complex |
JP6251678B2 (en) | 2011-09-22 | 2017-12-20 | アムジエン・インコーポレーテツド | CD27L antigen binding protein |
PE20141537A1 (en) | 2011-09-23 | 2014-11-17 | Oncomed Pharm Inc | AGENTS OF LINKING THE VASCULAR ENDOTHELIAL GROWTH FACTOR / LIGANDO 4 SIMILAR TO DELTA (VEGF / DLL4) AND USES OF THE SAME |
JP2014533929A (en) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Bispecific binding molecules for 5T4 and CD3 |
US9809649B2 (en) | 2011-09-23 | 2017-11-07 | Xbiotech, Inc. | Cachexia treatment |
WO2013043071A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
USD692162S1 (en) | 2011-09-30 | 2013-10-22 | Becton, Dickinson And Company | Single piece reagent holder |
WO2013049706A1 (en) | 2011-09-30 | 2013-04-04 | Becton, Dickinson And Company | Unitized reagent strip |
KR102017070B1 (en) | 2011-09-30 | 2019-09-02 | 다나-파버 캔서 인스티튜트 인크. | Therapeutic peptides |
WO2013044298A1 (en) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Antibodies against tl1a and uses thereof |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CN110511939A (en) | 2011-10-03 | 2019-11-29 | 现代泰克斯公司 | Nucleosides, nucleotide and nucleic acid of modification and application thereof |
AR088048A1 (en) | 2011-10-04 | 2014-05-07 | Univ Columbia | NOTCH1 HUMAN LURE |
US10196664B2 (en) | 2011-10-04 | 2019-02-05 | Icon Genetics Gmbh | Nicotiana benthamiana plants deficient in fucosyltransferase activity |
EP3275902A1 (en) | 2011-10-04 | 2018-01-31 | IGEM Therapeutics Limited | Ige anti-hmw-maa antibody |
WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
CA2851261A1 (en) | 2011-10-06 | 2013-04-11 | The Board Of Trustees Of The University Of Illinois | Myosin binding protein-c for use in methods relating to diastolic heart failure |
WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
AU2012323287B2 (en) | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
CN103906767A (en) | 2011-10-10 | 2014-07-02 | 米迪缪尼有限公司 | Treatment for rheumatoid arthritis |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
CA2851284A1 (en) | 2011-10-13 | 2013-04-18 | The Regents Of The University Of California | Treatment of breast cancer with companion diagnostic |
CN104080471B (en) | 2011-10-14 | 2018-08-10 | 诺华股份有限公司 | Antibody and method for Wnt approach relevant diseases |
EP2768971A1 (en) | 2011-10-20 | 2014-08-27 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for the detection and the treatment of cardiac remodeling |
RU2644243C2 (en) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Chimeric antigenic receptors to cd22 |
BR112014009536A2 (en) | 2011-10-21 | 2017-04-18 | Augurex Life Sciences Corp | 14-3-3 xitrulinated derivatives and their uses in the diagnosis of rheumatoid arthritis |
WO2013063095A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against sclerostin |
KR20140097205A (en) | 2011-10-28 | 2014-08-06 | 제넨테크, 인크. | Therapeutic combinations and methods of treating melanoma |
US9265817B2 (en) | 2011-10-28 | 2016-02-23 | Patrys Limited | PAT-LM1 epitopes and methods for using same |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
WO2013063516A1 (en) | 2011-10-28 | 2013-05-02 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
JP6184965B2 (en) | 2011-10-28 | 2017-08-23 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Polypeptide constructs and uses thereof |
WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
CN104053671A (en) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | Antibodies and methods of treating cancer |
EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
WO2013067202A1 (en) | 2011-11-04 | 2013-05-10 | Handylab, Inc. | Polynucleotide sample preparation device |
PT2776065T (en) | 2011-11-07 | 2020-09-25 | Medimmune Ltd | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
US20140294732A1 (en) | 2011-11-08 | 2014-10-02 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute | Early diagnostic of neurodegenerative diseases |
US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
US20140314787A1 (en) | 2011-11-08 | 2014-10-23 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute | Treatment for neurodegenerative diseases |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
WO2013071233A1 (en) | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for detecting infectious agents and a novel virus detected thereby |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
BR112014011331A2 (en) | 2011-11-11 | 2017-04-25 | Rinat Neuroscience Corp | trop-2 specific antibodies and their uses |
WO2013068571A1 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
US20130156766A1 (en) | 2011-11-15 | 2013-06-20 | Allergan, Inc. | Treatment of dry age related macular degeneration |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
HRP20230146T1 (en) | 2011-11-16 | 2023-04-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
HUE042477T2 (en) | 2011-11-16 | 2019-07-29 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
RU2657517C2 (en) | 2011-11-16 | 2018-06-14 | Сфинготек Гмбх | Adrenomedullin assay and methods for determining mature adrenomedullin |
HUE045940T2 (en) | 2011-11-16 | 2020-01-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
DK2594588T3 (en) | 2011-11-16 | 2014-07-21 | Adrenomed Ag | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig protein scaffold for use in therapy |
ES2494190T3 (en) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anti-adrenomedulin antibody (ADM) or anti-ADM antibody fragment or protein scaffold without anti-ADM Ig to reduce the risk of mortality in a patient suffering from a chronic or acute disease or an acute condition |
AR088694A1 (en) | 2011-11-17 | 2014-06-25 | Pfizer | CYTOTOXIC PEPTIDES AND CONJUGATES OF ANTIBODY-PHARMACY OF THE SAME |
US20140328864A1 (en) | 2011-11-22 | 2014-11-06 | Inserm (Institut National De La Sente Et De La Recherche Medicale) | Methods and pharmaceutical compositions for reducing airway hyperresponse |
WO2013078122A1 (en) | 2011-11-22 | 2013-05-30 | President And Fellows Of Harvard College | Diabetes diagnosis through the detection of glycated proteins in urine |
JP2015501639A (en) | 2011-11-23 | 2015-01-19 | アイジェニカ バイオセラピューティクス インコーポレイテッド | Anti-CD98 antibody and method of use thereof |
EP2797957B1 (en) | 2011-11-23 | 2019-06-19 | MedImmune, LLC | Binding molecules specific for her3 and uses thereof |
JP6082402B2 (en) | 2011-11-28 | 2017-02-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Pharmaceutical composition for use in the treatment of dysfunction associated with aging |
CN113416256A (en) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | Drug comprising transporter (carrier) that enters into cell to form immune complex |
WO2013079606A1 (en) | 2011-12-01 | 2013-06-06 | Ventana Medical Systems, Inc. | Automated dual stain of mirna and protein targets |
CA2857647C (en) | 2011-12-02 | 2022-04-19 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
KR20140103135A (en) | 2011-12-05 | 2014-08-25 | 노파르티스 아게 | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
CA2853138A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
JP6243345B2 (en) | 2011-12-05 | 2017-12-06 | ノバルティス アーゲー | Antibody to epidermal growth factor receptor 3 (HER3) |
AU2012347972B2 (en) | 2011-12-05 | 2018-05-10 | X-Body, Inc. | PDGF receptor beta binding polypeptides |
US10117932B2 (en) | 2011-12-08 | 2018-11-06 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
EP2788384B1 (en) | 2011-12-08 | 2017-08-09 | Amgen Inc. | Agonistic human lcat antigen binding proteins and their use in therapy |
WO2013090633A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
WO2013090635A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
CN106831985A (en) | 2011-12-21 | 2017-06-13 | 诺华股份有限公司 | The composition and method of the P factors are targeted for antibody |
TR201815709T4 (en) | 2011-12-22 | 2018-11-21 | Hoffmann La Roche | Ion exchange membrane chromatography. |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
EP2793944A4 (en) | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | Immunoglobulins and variants directed against pathogenic microbes |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
FR2984750B1 (en) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A HUMAN RECEPTOR ANTIBODY OF ANTI-MULLERIAN HORMONE TYPE II |
SG10201509629QA (en) | 2011-12-28 | 2015-12-30 | Amgen Inc | Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies |
TWI443107B (en) | 2011-12-29 | 2014-07-01 | Ind Tech Res Inst | Humanized anti-human cd34 monoclonal antibody and uses thereof |
EP2798355B1 (en) | 2011-12-30 | 2018-09-12 | Ventana Medical Systems, Inc. | Automated analysis of circulating tumor cells |
CA2861610A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
SG11201403756PA (en) | 2012-01-01 | 2014-11-27 | Qbi Entpr Ltd | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
US20140363448A1 (en) | 2012-01-02 | 2014-12-11 | Novartis Ag | Cdcp1 and breast cancer |
US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
BR112014016887A2 (en) | 2012-01-10 | 2018-08-14 | Biogen Idec Inc | enhancement of the transport of therapeutic molecules across the blood-brain barrier |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
WO2013104798A1 (en) | 2012-01-12 | 2013-07-18 | Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences | Modulators of immune responses |
AU2013209492B2 (en) | 2012-01-20 | 2018-02-08 | Genzyme Corporation | Anti-CXCR3 antibodies |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
IN2014DN07149A (en) | 2012-01-27 | 2015-04-24 | Neotope Biosciences Ltd | |
NZ625403A (en) | 2012-01-27 | 2016-03-31 | Abbvie Inc | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
MX2014009289A (en) | 2012-02-01 | 2015-09-08 | Compugen Ltd | C10rf32 antibodies, and uses thereof for treatment of cancer. |
CN104379601B (en) | 2012-02-03 | 2021-04-09 | 霍夫曼-拉罗奇有限公司 | Bispecific antibody molecules and antigen-transfected T-cells and their use in medicine |
CN104204812B (en) | 2012-02-03 | 2018-01-05 | 贝克顿·迪金森公司 | The external file that compatibility determines between distributing and test for molecule diagnostic test |
EA034778B1 (en) | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Cd47 antibodies and methods of use thereof |
US9546219B2 (en) | 2012-02-08 | 2017-01-17 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
ES2725569T3 (en) | 2012-02-10 | 2019-09-24 | Seattle Genetics Inc | Diagnosis and treatment of cancers that express CD30 |
EP2812432B1 (en) | 2012-02-10 | 2020-10-14 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
SI2814842T1 (en) | 2012-02-15 | 2018-10-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
EP3196214B1 (en) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
CA2864539C (en) | 2012-02-16 | 2022-06-07 | Santarus, Inc. | Antibody formulations |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
CN104334580B (en) | 2012-02-24 | 2018-03-30 | 艾伯维施特姆森特克斯有限责任公司 | Anti- SEZ6 antibody and application method |
BR112014020826A8 (en) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | ANTIBODY SPECIFICALLY BINDING TO AN Epitope, NUCLEIC ACID, VECTOR OR HOST CELL, DRUG CONJUGATE ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY, USE THEREOF, KIT AND METHOD OF PREPARATION OF THE CONJUGATE |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
CA2865928C (en) | 2012-03-02 | 2021-02-16 | Vaccinex, Inc. | Cxcl13 antagonist for the treatment of sjogren's syndrome |
EP2822575B1 (en) | 2012-03-03 | 2020-05-06 | ImmunGene, Inc. | Engineered antibody-interferon mutant fusion molecules |
FR2987627B1 (en) | 2012-03-05 | 2016-03-18 | Splicos | USE OF RBM39 AS A BIOMARKER |
SG11201405553YA (en) | 2012-03-08 | 2014-11-27 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
KR20190114003A (en) | 2012-03-15 | 2019-10-08 | 옥시레인 유케이 리미티드 | Methods and materials for treatment of pompe's disease |
EP3626254A1 (en) | 2012-03-16 | 2020-03-25 | University Health Network | Soluble toso protein and its use in treating autoimmune disorders |
WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
WO2013142299A1 (en) | 2012-03-20 | 2013-09-26 | Biogen Idec Ma Inc. | Jcv neutralizing antibodies |
EP2828291A1 (en) | 2012-03-21 | 2015-01-28 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Peptides derived from the d1-domain of nkp46 |
AU2013235726B2 (en) | 2012-03-23 | 2017-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
CA2866185C (en) | 2012-03-23 | 2021-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
MX365947B (en) | 2012-03-27 | 2019-06-19 | Genentech Inc | Improved harvest operations for recombinant proteins. |
ES2694679T3 (en) | 2012-03-27 | 2018-12-26 | Green Cross Corporation | Epitopes of epidermal growth factor receptor surface antigen and use thereof |
DK2831587T3 (en) | 2012-03-27 | 2018-07-23 | Ventana Med Syst Inc | Signaling conjugates and methods of use |
TWI605060B (en) | 2012-03-28 | 2017-11-11 | 賽諾菲公司 | Antibodies to bradykinin b1 receptor ligands |
US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
ES2702278T3 (en) | 2012-04-01 | 2019-02-28 | Technion Res & Dev Foundation | Extracellular matrix metalloproteinase (emmprin) inducer peptides and binding antibodies |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | Modified polynucleotides for the production of proteins |
EP2834366A4 (en) | 2012-04-02 | 2016-04-27 | Berg Llc | Interrogatory cell-based assays and uses thereof |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
AU2013243861A1 (en) | 2012-04-05 | 2014-10-23 | Ac Immune S.A. | Humanized Tau antibody |
SI2833907T1 (en) | 2012-04-06 | 2018-07-31 | Omeros Corporation | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
DK2838998T3 (en) | 2012-04-18 | 2018-01-15 | Cell Signaling Technology Inc | EGFR AND ROS1 IN CANCER |
US10114023B2 (en) | 2012-04-18 | 2018-10-30 | Massachusetts Institute Of Technology | Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV |
WO2013158217A1 (en) | 2012-04-20 | 2013-10-24 | Thomas Jefferson University | Engineered antibody for inhibition of fibrosis |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
WO2013163297A1 (en) | 2012-04-25 | 2013-10-31 | Momenta Pharmaceuticals, Inc. | Modified glycoproteins |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
HUE039118T2 (en) | 2012-04-27 | 2018-12-28 | Novo Nordisk As | Human cd30 ligand antigen binding proteins |
EP2844760A1 (en) | 2012-05-02 | 2015-03-11 | Algenics | Production of secreted therapeutic antibodies in microalgae |
EP2660323A1 (en) | 2012-05-02 | 2013-11-06 | Algenics | Production of secreted therapeutic antibodies in phaeodactylum tricornutum microalgae |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
EP2660324A1 (en) | 2012-05-02 | 2013-11-06 | Algenics | Production of secreted therapeutic antibodies in microalgae |
EA039663B1 (en) | 2012-05-03 | 2022-02-24 | Амген Инк. | Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
US9273140B2 (en) | 2012-05-10 | 2016-03-01 | Fujita Health University | Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D |
US9890378B2 (en) | 2012-05-11 | 2018-02-13 | Merck Sharp & Dohme Corp. | Surface anchored light chain bait antibody display system |
JP2015517490A (en) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | Method of treating a condition using an antibody that binds colony stimulating factor 1 receptor (CSF1R) |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
WO2013173364A2 (en) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
NZ724892A (en) | 2012-05-15 | 2018-04-27 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
BR112014028306A2 (en) | 2012-05-15 | 2018-04-17 | Morphotek, Inc. | methods for treating gastric cancer. |
AR091069A1 (en) | 2012-05-18 | 2014-12-30 | Amgen Inc | PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER |
BR112014028600B1 (en) | 2012-05-18 | 2022-11-22 | Genentech, Inc | SUSPENSION FORMULATIONS COMPRISING HIGH CONCENTRATION MONOCLONAL ANTIBODY, ITS METHOD OF PREPARATION, ITS USE AND DEVICE FOR SUBCUTANEOUS ADMINISTRATION, AND METHOD FOR PRODUCING AN ARTICLE OF MANUFACTURING |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
US20130336957A1 (en) | 2012-05-21 | 2013-12-19 | Abbvie, Inc. | Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography |
ES2835200T3 (en) | 2012-05-22 | 2021-06-22 | Us Health | Medical use of cells comprising anti-NY-ESO-1 T cell receptors |
US20150140010A1 (en) | 2012-05-22 | 2015-05-21 | Inserm 9Institut National De La Sante Et De La R- Echerche Medicale) | Methods for diagnosing and treating focal segmental glomerulosclerosis |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
SG11201408330XA (en) | 2012-05-24 | 2015-01-29 | Mountgate Group Ltd | Compositions and methods related to prevention and treatment of rabies infection |
WO2013177473A1 (en) | 2012-05-25 | 2013-11-28 | The University Of Vermont And State Agriculture College | Compositions and methods for assaying platelet reactivity and treatment selection |
WO2013181543A1 (en) | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
CN104602707A (en) | 2012-06-06 | 2015-05-06 | 昂考梅德药品有限公司 | Binding agents that modulate the hippo pathway and uses thereof |
JP6629069B2 (en) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | Canine anti-NGF antibody and method thereof |
US10335482B2 (en) | 2012-06-06 | 2019-07-02 | Bionor Immuno As | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer |
WO2013183032A2 (en) | 2012-06-08 | 2013-12-12 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2013188448A2 (en) | 2012-06-11 | 2013-12-19 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
US20150204873A1 (en) | 2012-06-18 | 2015-07-23 | Electonic Biosciences, Inc. | Cell-free assay device and methods of use |
BR112014031522A2 (en) | 2012-06-18 | 2017-08-01 | Omeros Corp | methods for inhibiting masp-3 dependent complement activation, for inhibiting masp-2 dependent complement activation, and for manufacturing a medicament |
WO2013192504A1 (en) | 2012-06-22 | 2013-12-27 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
EP4008270A1 (en) | 2012-06-22 | 2022-06-08 | Preprogen LLC | Method for obtaining fetal cells and fetal cellular components |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
US9457071B2 (en) | 2012-06-28 | 2016-10-04 | Hiroshima University | Histamine releaser contained in human sweat |
BR112014032916A2 (en) | 2012-06-28 | 2017-08-01 | Pfizer | anti-drug antibodies and their uses for drug monitoring |
EP2867674B1 (en) | 2012-06-28 | 2018-10-10 | UCB Biopharma SPRL | A method for identifying compounds of therapeutic interest |
US20150218238A1 (en) | 2012-06-29 | 2015-08-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Treating diseases by modulating a specific isoform of mkl1 |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
AU2013286866B2 (en) | 2012-07-02 | 2018-03-01 | Commonwealth Scientific And Industrial Research Organization | Paramyxovirus and methods of use |
JP6770312B2 (en) | 2012-07-05 | 2020-10-14 | ユセベ ファルマ ソシエテ アノニム | Treatment of bone diseases |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
US20150184154A1 (en) | 2012-07-05 | 2015-07-02 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | New treatment for neurodegenerative diseases |
EP2869818A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
US9610324B2 (en) | 2012-07-11 | 2017-04-04 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
UY34905A (en) | 2012-07-12 | 2014-01-31 | Abbvie Inc | IL-1 UNION PROTEINS |
WO2014011988A2 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
CN104427997B (en) | 2012-07-13 | 2020-12-11 | 宾夕法尼亚大学董事会 | Toxicity management of antitumor Activity of CARS |
WO2014013005A1 (en) | 2012-07-18 | 2014-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing and treating chronic kidney disease (ckd) |
US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
KR102165464B1 (en) | 2012-07-19 | 2020-10-14 | 레드우드 바이오사이언스 인코포레이티드 | Antibody specific for cd22 and methods of use thereof |
EP2877494B1 (en) | 2012-07-23 | 2020-07-15 | La Jolla Institute for Allergy and Immunology | Ptprs and proteoglycans in autoimmune disease |
WO2014016737A1 (en) | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
PL2877206T3 (en) | 2012-07-27 | 2020-12-14 | Baxalta GmbH | Compositions comprising chimeric ospa molecules and methods of use thereof |
GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
WO2014020140A1 (en) | 2012-08-02 | 2014-02-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
WO2014026033A1 (en) | 2012-08-08 | 2014-02-13 | University Of Florida Research Foundation, Inc. | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats |
ES2765573T3 (en) | 2012-08-13 | 2020-06-09 | Univ Rockefeller | Melanoma treatment and diagnosis |
WO2014027959A1 (en) | 2012-08-14 | 2014-02-20 | Nanyang Technological University | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
WO2014028939A2 (en) | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
US9989538B2 (en) | 2012-08-17 | 2018-06-05 | Hiroshima University | Monoclonal IgE antibody that binds to sweat allergy antigen protein |
JP6302909B2 (en) | 2012-08-18 | 2018-03-28 | アカデミア シニカAcademia Sinica | Cell-permeable probes for sialidase identification and imaging |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
WO2014031476A1 (en) | 2012-08-21 | 2014-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
SG11201501286PA (en) | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
WO2014034700A1 (en) | 2012-08-30 | 2014-03-06 | 国立大学法人広島大学 | CELL PROLIFERATION REGULATION COMPOSITION CONTAINING PEPTIDE COMPRISING PARTIAL AMINO ACID SEQUENCE FOR BBF2H7 (BBF2 human homologue on chromosome7) OR ANTIBODY CAPABLE OF BINDING TO SAID PEPTIDE |
AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
WO2014036562A2 (en) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
HUE049693T2 (en) | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9695247B2 (en) | 2012-09-03 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against ICOS for treating graft-versus-host disease |
UA115789C2 (en) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Antibody formulations and uses thereof |
US10682399B2 (en) | 2012-09-05 | 2020-06-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
UA105278C2 (en) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Process for the production of catalytically-active antibodies (abzymes) with sialidase activity |
ES2747836T3 (en) | 2012-09-06 | 2020-03-11 | Adelaide Research&Innovation Pty Ltd | Methods and products to prevent and / or treat metastatic cancer |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
JP6368308B2 (en) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | VISTA modulators for cancer diagnosis and treatment |
TWI595007B (en) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | Anti-mcam antibodies and associated methods of use |
EP2895197B1 (en) * | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
US9879065B2 (en) | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
ES2666131T3 (en) | 2012-09-27 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods to cause potent antitumor activity |
US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
NO2760138T3 (en) | 2012-10-01 | 2018-08-04 | ||
CN104684929A (en) | 2012-10-04 | 2015-06-03 | 埃克斯生物科技公司 | Treating vascular disease and complications thereof |
IN2015DN03202A (en) | 2012-10-04 | 2015-10-02 | Immunogen Inc | |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
KR20210063443A (en) | 2012-10-09 | 2021-06-01 | 바이오젠 엠에이 인코포레이티드 | Combination therapies and uses for treatment of demyelinating disorders |
EP2906597B1 (en) | 2012-10-15 | 2020-04-08 | Medimmune Limited | Antibodies to amyloid beta |
BR122016023101B1 (en) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile |
CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
JP2015535224A (en) | 2012-10-24 | 2015-12-10 | ナショナル リサーチ カウンシル オブ カナダ | Anti-Campylobacter jejuni antibody and use thereof |
EP2912061B1 (en) | 2012-10-24 | 2019-02-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | M971 chimeric antigen receptors |
EP2911681A1 (en) | 2012-10-26 | 2015-09-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
WO2014066864A2 (en) | 2012-10-26 | 2014-05-01 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
EP2914961A4 (en) | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | Methods and monitoring of treatment with a dll4 antagonist |
ES2782825T3 (en) | 2012-10-31 | 2020-09-16 | Univ Rockefeller | Metastatic Colon Cancer Treatment |
CA2889764C (en) | 2012-11-01 | 2023-10-10 | Martin Lipp | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
TW202210507A (en) | 2012-11-01 | 2022-03-16 | 美商艾伯維有限公司 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP3150256B1 (en) | 2012-11-02 | 2020-07-15 | TG Therapeutics Inc. | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
CA2890265C (en) | 2012-11-05 | 2023-01-17 | Pierre Fabre Medicament | Antigen binding proteins and their use as addressing product for the treatment of cancer |
CN105377288B (en) | 2012-11-05 | 2019-11-15 | 达纳-法伯癌症研究所股份有限公司 | The composition of XBP1, CD138 and CS1 peptide prepares the purposes of drug |
US8975033B2 (en) | 2012-11-05 | 2015-03-10 | The Johns Hopkins University | Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases |
PL2917195T3 (en) | 2012-11-05 | 2018-04-30 | Pfizer Inc. | Spliceostatin analogs |
CN104903351A (en) | 2012-11-07 | 2015-09-09 | 辉瑞公司 | Anti-notch3 antibodies and antibody-drug conjugates |
SG11201502876RA (en) | 2012-11-08 | 2015-06-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
EP2917347B1 (en) | 2012-11-08 | 2019-01-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of bone metastases |
PT2918603T (en) | 2012-11-08 | 2018-10-30 | Univ Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
CN104937099B (en) | 2012-11-09 | 2018-03-30 | 基因先端领域株式会社 | Anti- ADAM28 antibody for treating cancer |
EP2916835A4 (en) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | Compounds and methods for producing a conjugate |
AR093445A1 (en) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | METHODS TO TREAT OVARY CANCER WITH DLL4 ANTAGONISTS |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
KR20150085064A (en) | 2012-11-16 | 2015-07-22 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | Pictet-spengler ligation for protein chemical modification |
US20140161790A1 (en) | 2012-11-19 | 2014-06-12 | Xencor, Inc. | Engineered immunoglobulins with extended in vivo half-life |
EP3348568B1 (en) | 2012-11-19 | 2019-05-15 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses |
CN104956224B (en) | 2012-11-20 | 2017-12-12 | 美国政府卫生与公共服务部 | Measure Midkine or the horizontal measure for being used to diagnose growth of multiple effect growth factor |
TWI664192B (en) | 2012-11-20 | 2019-07-01 | 法商賽諾菲公司 | Anti-ceacam5 antibodies and uses thereof |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
PT2922554T (en) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Terminally modified rna |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
EP2925779A1 (en) | 2012-11-30 | 2015-10-07 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CN104968678B (en) | 2012-12-05 | 2018-12-11 | 诺华股份有限公司 | Target the composition and method of the antibody of EPO |
UA118255C2 (en) | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
TW201425336A (en) | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
EA034757B1 (en) | 2012-12-10 | 2020-03-17 | Байоджен Ма Инк. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
US10568869B2 (en) | 2012-12-11 | 2020-02-25 | Cornell University | Methods for diagnosing and treating prostate cancer |
ES2819573T3 (en) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Method for Producing Antibody-SN-38 Immunoconjugates with a CL2A Linker |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
PT2900277T (en) | 2012-12-13 | 2022-05-25 | Immunomedics Inc | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
EP3756687A3 (en) | 2012-12-13 | 2021-03-24 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
EP2931749B1 (en) | 2012-12-17 | 2019-04-24 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Use of monoclonal antibodies for the treatment of inflammation and bacterial infections |
MX2015007931A (en) | 2012-12-18 | 2015-10-05 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan. |
PL2935330T3 (en) | 2012-12-19 | 2019-11-29 | Aveo Pharmaceuticals Inc | Anti-notch3 antibodies |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
US9393327B2 (en) | 2012-12-19 | 2016-07-19 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
BR112015014621A2 (en) | 2012-12-21 | 2017-10-03 | Amplimmune Inc | ANTI-H7CR ANTIBODIES |
WO2014100542A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie, Inc. | High-throughput antibody humanization |
WO2014095088A1 (en) | 2012-12-21 | 2014-06-26 | Sykehuset Sørlandet Hf | Egfr targeted therapy of neurological disorders and pain |
AR094271A1 (en) | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | ANTI-BODY ANTIBODIES |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
EP3530284B1 (en) * | 2012-12-26 | 2023-10-25 | OncoSynergy, Inc. | Anti-integrin beta1 antibody compositions and methods of use thereof |
EA201690004A1 (en) | 2012-12-27 | 2016-07-29 | Санофи | ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION |
EP2938633B1 (en) | 2012-12-28 | 2018-02-07 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
MY173334A (en) | 2013-01-02 | 2020-01-16 | Ichnos Sciences SA | Antibodies that bind to tl1a and their uses |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
PL2946206T3 (en) | 2013-01-20 | 2019-07-31 | Dyax Corp. | Evaluation, assays and treatment of pkal-mediated disorders |
LT2948479T (en) | 2013-01-20 | 2018-11-26 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
AU2014213009B2 (en) | 2013-02-01 | 2019-01-03 | Kira Biotech Pty Limited | Anti-CD83 antibodies and use thereof |
EP2951589A1 (en) | 2013-02-01 | 2015-12-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting and preventing metastasis in triple negative breast cancers |
AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
ES2944477T3 (en) | 2013-02-06 | 2023-06-21 | Inhibrx Inc | Non-Platelet Reducing and Non-Red Cell Reducing CD47 Antibodies and Methods of Using Them |
WO2014124227A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
CN104995211B (en) | 2013-02-07 | 2019-09-13 | Csl有限公司 | IL-11R binding protein and its application |
PL2953969T3 (en) | 2013-02-08 | 2020-02-28 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
WO2015198217A2 (en) | 2013-02-08 | 2015-12-30 | Novartis Ag | Compositions and methods for long-acting antibodies targeting il-17 |
EP2956169B1 (en) | 2013-02-12 | 2018-04-11 | THE UNITED STATES OF AMERICA, represented by the S | Monoclonal antibodies that neutralize norovirus |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
JP2016506974A (en) | 2013-02-15 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Acceptor framework for CDR grafting |
BR112015019328A2 (en) | 2013-02-15 | 2017-08-22 | Perseus Proteomics Inc | HUMANIZED ANTI-CDH3 ANTIBODY, HUMANIZED ANTI-CDH3 ANTIBODY DRUG CONJUGATE, AND THEIR USE |
US9745558B2 (en) | 2013-02-18 | 2017-08-29 | Vegenics Pty Limited | VEGFR-3 ligand binding molecules and uses thereof |
EP2958939A1 (en) | 2013-02-20 | 2015-12-30 | ESBATech - a Novartis Company LLC | Acceptor framework for cdr grafting |
TW201446794A (en) | 2013-02-20 | 2014-12-16 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
ES2760023T3 (en) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Cancer treatment using humanized anti-EGFRvIII chimeric antigen receptor |
RS58873B1 (en) | 2013-02-22 | 2019-08-30 | Abbvie Stemcentrx Llc | Antidll3-antibody-pbd conjugates and uses thereof |
WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
FR3004184B1 (en) | 2013-02-26 | 2016-03-18 | Agronomique Inst Nat Rech | ANTI-GLUTEN ANTIBODY DESAMIDE AND USES THEREOF. |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
WO2014137355A1 (en) | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
RU2723937C2 (en) | 2013-03-13 | 2020-06-18 | Санофи | Compositions comprising cd38 antibodies and carfilzomib |
JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
EP2968468B1 (en) | 2013-03-13 | 2021-07-14 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
WO2014153056A2 (en) | 2013-03-14 | 2014-09-25 | Parkash Gill | Cancer treatment using antibodies that bing cell surface grp78 |
CA2899449A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
EP2970451A1 (en) | 2013-03-14 | 2016-01-20 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
EP2968550B1 (en) | 2013-03-14 | 2018-11-14 | Ffe Therapeutics LLC | Compositions and methods for treating angiogenesis-related disorders |
BR112015023239A8 (en) | 2013-03-14 | 2018-04-17 | Abbott Lab | hcv antibody-antigen combination assay and methods and compositions for use thereof |
SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
WO2014143342A1 (en) | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2014153195A1 (en) | 2013-03-14 | 2014-09-25 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta complexed with heparin |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
CA2899308C (en) | 2013-03-14 | 2017-04-18 | Abbvie Inc. | Low acidic species adalimumab compositions and uses thereof |
CA2906417C (en) | 2013-03-14 | 2022-06-21 | Robert Ziemann | Hcv core lipid binding domain monoclonal antibodies |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
EP2970479B1 (en) | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
WO2014142882A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US10035859B2 (en) * | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
US9850297B2 (en) | 2013-03-15 | 2017-12-26 | Amgen Inc. | Secreted frizzle-related protein 5 (SFRP5) binding proteins |
CA2903091C (en) | 2013-03-15 | 2022-09-06 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2014144632A2 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human pac1 antibodies |
NZ712300A (en) | 2013-03-15 | 2020-07-31 | Sutter West Bay Hospitals | Falz for use as a target for therapies to treat cancer |
WO2014143739A2 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
CN105142668B (en) | 2013-03-15 | 2018-04-27 | 达纳-法伯癌症研究院公司 | Therapeutic peptide |
CA2906784C (en) | 2013-03-15 | 2023-02-28 | The Centre For Drug Research And Development | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
RU2015144026A (en) | 2013-03-15 | 2017-04-20 | Эббви Байотекнолоджи Лтд. | ANTIBODIES AGAINST CD25 AND THEIR APPLICATION |
AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
WO2014168734A1 (en) | 2013-03-15 | 2014-10-16 | Cedars-Sinai Medical Center | Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof |
EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
CA2903576C (en) | 2013-03-15 | 2021-06-08 | Nai-Kong V. Cheung | High affinity anti-gd2 antibodies |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
ES2699599T3 (en) | 2013-03-15 | 2019-02-11 | Abbvie Biotherapeutics Inc | Fc variants |
CA2904527A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
BR112015023752B1 (en) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX |
US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
CN105392801A (en) | 2013-03-15 | 2016-03-09 | 比奥根Ma公司 | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
JP6259905B2 (en) | 2013-03-20 | 2018-01-10 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adrenomedullin to guide hypotension treatment |
WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
EP4285988A3 (en) | 2013-03-27 | 2024-03-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
ES2823648T3 (en) | 2013-04-01 | 2021-05-07 | Univ California | Methods and compositions for treating and preventing diseases associated with the AVB8 integrin |
US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
KR20210130260A (en) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc region variant |
US20140308751A1 (en) * | 2013-04-12 | 2014-10-16 | Siemens Healthcare Diagnostics Inc. | Assays for Analyte Homologs |
WO2014172390A2 (en) | 2013-04-15 | 2014-10-23 | Cedars-Sinai Medical Center | Methods for detecting cancer metastasis |
CN105392882A (en) | 2013-04-19 | 2016-03-09 | 加利福尼亚大学董事会 | Lone star virus |
CN109395064A (en) | 2013-04-19 | 2019-03-01 | 赛腾制药 | The derivative treatment of the cell factor of reduced vascular leak syndrome |
KR102069723B1 (en) | 2013-04-23 | 2020-01-23 | 세다르스-신나이 메디칼 센터 | Systems and methods for recording simultaneously visible light image and infrared light image from fluorophores |
TWI679019B (en) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | Anti-il-4/anti-il-13 bispecific antibody formulations |
AU2013388126B2 (en) | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
EP2992018B1 (en) | 2013-04-29 | 2019-02-13 | OGD2 Pharma | Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer |
US10745489B2 (en) | 2013-04-29 | 2020-08-18 | Ogd2 Pharma | Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EP3457138A3 (en) | 2013-04-30 | 2019-06-19 | Université de Montréal | Novel biomarkers for acute myeloid leukemia |
ES2802274T3 (en) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Sialylated glycoproteins |
PL2981822T3 (en) | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
WO2014182532A1 (en) | 2013-05-07 | 2014-11-13 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Mesothelin-specific immunocytokine and use thereof |
EP2994163B1 (en) | 2013-05-09 | 2019-08-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
WO2014183885A1 (en) | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
WO2014186750A2 (en) | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
WO2014190356A2 (en) | 2013-05-24 | 2014-11-27 | Amplimmune, Inc. | Anti-b7-h5 antibodies and their uses |
PT3004167T (en) | 2013-05-30 | 2018-11-13 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
ES2753419T3 (en) | 2013-06-07 | 2020-04-08 | Univ Duke | Complement factor H inhibitors |
EP3008210B1 (en) | 2013-06-13 | 2020-10-07 | University Of South Australia | Methods for detecting prostate cancer |
US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
WO2014202089A2 (en) | 2013-06-18 | 2014-12-24 | Roskilde Universitet | Variants of anti-freeze polypeptides |
US9890369B2 (en) | 2013-06-20 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
AR096601A1 (en) | 2013-06-21 | 2016-01-20 | Novartis Ag | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE |
WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
US9562101B2 (en) | 2013-06-21 | 2017-02-07 | Novartis Ag | Lectin-like oxidized LDL receptor 1 antibodies and methods of use |
DK3013350T3 (en) | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Use of semaphorin 4D inhibitory molecules in combination with an immunomodulatory therapy to inhibit tumor growth and metastases |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
SG11201509899PA (en) * | 2013-06-26 | 2016-01-28 | Numab Ag | Novel antibody frameworks |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
AU2013396206B2 (en) | 2013-06-28 | 2019-11-14 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
EP3013857B1 (en) | 2013-06-28 | 2021-06-23 | Singapore Health Services Pte Ltd | Trpm4 channel inhibitors for stroke treatment |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US20160176943A1 (en) | 2013-07-05 | 2016-06-23 | Inserm (Insititut National De La Sante Et De La Recherche Medicale) | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
ES2658039T3 (en) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use |
EP2824176A1 (en) | 2013-07-11 | 2015-01-14 | Siamed'xpress | Methods for producing sialylated therapeutic proteins |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
CN105452288B (en) | 2013-07-15 | 2019-08-13 | 美国卫生和人力服务部 | 16 E6 T cell receptor of anti-human papilloma virus (anti-HPV) |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
CN105814074B (en) | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | Humanized antibodies with ultralong complementarity determining regions |
WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
WO2015010791A2 (en) | 2013-07-24 | 2015-01-29 | Klareskog, Lars | Novel antibodies for the diagnosis and treatment of rheumatoid arthritis |
US10196458B2 (en) * | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
DK3028048T3 (en) | 2013-07-31 | 2019-01-21 | Bioventures Llc | COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN |
JP6510518B2 (en) | 2013-08-01 | 2019-05-08 | アジェンシス,インコーポレイテッド | Antibody-drug conjugate (ADC) that binds to the CD37 protein |
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
MX371455B (en) | 2013-08-02 | 2020-01-28 | Pfizer | Anti-cxcr4 antibodies and antibody-drug conjugates. |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
US20160178610A1 (en) | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
CN105531291A (en) | 2013-08-07 | 2016-04-27 | 阿斯图特医药公司 | Assays for timp2 having improved performance in biological samples |
KR102457731B1 (en) | 2013-08-08 | 2022-10-21 | 싸이튠 파마 | Combined pharmaceutical composition |
KR102564207B1 (en) | 2013-08-08 | 2023-08-10 | 싸이튠 파마 | IL-15 and IL-15R aplha sushi domain based modulokines |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
EP3030268B1 (en) | 2013-08-09 | 2022-07-27 | The Trustees Of The University Of Pennsylvania | Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers |
JP6463359B2 (en) | 2013-08-12 | 2019-01-30 | ジェネンテック, インコーポレイテッド | Compositions and methods for treating complement related conditions |
TWI592426B (en) | 2013-08-13 | 2017-07-21 | 賽諾菲公司 | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
CN112142845A (en) | 2013-08-13 | 2020-12-29 | 赛诺菲 | Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof |
CA2921398C (en) | 2013-08-14 | 2021-12-14 | The Governing Council Of The University Of Toronto | Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors |
TW201536318A (en) | 2013-08-14 | 2015-10-01 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
WO2015026846A1 (en) | 2013-08-19 | 2015-02-26 | Biogen Idec Ma Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
WO2015025054A1 (en) | 2013-08-22 | 2015-02-26 | Medizinische Universität Wien | Dye-specific antibodies for prestained molecular weight markers and methods producing the same |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
WO2015031645A1 (en) | 2013-08-28 | 2015-03-05 | Washington University | Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
ES2871418T3 (en) | 2013-08-28 | 2021-10-28 | Abbvie Stemcentrx Llc | Compositions and methods of conjugation of site-specific antibodies |
JP6736464B2 (en) | 2013-08-29 | 2020-08-05 | シティ・オブ・ホープCity of Hope | Cell-permeable conjugates and methods of use thereof |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
HUE055856T2 (en) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
WO2015034052A1 (en) | 2013-09-05 | 2015-03-12 | 国立大学法人 宮崎大学 | Antibody which specifically reacts with human integrin a6b4 |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
CA2923579C (en) | 2013-09-06 | 2023-09-05 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
US11545241B1 (en) | 2013-09-07 | 2023-01-03 | Labrador Diagnostics Llc | Systems and methods for analyte testing and data management |
JP6463361B2 (en) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugate |
CN104418947A (en) | 2013-09-11 | 2015-03-18 | 香港大学 | Anti-her2 and anti-igf-ir bi-specific antibodies and uses thereof |
CN105764924A (en) | 2013-09-12 | 2016-07-13 | 哈洛齐梅公司 | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2015036956A1 (en) | 2013-09-12 | 2015-03-19 | Institut National De La Sante Et De La Recherche Medicale | Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies |
CN104436157A (en) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | Influenza vaccine and therapy |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015050663A1 (en) | 2013-10-01 | 2015-04-09 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of bim |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
WO2015051199A2 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
WO2015054451A1 (en) | 2013-10-09 | 2015-04-16 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
EP3055331B1 (en) | 2013-10-11 | 2021-02-17 | Oxford Bio Therapeutics Limited | Conjugated antibodies against ly75 for the treatment of cancer |
CA2925393C (en) | 2013-10-11 | 2023-03-07 | Dimiter Dimitrov | Tem8 antibodies and their use |
NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
EP3057993B1 (en) | 2013-10-17 | 2020-08-12 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015057461A2 (en) | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use |
AU2014340449B2 (en) | 2013-10-21 | 2019-10-31 | Takeda Pharmaceutical Company Limited | Diagnosis and treatment of autoimmune diseases |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
CA3183645A1 (en) | 2013-10-25 | 2015-04-30 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
EP3063317B1 (en) | 2013-10-28 | 2020-06-03 | DOTS Technology Corp. | Allergen detection |
BR112016009403A2 (en) | 2013-10-31 | 2017-09-19 | Sanofi Sa | SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATMENT OF HUMAN CANCER |
EP3066118B1 (en) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
EP3066221A4 (en) | 2013-11-06 | 2017-09-20 | Astute Medical, Inc. | Assays for igfbp7 having improved performance in biological samples |
KR20160070191A (en) | 2013-11-06 | 2016-06-17 | 스템센트알엑스 인코포레이티드 | Novel anti-claudin antibodies and methods of use |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
US20160272673A1 (en) | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of dvd-igs |
JP6449876B2 (en) | 2013-11-07 | 2019-01-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Anti-human HER3 antibody that is non-competitive and allosteric for neuregulin and uses thereof |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
EP2871190A1 (en) | 2013-11-11 | 2015-05-13 | ATLAB Pharma | Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
US10758636B2 (en) | 2013-11-12 | 2020-09-01 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
WO2015073709A2 (en) | 2013-11-14 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Detection of atherosclerotic cardiovascular disease risk and heart failure risk |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3068419A1 (en) | 2013-11-15 | 2016-09-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of pancreatic cancers |
WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
US11191832B2 (en) | 2013-11-19 | 2021-12-07 | Prothena Biosciences Limited | Monitoring immunotherapy of Lewy body disease from constipation symptoms |
AU2014352843B2 (en) | 2013-11-21 | 2020-03-05 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
CA2927806C (en) | 2013-11-27 | 2023-01-10 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
DK3074038T3 (en) | 2013-11-28 | 2019-03-11 | Csl Ltd | METHOD OF TREATING DIABETIC NEPHROPATHY |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
US9321834B2 (en) | 2013-12-05 | 2016-04-26 | Leidos, Inc. | Anti-malarial compositions |
MX371187B (en) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Therapeutic peptides. |
EP3077416B1 (en) | 2013-12-06 | 2019-06-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
KR20160097294A (en) | 2013-12-09 | 2016-08-17 | 뉴욕 유니버시티 | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
WO2015089338A2 (en) | 2013-12-11 | 2015-06-18 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
SG11201604748YA (en) | 2013-12-12 | 2016-07-28 | Umc Utrecht Holding Bv | Immunoglobulin-like molecules directed against fibronectin-eda |
US9944694B2 (en) | 2013-12-13 | 2018-04-17 | Rijksuniversiteit Groningen | Antibodies against Staphylococcus aureus and uses therof |
TWI700295B (en) | 2013-12-16 | 2020-08-01 | 馬來西亞商Mab探索私人有限公司 | Antibodies specific for enteroviruses that infect humans |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
KR20160096194A (en) | 2013-12-18 | 2016-08-12 | 씨에스엘 리미티드 | Method of treating wounds |
EP3082878B1 (en) | 2013-12-19 | 2022-10-05 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
JP2017500017A (en) | 2013-12-20 | 2017-01-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
EP3087101A4 (en) | 2013-12-20 | 2017-12-06 | Novartis AG | Regulatable chimeric antigen receptor |
TW201609805A (en) | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | Multifunctional antibodies binding to EGFR and MET |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
SI3712174T1 (en) | 2013-12-24 | 2022-06-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
KR102384740B1 (en) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | Sulfonamide-containing linkage systems for drug conjugates |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2015106003A1 (en) | 2014-01-08 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy |
CA2936346A1 (en) | 2014-01-08 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody targeting cell surface deposited complement protein c3d and use thereof |
EP4101461A1 (en) | 2014-01-09 | 2022-12-14 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
EP3091982B1 (en) | 2014-01-09 | 2019-04-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
WO2015108998A2 (en) | 2014-01-15 | 2015-07-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Cartilage targeting agents and their use |
CA2937123A1 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3096798B1 (en) | 2014-01-21 | 2020-11-25 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
ES2963718T3 (en) | 2014-01-21 | 2024-04-01 | Novartis Ag | Antigen-presenting capacity of CAR-T cells enhanced by co-introduction of co-stimulatory molecules |
US20160333422A1 (en) | 2014-01-24 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
WO2015110935A1 (en) | 2014-01-27 | 2015-07-30 | Pfizer Inc. | Bifunctional cytotoxic agents |
RU2685728C2 (en) | 2014-01-29 | 2019-04-23 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Ligand-cytotoxic drug conjugate, production method and use thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
US11648335B2 (en) | 2014-01-31 | 2023-05-16 | Wake Forest University Health Sciences | Organ/tissue decellularization, framework maintenance and recellularization |
CA2940192C (en) | 2014-02-04 | 2022-09-27 | Thomas Jefferson University | Specific expression of half-trna in cancers |
CA2937539A1 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US10189908B2 (en) | 2014-02-05 | 2019-01-29 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants |
US10464997B2 (en) | 2014-02-11 | 2019-11-05 | Seattle Genetics, Inc. | Selective reduction of proteins |
KR102356951B1 (en) | 2014-02-11 | 2022-01-27 | 비스테라, 인크. | Antibody molecules to dengue virus and uses thereof |
US10675352B2 (en) | 2014-02-14 | 2020-06-09 | Centrose, Llc | Extracellular targeted drug conjugates |
EP3107557B1 (en) | 2014-02-17 | 2021-06-09 | Seagen Inc. | Hydrophilic antibody-drug conjugates |
JP6666848B2 (en) | 2014-02-18 | 2020-03-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1 / OBR complex signaling pathway |
WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
US10261084B1 (en) | 2014-02-19 | 2019-04-16 | Stc.Unm | Activated GTPase-based assays and kits for the diagnosis of sepsis and other infections |
EP3107935B1 (en) | 2014-02-20 | 2020-06-24 | Allergan, Inc. | Complement component c5 antibodies |
AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
CA2939586A1 (en) | 2014-02-27 | 2015-09-03 | Allergan, Inc. | Complement factor bb antibodies |
EP3122757B1 (en) | 2014-02-28 | 2023-09-06 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR102355308B1 (en) | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
UA121028C2 (en) | 2014-03-06 | 2020-03-25 | Нешнл Рісеч Каунсіл Оф Канада | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
AU2014385801B2 (en) | 2014-03-06 | 2020-11-12 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
JP6538707B2 (en) | 2014-03-07 | 2019-07-03 | ユニバーシティ ヘルス ネットワーク | Methods and compositions for modulating an immune response |
US10611833B2 (en) * | 2014-03-07 | 2020-04-07 | Welson Pharmaceuticals, Inc. | Humanized anti-human epidermal growth factor receptor antibody and application thereof |
KR20160127825A (en) | 2014-03-12 | 2016-11-04 | 프로테나 바이오사이언시즈 리미티드 | Anti-mcam antibodies and associated methods of use |
EP3116906A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
KR20160131073A (en) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Anti-laminin4 antibodies specific for lg4-5 |
TW201623331A (en) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | Anti-MCAM antibodies and associated methods of use |
US20170002077A1 (en) | 2014-03-13 | 2017-01-05 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
EP3925973A1 (en) | 2014-03-14 | 2021-12-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
KR102442436B1 (en) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Antibody molecules to lag-3 and uses thereof |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
ES2939760T3 (en) | 2014-03-15 | 2023-04-26 | Novartis Ag | Cancer treatment using a chimeric receptor for antigens |
WO2015140351A1 (en) | 2014-03-21 | 2015-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing myelination |
ES2800674T3 (en) | 2014-03-21 | 2021-01-04 | X Body Inc | Bispecific antigen-binding polypeptides |
US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
WO2015148515A1 (en) | 2014-03-24 | 2015-10-01 | Biogen Ma Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
US20170173083A1 (en) | 2014-03-26 | 2017-06-22 | The Brigham And Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
KR102555955B1 (en) | 2014-03-27 | 2023-07-18 | 다케다 파머수티컬 컴패니 리미티드 | Compositions and methods for treatment of diabetic macular edema |
WO2015145449A2 (en) | 2014-03-27 | 2015-10-01 | Yeda Research And Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
CN106415244B (en) | 2014-03-27 | 2020-04-24 | 中央研究院 | Reactive marker compounds and uses thereof |
CR20160506A (en) | 2014-03-28 | 2017-03-10 | Xencor Inc | Bispecific Antibodies that bind to CD38 and CD3 |
KR102530900B1 (en) | 2014-03-31 | 2023-05-12 | 암젠 케이-에이, 인크. | Methods of treating nail and scalp psoriasis |
WO2015153765A1 (en) | 2014-04-01 | 2015-10-08 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
KR102352573B1 (en) * | 2014-04-04 | 2022-01-18 | 바이오노믹스 인코포레이티드 | Humanized antibodies that bind lgr5 |
KR102487608B1 (en) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | Treatment of cancer using anti-cd19 chimeric antigen receptor |
DK3128997T3 (en) | 2014-04-08 | 2020-08-24 | Boston Pharmaceuticals Inc | BINDING MOLECULES SPECIFIC TO IL-21 AND USES THEREOF |
CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
AU2015243246B2 (en) | 2014-04-10 | 2018-09-06 | Obi Pharma Inc. | Antibodies, pharmaceutical compositions and uses thereof |
SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
US10544231B2 (en) | 2014-04-16 | 2020-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
MX2016013559A (en) | 2014-04-16 | 2017-04-27 | Biocon Ltd | Stable protein formulations comprising a molar excess of sorbitol. |
EP3134439B1 (en) | 2014-04-21 | 2018-12-26 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
TW201622746A (en) | 2014-04-24 | 2016-07-01 | 諾華公司 | Methods of improving or accelerating physical recovery after surgery for hip fracture |
PL3134095T3 (en) | 2014-04-25 | 2020-10-19 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
EP3804745A1 (en) | 2014-04-25 | 2021-04-14 | The Brigham and Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
ES2830849T3 (en) | 2014-04-25 | 2021-06-04 | Brigham & Womens Hospital Inc | Assay and method for treating subjects with immune-mediated diseases |
IL296691B2 (en) | 2014-04-25 | 2023-11-01 | 2Seventy Bio Inc | Mnd promoter chimeric antigen receptors |
NZ725423A (en) | 2014-04-25 | 2023-07-28 | Pf Medicament | Igf-1r antibody and its use as addressing vehicle for the treatment of cancer |
HUE044862T2 (en) | 2014-04-25 | 2019-11-28 | Pf Medicament | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
LT3134125T (en) | 2014-04-25 | 2020-01-10 | Pierre Fabre Médicament | Antibody-drug-conjugate and its use for the treatment of cancer |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
PL3137502T3 (en) | 2014-04-27 | 2021-03-08 | Famewave Ltd. | Humanized antibodies against ceacam1 |
US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
RS61516B1 (en) | 2014-04-30 | 2021-03-31 | Pfizer | Anti-ptk7 antibody-drug conjugates |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
CN106536561A (en) | 2014-05-01 | 2017-03-22 | 豪夫迈·罗氏有限公司 | Anti-factor D antibody variants and uses thereof |
US11760807B2 (en) | 2014-05-08 | 2023-09-19 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
US10058559B2 (en) | 2014-05-15 | 2018-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
MX2016014761A (en) | 2014-05-16 | 2017-05-25 | Amgen Inc | Assay for detecting th1 and th2 cell populations. |
WO2015175874A2 (en) | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
WO2015179404A1 (en) | 2014-05-19 | 2015-11-26 | The Johns Hopkins University | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer |
US20170198054A1 (en) | 2014-05-21 | 2017-07-13 | Dana-Farber Cancer Institute | Methods for treating cancer with anti bip or anti mica antibodies |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
AU2015268101B2 (en) | 2014-05-27 | 2021-01-28 | The University Of Queensland | Modulation of cellular stress |
TWI717319B (en) | 2014-05-27 | 2021-02-01 | 中央研究院 | Fucosidase from bacteroides and methods using the same |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
EP4116329A1 (en) | 2014-05-27 | 2023-01-11 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
EP3149031B1 (en) | 2014-05-29 | 2019-12-18 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human papillomavirus 16 e7 t cell receptors |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
JP6683628B2 (en) | 2014-06-04 | 2020-04-22 | シーダーズ−サイナイ メディカル センター | Methods for non-surgical repair of spinal compression fractures |
WO2015188131A1 (en) | 2014-06-05 | 2015-12-10 | Cedars-Sinai Medical Center | A novel and efficient method for reprogramming immortalized lymphoblastoid cell lines to induced pluripotent stem cells |
EP3151830A4 (en) | 2014-06-06 | 2018-02-07 | Redwood Bioscience, Inc. | Anti-her2 antibody-maytansine conjugates and methods of use thereof |
SG11201610170SA (en) | 2014-06-06 | 2017-01-27 | Bluebird Bio Inc | Improved t cell compositions |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
FR3021970B1 (en) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES |
US9911365B2 (en) | 2014-06-09 | 2018-03-06 | Bijan SIASSI | Virtual neonatal echocardiographic training system |
WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
AU2015274334B2 (en) | 2014-06-12 | 2020-12-17 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
EP3154579A1 (en) | 2014-06-13 | 2017-04-19 | Friedrich Miescher Institute for Biomedical Research | New treatment against influenza virus |
PT3157951T (en) * | 2014-06-17 | 2020-08-24 | Academia Sinica | Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
WO2015196142A1 (en) | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
CN106795222A (en) | 2014-06-23 | 2017-05-31 | 戊瑞治疗有限公司 | With the method for the Antybody therapy symptom for combining colony-stimulating factor 1 acceptor (CSF1R) |
EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
US20170327553A1 (en) | 2014-06-25 | 2017-11-16 | Novartis Ag | Compositions and methods for long acting proteins |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
EA036307B1 (en) * | 2014-06-26 | 2020-10-23 | Янссен Вэксинс Энд Превеншн Б.В. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
WO2015197593A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | MULTISPECIFIC NKp46 BINDING PROTEINS |
CA2952532A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN113694191A (en) | 2014-06-30 | 2021-11-26 | 默多克儿童研究所 | Therapeutic agent for helicobacter |
EP3164129A1 (en) | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
ES2903029T3 (en) | 2014-07-03 | 2022-03-30 | Univ Yale | DICKKOPF2 (DKK2) inhibition suppresses tumor formation |
US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
CN106686977B (en) | 2014-07-09 | 2022-03-25 | 豪夫迈·罗氏有限公司 | PH adjustment to improve thawing recovery of cell banks |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
AU2015289081B2 (en) | 2014-07-16 | 2020-02-06 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
HUE045108T2 (en) | 2014-07-16 | 2019-12-30 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
JP6738316B2 (en) | 2014-07-17 | 2020-08-12 | ノヴォ ノルディスク アクティーゼルスカブ | Site-directed mutagenesis of TREM-1 antibody to reduce viscosity |
JP2017528433A (en) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | Low immunoenhancing dose of mTOR inhibitor and CAR combination |
CA2955386A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
TWI719942B (en) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | Treatment of cancer using a cd33 chimeric antigen receptor |
ES2753551T3 (en) | 2014-07-22 | 2020-04-13 | Sutro Biopharma Inc | Anti-cd74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
US20170226216A1 (en) | 2014-07-24 | 2017-08-10 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
AU2015292326A1 (en) | 2014-07-24 | 2017-02-23 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP3453406B1 (en) | 2014-07-29 | 2021-04-14 | Cellectis | Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy |
US10544201B2 (en) | 2014-07-31 | 2020-01-28 | Cellectis | ROR1 specific multi-chain chimeric antigen receptor |
ES2848857T3 (en) | 2014-07-31 | 2021-08-12 | Us Gov Health & Human Services | Human monoclonal antibodies against EphA4 and their use |
CA2956471A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
EP3660042B1 (en) | 2014-07-31 | 2023-01-11 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
US20170275373A1 (en) | 2014-07-31 | 2017-09-28 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
UY36245A (en) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
ES2847311T3 (en) | 2014-08-05 | 2021-08-02 | MabQuest SA | Immunological reagents that bind to PD-1 |
JP6649358B2 (en) | 2014-08-07 | 2020-02-19 | ノバルティス アーゲー | Angiopoietin-like 4 antibodies and methods of use |
US9988443B2 (en) | 2014-08-07 | 2018-06-05 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
ES2743458T5 (en) | 2014-08-08 | 2023-06-08 | Us Health | Photocontrolled removal of targets in vitro and in vivo |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
AP2017009765A0 (en) | 2014-08-19 | 2017-02-28 | Merck Sharp & Dohme | Anti-tigit antibodies |
CN112410363A (en) | 2014-08-19 | 2021-02-26 | 诺华股份有限公司 | anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy |
WO2016026978A1 (en) | 2014-08-22 | 2016-02-25 | Universite Nice Sophia Antipolis | Methods and pharmaceutical compositions for treating drug addiction |
WO2016033114A1 (en) | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
ES2959649T3 (en) | 2014-08-28 | 2024-02-27 | Cedars Sinai Medical Center | Early detection of lung cancer by DNA methylation phenotyping of sputum-derived cells |
RU2741470C9 (en) | 2014-09-02 | 2021-04-27 | Иммьюноджен, Инк. | Methods for preparing antibody-drug conjugate compositions |
ES2777305T3 (en) | 2014-09-04 | 2020-08-04 | Cellectis | Trophoblastic glycoprotein-specific chimeric antigen receptors (5T4, TPBG) for cancer immunotherapy |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
WO2016037985A1 (en) | 2014-09-08 | 2016-03-17 | Ruprecht-Karls-Universität Heidelberg | Construct for the delivery of a molecule into the cytoplasm of a cell |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
WO2016044224A1 (en) | 2014-09-15 | 2016-03-24 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
WO2016043577A1 (en) | 2014-09-16 | 2016-03-24 | Academisch Medisch Centrum | Ig-like molecules binding to bmp4 |
ES2891332T3 (en) | 2014-09-17 | 2022-01-27 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
CA2961609C (en) | 2014-09-17 | 2023-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 antibodies (b7h3) |
WO2016044736A1 (en) * | 2014-09-18 | 2016-03-24 | Cell Signaling Technology, Inc. | Altered antibodies and methods of making the same |
JP7095990B2 (en) | 2014-09-18 | 2022-07-05 | シーダーズ-サイナイ メディカル センター | Compositions and Methods for Treating Fibrosis |
WO2016044588A1 (en) | 2014-09-19 | 2016-03-24 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
AU2015318036B2 (en) | 2014-09-19 | 2021-07-01 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
ES2796903T3 (en) | 2014-09-23 | 2020-11-30 | Hoffmann La Roche | Procedure for the use of anti-CD79b immunoconjugates |
EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
PT3197493T (en) | 2014-09-25 | 2021-06-04 | Aveo Pharmaceuticals Inc | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
SG11201702544WA (en) | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
KR102554634B1 (en) | 2014-09-30 | 2023-07-11 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | Binding molecules, especially antibodies, binding to l1cam (cd171) |
WO2016054555A2 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Combination therapies |
WO2016054598A2 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
RU2706361C2 (en) | 2014-10-09 | 2019-11-18 | Седарс-Синаи Медикал Сентер | Methods and systems for distinguishing irritable bowel syndrome from inflammatory intestinal disease and gluten disease |
CA3001724A1 (en) | 2014-10-10 | 2016-04-14 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
EP3206712B1 (en) * | 2014-10-14 | 2019-12-25 | Cellmid Limited | Improved midkine antibody |
AU2015333687B2 (en) | 2014-10-14 | 2021-03-18 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to PD-L1 and uses thereof |
MA41685A (en) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS |
MA41480A (en) | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | ANTIBODIES BOUND TO CCR6 AND THEIR USES |
KR102210104B1 (en) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | Butyrylcholinesterase zwitterionic polymer conjugates |
CN107073113A (en) | 2014-10-18 | 2017-08-18 | 辉瑞大药厂 | Anti- IL 7R antibody compositions |
US10040844B2 (en) | 2014-10-22 | 2018-08-07 | The Regents Of The University Of California | Proteolytic release of cell surface antigens for phage biopanning |
MA40835A (en) * | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES |
US10584175B2 (en) | 2014-10-23 | 2020-03-10 | La Trobe University | FN14-binding proteins and uses thereof |
NZ731491A (en) | 2014-10-23 | 2021-12-24 | Kira Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
MX2017004001A (en) * | 2014-10-24 | 2017-06-30 | Hoffmann La Roche | Vh-vl-interdomain angle based antibody humanization. |
CA2959821A1 (en) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
EP3212216A4 (en) | 2014-10-29 | 2018-04-18 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha2b variants |
ES2808153T3 (en) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Combination therapy for disease treatment |
EP4219725A3 (en) | 2014-10-31 | 2023-08-30 | The Trustees of the University of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
ES2910227T3 (en) | 2014-10-31 | 2022-05-12 | Univ Pennsylvania | Composition and methods for the stimulation and expansion of T cells |
CN106796235B (en) | 2014-11-03 | 2021-01-29 | 豪夫迈·罗氏有限公司 | Assays for detecting T cell immune subsets and methods of use thereof |
US10738078B2 (en) | 2014-11-03 | 2020-08-11 | Bristol-Myers Squibb Company | Use of caprylic acid precipitation for protein purification |
AU2015343339A1 (en) * | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
EP3215164A1 (en) | 2014-11-03 | 2017-09-13 | Immures S.r.l. | T cell receptors |
EP3215186A4 (en) | 2014-11-04 | 2018-10-24 | University of Southern California | COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS |
BR112017008666A2 (en) | 2014-11-05 | 2018-01-30 | Genentech, Inc. | anti-fgfr2 / 3 antibodies and methods of use |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
PE20171107A1 (en) | 2014-11-07 | 2017-08-07 | Eleven Biotherapeutics Inc | IMPROVED ANTIBODIES AGAINST IL-6 |
GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
EP3789403A1 (en) | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
CA2967222C (en) | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US20170306046A1 (en) | 2014-11-12 | 2017-10-26 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
EP3218397B8 (en) | 2014-11-14 | 2021-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2016081455A1 (en) | 2014-11-17 | 2016-05-26 | Pelican Therapeutics, Inc. | Human tnfrsf25 antibody |
SG11201704058TA (en) | 2014-11-18 | 2017-06-29 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
RU2711930C2 (en) | 2014-11-19 | 2020-01-23 | Иммуноджен, Инк. | Method of producing conjugates of cell-binding agent and cytotoxic agent |
US10195282B2 (en) | 2014-11-20 | 2019-02-05 | University Of Southern California | Use of alginate formulation for intraincisional drug delivery |
MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
US20170355755A1 (en) | 2014-11-21 | 2017-12-14 | Yale University | Compositions and methods for modulating salm5 and hvem |
US11229713B2 (en) | 2014-11-25 | 2022-01-25 | Bristol-Myers Squibb Company | Methods and compositions for 18F-radiolabeling of biologics |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
DK3223845T3 (en) | 2014-11-26 | 2021-08-16 | Xencor Inc | HETERODIMERING ANTIBODIES BINDING CD3 AND CD20 |
US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
CA2968878A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
MA41115A (en) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
WO2016087889A1 (en) | 2014-12-03 | 2016-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
CN107249643A (en) | 2014-12-09 | 2017-10-13 | 艾伯维公司 | The antibody drug conjugate of BCL XL inhibitor with cell permeability |
CA2970155A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
KR20170087500A (en) | 2014-12-11 | 2017-07-28 | 피에르 파브르 메디카먼트 | Anti-C10ORF54 antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
MA41142A (en) | 2014-12-12 | 2017-10-17 | Amgen Inc | ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL |
KR102584938B1 (en) | 2014-12-12 | 2023-10-05 | 2세븐티 바이오, 인코포레이티드 | Bcma chimeric antigen receptors |
EP3230313A2 (en) | 2014-12-12 | 2017-10-18 | Encare Biotech B.V. | Immunoglobulin-like molecules directed against fibronectin-eda |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
EP3835319A1 (en) | 2014-12-19 | 2021-06-16 | Alder Biopharmaceuticals, Inc. | Humanized anti-acth antibodies and use thereof |
AU2015367224B2 (en) | 2014-12-19 | 2020-12-10 | Monash University | IL-21 antibodies |
UY36449A (en) | 2014-12-19 | 2016-07-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 |
ES2870983T3 (en) | 2014-12-19 | 2021-10-28 | Univ Nantes | Anti-IL-34 antibodies |
EP3233921B1 (en) | 2014-12-19 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
MA41294A (en) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE |
JP7211703B2 (en) | 2014-12-22 | 2023-01-24 | ザ ロックフェラー ユニバーシティー | Anti-MERTK agonist antibody and use thereof |
ES2881484T3 (en) | 2014-12-22 | 2021-11-29 | Pd 1 Acquisition Group Llc | Anti-PD-1 antibodies |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
EP3237447B1 (en) | 2014-12-22 | 2020-12-02 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
US20170360929A1 (en) | 2014-12-23 | 2017-12-21 | Pfizer Inc. | Stable aqueous antibody formulation for anti tnf alpha antibodies |
KR102644115B1 (en) | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies to tigit |
JP2018504400A (en) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | LINGO-1 antagonist and use for treatment of demyelinating disorders |
NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
EP3733696A1 (en) | 2015-01-13 | 2020-11-04 | City of Hope | Ctla4-binding protein peptide-linker masks |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
CN107530423B (en) * | 2015-01-14 | 2022-04-05 | 布里格姆及妇女医院股份有限公司 | Treatment of cancer with anti-LAP monoclonal antibodies |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
WO2016115500A1 (en) | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
IL284430B2 (en) | 2015-01-20 | 2024-04-01 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
GB201501004D0 (en) | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
CN114230667A (en) | 2015-01-23 | 2022-03-25 | 赛诺菲 | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 |
TWI710571B (en) | 2015-01-24 | 2020-11-21 | 中央研究院 | Cancer markers and methods of use thereof |
CA2972072A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
US10308719B2 (en) | 2015-01-26 | 2019-06-04 | The University Of Chicago | IL13Rα2 binding agents and use thereof in cancer treatment |
ES2842212T3 (en) | 2015-01-26 | 2021-07-13 | Cellectis | Anti-CLL1 Specific Single Chain Chimeric Antigen Receptors (scCAR) for Cancer Immunotherapy |
CN107835820B (en) * | 2015-01-26 | 2021-10-15 | 芝加哥大学 | CAR T-cells recognizing cancer-specific IL13R alpha 2 |
TWI718121B (en) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
RU2699544C2 (en) | 2015-01-28 | 2019-09-06 | Пфайзер Инк. | Stable aqueous anti-vascular endothelial growth factor (vegf) antibody composition |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI711631B (en) * | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) * | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI786505B (en) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
WO2016122865A1 (en) | 2015-01-30 | 2016-08-04 | Salk Institute For Biological Studies | Compositions and methods for treating age-related diabetes and related disorders |
JP7170394B2 (en) | 2015-01-31 | 2022-11-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Compositions and methods for T cell delivery of therapeutic molecules |
CN107427590B (en) | 2015-02-02 | 2021-08-31 | 伯明翰大学 | Targeting moiety peptide epitope complexes with multiple T cell epitopes |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016124558A1 (en) | 2015-02-03 | 2016-08-11 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
CA2975875A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CN114773470A (en) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof |
US10988534B2 (en) | 2015-02-09 | 2021-04-27 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof |
EP3271388A1 (en) | 2015-02-09 | 2018-01-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies specific to glycoprotein (gp) of ebola virus and uses for the treatment and diagnosis of ebola virus infection |
WO2016128523A1 (en) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
US10906948B2 (en) | 2015-02-23 | 2021-02-02 | Seagull Therapeutics Sas | Non-natural Semaphorins 3 and their medical use |
KR20170140180A (en) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
CA2977493C (en) | 2015-03-03 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Display platform from bacterial spore coat proteins |
FI3265123T3 (en) | 2015-03-03 | 2023-01-31 | Antibodies, uses & methods | |
MA41629A (en) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY |
US10787520B2 (en) | 2015-03-04 | 2020-09-29 | Igm Biosciences, Inc. | Multimeric bispecific binding molecules specific for CD20 and CD3 |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
JP6783983B2 (en) * | 2015-03-06 | 2020-11-11 | ジーンフロンティア株式会社 | Anti-human membrane type ADAM28 antibody |
EP3265483B1 (en) | 2015-03-06 | 2019-12-11 | CSL Behring Lengnau AG | Modified von willebrand factor having improved half-life |
SG11201706657PA (en) * | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
CA2978095C (en) | 2015-03-13 | 2022-02-15 | Bristol-Myers Squibb Company | Use of alkaline washes during chromatography to remove impurities |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2016146134A1 (en) | 2015-03-16 | 2016-09-22 | Aarhus Universitet | Antibodies towards an extracellular region of nbcn1 |
CN107667120B (en) | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | anti-MUC 16 antibodies and uses thereof |
EP3270965B1 (en) | 2015-03-18 | 2020-05-06 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
US20180105555A1 (en) | 2015-03-20 | 2018-04-19 | Bristol-Myers Squibb Company | Use of dextran for protein purification |
MX2017012102A (en) | 2015-03-20 | 2018-01-12 | Pfizer | Bifunctional cytotoxic agents containing the cti pharmacophore. |
US20180105554A1 (en) | 2015-03-20 | 2018-04-19 | Bristol-Myers Squibb Company | Use of dextran sulfate to enhance protein a affinity chromatography |
PL3271389T3 (en) | 2015-03-20 | 2020-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to gp120 and their use |
WO2016151018A1 (en) | 2015-03-24 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
EP3277712A4 (en) | 2015-03-30 | 2018-09-26 | City of Hope | Mechanically interlocking complexes |
AU2016243160B2 (en) | 2015-03-30 | 2022-02-24 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
PL3277717T3 (en) | 2015-03-31 | 2021-05-31 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
US10214591B1 (en) | 2015-04-03 | 2019-02-26 | Alienor Farma | Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject |
WO2016162368A1 (en) | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive imaging of tumor pd-l1 expression |
PL3280441T3 (en) | 2015-04-07 | 2022-02-21 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
HUE059218T2 (en) | 2015-04-08 | 2022-11-28 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
JP6962819B2 (en) | 2015-04-10 | 2021-11-05 | アディマブ, エルエルシー | Method for Purifying Heterodimer Multispecific Antibody from Parent Homodimer Antibody Species |
WO2016166110A1 (en) | 2015-04-13 | 2016-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of haemorrhagic diseases |
BR112017019785B1 (en) | 2015-04-13 | 2022-11-16 | Pfizer Inc | BISPECIFIC ANTIBODY, ITS USE AND PHARMACEUTICAL COMPOSITION |
PL3283527T3 (en) | 2015-04-13 | 2021-06-14 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2016168766A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
SG10201909308XA (en) | 2015-04-17 | 2019-11-28 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
CN107847591B (en) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | Multivalent human immunodeficiency virus antigen binding molecules and uses thereof |
WO2016170027A1 (en) | 2015-04-22 | 2016-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of th17 mediated diseases |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
EP4194001A1 (en) | 2015-04-22 | 2023-06-14 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
JP6704000B2 (en) | 2015-04-24 | 2020-06-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Modulator of ROR1-ROR2 binding |
JOP20200116A1 (en) | 2015-04-24 | 2017-06-16 | Amgen Inc | Methods for treating or preventing migraine headache |
US20160319009A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
CA2988001C (en) * | 2015-04-30 | 2023-09-26 | Abcheck S.R.O. | Method for mass humanization of rabbit antibodies |
KR20170138570A (en) | 2015-04-30 | 2017-12-15 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Anti-aP2 antibodies and antigen binding substances for the treatment of metabolic disorders |
WO2016177833A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
DK3292150T3 (en) | 2015-05-04 | 2020-04-27 | Cytomx Therapeutics Inc | ACTIVABLE ANTI-CD166 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
BR112017023868A2 (en) * | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
EP3291839A1 (en) | 2015-05-05 | 2018-03-14 | The University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
US10259882B2 (en) | 2015-05-07 | 2019-04-16 | Agenus Inc. | Anti-OX40 antibodies |
AU2016262368B2 (en) | 2015-05-08 | 2019-05-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
CN107614680A (en) | 2015-05-14 | 2018-01-19 | 南加利福尼亚大学 | Utilize the optimization gene editing of recombinant nucleic acid inscribe enzyme system |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
US9574014B2 (en) | 2015-05-15 | 2017-02-21 | City Of Hope | Chimeric antigen receptor compositions |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
TW201706300A (en) | 2015-05-20 | 2017-02-16 | 瑟勒提斯公司 | Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy |
KR101997241B1 (en) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | Trispecific binding proteins and methods of use |
WO2016191246A2 (en) | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
CN113940996A (en) | 2015-05-27 | 2022-01-18 | Ucb生物制药私人有限公司 | Methods for treating neurological diseases |
PL3303394T3 (en) | 2015-05-29 | 2020-11-16 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
EP3303395B1 (en) | 2015-05-29 | 2019-12-11 | AbbVie Inc. | Anti-cd40 antibodies and uses thereof |
JP6797137B2 (en) | 2015-05-29 | 2020-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Antibodies to OX40 and its use |
JP2018080114A (en) | 2015-05-29 | 2018-05-24 | 株式会社アールテック・ウエノ | Anti-human VAP-1 monoclonal antibody |
WO2016196522A1 (en) | 2015-05-29 | 2016-12-08 | Cedars-Sinai Medical Center | Correlated peptides for quantitative mass spectrometry |
AU2016273028B2 (en) | 2015-06-05 | 2019-02-14 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor |
TW201709932A (en) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | CD123 antibodies and conjugates thereof |
SG10201912085WA (en) | 2015-06-12 | 2020-02-27 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
EP3307772B1 (en) | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
AU2016284866B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific antigen binding proteins |
CA2990518A1 (en) | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
CA2990852A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
BR112017028353A2 (en) | 2015-06-29 | 2018-09-04 | The Rockfeller University | cd40 antibodies with enhanced agonist activity |
CN114671951A (en) | 2015-06-29 | 2022-06-28 | 伊缪诺金公司 | anti-CD 123 antibodies and conjugates and derivatives thereof |
IL256295B2 (en) | 2015-06-30 | 2023-11-01 | Seagen Inc | Anti-ntb-a antibodies and related compositions and methods |
WO2017002934A1 (en) | 2015-07-01 | 2017-01-05 | 中外製薬株式会社 | Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag |
US20180201687A1 (en) | 2015-07-07 | 2018-07-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to myosin 18a and uses thereof |
WO2017011275A1 (en) | 2015-07-10 | 2017-01-19 | Nersissian Aram M | Factor viii protein compositions and methods of treating hemophilia a |
CN113350518A (en) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | Conjugated bridge linkers to cell binding molecules |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JP6953033B2 (en) * | 2015-07-13 | 2021-10-27 | ユニヴェルシテ ラヴァル | Humanized anti-S100A9 antibody and its use |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
RU2611685C2 (en) * | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Humanized monoclonal antibody specific to syndecan-1 |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
US11466093B2 (en) | 2015-07-27 | 2022-10-11 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
PT3317301T (en) | 2015-07-29 | 2021-07-09 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
EP3328994A4 (en) | 2015-07-31 | 2019-04-17 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
US20190008983A1 (en) | 2015-07-31 | 2019-01-10 | James R. Prudent | Extracellular drug conjugates targeting cd20 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
US11236159B2 (en) | 2015-08-03 | 2022-02-01 | Novartis Ag | Methods of treating FGF21-associated disorders |
KR20180030917A (en) | 2015-08-05 | 2018-03-26 | 얀센 바이오테크 인코포레이티드 | Anti-CD154 antibody and methods of use thereof |
JP7104462B2 (en) | 2015-08-06 | 2022-07-21 | シティ・オブ・ホープ | Cell-permeable protein-antibody conjugate and usage |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
MA45352A (en) | 2015-08-07 | 2018-06-13 | Univ Birmingham | IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY |
US10509035B2 (en) | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
RU2018107754A (en) | 2015-08-11 | 2019-09-12 | Селлектис | CELLS FOR IMMUNOTHERAPY CREATED FOR TARGETING OF CD38 ANTIGEN AND FOR INACTIVATION OF CD38 GENE |
WO2017027685A2 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
CN108137679B (en) | 2015-08-13 | 2022-07-19 | 纽约大学 | For Tau, of{p}Antibody-based molecules selective for the Ser404 epitope and their use in the diagnosis and treatment of Tau disease |
CA2994849A1 (en) | 2015-08-18 | 2017-02-23 | Aspyrian Therapeutics, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
CN114699525A (en) | 2015-08-18 | 2022-07-05 | 乐天医药生技股份有限公司 | Method for producing phthalocyanine dye conjugate and stable conjugate |
US11649435B2 (en) | 2015-08-28 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
EP3340995A4 (en) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
US11567078B2 (en) | 2015-08-31 | 2023-01-31 | Cedars-Sinai Medical Center | Blood cell biomarker for late onset Alzheimer's disease |
KR20180037294A (en) | 2015-08-31 | 2018-04-11 | 블루버드 바이오, 인코포레이티드. | Anti-sialyl Tn chimeric antigen receptor |
BR112018003186A2 (en) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anti-pd-1 antibodies and their methods of use |
WO2017037707A1 (en) | 2015-09-02 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
CA2997179A1 (en) | 2015-09-02 | 2017-03-09 | The Regents Of The Unversity Of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
JP7074341B2 (en) | 2015-09-02 | 2022-05-24 | イムテップ エス.アー.エス. | Anti-LAG-3 antibody |
AU2016318114B2 (en) | 2015-09-03 | 2023-04-20 | The Brigham And Women's Hospital, Inc. | Three-dimensional differentiation of epiblast spheroids to kidney organoids models stage-specific epithelial physiology, morphogenesis, and disease |
ES2883128T3 (en) | 2015-09-04 | 2021-12-07 | Health Research Inc | Anti-survivin antibodies for cancer therapy |
CN116063481A (en) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | Humanized anti-CD 40 antibodies and uses thereof |
US10000561B2 (en) | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
CA2996635A1 (en) | 2015-09-09 | 2017-03-16 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
MA42821A (en) | 2015-09-15 | 2018-07-25 | Amgen Inc | TETRAVALENT TETRASPECIFIC AND BISPECIFIC BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
CN108430506A (en) | 2015-09-15 | 2018-08-21 | 得克萨斯州大学系统董事会 | T cell receptor (TCR) binding antibody and application thereof |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
CA2998716A1 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017052679A1 (en) | 2015-09-21 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Departmnet Of Health & Human Service | Monoclonal antibodies specific for heartland virus and methods of their use |
JP7002446B2 (en) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | CD3 binding polypeptide |
US10647752B2 (en) | 2015-09-22 | 2020-05-12 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1 |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
RU2638457C2 (en) | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production |
WO2017058828A1 (en) | 2015-09-28 | 2017-04-06 | Children's Hospital Los Angeles | Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages |
US20190048089A1 (en) | 2015-09-30 | 2019-02-14 | Janssen Biotech, Inc. | Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use |
CA3000697A1 (en) | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
WO2017062505A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
CA2997809A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
AU2016335842A1 (en) | 2015-10-07 | 2018-04-12 | Obi Pharma, Inc. | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
CN108138171B (en) | 2015-10-08 | 2022-05-13 | 国立大学法人名古屋大学 | Method for preparing gene modified T cell for expressing chimeric antigen receptor |
WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
WO2017064716A1 (en) | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
US20180305458A1 (en) | 2015-10-16 | 2018-10-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
US20180057788A1 (en) | 2016-08-29 | 2018-03-01 | EMULATE, Inc. | Development of spinal cord on a microfluidic chip |
GB201518675D0 (en) | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
CA3002903A1 (en) * | 2015-10-23 | 2017-04-27 | Fred Hutchinson Cancer Research Center | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
US10138298B2 (en) * | 2015-10-23 | 2018-11-27 | The Regents Of The University Of California | Anti-IL-2 antibodies and compositions and uses thereof |
WO2017072196A1 (en) | 2015-10-26 | 2017-05-04 | Pierre Fabre Medicament | Composition for the treatment of igf-1r expressing cancer |
RU2754683C2 (en) | 2015-10-27 | 2021-09-06 | Юсб Биофарма Срл | Methods for treatment using anti-il-17a antibodies |
WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
CA3003252A1 (en) | 2015-10-28 | 2017-05-04 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
KR20180069066A (en) | 2015-10-30 | 2018-06-22 | 갤럭시 바이오테크, 엘엘씨 | Extremely powerful antibodies that bind to death receptor 4 and death receptor 5 |
CN108289951A (en) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody and conjugate |
SG11201803098VA (en) * | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
AR106543A1 (en) | 2015-11-02 | 2018-01-24 | Netris Pharma | NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL |
JP6412906B2 (en) | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Industrial Technology Research Institute | Compound, linker-drug and ligand-drug complex |
CN108350077A (en) | 2015-11-03 | 2018-07-31 | 糖模拟物有限公司 | Generate monoclonal antibody, the method and composition of candidate stem cell and the method using the antibody and candidate stem cell |
CN108697791B (en) | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | Antibodies that specifically bind to PD-1 and uses thereof |
WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
US11235063B2 (en) | 2015-11-03 | 2022-02-01 | Merck Patent Gmbh | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
WO2017079419A1 (en) | 2015-11-05 | 2017-05-11 | The Regents Of The University Of California | Cells labelled with lipid conjugates and methods of use thereof |
KR102432062B1 (en) | 2015-11-09 | 2022-08-12 | 오메로스 코포레이션 | Methods for treating conditions associated with masp-2 dependent complement activation |
SI3374398T1 (en) | 2015-11-10 | 2020-07-31 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
EP3374391B1 (en) | 2015-11-10 | 2024-04-17 | Visterra, Inc. | Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof |
AU2016353453B2 (en) | 2015-11-11 | 2022-08-11 | Serimmune Inc. | Methods and compositions for assessing antibody specificities |
CN116217729A (en) | 2015-11-12 | 2023-06-06 | 思进公司 | Glycan interaction compounds and methods of use |
EP3377533A2 (en) | 2015-11-19 | 2018-09-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
EP3903818A1 (en) | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
EA201891121A1 (en) | 2015-11-19 | 2018-12-28 | Бристол-Майерс Сквибб Компани | ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS |
WO2017091683A1 (en) | 2015-11-25 | 2017-06-01 | Visterra, Inc. | Antibody molecules to april and uses thereof |
US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
JP2019500327A (en) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
WO2017095744A1 (en) | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Method for preventing or treating nosocomial pneumonia |
EP3383910A1 (en) | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
EP3383903A1 (en) | 2015-11-30 | 2018-10-10 | Bristol-Myers Squibb Company | Anti human ip-10 antibodies and their uses |
ES2861449T3 (en) | 2015-12-02 | 2021-10-06 | Stcube & Co Inc | Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses |
KR20180100122A (en) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor) |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
KR20180093010A (en) | 2015-12-04 | 2018-08-20 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | New Cancer Therapeutic Antibodies |
US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
UY37003A (en) | 2015-12-04 | 2017-06-30 | Novartis Ag | COMPOSITIONS OF ANTIBODY INTEGRATED WITH CYTOQUINE AND METHODS FOR USE IN IMMUNOR REGULATION |
CN108699136B (en) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | Heterodimeric antibodies that bind CD3 and PSMA |
WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
CN112274649A (en) | 2015-12-10 | 2021-01-29 | 希望之城 | Cell penetrating cyanine conjugated antibodies |
CA2994447A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
BR112018012113A2 (en) | 2015-12-15 | 2018-12-04 | Oncoimmune Inc | chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
EP3390447A1 (en) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap antibodies and uses thereof |
JP2019502695A (en) | 2015-12-17 | 2019-01-31 | ノバルティス アーゲー | Combination of antibody molecule against PD-1 and C-Met inhibitor and use thereof |
CN108495651A (en) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | The antibody molecule and application thereof of anti-PD-1 |
US20180355043A1 (en) | 2015-12-17 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies Specifically Binding HLA-DR and Their Uses |
CN109152811A (en) | 2015-12-18 | 2019-01-04 | 阿吉尔瓦克斯公司 | Composition relevant to xCT peptide and method |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
JP2019506844A (en) | 2015-12-18 | 2019-03-14 | ノバルティス アーゲー | Antibodies targeting CD32b and methods of use thereof |
EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
SG11201805255TA (en) | 2015-12-23 | 2018-07-30 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
AU2016379425B2 (en) | 2015-12-24 | 2021-11-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
JP7141336B2 (en) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | Anti-myostatin antibodies and methods of use |
US20190008828A1 (en) | 2015-12-28 | 2019-01-10 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | antibodies and conjugates thereof |
SG11201805141QA (en) | 2015-12-31 | 2018-07-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating gastric cancer |
SG11201805605TA (en) | 2015-12-31 | 2018-07-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating ovarian cancer |
US11789021B2 (en) | 2015-12-31 | 2023-10-17 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating esophageal cancer |
AU2017204683B2 (en) | 2015-12-31 | 2023-03-16 | Syncerus S.À R.L. | Compositions and methods for assessing the risk of cancer occurrence |
US10736960B2 (en) | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
CN108713026B (en) | 2016-01-08 | 2023-01-06 | 美国全心医药生技股份有限公司 | Tetravalent anti-PSGL-1 antibodies and uses thereof |
CA3010678A1 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
WO2017123401A1 (en) | 2016-01-13 | 2017-07-20 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
CN109069627A (en) | 2016-01-14 | 2018-12-21 | 纪念斯隆-凯特琳癌症中心 | To the T cell receptor sample antibody of the derivative peptide specific of FOXP3 |
TW201936640A (en) | 2016-01-21 | 2019-09-16 | 美商輝瑞股份有限公司 | Antibodies specific for epidermal growth factor receptor variant III and their uses |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
EP3405497A2 (en) | 2016-01-22 | 2018-11-28 | Mabquest SA | Immunological reagents |
CA3011455A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
EP3407911B1 (en) | 2016-01-28 | 2022-05-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical composition for the treatment of cancer |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
EP3407912B1 (en) | 2016-01-28 | 2022-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for enhancing the potency of the immune checkpoint inhibitors |
WO2017136479A1 (en) | 2016-02-01 | 2017-08-10 | Cedars-Sinai Medical Center | Systems and methods for growth of intestinal cells in microfluidic devices |
US10337032B2 (en) | 2016-02-01 | 2019-07-02 | The University Of Manchester | Compositions and methods for recombinant biosynthesis of propane |
JP2019507126A (en) | 2016-02-01 | 2019-03-14 | ファイザー・インク | Tubulicin analogues and methods for their preparation |
BR112018015715A2 (en) | 2016-02-03 | 2019-02-05 | Amgen Inc | bispecific bcma and cd3 t cell coupling antibody constructs |
EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
JP2019509721A (en) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | Mutant smoothened and method of using the same |
RU2018130108A (en) | 2016-02-05 | 2020-03-06 | Иммуноджен, Инк. | EFFECTIVE METHOD FOR PRODUCING CONJUGATES BINDING A CELL AGENT CYTOTOXIC AGENT |
KR101843985B1 (en) | 2016-02-09 | 2018-03-30 | 오토텔릭 엘엘씨 | Compositions and methods for treating cancer |
KR20180103816A (en) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | Compositions and methods for treating pancreatic cancer |
GB201602413D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Method |
CA3011372A1 (en) | 2016-02-10 | 2017-08-17 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
JP2019509993A (en) | 2016-02-12 | 2019-04-11 | ヤンセン ファーマシューティカ エヌブイ | Anti-VISTA (B7H5) antibody |
EP3416688B1 (en) | 2016-02-15 | 2022-08-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Apelin for use in the treatment of post-operative cognitive dysfunction |
SG10202007836WA (en) | 2016-02-17 | 2020-09-29 | Seattle Genetics Inc | Bcma antibodies and use of same to treat cancer and immunological disorders |
AU2017219254B2 (en) | 2016-02-17 | 2019-12-12 | Novartis Ag | TGFbeta 2 antibodies |
ES2770787T3 (en) | 2016-02-19 | 2020-07-03 | Siwa Corp | Method and composition for treating cancer, destroying metastatic cancer cells and preventing cancer metastasis using advanced glycation end-product antibody (AGE) |
EP3420355A1 (en) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica GmbH | Method for the immobilization of biomolecules |
MX2018010295A (en) | 2016-02-26 | 2019-06-06 | Inst Nat Sante Rech Med | Antibodies having specificity for btla and uses thereof. |
JP7097815B2 (en) | 2016-02-29 | 2022-07-08 | シーダーズ-サイナイ メディカル センター | Methods of endogenous stem cell activation for tendon / ligament bone connections |
US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
SG11201807437XA (en) | 2016-03-01 | 2018-09-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific to human poliovirus receptor (pvr) |
KR102424496B1 (en) | 2016-03-02 | 2022-07-25 | 아이덱스 래보러토리즈, 인코포레이티드 | Methods and compositions for the detection and diagnosis of renal disease and periodontal disease |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
CN116063494A (en) | 2016-03-04 | 2023-05-05 | 洛克菲勒大学 | Antibodies to CD40 with enhanced agonist activity |
SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US10443054B2 (en) | 2016-03-06 | 2019-10-15 | Massachusetts Institute Of Technology | Methods for identifying and treating invasive/metastatic breast cancers |
US11340233B2 (en) | 2016-03-07 | 2022-05-24 | Pierre Fabre Medicament | Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
EP3216458A1 (en) | 2016-03-07 | 2017-09-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified vascular endothelial growth factor a (vegf-a) and its medical use |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
US10307455B2 (en) | 2016-03-10 | 2019-06-04 | Acceleron Pharma Inc. | Activin type 2 receptor antibodies |
KR102632796B1 (en) | 2016-03-10 | 2024-02-02 | 비엘라 바이오, 인크. | Ilt7 binding molecules and methods of using the same |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
AU2017234163B2 (en) | 2016-03-15 | 2023-01-19 | Mersana Therapeutics, Inc. | NaPi2b-targeted antibody-drug conjugates and methods of use thereof |
MA45324A (en) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
EP3429620A1 (en) | 2016-03-15 | 2019-01-23 | AstraZeneca AB | Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta |
PL3430404T3 (en) | 2016-03-15 | 2022-05-02 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease |
CN109476756B (en) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | Multi-specificity Fab fusion protein and application thereof |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
EP3430044A1 (en) | 2016-03-17 | 2019-01-23 | Numab Innovation AG | Anti-tnf alpha -antibodies and functional fragments thereof |
EA039201B1 (en) | 2016-03-17 | 2021-12-16 | Нумаб Инновейшн Аг | Anti-tnf-antibodies and functional fragments thereof |
CN109462996A (en) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | The method for diagnosing inflammatory bowel disease by RNASET2 |
LT3219727T (en) | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
PT3219726T (en) | 2016-03-17 | 2020-12-15 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
JP7049311B2 (en) | 2016-03-17 | 2022-04-06 | ヌマブ イノヴェイション アーゲー | Anti-TNFα antibodies and their functional fragments |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
AU2017238172A1 (en) | 2016-03-21 | 2018-09-13 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
CN108697799A (en) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | The application of anti-LGR5 monoclonal antibodies |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
CN108779180B (en) | 2016-03-23 | 2020-10-16 | 迈博斯生物医药(苏州)有限公司 | Novel anti-PD-L1 antibodies |
KR20180134351A (en) | 2016-03-25 | 2018-12-18 | 시애틀 지네틱스, 인크. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
US20170274076A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations of antibody molecules to dengue virus |
EP4321513A2 (en) | 2016-03-28 | 2024-02-14 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
BR112018070139A2 (en) | 2016-03-29 | 2019-02-05 | Geltor Inc | protein expression in gram-negative bacteria where the ratio of periplasmic volume to cytoplasmic volume is between 0.5: 1 and 10: 1 |
AU2017244108B2 (en) | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
CA3018253A1 (en) | 2016-03-31 | 2017-10-05 | University Of Southern California | A highly sensitive and specific luciferase based reporter assay for antigen detection |
IL305200A (en) | 2016-03-31 | 2023-10-01 | Omeros Corp | Masp-2 inhibitory agents for use in inhibiting angiogenesis |
CA3019590A1 (en) | 2016-04-01 | 2017-10-05 | Black Light Surgical, Inc. | Systems, devices, and methods for time-resolved fluorescent spectroscopy |
EP3439659A1 (en) | 2016-04-06 | 2019-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases |
US10766954B2 (en) * | 2016-04-06 | 2020-09-08 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
WO2017181098A2 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
CN109311977B (en) | 2016-04-15 | 2022-06-14 | H.伦德贝克公司 | Humanized anti-PACAP antibodies and uses thereof |
IL262396B2 (en) | 2016-04-15 | 2023-09-01 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
CA3020848A1 (en) | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
AU2017252212B2 (en) | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
EP3445779A1 (en) | 2016-04-22 | 2019-02-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
US20190135911A1 (en) | 2016-04-26 | 2019-05-09 | Five Prime Therapeutics, Inc. | Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1) |
IL297519B1 (en) | 2016-04-27 | 2024-02-01 | Abbvie Inc | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
US20190144503A1 (en) | 2016-04-27 | 2019-05-16 | Regents Of The University Of Minnesota | Methods for the identification of bifunctional compounds |
CN109310385A (en) | 2016-04-27 | 2019-02-05 | 免疫医疗公司 | Anti- TROP-2-SN-38 antibody drug conjugate is used for the effect of checkpoint inhibitor recurrence/refractory tumors therapy |
CN109071647B (en) | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | Anti-growth differentiation factor 15 antibody and application thereof |
PT3448419T (en) * | 2016-04-29 | 2023-07-26 | Brigham & Womens Hospital Inc | Interferon beta antibodies and uses thereof |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
EA201892417A1 (en) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | ANTIBODIES RECOGNIZING TAU |
KR20230070336A (en) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | Antibodies recognizing tau |
ES2941693T3 (en) | 2016-05-03 | 2023-05-24 | Inst Nat Sante Rech Med | Methods and pharmaceutical compositions for the treatment of tissue lesions |
WO2017191300A1 (en) | 2016-05-06 | 2017-11-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
CN109476742B (en) | 2016-05-09 | 2023-04-14 | 百时美施贵宝公司 | TL1A antibodies and uses thereof |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
TW201808336A (en) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | Treatment regimen using anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of tumors |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
KR102625416B1 (en) * | 2016-05-16 | 2024-01-15 | 다케다 파머수티컬 컴패니 리미티드 | Anti-factor ix padua antibodies |
DK3458102T3 (en) | 2016-05-17 | 2020-07-27 | Abbvie Biotherapeutics Inc | ANTI-CMET ANTIBODY DRUG CONJUGATES AND PROCEDURES FOR USE |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
EP3458036B1 (en) | 2016-05-20 | 2023-08-23 | Cedars-Sinai Medical Center | Treating or preventing alzheimer's disease and associated conditions |
BR112018073739A2 (en) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | single domain serum albumin binding protein |
US11549146B2 (en) | 2016-05-20 | 2023-01-10 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
DE102017110958A1 (en) | 2016-05-20 | 2017-11-23 | Christoph Karl | Pharmaceutical compositions containing anti-RANKL antibodies, calcium and vitamin D, useful in the treatment and / or prophylaxis of bone metabolism disorders and therapy-induced hypocalcemia |
EP3464357A1 (en) | 2016-05-24 | 2019-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections |
CN109415441B (en) | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | Antibodies and methods of making same |
US20190292259A1 (en) | 2016-05-24 | 2019-09-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
UA123111C2 (en) | 2016-05-27 | 2021-02-17 | Еббві Байотерапьютікс Інк. | Anti-cd40 antibodies and their uses |
CN109640964A (en) | 2016-05-27 | 2019-04-16 | Tg治疗有限公司 | For treating the combination of the anti-CD 20 antibodies, P13 kinases-δ selective depressant and BTK inhibitor of B cell proliferation sexual disorder |
CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
WO2017205745A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CN109476699B (en) | 2016-06-02 | 2021-10-12 | 艾伯维公司 | Glucocorticoid receptor agonists and immunoconjugates thereof |
EP3464354B1 (en) | 2016-06-02 | 2021-07-28 | Bloom Diagnostics AG | Antibodies that bind to human anti-müllerian hormone (amh) and their uses |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
US9982043B2 (en) | 2016-06-03 | 2018-05-29 | National Cheng Kung University | Use of IL-20 antagonists for treating pancreatic cancer |
EP3464371A1 (en) | 2016-06-06 | 2019-04-10 | City of Hope | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof |
US11136405B2 (en) | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
JP2019527537A (en) | 2016-06-07 | 2019-10-03 | マックス−デルブリュック−セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ−ゲマインシャフト | Chimeric antigen receptor and CAR-T cell binding to BCMA |
US11787848B2 (en) | 2016-06-08 | 2023-10-17 | Precigen, Inc. | CD33 specific chimeric antigen receptors |
PE20190177A1 (en) * | 2016-06-08 | 2019-02-01 | Abbvie Inc | ANTI-B7-H3 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES |
ES2963807T3 (en) | 2016-06-08 | 2024-04-02 | Xencor Inc | Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linking to CD32B |
CN109641962A (en) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | Anti- B7-H3 antibody and antibody drug conjugates |
JP2019526529A (en) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | Anti-B7-H3 antibody and antibody drug conjugate |
WO2017214186A1 (en) | 2016-06-09 | 2017-12-14 | University Of Leicester | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (mlp) as a biomarker for ovarian and pancreatic cancer |
US10005843B2 (en) | 2016-06-09 | 2018-06-26 | Pelican Therapeutics, Inc. | Anti-TNFRSF25 antibodies |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CN113773387A (en) | 2016-06-13 | 2021-12-10 | 天境生物科技(上海)有限公司 | PD-L1 antibodies and uses thereof |
CA3172367A1 (en) | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
WO2017216724A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
EP3472197A1 (en) | 2016-06-15 | 2019-04-24 | Sutro Biopharma, Inc. | Antibodies with engineered ch2 domains, compositions thereof and methods of using the same |
US10221395B2 (en) | 2016-06-16 | 2019-03-05 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
US20190240346A1 (en) | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
MA45493A (en) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | HCMC ENTRY INHIBITORS. |
CN116063545A (en) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | Heterodimeric antibodies that bind somatostatin receptor 2 |
WO2018005950A1 (en) | 2016-07-01 | 2018-01-04 | Five Prime Therapeutics, Inc. | Combined anti tumor therapy with a gitr agonist and cpg |
EP3478716A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7016470B2 (en) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
JP7076711B2 (en) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
US20190227082A1 (en) | 2016-07-06 | 2019-07-25 | Prothena Biosciences Limited | Assay for detecting total and s129 phosphorylated alpha-synuclein |
CN109690315A (en) | 2016-07-08 | 2019-04-26 | 豪夫迈·罗氏有限公司 | People's epididymal proteins 4 (HE4) are used to assess the purposes of the responsiveness of MUC16 positive cancer treatment |
RU2019103403A (en) | 2016-07-08 | 2020-08-10 | Сфинготек Гмбх | ADRENOMEDULLIN FOR ASSESSMENT OF STAGUE IN AN INDIVIDUAL WITH ACUTE HEART FAILURE |
KR20190039937A (en) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | Anti-ApoC3 antibodies and methods of use thereof |
US10793636B2 (en) | 2016-07-11 | 2020-10-06 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibodies |
US11091795B2 (en) | 2016-07-11 | 2021-08-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for diagnosing and treating arrhythmias |
SG11201811015RA (en) | 2016-07-12 | 2019-01-30 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
MX2019000327A (en) | 2016-07-13 | 2019-04-11 | Biogen Ma Inc | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders. |
CA3030603A1 (en) | 2016-07-14 | 2018-01-18 | University Of Southern California | Methods and composition for producing and using immune cells and stem cells for cell-based therapies |
SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
CA3030837A1 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
CN117330747A (en) | 2016-07-15 | 2024-01-02 | 武田药品工业株式会社 | Methods and materials for assessing response to plasmacytoid and plasma cell depleting therapies |
EP3485017A4 (en) | 2016-07-18 | 2020-03-04 | Helix Biopharma Corp. | Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
WO2018015881A1 (en) | 2016-07-18 | 2018-01-25 | Ramot At Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
CN110087673A (en) | 2016-07-19 | 2019-08-02 | 梯瓦制药澳大利亚股份有限公司 | Anti- CD47 combination therapy |
WO2018015573A2 (en) | 2016-07-22 | 2018-01-25 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Trem2 cleavage modulators and uses thereof |
EP3487867A2 (en) | 2016-07-22 | 2019-05-29 | Amgen Inc. | Methods of purifying fc-containing proteins |
MA45715A (en) | 2016-07-25 | 2019-05-29 | Biogen Ma Inc | ANTI-HSPA5 ANTIBODIES (GRP78) AND THEIR USES |
WO2018022786A1 (en) * | 2016-07-26 | 2018-02-01 | Washington University | Antibodies to zika virus and methods of use thereof |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
EP3491387A1 (en) | 2016-07-28 | 2019-06-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
SG11201900677SA (en) | 2016-07-28 | 2019-02-27 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
US11186634B2 (en) | 2016-07-29 | 2021-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies targeting tumor associated macrophages and uses thereof |
MX2019001184A (en) | 2016-07-29 | 2019-09-26 | Juno Therapeutics Inc | Anti-idiotypic antibodies against anti-cd19 antibodies. |
JOP20170154B1 (en) | 2016-08-01 | 2023-03-28 | Omeros Corp | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
US20190161542A1 (en) | 2016-08-01 | 2019-05-30 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
CN110072887A (en) | 2016-08-02 | 2019-07-30 | 威特拉公司 | Engineered polypeptide and its application |
CN109563143A (en) | 2016-08-02 | 2019-04-02 | 瓦西尼斯公司 | The modification method in polynucleotides library is generated in vaccinia virus/eukaryocyte |
JP7109789B2 (en) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | Compositions and methods for TCR reprogramming using fusion proteins |
US11712480B2 (en) | 2016-08-03 | 2023-08-01 | Pfizer Inc. | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
EP3493845A4 (en) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
CN116271014A (en) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
WO2018029586A1 (en) | 2016-08-07 | 2018-02-15 | Novartis Ag | Mrna-mediated immunization methods |
EA201990470A1 (en) | 2016-08-09 | 2019-09-30 | Сиэтл Дженетикс, Инк. | MEDICINE CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES |
CN109790201A (en) | 2016-08-12 | 2019-05-21 | 百时美施贵宝公司 | Method for purifying proteins |
US11198730B2 (en) * | 2016-08-15 | 2021-12-14 | Fuso Pharmaceutical Industries, Ltd. | Anti-LAG-3 antibody |
MY194032A (en) | 2016-08-17 | 2022-11-09 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
EP3502141A4 (en) | 2016-08-22 | 2020-04-08 | Fudan University | Antibody targeted to tissue factor, preparation method therefor, and use thereof |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
CN106938051B (en) | 2016-08-22 | 2019-10-11 | 复旦大学 | Target the antibody-drug conjugates of tissue factor |
WO2018038684A1 (en) | 2016-08-26 | 2018-03-01 | Agency For Science, Technology And Research | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |
BR112019003866A2 (en) | 2016-08-29 | 2019-07-16 | Psioxus Therapeutics Ltd | bispecific mab fragment-stimulated adenovirus with t-cell redirection (bite) |
WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
WO2018049263A1 (en) | 2016-09-09 | 2018-03-15 | Tg Therapeutics, Inc. | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
TW201825674A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing bispecific engager molecules |
BR112019004873A2 (en) | 2016-09-14 | 2019-06-11 | Teneobio Inc | cd3 binding antibodies |
PL3512547T3 (en) | 2016-09-14 | 2021-03-08 | Abbvie Biotherapeutics Inc. | Anti-pd-1 antibodies |
US11307205B2 (en) | 2016-09-19 | 2022-04-19 | University Of Southern California | Non-radioactive cytotoxicity assays |
WO2018050111A1 (en) | 2016-09-19 | 2018-03-22 | I-Mab | Anti-gm-csf antibodies and uses thereof |
KR20240035625A (en) | 2016-09-21 | 2024-03-15 | 넥스트큐어 인코포레이티드 | Antibodies for siglec-15 and methods of use thereof |
JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
BR112019005333A2 (en) * | 2016-09-21 | 2019-06-11 | Aptevo Research And Development Llc | cd123 binding proteins and related compositions and methods |
JP6937368B2 (en) | 2016-09-23 | 2021-09-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | How to treat intractable migraine |
WO2018057955A1 (en) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
EP3515948A4 (en) | 2016-09-23 | 2020-04-08 | CSL Limited | Coagulation factor binding proteins and uses thereof |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
KR20190059305A (en) | 2016-09-30 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | A safe and effective way to treat psoriasis with anti-IL23-specific antibodies |
EP3519824A1 (en) | 2016-10-03 | 2019-08-07 | Abbott Laboratories | Improved methods of assessing uch-l1 status in patient samples |
EP3523330A1 (en) | 2016-10-04 | 2019-08-14 | Fairbanks Pharmaceuticals, Inc. | Anti-fstl3 antibodies and uses thereof |
EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
MX2019003899A (en) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins. |
MA46529A (en) | 2016-10-11 | 2019-08-21 | Agenus Inc | ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE |
US11186626B2 (en) | 2016-10-11 | 2021-11-30 | Integrated Biotherapeutics, Inc. | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop |
US20190233512A1 (en) | 2016-10-12 | 2019-08-01 | Sutro Biopharma, Inc. | Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies |
MX2019004371A (en) | 2016-10-13 | 2019-11-18 | Massachusetts Inst Technology | Antibodies that bind zika virus envelope protein and uses thereof. |
AU2017342555A1 (en) | 2016-10-14 | 2019-05-30 | Children's Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
WO2018071576A1 (en) | 2016-10-14 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of tumors by inhibition of cd300f |
EP3526241A1 (en) | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Il15/il15r heterodimeric fc-fusion proteins |
US11638762B2 (en) | 2016-10-18 | 2023-05-02 | Seagen Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
CA3040343A1 (en) | 2016-10-19 | 2018-04-26 | California Institute For Biomedical Research | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
SI3529262T1 (en) | 2016-10-21 | 2021-12-31 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Methods for promoting t cells response |
WO2018075974A2 (en) * | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
US10322174B2 (en) | 2016-10-26 | 2019-06-18 | Cedars-Sinai Medical Center | Neutralizing anti-TL1A monoclonal antibodies |
MX2019004940A (en) | 2016-10-26 | 2019-09-26 | Leap Therapeutics Inc | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody. |
WO2018081578A1 (en) | 2016-10-28 | 2018-05-03 | Astute Medical, Inc. | Use of antibodies to timp-2 for the improvement of renal function |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
CA3041843A1 (en) | 2016-11-02 | 2018-05-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
CA3042989A1 (en) | 2016-11-07 | 2018-05-11 | Junho Chung | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
CA3041717A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
AU2017356317A1 (en) | 2016-11-14 | 2019-05-30 | Amgen Inc. | Bispecific or biparatopic antigen binding proteins and uses thereof |
JP7138350B2 (en) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Conjugate conjugates, cell-binding molecule-drug conjugates containing the conjugates, and methods of using and producing the conjugates and conjugates |
JP2020500020A (en) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | Compositions, methods, and therapeutic uses related to the fusogenic protein MINION |
EP3538101A4 (en) | 2016-11-14 | 2020-08-05 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
JP7217229B2 (en) | 2016-11-15 | 2023-02-02 | ハー・ルンドベック・アクチエゼルスカベット | Agents, uses and methods for the treatment of synucleinopathies |
WO2018093841A1 (en) | 2016-11-16 | 2018-05-24 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-il-23 specific antibody |
AR110079A1 (en) * | 2016-11-16 | 2019-02-20 | Bayer Healthcare Llc | FACTOR VIII ADDRESSED TO RED BLOODS AND METHOD FOR USE |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
DK3541833T3 (en) | 2016-11-17 | 2024-04-02 | 2Seventy Bio Inc | TGFß signal converter |
JOP20190100A1 (en) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | Anti-gitr antigen-binding proteins and methods of use thereof |
KR102221364B1 (en) | 2016-11-21 | 2021-03-04 | 쿠레아브 게엠베하 | Anti-GP73 Antibody and Immunoconjugate |
WO2018091720A1 (en) | 2016-11-21 | 2018-05-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of metastases |
CN110177803A (en) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | For using fusion protein to carry out the composition and method that TCR is reprogramed |
EP3544628A4 (en) | 2016-11-23 | 2020-11-18 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
WO2018098363A2 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
KR102275008B1 (en) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | prostate specific membrane antigen binding protein |
MX2019006045A (en) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Psma targeting trispecific proteins and methods of use. |
WO2018106712A1 (en) | 2016-12-05 | 2018-06-14 | The Administrators Of The Tulane Educational Fund | Arenavirus monoclonal antibodies and uses |
US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
JP6992068B2 (en) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | Anti-CTLA-4 antibodies and how to use them |
KR102650524B1 (en) | 2016-12-09 | 2024-03-26 | 알렉터 엘엘씨 | Anti-SIRP-alpha antibody and methods of use thereof |
JP7244987B2 (en) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | Multidrug Antibody Drug Conjugates |
US11155635B2 (en) * | 2016-12-14 | 2021-10-26 | Pangen Biotech Inc. | Anti-coagulation factor VIII antibody and use thereof |
CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
US10836818B2 (en) | 2016-12-15 | 2020-11-17 | The National Institute For Biotechnology I | Anti-PCNA monoclonal antibodies and use thereof |
BR112019012328A2 (en) | 2016-12-15 | 2019-11-19 | Abbvie Biotherapeutics Inc | anti-ox40 antibodies and their uses |
JP7144755B2 (en) | 2016-12-16 | 2022-09-30 | ハー・ルンドベック・アクチエゼルスカベット | Drugs, uses and methods |
CA3046850A1 (en) | 2016-12-16 | 2018-06-21 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
US20180214542A1 (en) | 2016-12-22 | 2018-08-02 | Sanofi | Humanized cxcr3 antibodies with depleting activity and methods of use thereof |
BR112019012686A2 (en) | 2016-12-22 | 2019-11-19 | Genentech Inc | methods and formulations for reducing the reconstitution time of lyophilized polypeptides |
WO2018119288A1 (en) | 2016-12-22 | 2018-06-28 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
CN106519034B (en) | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | anti-PD-1 antibodies and uses thereof |
JP7110199B2 (en) | 2016-12-23 | 2022-08-01 | ノバルティス アーゲー | Methods of treatment with anti-factor XI/XIa antibodies |
US20190322767A1 (en) | 2016-12-23 | 2019-10-24 | Innate Pharma | Heterodimeric antigen binding proteins |
JP7139332B2 (en) | 2016-12-23 | 2022-09-20 | ノバルティス アーゲー | Factor XI Antibodies and Methods of Use |
JOP20190134A1 (en) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | Anti-neuropilin antigen-binding proteins and methods of use thereof |
JP7360324B2 (en) | 2016-12-23 | 2023-10-12 | ビステラ, インコーポレイテッド | Binding polypeptides and methods of making them |
WO2018122249A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
WO2018122245A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting the survival time of patients suffering from cms3 colorectal cancer |
EP3565836A1 (en) | 2017-01-04 | 2019-11-13 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
US11564982B2 (en) | 2017-01-04 | 2023-01-31 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
AU2018206560A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
US20190315852A1 (en) | 2017-01-05 | 2019-10-17 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
EP3565596A4 (en) | 2017-01-05 | 2020-12-16 | Brown University | Methods and compositions relating to anti-chi3l1 antibody reagents |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
AU2018206279B2 (en) | 2017-01-06 | 2020-09-03 | Abl Bio Inc. | Anti-alpha-syn antibody and use thereof |
KR102646046B1 (en) | 2017-01-06 | 2024-03-08 | 바이오션, 인코포레이티드 | ERBB2 antibody and uses thereof |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US11197928B2 (en) * | 2017-01-13 | 2021-12-14 | Board Of Regents, The University Of Texas System | Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate |
JOP20190177A1 (en) | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
WO2018136435A1 (en) | 2017-01-17 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating lysosomal storage diseases and disorders |
CN110431150A (en) | 2017-01-18 | 2019-11-08 | 威特拉公司 | Antibody molecule-drug conjugates and application thereof |
MX2019007848A (en) | 2017-01-20 | 2019-09-09 | Tayu Huaxia Biotech Medical Group Co Ltd | Anti-pd-1 antibodies and uses thereof. |
LT3383916T (en) | 2017-01-24 | 2022-06-10 | I-Mab Biopharma Us Limited | Anti-cd73 antibodies and uses thereof |
AU2018211561B2 (en) | 2017-01-24 | 2020-04-30 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
WO2018140630A1 (en) | 2017-01-25 | 2018-08-02 | Northwestern University | Autophagy inducers for treatment of cns conditions |
ES2912408T3 (en) | 2017-01-26 | 2022-05-25 | Novartis Ag | CD28 compositions and methods for therapy with chimeric receptors for antigens |
WO2018139608A1 (en) | 2017-01-27 | 2018-08-02 | 株式会社A-Clip研究所 | Preventive and/or therapeutic agent for infectious diseases or inflammatory diseases |
EP3574012A1 (en) | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
JP2020506916A (en) | 2017-01-30 | 2020-03-05 | ヤンセン バイオテツク,インコーポレーテツド | Anti-TNF antibodies, compositions and methods for the treatment of active psoriatic arthritis |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
KR20190115042A (en) | 2017-02-07 | 2019-10-10 | 얀센 바이오테크 인코포레이티드 | Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Ankylosing Spondylitis |
WO2018146594A1 (en) | 2017-02-08 | 2018-08-16 | Novartis Ag | Fgf21 mimetic antibodies and uses thereof |
CN110520157A (en) | 2017-02-09 | 2019-11-29 | 纪念斯隆凯特琳癌症中心 | Anti- KIR3DL1 antibody |
WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
JP7145162B2 (en) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク,インコーポレイテッド | Treatment of hidradenitis suppurativa |
MX2019009117A (en) | 2017-02-17 | 2019-09-13 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof. |
CA3053774A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
WO2018156777A1 (en) | 2017-02-22 | 2018-08-30 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
JP2018139530A (en) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
CN111148760A (en) | 2017-02-27 | 2020-05-12 | 卡拉斯医疗有限公司 | Antibody constructs and methods of treating cancer |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
JP7116736B2 (en) | 2017-03-02 | 2022-08-10 | ノバルティス アーゲー | engineered heterodimeric proteins |
CN110392697A (en) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | There is the antibody and application thereof of specificity to NECTIN-4 |
EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | Glycan-interacting compounds and methods of use |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
CA3056088A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
EP3596126A4 (en) | 2017-03-15 | 2021-03-03 | Tsinghua University | Novel anti-trkb antibodies |
JOP20180021A1 (en) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | Anti-phf-tau antibodies and uses thereof |
JP7308150B2 (en) | 2017-03-16 | 2023-07-13 | イナート・ファルマ・ソシエテ・アノニム | Compositions and methods for treating cancer |
WO2018169090A1 (en) | 2017-03-17 | 2018-09-20 | 国立大学法人大阪大学 | Agent for suppressing or reducing photoreception sensitivity |
WO2018170488A1 (en) | 2017-03-17 | 2018-09-20 | Gilead Sciences, Inc. | Method of purifying an antibody |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
PL3600419T3 (en) | 2017-03-20 | 2024-02-19 | Vaccinex, Inc. | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
TWI808963B (en) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | Treatment of lupus using humanized anti-cxcr5 antibodies |
JP7346300B2 (en) | 2017-03-23 | 2023-09-19 | アボット・ラボラトリーズ | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in human subjects using the early biomarker ubiquitin carboxy-terminal hydrolase L1 |
JP2020512312A (en) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | Process for the preparation of glucuronide drug-linker and its intermediates |
AU2018240117A1 (en) | 2017-03-24 | 2019-09-19 | Beth Israel Deaconess Medical Center, Inc. | Methods for preventing and treating heart disease |
WO2018183182A1 (en) | 2017-03-27 | 2018-10-04 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
EP3600283A4 (en) | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
JOP20190203A1 (en) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
EP3601343B1 (en) | 2017-03-30 | 2022-05-04 | ECS-Progastrin SA | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
JP7291398B2 (en) | 2017-03-30 | 2023-06-15 | ザ ユニバーシティー オブ クイーンズランド | Chimeric molecules and uses thereof |
US11561225B2 (en) | 2017-03-30 | 2023-01-24 | Progastrine Et Cancers S.À R.L. | Compositions and methods for treating lung cancer |
WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
KR20200020662A (en) | 2017-04-03 | 2020-02-26 | 온콜로지, 인크. | How to Treat Cancer Using PS-Targeted Antibodies with Immuno-Oncology Agent |
CN110352201A (en) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | The subcutaneous administration of antibody drug conjugate for cancer therapy |
EP3606554A4 (en) | 2017-04-05 | 2020-12-09 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
JOP20190243A1 (en) | 2017-04-12 | 2019-10-13 | Medimmune Llc | Treatment of asthma with anti-tslp antibody |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
JP7160833B2 (en) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | anti-SIRP alpha antibody |
KR102629972B1 (en) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | Anti-CD137 antibody and methods of using the same |
US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
EP3610010A4 (en) | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
MX2019012137A (en) | 2017-04-14 | 2020-07-20 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating cancers. |
US20230227566A1 (en) | 2017-04-14 | 2023-07-20 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating lung cancers |
JP7344797B2 (en) | 2017-04-15 | 2023-09-14 | アボット・ラボラトリーズ | Methods to aid in hyperacute diagnosis and determination of traumatic brain injury in human subjects using early biomarkers |
WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
CN110506056A (en) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | Anti- APOC3 antibody and its application method |
SG11201909563VA (en) | 2017-04-27 | 2019-11-28 | Seattle Genetics Inc | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
JP7175917B2 (en) | 2017-04-27 | 2022-11-21 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Novel ALK2 inhibitors and methods for inhibiting BMP signaling |
WO2018196782A1 (en) | 2017-04-27 | 2018-11-01 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CN110603449A (en) | 2017-04-28 | 2019-12-20 | 雅培实验室 | Method for determining traumatic brain injury using early biomarkers from at least two samples of the same human subject for aiding hyperacute diagnosis |
WO2018201047A1 (en) | 2017-04-28 | 2018-11-01 | Elstar Therapeutics, Inc. | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof |
CA3060935A1 (en) | 2017-05-01 | 2018-11-08 | The Children's Medical Center Coporation | Methods and compositions relating to anti-pd1 antibody reagents |
PL3618863T3 (en) | 2017-05-01 | 2023-11-06 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
US11597774B2 (en) | 2017-05-04 | 2023-03-07 | City Of Hope | Antibody variable domains and antibody constructs |
CA3062553C (en) | 2017-05-05 | 2024-02-06 | Fusion Pharmaceuticals Inc. | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
AU2018261951A1 (en) | 2017-05-05 | 2019-10-31 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
US11433148B2 (en) | 2017-05-05 | 2022-09-06 | Centre For Probe Development And Commercialization | IGF-1R monoclonal antibodies and uses thereof |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
CN110621337B (en) | 2017-05-10 | 2021-11-09 | 浙江时迈药业有限公司 | anti-LAG 3 human monoclonal antibodies and uses thereof |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
WO2018209301A1 (en) | 2017-05-11 | 2018-11-15 | Cytodyn Inc. | Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents |
EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
US11524999B2 (en) | 2017-05-12 | 2022-12-13 | The Trustees Of The University Of Pennsylvania | Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
US20200171150A1 (en) | 2017-05-19 | 2020-06-04 | Syndax Pharmaceuticals, Inc. | Combination therapies |
US11421032B2 (en) | 2017-05-22 | 2022-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for inhibition of MICA/B shedding |
CA3063344A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Novel cd73 antibody, preparation and uses thereof |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
JP2020520671A (en) | 2017-05-24 | 2020-07-16 | ノバルティス アーゲー | Antibody-cytokine grafted proteins and methods of use |
WO2018217940A2 (en) | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
JOP20190271A1 (en) | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
ES2923143T3 (en) | 2017-05-25 | 2022-09-23 | Bristol Myers Squibb Co | Antagonistic monoclonal antibodies against CD40 and their uses |
WO2018218169A1 (en) | 2017-05-25 | 2018-11-29 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
US10849548B2 (en) | 2017-05-30 | 2020-12-01 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
JOP20190259A1 (en) | 2017-05-31 | 2019-10-31 | Amgen Inc | Anti-jagged1 antigen binding proteins |
US20200148768A1 (en) | 2017-05-31 | 2020-05-14 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
JP7348072B2 (en) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | Triple combination antibody therapy |
SI3630143T1 (en) | 2017-06-01 | 2023-11-30 | Akamis Bio Limited | Oncolytic virus and method |
MX2019014465A (en) | 2017-06-02 | 2020-01-23 | Pfizer | Antibodies specific for flt3 and their uses. |
PE20200294A1 (en) | 2017-06-05 | 2020-02-05 | Janssen Biotech Inc | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE |
KR20200026209A (en) | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand |
EP3634992B1 (en) | 2017-06-08 | 2024-03-27 | The Brigham And Women's Hospital, Inc. | Methods and compositions for identifying epitopes |
WO2018226336A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
GB201709379D0 (en) * | 2017-06-13 | 2017-07-26 | Univ Leuven Kath | Humanised ADAMTS13 binding antibodies |
CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
JP7237853B2 (en) | 2017-06-20 | 2023-03-13 | アムジエン・インコーポレーテツド | A method of treating or ameliorating a metabolic disorder using a binding protein against the gastric inhibitory peptide receptor (GIPR) in combination with a GLP-1 agonist |
CN111386347A (en) | 2017-06-21 | 2020-07-07 | 北卡罗来纳大学教堂山分校 | Methods and compositions for targeting chimeric antigen receptors of cancer cells |
EP3641802A1 (en) | 2017-06-22 | 2020-04-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EP3645740A4 (en) * | 2017-06-25 | 2021-08-18 | Systimmune, Inc. | Anti-pd-1 antibodies and methods of making and using thereof |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
CN110785433A (en) | 2017-06-28 | 2020-02-11 | 诺华股份有限公司 | Method for preventing and treating urinary incontinence |
JP2020526584A (en) | 2017-06-28 | 2020-08-31 | ザ ロックフェラー ユニバーシティー | Anti-MERTK Agonist Antibodies-Drug Conjugates and Their Use |
CN111132733A (en) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain |
WO2019010131A1 (en) | 2017-07-03 | 2019-01-10 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
US11623954B2 (en) * | 2017-07-10 | 2023-04-11 | Innate Pharma | Siglec-9-neutralizing antibodies |
EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
CN111316099A (en) | 2017-07-12 | 2020-06-19 | 约翰霍普金斯大学 | Proteoliposome-based ZNT8 autoantigen for diagnosis of type 1 diabetes |
US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
CR20200076A (en) | 2017-07-14 | 2020-06-10 | Pfizer | Antibodies to madcam |
EP3431496A1 (en) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti- isoasp7 amyloid beta antibodies and uses thereof |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
WO2019018647A1 (en) | 2017-07-20 | 2019-01-24 | Pfizer Inc. | Anti-gd3 antibodies and antibody-drug conjugates |
CA3070095A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
WO2019020480A1 (en) | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat hcmv related diseases |
EP3658173A1 (en) | 2017-07-25 | 2020-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating monocytopoiesis |
US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
EP3625254B1 (en) | 2017-07-31 | 2023-12-13 | F. Hoffmann-La Roche AG | Three-dimensional structure-based humanization method |
JP7262440B2 (en) * | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス,インコーポレーテッド | Anti-CD47 antibody and uses thereof |
CR20190486A (en) | 2017-08-03 | 2020-02-10 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
JP2020529986A (en) | 2017-08-04 | 2020-10-15 | アムジエン・インコーポレーテツド | Cysteine-MAB conjugation method |
TWI818919B (en) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
WO2019035034A1 (en) | 2017-08-16 | 2019-02-21 | The Broad Institute, Inc. | Neuronal assay method involving calcineurin |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
EP3444272A1 (en) | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
IL272773B1 (en) | 2017-08-22 | 2024-02-01 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
JP7395465B2 (en) | 2017-08-23 | 2023-12-11 | マックス-デルブリュック-セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ-ゲマインシャフト | Chimeric antigen receptor and CAR-T cells that bind to CXCR5 |
WO2019046338A1 (en) | 2017-08-28 | 2019-03-07 | Angiex, Inc. | Anti-tm4sf1 antibodies and methods of using same |
CN111133005A (en) | 2017-09-07 | 2020-05-08 | 奥古斯塔大学研究所公司 | Programmed cell death protein 1 antibodies |
WO2019051204A1 (en) | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of il4 receptor targeted agents, interferon gamma, and interferon alpha for use in treating ovarian cancer |
JP2020533022A (en) * | 2017-09-11 | 2020-11-19 | モナシュ ユニバーシティー | Binding protein to human thrombin receptor PAR4 |
SG11202001606XA (en) | 2017-09-13 | 2020-03-30 | Five Prime Therapeutics Inc | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
EP3681517A4 (en) | 2017-09-15 | 2021-05-19 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
KR20200051802A (en) | 2017-09-18 | 2020-05-13 | 서트로 바이오파마, 인크. | Anti-folate receptor alpha antibody conjugates and uses thereof |
MX2020003046A (en) * | 2017-09-19 | 2020-10-12 | Univ British Columbia | Anti-hla-a2 antibodies and methods of using the same. |
CA3076547A1 (en) | 2017-09-20 | 2019-03-28 | The University Of British Columbia | Novel anti-hla-a2 antibodies and uses thereof |
CN111655340A (en) | 2017-09-20 | 2020-09-11 | 国家医疗保健研究所 | Methods and pharmaceutical compositions for modulating autophagy |
CN111492246A (en) | 2017-09-20 | 2020-08-04 | 梅尔莎纳医疗公司 | Compositions and methods for predicting response to NAPI2B targeted therapy |
CA3074933A1 (en) | 2017-09-21 | 2019-03-28 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
EP3684803A1 (en) * | 2017-09-22 | 2020-07-29 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
EP3854414A1 (en) | 2017-09-25 | 2021-07-28 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
WO2019067592A1 (en) | 2017-09-27 | 2019-04-04 | University Of Georgia Research Foundation | Treatment and detection of infection and disease associated with different fungal pathogens |
EP3688030A1 (en) * | 2017-09-27 | 2020-08-05 | Elasmogen Ltd | Specific binding molecules |
US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
WO2019064053A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
US20200354452A1 (en) | 2017-09-29 | 2020-11-12 | City Of Hope | Cars and bispecific antibodies for treatment of mantle cell lymphoma |
US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
KR20200058540A (en) | 2017-10-02 | 2020-05-27 | 비스테라, 인크. | Antibody molecules against CD138 and uses thereof |
EP3461841B1 (en) | 2017-10-02 | 2019-09-11 | Certest Biotec, S.L. | Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter |
WO2019070161A2 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
EP3693013A4 (en) | 2017-10-06 | 2021-06-30 | Ono Pharmaceutical Co., Ltd. | Bispecific antibody |
JP7357609B2 (en) | 2017-10-06 | 2023-10-06 | ノボ ノルディスク エー/エス | anti-transthyretin antibody |
AU2018348431A1 (en) | 2017-10-10 | 2020-03-12 | Numab Therapeutics AG | Antibodies targeting CD137 and methods of use thereof |
MA50353A (en) | 2017-10-10 | 2020-08-19 | Numab Therapeutics AG | TARGETING ANTIBODIES PDL1 AND ASSOCIATED METHODS OF USE |
EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
AU2018348429A1 (en) | 2017-10-10 | 2020-03-12 | Numab Therapeutics AG | Multispecific antibody |
EP3470429A1 (en) | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
EP3470428A1 (en) | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting cd137 and methods of use thereof |
WO2019074124A1 (en) | 2017-10-12 | 2019-04-18 | Keio University | Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof |
EP3694871A4 (en) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
US11136403B2 (en) | 2017-10-13 | 2021-10-05 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
CA3072634A1 (en) | 2017-10-18 | 2019-04-25 | Sabine Rauth | Human serum albumin variants and uses thereof |
CN111480076A (en) | 2017-10-18 | 2020-07-31 | 艾德里诺医药公司 | Therapy monitoring under treatment with anti-Adrenomedullin (ADM) binding agents |
CN111655725A (en) | 2017-10-19 | 2020-09-11 | 德比奥药物国际股份有限公司 | Combination for the treatment of cancer |
EP3698808A4 (en) | 2017-10-20 | 2021-07-14 | Hyogo College Of Medicine | Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
AU2018356441A1 (en) | 2017-10-25 | 2020-04-16 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
SG11202003980PA (en) | 2017-10-31 | 2020-05-28 | Staten Biotechnology B V | Anti-apoc3 antibodies and methods of use thereof |
TW201922294A (en) | 2017-10-31 | 2019-06-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and cytarabine |
KR20200074127A (en) | 2017-11-02 | 2020-06-24 | 옥스포드 바이오테라퓨틱스 리미티드 | Antibodies and methods of use |
US10597462B1 (en) * | 2017-11-08 | 2020-03-24 | University Of Puerto Rico | Anti-TLT-1 antibody and uses thereof |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018364630A1 (en) | 2017-11-09 | 2020-05-21 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
CA3082410A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
CN111356701B (en) | 2017-11-17 | 2023-11-21 | Abl生物公司 | Anti-alpha-synuclein antibodies and uses thereof |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
EP3713959A1 (en) | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
EP3713965A1 (en) | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
EP3713966A1 (en) * | 2017-11-22 | 2020-09-30 | Vacara AB | Antibodies to citrullinated proteins |
EP3489259A1 (en) | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
AU2018371271A1 (en) | 2017-11-27 | 2020-06-11 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
WO2019101995A1 (en) | 2017-11-27 | 2019-05-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for cardiac regeneration |
SG11202004187UA (en) | 2017-11-29 | 2020-06-29 | Prothena Biosciences Ltd | Lyophilized formulation of a monoclonal antibody against transthyretin |
US20210179721A1 (en) | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
US11365250B2 (en) | 2017-11-29 | 2022-06-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cancer therapy |
JP7402158B2 (en) * | 2017-11-30 | 2023-12-20 | ジェネンテック, インコーポレイテッド | Anti-PD-L1 antibodies and methods of using them to detect PD-L1 |
WO2019106126A1 (en) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mdm2 modulators for the diagnosis and treatment of liposarcoma |
SG11202004751TA (en) | 2017-12-01 | 2020-06-29 | Seattle Genetics Inc | Humanized anti-liv1 antibodies for the treatment of breast cancer |
AR113862A1 (en) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | ANTI-CD47 ANTIBODIES AND THEIR USES TO TREAT CANCER |
US11629198B2 (en) * | 2017-12-05 | 2023-04-18 | The Trustees Of The University Of Pennsylvania | Fusion proteins and antibodies targeting human red blood cell antigens |
CA3084687C (en) | 2017-12-05 | 2024-01-02 | Progastrine Et Cancers S.A R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
CA3083783A1 (en) | 2017-12-06 | 2019-06-13 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
EP3720881A1 (en) | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
CA3067057A1 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
JP7379165B2 (en) | 2017-12-09 | 2023-11-14 | アボット・ラボラトリーズ | Methods for aiding in diagnosing and assessing traumatic brain injury in human subjects using a combination of GFAP and UCH-L1 |
US20210163592A1 (en) | 2017-12-11 | 2021-06-03 | Amgen Inc | Continuous manufacturing process for bispecific antibody products |
BR112020011875A2 (en) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | bispecific antibody to a-syn / igf1r and use thereof |
MA51154A (en) | 2017-12-15 | 2020-10-21 | Aleta Biotherapeutics Inc | CD19 VARIANTS |
MA51184A (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | ANTI-CCT5 BINDING MOLECULES AND RELATED METHODS OF USE |
CA3086199A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
WO2019121872A1 (en) | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of liver cancer |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
KR20200104364A (en) | 2017-12-27 | 2020-09-03 | 테네오바이오, 인코포레이티드 | CD3-delta/epsilon heterodimer specific antibody |
WO2019133902A2 (en) | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
UY38041A (en) | 2017-12-29 | 2019-06-28 | Amgen Inc | CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3 |
EP3732193A1 (en) | 2017-12-29 | 2020-11-04 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
CA3086879A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
BR112020013621A2 (en) | 2018-01-12 | 2020-12-01 | Amgen Inc. | antibodies against pac1 and uses thereof |
EP3743101A2 (en) | 2018-01-25 | 2020-12-02 | ACM Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
JP2021510594A (en) | 2018-01-25 | 2021-04-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Antagonist of IL-33 for use in methods of preventing ischemia-reperfusion injury of organs |
TW201940881A (en) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | Combining progastrin detection with other cancer biomarkers in cancer diagnosis |
SG11202006379UA (en) * | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
JP7268038B2 (en) | 2018-01-31 | 2023-05-02 | アレクトル エルエルシー | ANTI-MS4A4A ANTIBODY AND METHOD OF USE THEREOF |
JP2021511811A (en) | 2018-02-01 | 2021-05-13 | ファイザー・インク | CD70-specific antibodies and their use |
WO2019152742A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Chimeric antigen receptors targeting cd70 |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
AU2019219071A1 (en) | 2018-02-08 | 2020-07-30 | Sphingotec Gmbh | Adrenomedullin (ADM) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
EP3749363A1 (en) | 2018-02-08 | 2020-12-16 | Amgen Inc. | Low ph pharmaceutical antibody formulation |
TWI804572B (en) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
US11834487B2 (en) | 2018-02-12 | 2023-12-05 | Hadasit Medical Research Services & Development Ltd. | Modulation of SLAMF6 splice variants for cancer therapy |
WO2019157772A1 (en) | 2018-02-13 | 2019-08-22 | 和元生物技术(上海)股份有限公司 | Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy |
WO2019158512A1 (en) | 2018-02-13 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prognosis and the treatment of glioblastoma |
EP3752530A1 (en) | 2018-02-14 | 2020-12-23 | ABBA Therapeutics AG | Anti-human pd-l2 antibodies |
SG11202007702UA (en) | 2018-02-14 | 2020-09-29 | Viela Bio Inc | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
KR20200122351A (en) | 2018-02-20 | 2020-10-27 | 시애틀 지네틱스, 인크. | Hydrophobic auristatin F compound and conjugates thereof |
CN111971299A (en) | 2018-02-21 | 2020-11-20 | 美国政府(由卫生和人类服务部的部长所代表) | Neutralizing antibodies to HIV-1Env and uses thereof |
US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
AU2019225393A1 (en) | 2018-02-23 | 2020-08-20 | Cartherics Pty. Ltd. | T cell disease treatment targeting TAG-72 |
US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
KR20200144541A (en) | 2018-02-27 | 2020-12-29 | 이씨에스-프로가스트린 에스에이 | Progastrin as a biomarker for immunotherapy |
US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
EP3762015A4 (en) | 2018-03-05 | 2022-04-27 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2019170131A1 (en) | 2018-03-07 | 2019-09-12 | 复旦大学 | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof |
EP3765499A1 (en) | 2018-03-12 | 2021-01-20 | Zoetis Services LLC | Anti-ngf antibodies and methods thereof |
JP2021517564A (en) | 2018-03-12 | 2021-07-26 | メモリアル スローン ケタリング キャンサー センター | Bispecific binding factors and their use |
CN110272490B (en) | 2018-03-14 | 2021-05-14 | 上海开拓者生物医药有限公司 | Targeted CTLA-4 antibody, preparation method and application thereof |
EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
MX2020009296A (en) * | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use. |
WO2019183266A1 (en) * | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
WO2019183551A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
EP3774901A1 (en) | 2018-03-26 | 2021-02-17 | Sutro Biopharma, Inc. | Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies |
FI3775909T3 (en) | 2018-03-26 | 2023-08-01 | Glycanostics S R O | Means and methods for glycoprofiling of a protein |
EP3775206A1 (en) | 2018-03-28 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
CN112313248A (en) | 2018-03-29 | 2021-02-02 | 百时美施贵宝公司 | Method for purifying monomeric monoclonal antibodies |
CA3093457A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
CN110343178B (en) | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | Anti-human LAG-3 monoclonal antibody and application thereof |
WO2019193375A1 (en) | 2018-04-04 | 2019-10-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fzd7 inhibitors for the treatment of retinal neovascularization |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CN112334485A (en) | 2018-04-06 | 2021-02-05 | 百进生物科技公司 | Anti-tetraspanin 33agents and compositions thereof and methods of making and using |
EP3774912A1 (en) | 2018-04-10 | 2021-02-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation |
CN112004558A (en) | 2018-04-12 | 2020-11-27 | 米迪亚制药有限责任公司 | LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer |
US20210164984A1 (en) | 2018-04-13 | 2021-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
KR20210010862A (en) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof |
WO2019204655A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
WO2019201995A1 (en) | 2018-04-20 | 2019-10-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
WO2019209952A2 (en) | 2018-04-23 | 2019-10-31 | Emory University | Vip antagonists and uses in treating cancer |
EP3785732A4 (en) | 2018-04-24 | 2022-02-23 | Ampsource Biopharma Shanghai Inc. | Antibody against tim-3 and application thereof |
CA3098374A1 (en) | 2018-04-25 | 2019-10-31 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
WO2019207030A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
WO2019207066A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of sjögren's syndrome |
EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019211369A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
US11155638B2 (en) * | 2018-05-08 | 2021-10-26 | Rhode Island Hospital | Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications |
CA3097679A1 (en) | 2018-05-09 | 2019-11-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin4 |
WO2019217913A1 (en) | 2018-05-10 | 2019-11-14 | Sensei Biotherapeutics, Inc. | Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof |
WO2019222130A1 (en) | 2018-05-15 | 2019-11-21 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and flt3 inhibitors |
CN110483639A (en) | 2018-05-15 | 2019-11-22 | 复旦大学 | Target antibody and the antibody-drug conjugates and its preparation method and application of AXL |
US20210238238A1 (en) | 2018-05-16 | 2021-08-05 | Csl Limited | Soluble complement receptor type i variants and uses thereof |
JP7080352B2 (en) * | 2018-05-16 | 2022-06-03 | モルフォシス・アーゲー | Antibodies targeting glycoprotein VI |
CN112166119A (en) * | 2018-05-18 | 2021-01-01 | 陈扎克伯格生物中心公司 | Method for isolating allergen-specific antibodies from humans and uses thereof |
MX2020012376A (en) | 2018-05-18 | 2021-03-09 | Incyte Corp | Fused pyrimidine derivatives as a2a / a2b inhibitors. |
EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
TWI816396B (en) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | Antibodies specific for gucy2c and uses thereof |
MX2020012539A (en) | 2018-05-23 | 2021-02-16 | Pfizer | Antibodies specific for cd3 and uses thereof. |
WO2019225787A1 (en) | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | Anti-b7-h3 antibody and use thereof |
JP2021524255A (en) | 2018-05-24 | 2021-09-13 | ヤンセン バイオテツク,インコーポレーテツド | Unispecific and bispecific antibodies Anti-TMEFF2 antibodies and their use |
EA202092847A1 (en) * | 2018-05-24 | 2021-04-20 | Янссен Байотек, Инк. | ANTIBODIES TO CD3 AND THEIR APPLICATION |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
US11319373B2 (en) | 2018-05-25 | 2022-05-03 | Alector Llc | Anti-SIRPA antibodies and methods of use thereof |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
UY38247A (en) | 2018-05-30 | 2019-12-31 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
AU2019278875A1 (en) | 2018-05-31 | 2020-10-22 | Glyconex Inc. | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
MX2020012888A (en) | 2018-06-01 | 2021-04-28 | Rakuten Medical Inc | Phthalocyanine dye conjugate compositions. |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
PE20210320A1 (en) | 2018-06-01 | 2021-02-16 | Novartis Ag | BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM |
WO2019234099A1 (en) | 2018-06-06 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction |
TW202015740A (en) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | Camptothecin conjugates |
JP7269963B2 (en) | 2018-06-08 | 2023-05-09 | クリスタル バイオサイエンス インコーポレイテッド | Transgenic animals for producing diverse antibodies with the same light chain I |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
JP2021527409A (en) | 2018-06-14 | 2021-10-14 | ブルーバード バイオ, インコーポレイテッド | CD79A chimeric antigen receptor |
US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CA3099893A1 (en) | 2018-06-18 | 2019-12-26 | Innate Pharma | Compositions and methods for treating cancer |
WO2019246293A2 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
KR20210030366A (en) | 2018-06-20 | 2021-03-17 | 인사이트 코포레이션 | Anti-PD-1 antibodies and uses thereof |
US20210276971A1 (en) | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
TW202016144A (en) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
AU2019288677A1 (en) | 2018-06-21 | 2021-01-14 | Yumanity Therapeutics, Inc. | Compositions and methods for the treatment and prevention of neurological disorders |
MX2020014101A (en) | 2018-06-22 | 2021-05-27 | Junten Bio Co Ltd | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte. |
CN112638478A (en) | 2018-06-29 | 2021-04-09 | 希望之城公司 | CD6 targeting chimeric antigen receptors for the treatment of certain autoimmune disorders |
WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
KR20210025614A (en) | 2018-06-29 | 2021-03-09 | 알렉터 엘엘씨 | Anti-SIRP-beta1 antibody and method of use thereof |
EP3813800A1 (en) | 2018-06-29 | 2021-05-05 | Incyte Corporation | Formulations of an axl/mer inhibitor |
EP3814369A1 (en) | 2018-06-29 | 2021-05-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
TW202019473A (en) | 2018-07-02 | 2020-06-01 | 美商安進公司 | Anti-steap1 antigen-binding protein |
EA202092904A1 (en) | 2018-07-03 | 2021-04-22 | Бристол-Маерс Сквибб Компани | METHODS FOR OBTAINING RECOMBINANT PROTEINS |
DE202019005887U1 (en) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020007898A1 (en) | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
AU2019301138A1 (en) | 2018-07-11 | 2021-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (FTC, 2',3'-dideoxy-5-fluoro-3'-thiacytidine) |
CN110713537B (en) | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | SEMA4D antibody and preparation method and application thereof |
WO2020014617A1 (en) | 2018-07-13 | 2020-01-16 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
TW202019965A (en) | 2018-07-16 | 2020-06-01 | 美商安進公司 | Method of treating multiple myeloma |
MX2021000268A (en) | 2018-07-17 | 2021-06-08 | Humabs Biomed Sa | Antibodies against campylobacter species. |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
EP3824287A1 (en) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Receptor for vista |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
MX2021001221A (en) | 2018-07-30 | 2021-06-23 | Amgen Res Munich Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3. |
EP3829642A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Pharmaceutical formulations of masked antibodies |
JP7401166B2 (en) | 2018-08-01 | 2023-12-19 | イムチェック セラピューティクス エスエーエス | Anti-BTN3A antibodies and their use in the treatment of cancer or infectious disorders |
WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
JP2022532812A (en) | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | Anti-IL1RAP antibody composition |
US11407825B2 (en) | 2018-08-17 | 2022-08-09 | Mersana Therapeutics, Inc. | NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
US20220363763A1 (en) | 2018-08-21 | 2022-11-17 | Abl Bio Inc. | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
CN112867503A (en) | 2018-08-24 | 2021-05-28 | 希望之城 | Masked cytokine conjugates |
CA3109732A1 (en) | 2018-08-27 | 2020-03-05 | Affimed Gmbh | Cryopreserved nk cells preloaded with an antibody construct |
CA3110689A1 (en) | 2018-08-30 | 2020-03-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
CN113039209A (en) | 2018-08-30 | 2021-06-25 | T细胞受体治疗公司 | Compositions and methods for TCR reprogramming using fusion proteins |
US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
TW202016307A (en) | 2018-08-31 | 2020-05-01 | 美商阿列克特有限責任公司 | Anti-cd33 antibodies and methods of use thereof |
US20220048995A1 (en) | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
WO2020053122A1 (en) | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of her2/neu antibody with heme for treating cancer |
WO2020056170A1 (en) | 2018-09-12 | 2020-03-19 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
US20220105176A1 (en) | 2018-09-12 | 2022-04-07 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
WO2020060944A1 (en) | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
KR20210089143A (en) | 2018-09-18 | 2021-07-15 | 메리맥 파마슈티컬즈, 인크. | Anti-TNFR2 antibodies and uses thereof |
WO2020058372A1 (en) | 2018-09-19 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
CN113015746A (en) | 2018-09-19 | 2021-06-22 | 拉荷亚免疫研究所 | PTPRS and proteoglycans in rheumatoid arthritis |
KR20230148273A (en) | 2018-09-24 | 2023-10-24 | 얀센 바이오테크 인코포레이티드 | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
WO2020064702A1 (en) | 2018-09-25 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma |
JP7425049B2 (en) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | DLL3 binding protein and method of use |
EP3856343A1 (en) | 2018-09-25 | 2021-08-04 | Biolegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
CA3114137A1 (en) | 2018-09-26 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof |
US20220242957A1 (en) | 2018-09-27 | 2022-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
SG11202103104RA (en) | 2018-09-27 | 2021-04-29 | Tizona Therapeutics | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies |
WO2020065408A1 (en) | 2018-09-27 | 2020-04-02 | Pierre Fabre Medicament | Sulfomaleimide-based linkers and corresponding conjugates |
BR112021005669A2 (en) | 2018-09-28 | 2021-06-22 | Amgen Inc. | antibodies against soluble bcma |
BR112021005665A2 (en) | 2018-09-28 | 2021-06-22 | Pierre Fabre Medicament | new immunocytokines for cancer treatment |
US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
WO2020065594A1 (en) | 2018-09-28 | 2020-04-02 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
WO2020070062A1 (en) | 2018-10-01 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma |
JP2022503959A (en) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | IL-12 heterodimer FC-fusion protein |
CN112969503A (en) | 2018-10-03 | 2021-06-15 | 斯塔滕生物技术有限公司 | Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof |
JP2022513338A (en) * | 2018-10-03 | 2022-02-07 | ネペンザ・バイオサイエンシズ・エルエルシー | Anti-CD79 antibody and its use |
WO2020070240A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases |
EP3861021A4 (en) | 2018-10-05 | 2022-06-22 | Research Institute at Nationwide Children's Hospital | Compositions and methods for enzymatic disruption of bacterial biofilms |
EP3636320A1 (en) | 2018-10-09 | 2020-04-15 | Numab Therapeutics AG | Antibodies targeting cd137 and methods of use thereof |
US20210347898A1 (en) | 2018-10-09 | 2021-11-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis |
US20210395379A1 (en) | 2018-10-09 | 2021-12-23 | Numab Therapeutics AG | Antibodies targeting cd137 and methods of use thereof |
EP3864127A1 (en) | 2018-10-10 | 2021-08-18 | Boehringer Ingelheim International GmbH | Method for membrane gas transfer in high density bioreactor culture |
CN113164780A (en) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | anti-LAP antibody variants and uses thereof |
AU2019356564A1 (en) | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
WO2020077286A1 (en) | 2018-10-12 | 2020-04-16 | Quidel Corporation | Extraction reagent for use in an assay for detection of group a streptococcus |
UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
US20210340240A1 (en) | 2018-10-18 | 2021-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale | Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor |
BR112021007690A2 (en) | 2018-10-22 | 2021-08-10 | Shanghai GenBase Biotechnology Co., Ltd. | anti-cldn18.2 antibody and its use |
GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
CA3100232A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
TW202029980A (en) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
AU2019373090B2 (en) | 2018-10-31 | 2023-05-25 | The University Of Sydney | Compositions and methods for treating viral infections |
WO2020089473A2 (en) * | 2018-11-01 | 2020-05-07 | Bioinvent International Ab | Novel agonistic antibody molecules |
KR20210108363A (en) | 2018-11-02 | 2021-09-02 | 오클라호마 메디컬 리써치 화운데이션 | Monoclonal antibodies to ELTD1 and uses thereof |
WO2020095104A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
CA3118186A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd | Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof |
JP2022512860A (en) | 2018-11-06 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and Pharmaceutical Compositions for the Treatment of Acute Myeloid Leukemia by Eradication of Leukemia Stem Cells |
CN111153995B (en) | 2018-11-07 | 2020-12-25 | 上海怀越生物科技有限公司 | NKG2A antibody, and preparation method and application thereof |
CA3117386A1 (en) | 2018-11-08 | 2020-05-14 | Cedars-Sinai Medical Center | Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients |
CN113166269A (en) | 2018-11-13 | 2021-07-23 | 指南针制药有限责任公司 | Multispecific binding constructs against checkpoint molecules and uses thereof |
TW202033555A (en) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | Anti-nkg2a antibodies and uses thereof |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
AR117091A1 (en) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES |
CN113395979A (en) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies |
EP3883961A1 (en) | 2018-11-20 | 2021-09-29 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
CN113164594A (en) | 2018-11-20 | 2021-07-23 | 株式会社英仙蛋白质科学 | Inhibitors of iron uptake into cells |
WO2020103836A1 (en) | 2018-11-20 | 2020-05-28 | 上海开拓者生物医药有限公司 | Ox40 antibody, preparation method thereof and use thereof |
EA202190986A1 (en) | 2018-11-26 | 2021-12-14 | Фоти Севен, Инк. | HUMANIZED ANTIBODIES TO c-Kit |
EP3886869A4 (en) | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
CN111234018A (en) | 2018-11-29 | 2020-06-05 | 上海开拓者生物医药有限公司 | Fully human anti-GITR antibody and preparation method thereof |
CA3121562A1 (en) | 2018-11-30 | 2020-06-04 | Abl Bio Inc. | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
CN111253485A (en) | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | Anti-human TIM-3 monoclonal antibody and application thereof |
WO2020115556A1 (en) | 2018-12-03 | 2020-06-11 | Fusion Pharmaceuticals Inc. | Radioimmunoconjugates and checkpoint inhibitor combination therapy |
CN111253488A (en) | 2018-12-03 | 2020-06-09 | 上海开拓者生物医药有限公司 | CD47 antibody and preparation method and application thereof |
WO2020117627A1 (en) | 2018-12-03 | 2020-06-11 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
CN113660944A (en) | 2018-12-11 | 2021-11-16 | Q32生物公司 | Fusion protein constructs for complement-associated diseases |
CN111303283A (en) | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | anti-IL-17A antibodies and uses thereof |
CN111303284A (en) | 2018-12-12 | 2020-06-19 | 尚华科创投资管理(江苏)有限公司 | Monoclonal antibody for resisting human interleukin 5(IL-5) and application thereof |
WO2020120786A1 (en) | 2018-12-14 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
AR117343A1 (en) | 2018-12-18 | 2021-07-28 | Novartis Ag | REVERSIBLE BINDING AGENTS FOR ANTI-FACTOR XI / XIa ANTIBODIES AND USES OF THEM |
WO2020128863A1 (en) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anti-tnf-alpha antibodies |
EP3898686A1 (en) | 2018-12-20 | 2021-10-27 | Novartis AG | Pharmaceutical combinations |
TW202031684A (en) | 2018-12-20 | 2020-09-01 | 日商協和麒麟股份有限公司 | Fn14 antibodies and uses thereof |
EP3883609A2 (en) | 2018-12-20 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
JP2022514381A (en) | 2018-12-20 | 2022-02-10 | セダーズ-シナイ メディカル センター | Kurazakizumab in the treatment of chronic antibody-mediated rejection of organ transplants |
WO2020132560A2 (en) | 2018-12-21 | 2020-06-25 | Aim Immunotech Inc. | Compositions and methods for cancer therapy |
US20220090125A1 (en) | 2018-12-21 | 2022-03-24 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
BR112021012040A2 (en) | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Bifunctional anti-PD-1/SIRPA molecule |
US20220211798A1 (en) | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
JP2022515223A (en) | 2018-12-21 | 2022-02-17 | オーエスイー・イミュノセラピューティクス | Bifunctional molecule for human PD-1 |
KR20210108978A (en) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | Bifunctional Anti-PD-1/IL-7 Molecules |
CN113166246A (en) | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | Antibody and application thereof |
BR112021013157A8 (en) | 2019-01-03 | 2022-12-06 | Inst Nat Sante Rech Med | USES OF AN NRP-1 INHIBITOR, USE OF A COMBINATION, USE OF A MULTIESPECIFIC ANTIBODY, EX VIVO METHOD TO PREDICT, USE OF AN INHIBITOR, MULTIESPECIFIC ANTIBODY, MODIFIED CELL POPULATION, EX VIVO METHOD OF PRODUCTION AND USE OF A POPULATION OF T CELLS |
KR20210113597A (en) | 2019-01-08 | 2021-09-16 | 하. 룬드벡 아크티에셀스카브 | Acute and Rapid Treatment of Headache with Anti-CGRP Antibodies |
CN111434688A (en) | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | CD73 antibody and preparation method and application thereof |
KR20210117277A (en) | 2019-01-13 | 2021-09-28 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | Antibodies specific for human nectin-2 |
WO2020150214A1 (en) | 2019-01-14 | 2020-07-23 | University Of Virginia Patent Foundation | Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury |
KR20210116540A (en) | 2019-01-15 | 2021-09-27 | 얀센 바이오테크 인코포레이티드 | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
CN109762067B (en) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
CN113597433A (en) | 2019-01-18 | 2021-11-02 | 詹森生物科技公司 | GPRC5D chimeric antigen receptors and cells expressing these receptors |
GB201900724D0 (en) | 2019-01-18 | 2019-03-06 | King S College London | Antibody |
CN113396162A (en) | 2019-01-22 | 2021-09-14 | 百时美施贵宝公司 | Antibodies against IL-7R alpha subunit and uses thereof |
WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
CN113330031A (en) | 2019-01-23 | 2021-08-31 | 詹森生物科技公司 | anti-TNF antibody compositions for use in methods of treating psoriatic arthritis |
US20220073600A1 (en) | 2019-01-28 | 2022-03-10 | Maple Biotech Llc | Methods for treating disease using psmp antagonists |
JP2020117502A (en) | 2019-01-28 | 2020-08-06 | ファイザー・インク | Method of treating signs and symptoms of osteoarthritis |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
EP3917954A1 (en) | 2019-01-31 | 2021-12-08 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
JP2022519273A (en) | 2019-02-05 | 2022-03-22 | シージェン インコーポレイテッド | Anti-CD228 antibody and antibody drug conjugate |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
KR20210125034A (en) | 2019-02-15 | 2021-10-15 | 우시 바이올로직스 아일랜드 리미티드 | Method for preparing antibody-drug conjugates with improved homogeneity |
US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
JP2020143045A (en) | 2019-02-18 | 2020-09-10 | ファイザー・インク | Method of treatment of chronic low back pain |
WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
JP2022521937A (en) | 2019-02-21 | 2022-04-13 | マレンゴ・セラピューティクス,インコーポレーテッド | Antibody molecules that bind to NKp30 and their use |
CN114126714A (en) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | anti-TCR antibody molecules and uses thereof |
JP2022521750A (en) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecule that binds to calreticulin and its use |
CN114026122A (en) | 2019-02-21 | 2022-02-08 | 马伦戈治疗公司 | Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof |
CA3130281A1 (en) | 2019-02-21 | 2020-08-27 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies |
US20220088075A1 (en) | 2019-02-22 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
CN112142847B (en) | 2019-02-22 | 2023-05-05 | 武汉友芝友生物制药股份有限公司 | Engineered Fc fragments, antibodies comprising same and uses thereof |
CN112703013B (en) | 2019-02-22 | 2022-09-30 | 武汉友芝友生物制药股份有限公司 | CD3 antigen binding fragment and application thereof |
JP2022521428A (en) | 2019-02-25 | 2022-04-07 | ザ・ユニバーシティ・オブ・シカゴ | Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents. |
US11242407B2 (en) | 2019-02-26 | 2022-02-08 | Inspirna, Inc. | High-affinity anti-MERTK antibodies and uses thereof |
TW202045206A (en) | 2019-02-27 | 2020-12-16 | 美商健生生物科技公司 | Antibody formulation |
EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
EP3930846A1 (en) | 2019-03-01 | 2022-01-05 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
JP2022524588A (en) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | Tau recognition antibody |
US20220153830A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
KR20210142006A (en) | 2019-03-14 | 2021-11-23 | 다케다 파머수티컬 컴패니 리미티드 | Plasma kallikrein inhibitors and uses thereof for the treatment of hereditary angioedema attacks |
CA3133388A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
EP3938391A1 (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
CN113825765A (en) | 2019-03-14 | 2021-12-21 | 詹森生物科技公司 | Method for producing anti-IL 12/IL23 antibody composition |
US20200331996A1 (en) | 2019-03-18 | 2020-10-22 | Janssen Biotech, Inc. | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody |
KR20210141948A (en) | 2019-03-19 | 2021-11-23 | 앨버트 아인슈타인 컬리지 오브 메디신 | Monoclonal Antibodies for Prevention and Treatment of Herpes Simplex Virus Infection |
SG11202109932WA (en) | 2019-03-20 | 2021-10-28 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
EP3942026A1 (en) | 2019-03-22 | 2022-01-26 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
US20220154191A1 (en) | 2019-03-25 | 2022-05-19 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic t-cell activity by inhibiting ebag9 |
US20220177558A1 (en) | 2019-03-25 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
JP2022528324A (en) | 2019-03-26 | 2022-06-10 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | Treatment with anti-IL13R antibody or binding fragment thereof |
JP2022527506A (en) | 2019-03-27 | 2022-06-02 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Recombinant protein with CD40 activation properties |
JP2022524215A (en) | 2019-03-28 | 2022-04-28 | ダニスコ・ユーエス・インク | Modified antibody |
JP2022527941A (en) | 2019-03-29 | 2022-06-07 | ラクテン・メディカル,インコーポレイテッド | Methods for photoimmunotherapy and related biomarkers |
MX2021011830A (en) | 2019-03-29 | 2022-01-24 | Atarga Llc | Anti fgf23 antibody. |
US20220042954A1 (en) | 2019-03-29 | 2022-02-10 | Bristol-Myers Squibb Company | Methods of measuring hydrophobicity of chromatographic resins |
TW202102266A (en) | 2019-04-01 | 2021-01-16 | 美商建南德克公司 | Compositions and methods for stabilizing protein-containing formulations |
KR20220047536A (en) | 2019-04-01 | 2022-04-18 | 레이크파르마, 인코퍼레이티드 | BTLA-binding (CD272) antibody for modulation of immune response and treatment of disease |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
JP2022527860A (en) | 2019-04-02 | 2022-06-06 | ケンジョッケティ バイオテクノロジー,インク. | Emission Pump-Cancer Antigen Multispecific Antibodies and Their Related Compositions, Reagents, Kits and Methods |
US20220175815A1 (en) | 2019-04-03 | 2022-06-09 | Orega Biotech | Combination therapies based on pd1 and il-17b inhibitors |
TW202102544A (en) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
JP2022526194A (en) | 2019-04-10 | 2022-05-23 | エレベートバイオ テクノロジーズ,インコーポレイテッド | FLT3-specific chimeric antigen receptor and its usage |
CA3136691A1 (en) | 2019-04-12 | 2020-10-15 | Geltor, Inc. | Recombinant elastin and production thereof |
CN113474374A (en) | 2019-04-16 | 2021-10-01 | 四川科伦博泰生物医药股份有限公司 | anti-FXI/FXIa antibodies and uses thereof |
WO2020213084A1 (en) | 2019-04-17 | 2020-10-22 | Keio University | Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof |
US11124572B2 (en) * | 2019-04-18 | 2021-09-21 | Qlsf Biotherapeutics Inc. | Humanized anti-PD-L1 antibodies |
BR112021021165A2 (en) | 2019-04-24 | 2022-01-04 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and their use |
JP2022531001A (en) | 2019-05-03 | 2022-07-05 | セルジーン コーポレーション | Anti-BCMA antibody conjugate, composition containing the conjugate, and method for producing and using the conjugate. |
MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
SG11202112223XA (en) | 2019-05-10 | 2021-12-30 | Takeda Pharmaceuticals Co | Antibody drug conjugates |
US20220259561A1 (en) | 2019-05-14 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof |
JP2022531978A (en) | 2019-05-15 | 2022-07-12 | ネオティーエックス セラピューティクス リミテッド | Cancer treatment |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
EP3981786A4 (en) | 2019-05-23 | 2023-07-26 | Xiamen University | Novel anti-hepatitis b virus antibody and uses thereof |
KR20220012270A (en) | 2019-05-23 | 2022-02-03 | 에이씨 이뮨 에스.에이. | Anti-TDP-43 binding molecules and uses thereof |
EP3744400A1 (en) | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml) |
AU2020283890A1 (en) | 2019-05-30 | 2021-12-16 | Amgen Inc. | Engineering the hinge region to drive antibody dimerization |
AU2020288404A1 (en) | 2019-06-03 | 2022-02-03 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
BR112021024402A2 (en) | 2019-06-03 | 2022-02-15 | Univ Chicago | Methods and compositions for treating cancer with cancer-targeting adjuvants |
EP3976648A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
IT201900008376A1 (en) | 2019-06-07 | 2020-12-07 | Univ Degli Studi Di Modena E Reggio Emilia | ANTIBODIES WITH ANTI-TUMOR ACTIVITY |
CN114269749A (en) | 2019-06-10 | 2022-04-01 | 苏特罗生物制药公司 | 5H-pyrrolo [3,2-d ] pyrimidine-2, 4-diamino compounds and antibody conjugates thereof |
WO2020252066A1 (en) | 2019-06-11 | 2020-12-17 | Alector Llc | Anti-sortilin antibodies for use in therapy |
CA3141561A1 (en) | 2019-06-12 | 2020-12-17 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
AU2020290573A1 (en) | 2019-06-13 | 2021-11-04 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
WO2020257289A2 (en) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
EP3983410A1 (en) | 2019-06-17 | 2022-04-20 | Sutro Biopharma, Inc. | 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis |
EP3753954A1 (en) | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
CA3144324A1 (en) | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
EP3990493A1 (en) | 2019-06-28 | 2022-05-04 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
BR112021026410A2 (en) | 2019-07-01 | 2022-02-08 | Tonix Pharma Ltd | Anti-cd154 antibodies and uses thereof |
JP2022539248A (en) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | Recombinant AD35 vectors and related gene therapy improvements |
CN114269783B (en) | 2019-07-02 | 2024-03-26 | 美国政府(由卫生和人类服务部的部长所代表) | Monoclonal antibody binding to EGFRVIII and application thereof |
US20220372137A1 (en) | 2019-07-03 | 2022-11-24 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021006212A1 (en) | 2019-07-08 | 2021-01-14 | テルモ株式会社 | Hybridoma and method for producing same, and monoclonal antibody and method for producing same |
CA3145385A1 (en) | 2019-07-08 | 2021-01-14 | Steven D. Goodman | Antibody compositions for disrupting biofilms |
CN113968910A (en) | 2019-07-11 | 2022-01-25 | 武汉友芝友生物制药有限公司 | Tetravalent symmetric bispecific antibodies |
JPWO2021010326A1 (en) | 2019-07-12 | 2021-01-21 | ||
WO2021008523A1 (en) | 2019-07-15 | 2021-01-21 | 上海君实生物医药科技股份有限公司 | Anti-tigit antibodies and application thereof |
KR20220057530A (en) * | 2019-07-17 | 2022-05-09 | 제미니 테라퓨틱스 서브, 인코포레이티드 | Factor H-enhancing antibodies and uses thereof |
CN114423464A (en) | 2019-07-22 | 2022-04-29 | 西根股份有限公司 | Humanized anti-LIV 1 antibodies for the treatment of cancer |
JP2022542863A (en) | 2019-07-24 | 2022-10-07 | ハー・ルンドベック・アクチエゼルスカベット | Anti-mGluR5 antibody and uses thereof |
TW202118792A (en) | 2019-07-26 | 2021-05-16 | 美商健生生物科技公司 | Anti-hk2 chimeric antigen receptor (car) |
EP4004025A1 (en) | 2019-07-26 | 2022-06-01 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
CN114341186A (en) | 2019-07-30 | 2022-04-12 | 魁尔斯弗生物治疗股份有限公司 | Bispecific anti-LRRC 15 and CD3 epsilon antibodies |
CN114174343A (en) | 2019-07-30 | 2022-03-11 | 小野药品工业株式会社 | Bispecific antibodies |
KR20220058540A (en) | 2019-07-31 | 2022-05-09 | 알렉터 엘엘씨 | Anti-MS4A4A antibodies and methods of use thereof |
WO2021019706A1 (en) | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Method for producing cell mass containing car-expressing immunocytes |
EP4007808A1 (en) | 2019-08-01 | 2022-06-08 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
AU2020319875A1 (en) | 2019-08-01 | 2022-02-17 | Incyte Corporation | A dosing regimen for an IDO inhibitor |
AU2020322474A1 (en) | 2019-08-01 | 2022-03-10 | Vaccinex,Inc. | Combined inhibition of semaphorin-4D and TGFβ and compositions therefor |
US20220275105A1 (en) | 2019-08-02 | 2022-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction |
JP2022543259A (en) | 2019-08-02 | 2022-10-11 | オレガ・バイオテック | Novel IL-17B antibody |
WO2021026028A1 (en) | 2019-08-02 | 2021-02-11 | Cytodyn Inc. | Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents |
EP4031658A1 (en) | 2019-08-07 | 2022-07-27 | DB Biotech, AS | Improved horseradish peroxidase polypeptides |
MX2022001515A (en) | 2019-08-07 | 2022-04-06 | Rakuten Medical Inc | Cetuximab-ir700 conjugate compositions. |
US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
AU2020329217A1 (en) | 2019-08-12 | 2022-07-28 | Aptevo Research And Development Llc | 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40 |
MX2022001841A (en) | 2019-08-12 | 2022-08-17 | Biond Biologics Ltd | Antibodies against ilt2 and use thereof. |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CR20220076A (en) | 2019-08-30 | 2022-06-24 | Agenus Inc | Anti-cd96 antibodies and methods of use thereof |
JP2022546061A (en) | 2019-08-30 | 2022-11-02 | 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Therapy induction and/or therapy monitoring for treatment of shock |
WO2021043206A1 (en) | 2019-09-03 | 2021-03-11 | 百奥泰生物制药股份有限公司 | Anti-tigit immunosuppressant and application thereof |
US20220332799A1 (en) | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
EP4025606A1 (en) | 2019-09-04 | 2022-07-13 | Y-Biologics Inc. | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
WO2021045184A1 (en) | 2019-09-04 | 2021-03-11 | 株式会社ペルセウスプロテオミクス | Therapeutic agent for polycythemia |
MX2022002981A (en) | 2019-09-10 | 2022-04-06 | Amgen Inc | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity. |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
JP2022548881A (en) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy |
MX2022003212A (en) * | 2019-09-18 | 2022-04-25 | Genentech Inc | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use. |
BR112022004851A2 (en) | 2019-09-19 | 2022-08-23 | Leap Therapeutics Inc | USE OF DKK-1 INHIBITORS TO TREAT CANCER |
MX2022003268A (en) | 2019-09-19 | 2022-06-02 | Seagen Inc | Selective drug release from internalized conjugates of biologically active compounds. |
EP4032907A4 (en) | 2019-09-20 | 2023-07-05 | Shanghai Genbase Biotechnology Co., Ltd. | Bcma-targeted antibody and chimeric antigen receptor |
EP4041767A1 (en) | 2019-09-26 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
CN114450304B (en) | 2019-09-27 | 2023-12-12 | 国家医疗保健研究所 | anti-Mullera tube inhibiting substance antibodies and uses thereof |
WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
JP2022550067A (en) | 2019-09-27 | 2022-11-30 | ヤンセン バイオテツク,インコーポレーテツド | Anti-CEACAM antibody and use thereof |
US20220290151A1 (en) | 2019-09-27 | 2022-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of müllerian inhibiting substance inhibitors for treating cancer |
KR20220070201A (en) | 2019-09-30 | 2022-05-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Anti-PD-1 antibodies and uses thereof |
AU2020358979A1 (en) | 2019-10-03 | 2022-04-21 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
CA3155634A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Anti-pd-l1 antibodies and antibody-drug conjugates |
WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
KR20220079606A (en) | 2019-10-04 | 2022-06-13 | 씨젠 인크. | Camptothecin Peptide Conjugate |
US20220363776A1 (en) | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
US20240050529A1 (en) | 2019-10-07 | 2024-02-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
JP2022552282A (en) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | Antibodies specific for glycosylated LAG3 and methods of use thereof |
EP3804754A1 (en) | 2019-10-09 | 2021-04-14 | OSE Immunotherapeutics | Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021076930A1 (en) | 2019-10-18 | 2021-04-22 | The Regents Of The University Of California | Plxdc activators and their use in the treatment of blood vessel disorders |
TW202128166A (en) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Combination therapies |
EP4048285A1 (en) | 2019-10-21 | 2022-08-31 | Novartis AG | Tim-3 inhibitors and uses thereof |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
CA3158638A1 (en) | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
EP4051298A1 (en) | 2019-11-01 | 2022-09-07 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
JP2022553813A (en) | 2019-11-08 | 2022-12-26 | アムジエン・インコーポレーテツド | Engineering charge-pair mutations for pairing hetero-IgG molecules |
WO2021097344A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
CA3158206A1 (en) * | 2019-11-15 | 2021-05-20 | Jonathan S. Wall | Modified immunoglobulins for targeting amyloid deposits cross-reference to related applications |
WO2021097338A1 (en) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
AU2020387709A1 (en) | 2019-11-18 | 2022-07-07 | Janssen Biotech, Inc. | Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof |
AU2019474716A1 (en) | 2019-11-19 | 2022-07-07 | Protalix Ltd. | Removal of constructs from transformed cells |
WO2021102049A1 (en) | 2019-11-19 | 2021-05-27 | Amgen Inc. | Novel multispecific antibody format |
EP3825330A1 (en) | 2019-11-19 | 2021-05-26 | International-Drug-Development-Biotech | Anti-cd117 antibodies and methods of use thereof |
CN114787181A (en) | 2019-11-21 | 2022-07-22 | Inserm(法国国家健康医学研究院) | Novel immunotherapy targeting PD-1 with anti-PD-1/IL-15 immunocytokines |
WO2021099600A1 (en) | 2019-11-22 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
CA3158661A1 (en) | 2019-11-22 | 2021-05-27 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
JP2023550743A (en) | 2019-11-22 | 2023-12-05 | メドイミューン・リミテッド | Fusion proteins containing E2 ubiquitin or ubiquitin-like conjugate domains and targeting the domain for specific proteolysis |
WO2021107082A1 (en) | 2019-11-27 | 2021-06-03 | 株式会社ペルセウスプロテオミクス | Therapeutic agent for carcinomatous peritonitis |
US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
CN115052626A (en) | 2019-12-03 | 2022-09-13 | 埃沃特克国际有限责任公司 | Interferon-associated antigen binding proteins for the treatment of hepatitis B infection |
JP2023504543A (en) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | MASP-2 inhibitors and methods of use |
US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
WO2021113780A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
JP2023504740A (en) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | Anti-idiotypic antibodies against BCMA target binding domains and related compositions and methods |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
WO2021111636A1 (en) | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | Anti-gdf15 antibody |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
EP4072683A1 (en) | 2019-12-09 | 2022-10-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Antibodies targeting cell surface deposited complement protein c3d and use thereof |
US20230227559A1 (en) | 2019-12-10 | 2023-07-20 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
WO2021119397A1 (en) | 2019-12-13 | 2021-06-17 | Rgenix, Inc. | Metal salts and uses thereof |
EP4047019A4 (en) | 2019-12-13 | 2023-11-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
CN115666704A (en) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract |
CR20220329A (en) | 2019-12-13 | 2022-11-23 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
JP2023509359A (en) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Combination anticancer therapy with inducers of iron-dependent cell degradation |
IL293751A (en) | 2019-12-18 | 2022-08-01 | Teneofour Inc | Heavy chain antibodies binding to cd38 |
CN115298213A (en) | 2019-12-19 | 2022-11-04 | 奎多公司 | Monoclonal antibody fusion |
AU2020409124A1 (en) | 2019-12-20 | 2022-06-30 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
JP2023507525A (en) | 2019-12-23 | 2023-02-22 | セレクティス | A Novel Mesothelin-Specific Chimeric Antigen Receptor (CAR) for Cancer Immunotherapy of Solid Tumors |
EP4081554A1 (en) | 2019-12-27 | 2022-11-02 | Affimed GmbH | Method for the production of bispecific fcyriii x cd30 antibody construct |
WO2021138454A1 (en) | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
CA3166549A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to cd33 and uses thereof |
EP4087874A1 (en) | 2020-01-06 | 2022-11-16 | HiFiBiO (HK) Limited | Anti-tnfr2 antibody and uses thereof |
CA3163988A1 (en) | 2020-01-07 | 2021-07-15 | Germain MARGALL DUCOS | Anti-galectin-9 antibody and uses thereof |
AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
BR112022013589A2 (en) | 2020-01-08 | 2022-09-13 | Regeneron Pharma | TREATMENT OF PROGRESSIVE OSSIFYING FIBRODYSPLASIA |
US20230192889A1 (en) | 2020-01-13 | 2023-06-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
TW202140553A (en) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | Antibody molecules to c5ar1 and uses thereof |
BR112022012310A2 (en) | 2020-01-17 | 2022-09-06 | Novartis Ag | A COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETYLING AGENT FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA |
CN115427447A (en) | 2020-01-17 | 2022-12-02 | 百进生物科技公司 | anti-TLR 7 agents and compositions and methods of making and using the same |
CN113138276B (en) | 2020-01-19 | 2022-09-16 | 厦门万泰凯瑞生物技术有限公司 | Method for detecting HBcAg and antibody |
TWI793503B (en) | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | ANTI-IL-1β ANTIBODIES |
US20230062361A1 (en) | 2020-01-21 | 2023-03-02 | Celex Oncology Innovations Limited | Monoclonal antibodies against neonatal nav1.5 |
JP2023511163A (en) | 2020-01-22 | 2023-03-16 | 上海森輝医薬有限公司 | Drug conjugate of eribulin derivative, preparation method thereof and pharmaceutical application thereof |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
EP4093426A1 (en) | 2020-01-24 | 2022-11-30 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
CN115087668A (en) | 2020-01-31 | 2022-09-20 | 奥斯瓦道·克鲁兹基金会 | Antibody, use thereof, pharmaceutical composition, diagnostic method for fungal infection, diagnostic kit for fungal infection, and therapeutic method for fungal infection |
EP4097143A1 (en) | 2020-01-31 | 2022-12-07 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
CA3166627A1 (en) | 2020-02-03 | 2021-08-12 | Davide Corti | Antibodies against sars-cov-2 and methods of using the same |
EP4100435A1 (en) | 2020-02-05 | 2022-12-14 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
US20230070181A1 (en) | 2020-02-05 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of cancer disease by targeting an epigenetic factor |
EP4103608A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
WO2021160266A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
CN113248611A (en) | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | anti-BCMA antibody, pharmaceutical composition and application thereof |
US20230096030A1 (en) | 2020-02-13 | 2023-03-30 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
JP2023513312A (en) | 2020-02-13 | 2023-03-30 | アムジェン インコーポレイテッド | Formulations of human anti-TSLP antibodies and methods of treating inflammatory diseases |
EP4103612A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
WO2021163588A1 (en) | 2020-02-13 | 2021-08-19 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
WO2021160269A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
UY39089A (en) | 2020-02-18 | 2021-08-31 | Amgen Inc | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF USE OF THE SAME |
EP4093762A1 (en) | 2020-02-20 | 2022-11-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Epstein-barr virus monoclonal antibodies and uses thereof |
EP4106806A1 (en) | 2020-02-21 | 2022-12-28 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
CA3168729A1 (en) | 2020-02-24 | 2021-09-02 | Melinda MATA | Methods for expanding t cells for the treatment of cancer and related malignancies |
CA3168882A1 (en) | 2020-02-25 | 2021-09-02 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
DK3872091T3 (en) | 2020-02-26 | 2023-09-11 | Vir Biotechnology Inc | ANTIBODIES AGAINST SARS-COV-2 |
EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
US20230105029A1 (en) | 2020-02-27 | 2023-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding il4r and uses thereof |
MX2022010207A (en) | 2020-02-27 | 2022-11-16 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock. |
CA3169447A1 (en) | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
JP2023516615A (en) | 2020-02-27 | 2023-04-20 | 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | DPP3 for NT-ADM Antibody Therapy Guidance, Monitoring, and Stratification in Patients with Shock |
JP2023516952A (en) | 2020-02-28 | 2023-04-21 | ジェンザイム・コーポレーション | Modified binding polypeptides for optimized drug conjugation |
US20230045494A1 (en) | 2020-02-28 | 2023-02-09 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
AU2021229611A1 (en) | 2020-03-03 | 2022-10-27 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
CA3174103A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
TW202200615A (en) | 2020-03-12 | 2022-01-01 | 美商安進公司 | Method for treatment and prophylaxis of crs in patients |
IL296385A (en) | 2020-03-16 | 2022-11-01 | Adrenomed Ag | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
JP2023518731A (en) | 2020-03-16 | 2023-05-08 | 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | DPP3 in patients infected with coronavirus |
EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
EP4121459A1 (en) | 2020-03-19 | 2023-01-25 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
AU2021243080A1 (en) | 2020-03-25 | 2022-09-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for antibody medicament conjugate |
EP4129345A4 (en) | 2020-03-25 | 2023-11-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody drug conjugate and use thereof |
CN115698069A (en) | 2020-03-26 | 2023-02-03 | 思进公司 | Methods of treating multiple myeloma |
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
WO2021202590A1 (en) | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
WO2021197340A1 (en) | 2020-03-31 | 2021-10-07 | 百奥泰生物制药股份有限公司 | Antibody and fusion protein for treating coronaviruses and use thereof |
EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
WO2021203024A1 (en) | 2020-04-03 | 2021-10-07 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
US20230174674A1 (en) | 2020-04-04 | 2023-06-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
WO2021205438A1 (en) | 2020-04-06 | 2021-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |
CA3077973A1 (en) | 2020-04-06 | 2021-10-06 | H. Lundbeck A/S | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
WO2021207348A1 (en) | 2020-04-07 | 2021-10-14 | Albert Einstein College Of Medicine | Method of treating and preventing ocular disease with hsv-2 delta gd |
EP4132954A1 (en) | 2020-04-08 | 2023-02-15 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of cdon inhibitors for the treatment of endothelial dysfunction |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
CN115697395A (en) | 2020-04-10 | 2023-02-03 | 瓦努迪斯有限公司 | Natural antibodies in prophylaxis and therapy |
BR112022020332A2 (en) | 2020-04-10 | 2022-12-13 | Seagen Inc | ANTIBODY-DRUG CONJUGATE COMPOUND, COMPOSITION, METHOD OF TREATMENT OF CANCER AND AN AUTOIMMUNE DISORDER |
CA3179937A1 (en) | 2020-04-10 | 2021-10-14 | Rakuten Medical, Inc. | Phthalocyanine dye compounds, conjugates and methods of use thereof |
CA3175523A1 (en) | 2020-04-13 | 2021-10-21 | Antti Virtanen | Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample |
BR112022020706A2 (en) | 2020-04-14 | 2022-11-29 | Vir Biotechnology Inc | ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF THEIR USE |
WO2021211924A1 (en) | 2020-04-16 | 2021-10-21 | Janssen Biotech, Inc. | Treatment of atopic dermatitis |
PE20230108A1 (en) | 2020-04-17 | 2023-01-25 | Zoetis Services Llc | VARIANTS OF CANINE ANTIBODIES |
EP4136109A1 (en) | 2020-04-17 | 2023-02-22 | Zoetis Services LLC | Feline antibody variants |
EP4136115A2 (en) | 2020-04-17 | 2023-02-22 | New York University | Therapeutic musk antibodies |
BR112022021085A2 (en) | 2020-04-21 | 2022-12-27 | Jjp Biologics Sp Z O O | HUMANIZED HUMAN ANTI-CD89 ANTIBODIES AND THEIR USES |
WO2021216756A2 (en) | 2020-04-22 | 2021-10-28 | Igm Biosciences, Inc. | Pd-1 agonist multimeric binding molecules |
BR112022020592A2 (en) | 2020-04-24 | 2022-11-29 | Sanofi Sa | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDIN AND TIPIRACILL |
KR20230005268A (en) | 2020-04-24 | 2023-01-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Anti-CD19 Antibodies and Uses Thereof |
BR112022020497A2 (en) | 2020-04-24 | 2022-12-06 | Sanofi Sa | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY AND FOLFOX CONJUGATES |
KR20230005176A (en) | 2020-04-24 | 2023-01-09 | 사노피 | Anti-tumor combination containing an anti-CEACAM5 antibody conjugate and cetuximab |
MX2022013402A (en) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri. |
EP4139363A1 (en) | 2020-04-24 | 2023-03-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
GB202006093D0 (en) | 2020-04-24 | 2020-06-10 | King S College London | Composition |
CN113637082A (en) | 2020-04-27 | 2021-11-12 | 启愈生物技术(上海)有限公司 | Bispecific antibody targeting human claudin and human PDL1 protein and application thereof |
MX2022013493A (en) | 2020-04-27 | 2023-02-22 | Magenta Therapeutics Inc | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS <i>IN VIVO. |
CN115996951A (en) | 2020-04-30 | 2023-04-21 | 赛罗帕私人有限公司 | anti-CD 103 antibodies |
US20230167193A1 (en) | 2020-05-01 | 2023-06-01 | Novartis Ag | Immunoglobulin variants |
EP4143236A1 (en) | 2020-05-01 | 2023-03-08 | Novartis AG | Engineered immunoglobulins |
WO2021225781A2 (en) | 2020-05-07 | 2021-11-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
EP4146690A1 (en) | 2020-05-08 | 2023-03-15 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 |
EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
AU2021271960A1 (en) | 2020-05-12 | 2023-02-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | ST2 antigen binding protein |
JP2023525053A (en) | 2020-05-12 | 2023-06-14 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | A new method to treat cutaneous T-cell lymphoma and TFH-derived lymphoma |
AU2020447878A1 (en) | 2020-05-12 | 2023-02-02 | Biotheus Inc. | Anti-CD73 antibody and use thereof |
US20230183366A1 (en) | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
EP4151655A1 (en) | 2020-05-14 | 2023-03-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
IL298184A (en) | 2020-05-15 | 2023-01-01 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Antibody drug conjugate, preparation method therefor and use thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021233962A1 (en) | 2020-05-19 | 2021-11-25 | Institut Curie | Methods for the diagnosis and treatment of cytokine release syndrome |
JP2023527293A (en) | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | MAGEB2 binding construct |
KR20230042222A (en) | 2020-05-26 | 2023-03-28 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Polypeptides and Uses Thereof for Vaccine Purposes |
KR20230029671A (en) | 2020-05-27 | 2023-03-03 | 아리아리스 테라퓨틱스, 인크. | Anti-human NR1 antibody derivatives |
EP3915641A1 (en) | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
WO2021243320A2 (en) | 2020-05-29 | 2021-12-02 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3 |
CN113754766A (en) | 2020-06-02 | 2021-12-07 | 明慧医药(上海)有限公司 | anti-B7-H3 antibody and preparation and application thereof |
IL298111A (en) | 2020-06-02 | 2023-01-01 | Arcus Biosciences Inc | Antibodies to tigit |
WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
CN115803062A (en) | 2020-06-03 | 2023-03-14 | 博泰康医药公司 | Antibodies to trophoblast cell surface antigen 2 (TROP-2) |
CN116529267A (en) | 2020-06-04 | 2023-08-01 | 肯乔克蒂生物技术股份有限公司 | ABCG2 efflux pump-cancer antigen multispecific antibodies and related compositions, reagents, kits and methods |
CN115917317A (en) | 2020-06-08 | 2023-04-04 | 詹森生物科技公司 | Cell-based assay for determining in vitro tumor killing activity of immune cells expressing chimeric antigens |
KR20230021747A (en) | 2020-06-11 | 2023-02-14 | 백시넥스 인코포레이티드 | Use of CXCL13 Binding Molecules to Promote Peripheral Nerve Regeneration |
IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
TW202207983A (en) | 2020-06-12 | 2022-03-01 | 美商維爾生物科技股份有限公司 | Antibody therapies for sars-cov-2 infection |
EP4165076A1 (en) | 2020-06-15 | 2023-04-19 | Sarepta Therapeutics, Inc. | Adeno-associated virus antibodies and fragments thereof |
EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
EP4169949A1 (en) | 2020-06-23 | 2023-04-26 | Jiangsu Kanion Pharmaceutical Co., Ltd. | Anti-cd38 antibody and use thereof |
EP4172206A1 (en) | 2020-06-24 | 2023-05-03 | Visterra, Inc. | Antibody molecules to april and uses thereof |
US20230305023A1 (en) | 2020-06-25 | 2023-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment and diagnostic of pathological conditions associated with intense stress |
AU2021297152A1 (en) | 2020-06-25 | 2023-02-02 | The Sydney Children's Hospitals Network | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
TW202216771A (en) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | Ccr8 antibodies for therapeutic applications |
JP2023532339A (en) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Viruses engineered to promote sanotransmission and their use in treating cancer |
WO2022005883A1 (en) | 2020-06-29 | 2022-01-06 | Zoetis Services Llc | Feline antibody variants for improving stability |
US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
TW202214683A (en) | 2020-07-09 | 2022-04-16 | 大陸商北京凱因科技股份有限公司 | Antibody binding to hepatitis b virus surface antigen and use thereof |
JP2023534683A (en) | 2020-07-13 | 2023-08-10 | 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 | ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF |
TW202216761A (en) | 2020-07-16 | 2022-05-01 | 瑞士商諾華公司 | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
EP4182475A2 (en) | 2020-07-17 | 2023-05-24 | Onena Medicines S.L. | Antibodies against lefty proteins |
AU2021311701A1 (en) | 2020-07-21 | 2023-02-16 | Shanghai Junshi Biosciences Co., Ltd. | Anti-CTLA-4 antibody and use thereof |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
US20230303711A1 (en) | 2020-07-31 | 2023-09-28 | Bio-Thera Solutions, Ltd. | Anti-cd47 antibody and use thereof |
KR20230042301A (en) | 2020-08-04 | 2023-03-28 | 애벗트 라보라토리이즈 | Improved methods and kits for detecting SARS-COV-2 proteins in samples |
KR20230084469A (en) | 2020-08-04 | 2023-06-13 | 애보트 라피드 다이어그노스틱스 인터내셔널 언리미티드 컴퍼니 | Assays to detect SARS-COV-2 |
US20230324408A1 (en) | 2020-08-05 | 2023-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
US20230287126A1 (en) | 2020-08-07 | 2023-09-14 | Bio-Thera Solutions, Ltd. | Anti-pd-l1 antibody and use thereof |
KR20230077722A (en) | 2020-08-10 | 2023-06-01 | 지브이20 테라퓨틱스 엘엘씨 | Compositions and methods for targeting IGSF8 to treat autoimmune diseases and cancer |
WO2022035998A1 (en) | 2020-08-11 | 2022-02-17 | City Of Hope | Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells |
BR112023002301A2 (en) | 2020-08-12 | 2023-10-03 | Biond Biologics Ltd | ANTIBODIES AGAINST ILT2 AND THEIR USE |
WO2022034228A1 (en) | 2020-08-14 | 2022-02-17 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
KR20230052279A (en) | 2020-08-19 | 2023-04-19 | 아스테라스 세이야쿠 가부시키가이샤 | Human non-naturally occurring modified FC region of IGG that specifically binds non-naturally occurring modified FC receptors |
EP4200338A1 (en) | 2020-08-20 | 2023-06-28 | Amgen Inc. | Antigen binding proteins with non-canonical disulfide in fab region |
US20230331862A1 (en) * | 2020-08-21 | 2023-10-19 | Shanghai GenBase Biotechnology Co., Ltd. | Antibody specifically bound to glycosylated ceacam5 |
TW202227616A (en) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | Methods for isolating cd8+ selected t cells |
US20240009310A1 (en) | 2020-08-24 | 2024-01-11 | Charité - Universitätsmedizin Berlin | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 |
US20230321242A1 (en) | 2020-08-24 | 2023-10-12 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
MX2023002093A (en) | 2020-08-25 | 2023-03-15 | Bristol Myers Squibb Co | Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies. |
EP4204458A1 (en) | 2020-08-26 | 2023-07-05 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
KR20230074144A (en) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | Antibody molecules that bind to NKp30 and uses thereof |
CN114106173A (en) | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | anti-OX 40 antibodies, pharmaceutical compositions and uses thereof |
AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
KR20230060509A (en) | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | Nectin-4 Antibodies and Uses Thereof |
MX2023002330A (en) | 2020-09-04 | 2023-03-21 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof. |
WO2022049273A1 (en) | 2020-09-07 | 2022-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of inflammatory bowel diseases |
EP4211166A1 (en) | 2020-09-11 | 2023-07-19 | MedImmune Limited | Therapeutic b7-h4 binding molecules |
EP4211663A2 (en) | 2020-09-12 | 2023-07-19 | MedImmune Limited | A scoring method for an anti-b7h4 antibody-drug conjugate therapy |
PE20240214A1 (en) | 2020-09-15 | 2024-02-16 | Bayer Ag | NEW ANTI-A2AP ANTIBODIES AND USES THEREOF |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
US20230357815A1 (en) | 2020-09-22 | 2023-11-09 | Bristol-Myers Squibb Company | Methods for increasing productivity of therapeutic proteins |
GB202015235D0 (en) | 2020-09-25 | 2020-11-11 | Ucl Business Plc | Anti-CD45 antibodies and related therapeutics |
EP4217385A2 (en) | 2020-09-28 | 2023-08-02 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 |
CA3194936A1 (en) | 2020-09-28 | 2022-03-31 | Zoetis Services Llc | Canine antibody variants |
WO2022067348A1 (en) | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
EP4221744A1 (en) | 2020-09-29 | 2023-08-09 | Zoetis Services LLC | Feline antibody variants |
WO2022074646A1 (en) | 2020-10-05 | 2022-04-14 | Protalix Ltd. | Dicer-like knock-out plant cells |
US20230375571A1 (en) | 2020-10-05 | 2023-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling |
EP4225786A2 (en) | 2020-10-07 | 2023-08-16 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
US20230365709A1 (en) | 2020-10-08 | 2023-11-16 | Affimed Gmbh | Trispecific binders |
WO2022075439A1 (en) | 2020-10-08 | 2022-04-14 | 国立大学法人東海国立大学機構 | Method for determining sensitivity or medicinal effect of anti-transferrin receptor antibody |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
AU2021360782A1 (en) | 2020-10-14 | 2023-06-08 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
EP4229081A1 (en) | 2020-10-15 | 2023-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
US20230414700A1 (en) | 2020-10-15 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tg2 inhibitors for improving mucociliary clearance in respiratory diseases |
EP4229086A1 (en) | 2020-10-15 | 2023-08-23 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
CN116670169A (en) | 2020-10-16 | 2023-08-29 | 魁尔斯弗生物治疗股份有限公司 | Multispecific binding compounds that bind to PD-L1 |
AU2021366287A1 (en) | 2020-10-20 | 2023-04-13 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
WO2022084399A1 (en) | 2020-10-21 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | C-terminal sparc fragments for treating cancer |
WO2022090801A2 (en) | 2020-10-26 | 2022-05-05 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
CA3197465A1 (en) | 2020-11-02 | 2022-05-05 | UCB Biopharma SRL | Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
WO2022097090A1 (en) | 2020-11-05 | 2022-05-12 | Novartis Ag | Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors |
EP4240761A1 (en) | 2020-11-05 | 2023-09-13 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease |
AU2021374036A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022096633A1 (en) | 2020-11-06 | 2022-05-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treating polycystic ovary syndrome (pcos) |
IL301926A (en) | 2020-11-06 | 2023-06-01 | Amgen Inc | Antigen binding domain with reduced clipping rate |
EP4242232A1 (en) | 2020-11-06 | 2023-09-13 | Bio-Thera Solutions, Ltd. | Bispecific antibody and use thereof |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
CN116472288A (en) | 2020-11-06 | 2023-07-21 | 诺华股份有限公司 | Antibody Fc variants |
AR124019A1 (en) | 2020-11-06 | 2023-02-01 | Amgen Res Munich Gmbh | POLYPEPTIDE CONSTRUCTIONS THAT BIND CD3 |
EP4240768A2 (en) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
PE20231947A1 (en) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | ANTIBODY AND DRUG CONJUGATES |
JP2023548595A (en) | 2020-11-10 | 2023-11-17 | アムジエン・インコーポレーテツド | Novel linkers for multispecific antigen binding domains |
US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
WO2022101302A1 (en) | 2020-11-12 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
MX2023005609A (en) | 2020-11-13 | 2023-05-29 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells. |
PE20240224A1 (en) | 2020-11-16 | 2024-02-16 | Astellas Pharma Inc | BISPECIFIC ANTI-TSPAN8/ANTI-CD3 ANTIBODY AND ANTI-TSPAN8 ANTIBODY |
MX2023005896A (en) | 2020-11-20 | 2023-07-03 | Zoetis Services Llc | Bovine antibody variants. |
EP4247845A1 (en) | 2020-11-23 | 2023-09-27 | VIR Biotechnology, Inc. | Anti-influenza antibodies and combinations thereof |
MX2023005654A (en) | 2020-11-23 | 2023-07-31 | Vir Biotechnology Inc | Broadly neutralizing antibodies against influenza neuraminidase. |
AU2021382620A1 (en) | 2020-11-23 | 2023-06-15 | Humabs Biomed Sa | Antibodies against influenza a viruses |
TW202235107A (en) | 2020-11-25 | 2022-09-16 | 美商維爾生物科技股份有限公司 | Antibodies that bind to multiple betacoronaviruses |
EP4251282A1 (en) | 2020-11-27 | 2023-10-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
TW202241436A (en) | 2020-11-30 | 2022-11-01 | 美商英塞特公司 | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
MX2023006426A (en) | 2020-12-01 | 2023-07-17 | Aptevo Res And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies. |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022119841A1 (en) | 2020-12-01 | 2022-06-09 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
KR20230117169A (en) | 2020-12-02 | 2023-08-07 | 알렉터 엘엘씨 | Methods of Using Anti-Sortilin Antibodies |
EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
TW202237638A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
TW202237639A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
US20240002911A1 (en) | 2020-12-10 | 2024-01-04 | Phitonex, Inc. | Methods Of Signal Amplification |
WO2022125755A1 (en) | 2020-12-10 | 2022-06-16 | Thermo Fisher Scientific Inc. | Method and composition for multiplexed and multimodal single cell analysis |
US20240052042A1 (en) | 2020-12-14 | 2024-02-15 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof |
MX2023006898A (en) | 2020-12-18 | 2023-06-26 | Zoetis Services Llc | Mutations in feline antibody constant regions. |
CA3202339A1 (en) | 2020-12-18 | 2022-06-23 | Mei Jang | Protein compositions and methods for producing and using the same |
EP4262976A1 (en) | 2020-12-21 | 2023-10-25 | Flagship Pioneering Innovations V, Inc. | Use of cell turnover factors for increasing tissue regeneration |
CA3205280A1 (en) | 2020-12-23 | 2022-06-30 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
WO2022144384A1 (en) | 2020-12-29 | 2022-07-07 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-april antibodies and uses thereof |
KR20230157940A (en) | 2020-12-29 | 2023-11-17 | 인사이트 코포레이션 | Combination therapy comprising A2A/A2B inhibitors, PD-1/PD-L1 inhibitors and anti-CD73 antibodies |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
CN114685669A (en) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | Antibodies that bind TROP2 and uses thereof |
US20240092892A1 (en) | 2020-12-30 | 2024-03-21 | Bio-Thera Solutions, Ltd. | Anti-cldn18.2 antibody, and preparation method therefor and use thereof |
CN117043189A (en) | 2020-12-31 | 2023-11-10 | 诺纳生物(苏州)有限公司 | Human LIFR antigen binding protein and its preparation method and application |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
CN116963750A (en) | 2021-01-06 | 2023-10-27 | 通尼克斯制药有限公司 | Methods of inducing immune tolerance using modified anti-CD 154 antibodies |
AU2022207252A1 (en) | 2021-01-13 | 2023-08-03 | Astellas Pharma Inc. | MULTISPECIFIC ANTIBODY BINDING TO ActRIIA, ActRIIB, AND Fn14 |
CN114763381A (en) | 2021-01-13 | 2022-07-19 | 博生吉医药科技(苏州)有限公司 | B7-H3 chimeric antigen receptor modified T cell and application thereof |
EP4277664A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
WO2022153195A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
BR112023014128A2 (en) | 2021-01-15 | 2023-10-31 | Seagen Inc | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES |
WO2022155410A1 (en) | 2021-01-15 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions relating to anti-mfsd2a antibodies |
US20220226442A1 (en) | 2021-01-20 | 2022-07-21 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
CA3208778A1 (en) | 2021-01-22 | 2022-07-28 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
EP4281484A1 (en) | 2021-01-22 | 2023-11-29 | Bionecure Therapeutics, Inc. | Anti-her-2/trop-2 constructs and uses thereof |
TW202246314A (en) * | 2021-01-28 | 2022-12-01 | 美商特蘭治療公司 | Anti-spike glycoprotein antibodies and the therapeutic use thereof |
CN116802205A (en) | 2021-01-28 | 2023-09-22 | 硕腾服务有限责任公司 | Mutations in canine antibody constant regions |
US20240059789A1 (en) | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
WO2022165277A1 (en) | 2021-01-29 | 2022-08-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer |
EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
JP2024504195A (en) | 2021-01-29 | 2024-01-30 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Chlamydia trachomatis antigenic polypeptides and their use for vaccine purposes |
CA3206244A1 (en) | 2021-02-03 | 2022-08-11 | Kung-Pern WANG | Immunostimulatory compounds and conjugates |
AU2022219332A1 (en) | 2021-02-09 | 2023-09-21 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cd112r antibody and use thereof |
EP4293038A1 (en) | 2021-02-10 | 2023-12-20 | Xiamen University | Epitope peptide and antibody for preventing and treating eb virus infection and related diseases |
JP2024507124A (en) | 2021-02-11 | 2024-02-16 | ネクチン セラピューティクス リミテッド | Antibodies against CD112R and uses thereof |
CA3208365A1 (en) | 2021-02-15 | 2022-08-18 | Chantal KUHN | Cell therapy compositions and methods for modulating tgf-b signaling |
JP2024506694A (en) | 2021-02-16 | 2024-02-14 | ヤンセン バイオテツク,インコーポレーテツド | Materials and methods for enhanced linker targeting |
EP4294827A1 (en) | 2021-02-19 | 2023-12-27 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
CN117321076A (en) | 2021-02-19 | 2023-12-29 | 美国卫生及公众服务部代表 | Single domain antibodies neutralizing SARS-CoV-2 |
JP2022128212A (en) * | 2021-02-22 | 2022-09-01 | シスメックス株式会社 | Monoclonal antibody, measurement reagent for cytokeratin 18 fragment, reagent kit, and measurement method |
CA3211686A1 (en) | 2021-02-26 | 2022-09-01 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
WO2022184853A1 (en) | 2021-03-03 | 2022-09-09 | Pierre Fabre Medicament | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
AU2022230408A1 (en) | 2021-03-03 | 2023-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | La protien as a novel regulator of osteoclastogenesis |
WO2022184910A1 (en) | 2021-03-04 | 2022-09-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of a periostin antibody for treating inflammation, fibrosis and lung diseases |
JP2024512337A (en) | 2021-03-05 | 2024-03-19 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | Anti-CLDN6 antibody and its use |
EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
MX2023008176A (en) | 2021-03-09 | 2023-07-18 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Ror1 binding protein and use thereof. |
CN117157319A (en) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | Heterodimeric antibodies that bind CD3 and CLDN6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
WO2022190034A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
WO2022197782A1 (en) | 2021-03-17 | 2022-09-22 | Receptos Llc | Methods of treating atopic dermatitis with anti il-13 antibodies |
CA3213625A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2022197947A1 (en) | 2021-03-18 | 2022-09-22 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
EP4308607A2 (en) | 2021-03-18 | 2024-01-24 | MedImmune Limited | Therapeutic binding molecule that binds to ccr9 |
AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
KR20230158573A (en) | 2021-03-22 | 2023-11-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods for Assessing Potency of Viral Vector Particles |
KR20230159851A (en) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | How to Determine the Potency of a Therapeutic Cell Composition |
WO2022204274A1 (en) | 2021-03-23 | 2022-09-29 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
AU2022246048A1 (en) | 2021-03-26 | 2023-08-31 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022201122A1 (en) | 2021-03-26 | 2022-09-29 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
EP4314047A1 (en) | 2021-03-30 | 2024-02-07 | Bayer Aktiengesellschaft | Anti-sema3a antibodies and uses thereof |
KR20230165276A (en) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Thanotransmission polypeptides and their use in the treatment of cancer |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
EP4314078A1 (en) | 2021-04-02 | 2024-02-07 | Amgen Inc. | Mageb2 binding constructs |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
WO2022215054A1 (en) | 2021-04-09 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
CN117440798A (en) | 2021-04-12 | 2024-01-23 | Acm 生物实验室私人有限公司 | Polymer vesicles comprising soluble encapsulated polynucleotides and ionizable lipids, methods of making and uses thereof |
WO2022218998A1 (en) | 2021-04-13 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating hepatitis b and d virus infection |
EP4323402A1 (en) | 2021-04-14 | 2024-02-21 | Villaris Therapeutics, Inc. | Anti-cd122 antibodies and uses thereof |
AU2022262600A1 (en) | 2021-04-20 | 2023-10-05 | Seagen Inc. | Modulation of antibody-dependent cellular cytotoxicity |
CN117651714A (en) | 2021-04-20 | 2024-03-05 | 美国安进公司 | Balanced charge distribution in electrostatic steering of chain pairing in multispecific and monovalent IgG molecule assembly |
CR20230490A (en) | 2021-04-22 | 2023-11-16 | Nat Cancer Ct | Anti-cldn4/anti-cd137 bispecific antibody |
EP4326762A2 (en) | 2021-04-23 | 2024-02-28 | Amgen Inc. | Modified anti-tslp antibodies |
CA3216655A1 (en) | 2021-04-23 | 2022-10-27 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
KR20240001136A (en) | 2021-04-23 | 2024-01-03 | 킹스칼리지런던 | Compositions Comprising IgE Antibodies |
EP4330284A2 (en) | 2021-04-26 | 2024-03-06 | Millennium Pharmaceuticals, Inc. | Anti-clec12a antibodies and uses thereof |
WO2022232035A1 (en) | 2021-04-26 | 2022-11-03 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
WO2022232376A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
TW202309088A (en) | 2021-04-30 | 2023-03-01 | 法商皮爾法伯製藥公司 | New stable anti-vista antibody |
WO2022232488A1 (en) | 2021-04-30 | 2022-11-03 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
WO2022229412A1 (en) | 2021-04-30 | 2022-11-03 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
WO2022235628A1 (en) | 2021-05-04 | 2022-11-10 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
CN117279947A (en) | 2021-05-06 | 2023-12-22 | 安进研发(慕尼黑)股份有限公司 | Antigen binding molecules targeting CD20 and CD22 for use in proliferative diseases |
WO2022235940A1 (en) | 2021-05-06 | 2022-11-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
WO2022241057A1 (en) | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
AU2022279156A1 (en) | 2021-05-18 | 2023-11-02 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
EP4340876A1 (en) | 2021-05-19 | 2024-03-27 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate combination therapy with bevacizumab |
WO2022243937A1 (en) | 2021-05-20 | 2022-11-24 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
CA3218489A1 (en) | 2021-05-24 | 2022-12-01 | Vir Biotechnology, Inc. | Engineered polypeptides |
EP4347657A1 (en) | 2021-05-25 | 2024-04-10 | Seagen Inc. | Methods of quantifying anti-cd40 antibodies |
KR20240015670A (en) | 2021-05-28 | 2024-02-05 | 씨젠 인크. | Anthracycline antibody conjugate |
EP4348263A1 (en) | 2021-05-28 | 2024-04-10 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
WO2022253756A1 (en) | 2021-06-01 | 2022-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of b cell depleting agents for the treatment of rheumatic heart disease |
US11345742B1 (en) * | 2021-06-07 | 2022-05-31 | Ossianix, Inc. | Shark VNARs for treating COVID-19 |
CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
AU2022288123A1 (en) | 2021-06-09 | 2023-11-30 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
EP4351732A1 (en) | 2021-06-09 | 2024-04-17 | Evotec International GmbH | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection |
AU2022293999A1 (en) | 2021-06-14 | 2023-11-30 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
BR112023026199A2 (en) | 2021-06-14 | 2024-03-05 | Abbott Lab | METHODS FOR DIAGNOSING OR ASSISTING IN THE DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, OVERPRESSURIZATION WAVE AND/OR GUST OF WIND |
EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
EP4355780A1 (en) | 2021-06-18 | 2024-04-24 | Alligator Bioscience AB | Novel combination therapies and uses thereof |
AU2022291974A1 (en) | 2021-06-18 | 2024-01-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-il-36r antibody and use thereof |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
WO2022269473A1 (en) | 2021-06-23 | 2022-12-29 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
KR20240025597A (en) | 2021-06-29 | 2024-02-27 | 씨젠 인크. | Methods of treating cancer with a combination of afucosylated anti-CD70 antibody and CD47 antagonist |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
TW202315638A (en) | 2021-07-01 | 2023-04-16 | 美商得納利醫療公司 | Oligonucleotide conjugates targeted to the transferrin receptor |
WO2023275621A1 (en) | 2021-07-01 | 2023-01-05 | Compugen Ltd. | Anti-tigit and anti-pvrig in monotherapy and combination treatments |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-il12/il23 antibody compositions |
AU2022306144A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023285362A1 (en) | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
WO2023005805A1 (en) | 2021-07-26 | 2023-02-02 | 北京万泰生物药业股份有限公司 | General affinity epitope polypeptide for human rhinovirus, and antibody and uses thereof |
WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
AU2022318416A1 (en) | 2021-07-29 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
IL310437A (en) | 2021-07-29 | 2024-03-01 | Inst Nat Sante Rech Med | Humanized anti-human βig-h3 protein and uses thereof |
WO2023006391A1 (en) | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Anti-cd47 antibodies and use thereof |
AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
WO2023006390A1 (en) | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Mesothelin antibodies and use thereof |
AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
WO2023012343A1 (en) | 2021-08-06 | 2023-02-09 | Institut Du Cancer De Montpellier | Methods for the treatment of cancer |
AU2022328390A1 (en) | 2021-08-10 | 2024-03-21 | Adimab, Llc | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023019200A1 (en) | 2021-08-11 | 2023-02-16 | Viela Bio, Inc. | Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
IL310662A (en) | 2021-08-23 | 2024-04-01 | Immunitas Therapeutics Inc | Anti-cd161 antibodies and uses thereof |
CN116059391A (en) | 2021-08-26 | 2023-05-05 | 上海君实生物医药科技股份有限公司 | anti-CLDN-18.2 antibody drug conjugate and use thereof |
AU2022335718A1 (en) | 2021-08-26 | 2024-03-28 | Glycanostics S.R.O | Glycoprotein biomarkers for diagnosing cancer |
CN117836003A (en) | 2021-08-26 | 2024-04-05 | 株式会社英仙蛋白质科学 | ROS (reactive oxygen species) production enhancer |
CN117813325A (en) | 2021-08-27 | 2024-04-02 | H.隆德贝克有限公司 | Treatment of cluster headache with anti-CGRP antibodies |
WO2023025932A1 (en) | 2021-08-27 | 2023-03-02 | Medimmune Limited | Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody |
CN117881784A (en) | 2021-08-31 | 2024-04-12 | 大正制药株式会社 | Anti-growth hormone antibodies |
AU2022339759A1 (en) | 2021-08-31 | 2024-03-07 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
CA3230613A1 (en) | 2021-09-01 | 2023-03-09 | Daren J. AUSTIN | Antibody therapies for sars-cov-2 infection in pediatric subjects |
WO2023034871A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
WO2023031366A1 (en) | 2021-09-02 | 2023-03-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
AU2022346688A1 (en) | 2021-09-14 | 2024-04-04 | Glycanostics S.R.O | Use of lectins to determine mammaglobin-a glycoforms in breast cancer |
WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023044280A1 (en) | 2021-09-20 | 2023-03-23 | Eli Lilly And Company | Anti-il-1-beta antibodies |
WO2023049687A1 (en) | 2021-09-21 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
TW202327650A (en) | 2021-09-23 | 2023-07-16 | 美商思進公司 | Methods of treating multiple myeloma |
CA3232171A1 (en) | 2021-09-24 | 2023-03-30 | Zhenzhen Lu | Anti-cd40 antibody and use thereof |
WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2023048726A1 (en) | 2021-09-27 | 2023-03-30 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
CA3232176A1 (en) | 2021-09-30 | 2023-04-06 | Beth MCQUISTON | Methods and systems of diagnosing brain injury |
CA3232806A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
WO2023064947A1 (en) | 2021-10-15 | 2023-04-20 | Regenxbio Inc. | Antibodies and methods of using thereof |
CA3235627A1 (en) | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
TW202330612A (en) | 2021-10-20 | 2023-08-01 | 日商武田藥品工業股份有限公司 | Compositions targeting bcma and methods of use thereof |
GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
CA3234598A1 (en) | 2021-10-27 | 2023-05-04 | Daniel Olive | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
WO2023073599A1 (en) | 2021-10-28 | 2023-05-04 | Novartis Ag | Engineered fc variants |
WO2023075702A1 (en) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US11542340B1 (en) | 2021-10-29 | 2023-01-03 | Biodesix, Inc. | Antibodies targeting pulmonary nodule specific biomarkers and uses thereof |
WO2023081160A1 (en) | 2021-11-02 | 2023-05-11 | Visterra, Inc. | Fc variants with abolished binding to fcgammar and c1q |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
AR127568A1 (en) | 2021-11-03 | 2024-02-07 | Affimed Gmbh | CD16A BISPECIFIC LIGANDS |
WO2023079057A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
EP4180518A1 (en) | 2021-11-12 | 2023-05-17 | Istituto Europeo di Oncologia S.r.l. | T cells and uses thereof |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
TW202334202A (en) | 2021-11-16 | 2023-09-01 | 瑞士商Ac免疫有限公司 | Novel molecules for therapy and diagnosis |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023088968A1 (en) | 2021-11-17 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Universal sarbecovirus vaccines |
WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023102077A1 (en) | 2021-12-01 | 2023-06-08 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
WO2023102463A1 (en) | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
WO2023104904A2 (en) | 2021-12-08 | 2023-06-15 | Genclis | The sars-cov-2 and variants use two independent cell receptors to replicate |
WO2023105528A1 (en) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
TW202334231A (en) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | Treatment paradigm for an anti-cd19 antibody therapy |
WO2023129942A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
US20230227545A1 (en) | 2022-01-07 | 2023-07-20 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
TW202342548A (en) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | Anti-idiotype antibody molecules and uses thereof |
US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
WO2023156549A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
TW202337905A (en) | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | Glycosylated form of anti-il13r antibody |
WO2023166081A1 (en) | 2022-03-02 | 2023-09-07 | Heidelberg Immunotherapeutics Gmbh | Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023170239A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Methods and tools for conjugation to antibodies |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
TW202345899A (en) | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
TW202400636A (en) | 2022-03-11 | 2024-01-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
TW202346355A (en) | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
TW202400137A (en) | 2022-03-17 | 2024-01-01 | 美商思進公司 | Camptothecin conjugates |
EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
US20240103010A1 (en) | 2022-03-18 | 2024-03-28 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
TW202402790A (en) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | Methods for reducing respiratory infections |
WO2023186968A1 (en) | 2022-03-29 | 2023-10-05 | Netris Pharma | Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
WO2023201256A1 (en) | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
US20230357381A1 (en) | 2022-04-26 | 2023-11-09 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
TW202346368A (en) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2023218099A1 (en) | 2022-05-13 | 2023-11-16 | argenx BV | In utero treatment of a fetus having genetic disease/neuromuscular disease |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
US20230374122A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
WO2023230448A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Combination immunotherapy for influenza |
WO2023230445A2 (en) | 2022-05-23 | 2023-11-30 | Humabs Biomed Sa | Broadly neutralizing antibodies against influenza neuraminidase |
WO2023230532A1 (en) | 2022-05-26 | 2023-11-30 | Compugen Ltd. | Anti-tigit antibody formulation |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
EP4296279A1 (en) | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
WO2023247050A1 (en) | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
WO2024003103A1 (en) | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
GB202209786D0 (en) | 2022-07-04 | 2022-08-17 | Ucl Business Ltd | B7H3 Binders |
WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
WO2024015463A1 (en) | 2022-07-12 | 2024-01-18 | Leap Therapeutics, Inc. | Combination therapy |
WO2024013724A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody-drug conjugates |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
GB202210679D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-12rb2 |
GB202210680D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-35r |
WO2024018426A1 (en) | 2022-07-22 | 2024-01-25 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
US20240108744A1 (en) | 2022-07-27 | 2024-04-04 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
WO2024026411A1 (en) | 2022-07-27 | 2024-02-01 | Humabs Biomed Sa | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
WO2024030577A1 (en) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024042212A1 (en) | 2022-08-26 | 2024-02-29 | Medimmune Limited | Treatment of asthma with an anti-interleukin-33 antibody |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024050354A1 (en) | 2022-08-31 | 2024-03-07 | Washington University | Alphavirus antigen binding antibodies and uses thereof |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024050526A1 (en) | 2022-09-02 | 2024-03-07 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating long qt syndrome |
WO2024054157A1 (en) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
WO2024052517A2 (en) | 2022-09-09 | 2024-03-14 | Bayer Aktiengesellschaft | Medical use of ccr8 antibodies and dosing schedule |
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024056862A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
US20240101718A1 (en) | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
EP4345109A1 (en) | 2022-09-30 | 2024-04-03 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease |
WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
GB202215115D0 (en) | 2022-10-13 | 2022-11-30 | Univ Nottingham | VEGF antibodies |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4845198A (en) * | 1984-05-21 | 1989-07-04 | Immunex Corporation | Hybridoma antibody which binds IL-2 receptor |
US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
JPS6147500A (en) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
JPS61134325A (en) * | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
AU596585B2 (en) * | 1985-03-18 | 1990-05-10 | Genelabs Incorporated | Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector |
US4816565A (en) | 1985-08-13 | 1989-03-28 | Tasuku Honjo | Interleukin 2 receptor and a method for production thereof |
US5336489A (en) | 1985-09-05 | 1994-08-09 | The Beth Israel Hospital Association | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins |
DE3689123T2 (en) * | 1985-11-01 | 1994-03-03 | Xoma Corp | MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE. |
US5552304A (en) | 1985-11-19 | 1996-09-03 | Schering Corporation | CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4) |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
ATE143052T1 (en) * | 1986-07-07 | 1996-10-15 | Centocor Inc | CHIMERIC MUINE-HUMAN IMMUNOGLOBULIN SPECIFIC FOR TUMOR-ASSOCIATED 17-1A ANTIGEN |
US5362490A (en) | 1986-07-25 | 1994-11-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Human myelomonocyte interferon-gamma, and process for preparation and use thereof |
IL84285A (en) * | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
US4975467A (en) | 1987-03-17 | 1990-12-04 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions |
NL8700927A (en) * | 1987-04-16 | 1988-11-16 | Stichting Rega V Z W | ANTI-INTERFERON GAMMA ANTIBODIES; AND THEIR THERAPEUTIC APPLICATION. |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
CA1335792C (en) | 1987-08-18 | 1995-06-06 | Chaim O. Jacob | Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
AU625613B2 (en) | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
CA1339198C (en) * | 1988-02-12 | 1997-08-05 | Gregory Paul Winter | Antibodies to the antigen campath-1 |
JPH02503867A (en) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | IL-2 receptor-specific chimeric antibody |
EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
KR0161525B1 (en) * | 1988-10-19 | 1998-12-01 | 리챠드 지. 워터맨 | A novel family of high affinity, modified antibodies for cancer treatment |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2011450C (en) * | 1989-03-07 | 2002-06-04 | Tadatsugu Taniguchi | Recombinant b-chain of the il-2 receptor |
GB8905400D0 (en) | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
IT1231727B (en) | 1989-08-11 | 1991-12-21 | Enrico Savoldi | USEFUL PEPTIDES FOR THE DETERMINATION AND PURIFICATION OF ANTIBODIES INTERFERONE RANGE. |
IL91562A0 (en) | 1989-09-07 | 1990-04-29 | Yeda Res & Dev | Interferon-gamma receptor fragment and its production |
GB2268745B (en) | 1989-12-21 | 1994-05-11 | Celltech Ltd | Heavy and light chains having a variable domain comprising acceptor framework residues and donor antigen binding residues |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE4014753A1 (en) | 1990-05-08 | 1991-11-14 | Elpag Ag Chur | PIPE RADIATOR WITH FUSE |
US5192773A (en) | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE122004000008I1 (en) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanized heregulin antibody. |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2149529C (en) | 1992-11-16 | 2006-05-02 | Fernado J. R. Do Couto | Peptides and anti-sense peptides with broad neoplastic specificity |
DE69322289T2 (en) | 1992-12-29 | 1999-05-20 | Genentech Inc | TREATMENT OF INFLAMMABLE INTESTINAL DISEASES WITH INTERFERON GAMMA INHIBITORS |
US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5780027A (en) | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
GB2304342A (en) | 1995-08-18 | 1997-03-19 | Univ Manchester | Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma |
US20020025316A1 (en) | 1995-08-18 | 2002-02-28 | Ferguson Mark Williams James | Pharmaceutical composition containing inhibitors of interferon-gamma |
AU2452797A (en) | 1996-04-10 | 1997-10-29 | Board Of Trustees Of The University Of Illinois, The | Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions |
US5830454A (en) | 1996-08-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Method for treating cell mediated autoimmune disorders using interleukin-9 |
SI20110A (en) | 1997-03-18 | 2000-06-30 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
EP1015480A2 (en) | 1997-08-18 | 2000-07-05 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
US6544504B1 (en) | 1999-07-28 | 2003-04-08 | Schering Corporation | Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
US6346247B1 (en) | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
WO2001051046A1 (en) | 2000-01-14 | 2001-07-19 | University Of Virginia Patent Foundation | Airway alkalinization as therapy for airway diseases |
US6534059B2 (en) | 2001-06-05 | 2003-03-18 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
-
1990
- 1990-12-19 US US07/634,278 patent/US5530101A/en not_active Expired - Lifetime
-
1991
- 1991-12-19 EP EP03078175A patent/EP1386932A1/en not_active Withdrawn
- 1991-12-19 EP EP92903551A patent/EP0566647B1/en not_active Expired - Lifetime
- 1991-12-19 DE DE69133326T patent/DE69133326T2/en not_active Expired - Lifetime
- 1991-12-19 KR KR1019930701887A patent/KR100231090B1/en not_active IP Right Cessation
- 1991-12-19 AU AU91726/91A patent/AU671949B2/en not_active Expired
- 1991-12-19 CA CA002098404A patent/CA2098404C/en not_active Expired - Lifetime
- 1991-12-19 AT AT92903551T patent/ATE251639T1/en not_active IP Right Cessation
- 1991-12-19 WO PCT/US1991/009711 patent/WO1992011018A1/en active IP Right Grant
- 1991-12-19 JP JP50375892A patent/JP3276369B2/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/484,537 patent/US6180370B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,040 patent/US5693761A/en not_active Expired - Lifetime
- 1995-06-07 US US08/487,200 patent/US5693762A/en not_active Expired - Lifetime
- 1995-06-07 US US08/477,728 patent/US5585089A/en not_active Expired - Lifetime
-
1996
- 1996-12-19 AU AU75481/96A patent/AU7548196A/en not_active Abandoned
-
2000
- 2000-11-22 US US09/718,998 patent/US7022500B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5530101A (en) | 1996-06-25 |
CA2098404A1 (en) | 1992-06-20 |
US6180370B1 (en) | 2001-01-30 |
EP0566647B1 (en) | 2003-10-08 |
DE69133326T2 (en) | 2004-08-05 |
EP0566647A1 (en) | 1993-10-27 |
US7022500B1 (en) | 2006-04-04 |
US5693762A (en) | 1997-12-02 |
WO1992011018A1 (en) | 1992-07-09 |
KR100231090B1 (en) | 1999-11-15 |
DE69133326D1 (en) | 2003-11-13 |
JP3276369B2 (en) | 2002-04-22 |
JPH06503963A (en) | 1994-05-12 |
AU671949B2 (en) | 1996-09-19 |
US5585089A (en) | 1996-12-17 |
EP1386932A1 (en) | 2004-02-04 |
EP0566647A4 (en) | 1995-06-14 |
ATE251639T1 (en) | 2003-10-15 |
US5693761A (en) | 1997-12-02 |
AU9172691A (en) | 1992-07-22 |
AU7548196A (en) | 1997-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2098404C (en) | Improved humanized immunoglobulins | |
US20080160018A1 (en) | Humanized immunoglobulins | |
CA2328851C (en) | Humanized immunoglobulins and their production and use | |
US7524498B2 (en) | Human immunomodulatory monoclonal antibodies for the treatment of cancer | |
US5714350A (en) | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |